{"4a88d32e02a401a80877b0fdb03dcdb4e8654dba": [["IntroductionThe coronavirus disease (COVID-19) is a communicable infectious disease caused by the newly circulating coronavirus (WHO, 2020a).", [["coronavirus disease", "DISEASE", 16, 35], ["infectious disease", "DISEASE", 65, 83], ["coronavirus", "ORGANISM", 16, 27], ["coronavirus", "ORGANISM", 116, 127], ["The coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 37, 42], ["a communicable infectious disease", "PROBLEM", 50, 83], ["the newly circulating coronavirus", "PROBLEM", 94, 127], ["coronavirus disease", "OBSERVATION", 16, 35], ["infectious", "OBSERVATION", 65, 75]]], ["As of 21 April 2020, confirmed cases of coronavirus have been found in 213 countries; 2 356 414 people worldwide are known to be infected and the number of reported deaths has reached 160 120 (WHO, 2020b) .", [["coronavirus", "DISEASE", 40, 51], ["deaths", "DISEASE", 165, 171], ["coronavirus", "ORGANISM", 40, 51], ["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["coronavirus", "PROBLEM", 40, 51], ["infected", "OBSERVATION", 129, 137]]], ["A genus of the Coronaviridae family, it spreads through droplets released during coughing, sneezing or secretions of the infected person and targets the human respiratory system.", [["coughing", "DISEASE", 81, 89], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 15, 28], ["human", "ORGANISM", 153, 158], ["person", "SPECIES", 130, 136], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 153, 158], ["coughing", "PROBLEM", 81, 89], ["sneezing", "PROBLEM", 91, 99], ["secretions of the infected person", "PROBLEM", 103, 136], ["genus", "OBSERVATION", 2, 7], ["respiratory system", "ANATOMY", 159, 177]]], ["The seriousness of the virus can be gauged by the rate of its rapid spread around the world (Lipsitch, Swedlow, & Finelli, 2020) and the many infected persons confined in isolation wards in health centres (Munster, Koopmans, Doremalen, Riel, & Wit, 2020) .", [["persons", "ORGANISM", 151, 158], ["persons", "SPECIES", 151, 158], ["the virus", "PROBLEM", 19, 28], ["virus", "OBSERVATION", 23, 28], ["infected", "OBSERVATION", 142, 150]]], ["Due to the lack of either a vaccine or drug for coronavirus, non-pharmaceutical measures are being introduced as preventive and controlling measures (Tian et al., 2020) .", [["coronavirus", "DISEASE", 48, 59], ["coronavirus", "ORGANISM", 48, 59], ["coronavirus", "SPECIES", 48, 59], ["a vaccine", "TREATMENT", 26, 35], ["coronavirus", "PROBLEM", 48, 59], ["non-pharmaceutical measures", "TREATMENT", 61, 88]]], ["In order to shield people from exposure to the coronavirus, most countries have introduced lockdowns on human mobility.", [["coronavirus", "DISEASE", 47, 58], ["people", "ORGANISM", 19, 25], ["coronavirus", "ORGANISM", 47, 58], ["human", "ORGANISM", 104, 109], ["people", "SPECIES", 19, 25], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["the coronavirus", "PROBLEM", 43, 58]]], ["Besides health challenges, the coronavirus has given rise to various rumours and fake information on social media platform (Shimizu, 2020; Tasnim, Hossain, & Mazumder, 2020) .", [["coronavirus", "DISEASE", 31, 42], ["coronavirus", "ORGANISM", 31, 42], ["the coronavirus", "PROBLEM", 27, 42]]], ["With the closure of physical spaces, librarians are working in virtual spaces to provide remote services, resources and support for research, innovation and public health in the current health crisis.", [["the closure of physical spaces", "TREATMENT", 5, 35], ["remote services", "TREATMENT", 89, 104], ["closure", "OBSERVATION", 9, 16]]], ["However, the biggest challenge in the COVID-19 crisis for librarians is to keep providing their usual services to library users.", [["biggest", "OBSERVATION_MODIFIER", 13, 20]]], ["The intention of this paper is to present a summary of the broader initiatives taken by the librarians across the globe.", [["globe", "ANATOMY", 114, 119]]], ["A desktop analysis of selected websites of library association was carried out to identify innovative approaches taken by health science librarians during this unprecedented pandemic.IntroductionThe author suggests that health science librarians have three important roles to play during the COVID-19 pandemic:Introduction1.", [["A desktop analysis", "TEST", 0, 18]]], ["To provide awareness on preventive measures relating to COVID-19 2.", [["preventive measures", "TREATMENT", 24, 43], ["COVID", "TEST", 56, 61]]], ["To support researchers working on COVID-19Scope of paperThe paper uses the method of desktop analysis to review the initiatives undertaken by health science librarians around the world in response of COVID-19 (coronavirus) pandemic.Objectives of this paper\u2022 To explore initiatives undertaken by health science librarians for to raise public awareness on preventive measures for dealing with COVID-19.Objectives of this paper\u2022 To identify problems faced by health science librarians in providing document delivery services in this global lockdown.Objectives of this paper\u2022 To identify useful resources and websites providing the latest COVID-19 research findings which health science librarians can access to support researchers and faculty.MethodologyA desktop analysis approach was used in the study.", [["COVID-19", "CHEMICAL", 200, 208], ["coronavirus) pandemic", "DISEASE", 210, 231], ["COVID-19", "ORGANISM", 200, 208], ["coronavirus", "ORGANISM", 210, 221], ["COVID-19", "SPECIES", 200, 208], ["desktop analysis", "TEST", 85, 101], ["COVID", "TEST", 200, 205], ["pandemic", "PROBLEM", 223, 231], ["preventive measures", "TREATMENT", 354, 373], ["COVID", "TEST", 391, 396], ["the latest COVID", "TEST", 624, 640], ["the study", "TEST", 791, 800]]], ["To explore the role of librarians and library associations around the world, the author examined the official websites of some of the oldest library associations and organisations with an international scope.", [["an international scope", "TEST", 185, 207]]], ["A summary of sources used in the study is listed in Table 1 .MethodologyTo meet the objectives of study, data were extracted from the dedicated COVID-19 pages created by these library associations.MethodologyFindings: how health science librarians are responding to the pandemic The findings in this paper are organised under the three study objectives.Initiatives by health science librarians togenerate public awareness about COVID-19.Initiatives by health science librarians toThe key measures to prevent infection from COVID-19 are as follows: social distancing; using masks; using sanitizers; and hand washing.", [["hand", "ANATOMY", 602, 606], ["infection", "DISEASE", 508, 517], ["COVID-19", "CHEMICAL", 428, 436], ["hand", "ORGANISM_SUBDIVISION", 602, 606], ["COVID-19 pages", "DNA", 144, 158], ["the study", "TEST", 29, 38], ["study", "TEST", 98, 103], ["COVID", "TEST", 428, 433], ["infection", "PROBLEM", 508, 517], ["sanitizers", "TREATMENT", 586, 596], ["hand washing", "TREATMENT", 602, 614], ["infection", "OBSERVATION", 508, 517]]], ["Library associations and individual libraries have been designing posters to educate people regarding COVID-19.", [["people", "ORGANISM", 85, 91], ["people", "SPECIES", 85, 91], ["COVID", "TEST", 102, 107]]], ["These posters aim to educate people on social distancing, the use of masks and how to wash hands properly.Initiatives by health science librarians toLibrarians are also playing a vital role in motivating COVID-19-infected people to share As a result of lockdown in most countries, libraries are closed.", [["people", "ORGANISM", 29, 35], ["hands", "ORGANISM_SUBDIVISION", 91, 96], ["COVID-19", "ORGANISM", 204, 212], ["people", "ORGANISM", 222, 228], ["people", "SPECIES", 29, 35], ["people", "SPECIES", 222, 228], ["libraries", "TREATMENT", 281, 290]]], ["But some libraries, such as the US Library of Congress, need to support their parent bodies and therefore remain open.", [["libraries", "OBSERVATION", 9, 18]]], ["Some libraries are offering home delivery of documents and consequently sanitizing of documents has become a big concern.", [["Some libraries", "PROBLEM", 0, 14], ["home delivery", "TREATMENT", 28, 41], ["libraries", "OBSERVATION", 5, 14]]], ["At present, no research has been conducted on the transmission of corona virus through library document surfaces (such as book cloth, book jackets, coated and uncoated papers) which is a cause for concern amongst Access to the right information at the right time is critical for researchers working on COVID-19.", [["corona virus", "ORGANISM", 66, 78], ["corona virus", "SPECIES", 66, 78], ["COVID", "TEST", 302, 307], ["no", "UNCERTAINTY", 12, 14], ["right", "ANATOMY_MODIFIER", 227, 232], ["right", "ANATOMY_MODIFIER", 252, 257]]], ["Various publishers are offering free access to econtent on COVID-19.", [["COVID-19", "DNA", 59, 67], ["COVID", "TEST", 59, 64]]], ["Coren (2020) observes that scientific papers on COVID-19 are doubling every 14 days.", [["COVID-19", "CHEMICAL", 48, 56]]], ["Another study by Reuters reveals that owing to the pace at which academic papers on COVID-19 are being published papers are not always being peer reviewed which can leading to false information being published (Sharma, Scarr, & Kelland, 2020) .", [["Another study", "TEST", 0, 13]]], ["Librarians using keywords and other tools have the skills to monitor recent publications and provide the most reliable papers to researchers.Initiatives by health science librarians toThe WHO has created an important database of global literature on COVID-19.", [["COVID-19", "DNA", 250, 258], ["COVID", "TEST", 250, 255]]], ["Figure 1 shows a screenshot of this resource.Initiatives by health science librarians toElsevier has created a Novel Coronavirus Information Center to provide free information related to SARS-CoV-2 and COVID-19 (Elsevier, 2020 https://www.elsevier.com/connect/corona virus-information-center).", [["SARS", "DISEASE", 187, 191], ["SARS", "TEST", 187, 191], ["CoV", "TEST", 192, 195], ["COVID", "TEST", 202, 207]]], ["Some researchers have taken the initiative to create a COVID-19 open research dataset (CORD-19) which comprises about 24 000 research papers for researchers working on COVID-19.", [["a COVID", "TEST", 53, 60], ["COVID", "TEST", 168, 173], ["CORD", "ANATOMY", 87, 91]]], ["Figure 2 shows a snapshot of the CORD-19 data set.Initiatives by health science librarians toSome major publishers are providing free access to articles on COVID-19.", [["CORD", "DNA", 33, 37], ["COVID-19", "DNA", 156, 164], ["COVID", "TEST", 156, 161], ["CORD", "ANATOMY", 33, 37]]], ["Table 3 lists some of the major journal publishers providing free access and the links to their articles on COVID-19.Initiatives by health science librarians toSome librarians have also compiled material on recorded knowledge related to past pandemics and disasters which might help in the present crisis.", [["COVID-19", "DNA", 108, 116], ["COVID", "TEST", 108, 113]]], ["The Library History Round Table of American Library Association has assembled an exhaustive list of resources related to epidemics or related disasters.", [["epidemics", "PROBLEM", 121, 130]]], ["The Society of American Archivists (2020 https://www2.archivists.org/resources-forresponse-to-covid-19-health-crisis) has also put together a compendium of resources of global initiatives taken in response of COVID-19 crisis.ConclusionIn the current health crisis created by COVID-19, the role of librarians has of necessity expanded significantly.", [["global initiatives", "TREATMENT", 169, 187], ["COVID", "TEST", 209, 214], ["COVID", "TEST", 275, 280]]], ["Library professionals have always been committed to providing people with information; during the pandemic they are finding new ways to support their mission as demonstrated in this paper.", [["people", "ORGANISM", 62, 68], ["people", "SPECIES", 62, 68]]]], "ece09d9492d3605d3216709a1e178c2d0786b240": [["IntroductionThe coronavirus (CoV) has various strains, the most prominent of which is severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS), and newly identified 2019 novel CoV (SARS-CoV2) [1, 2] .", [["acute respiratory syndrome", "DISEASE", 93, 119], ["SARS", "DISEASE", 121, 125], ["middle east respiratory syndrome", "DISEASE", 128, 160], ["coronavirus", "ORGANISM", 16, 27], ["CoV", "ORGANISM", 29, 32], ["CoV", "ORGANISM", 201, 204], ["coronavirus", "SPECIES", 16, 27], ["CoV", "SPECIES", 29, 32], ["various strains", "PROBLEM", 38, 53], ["severe acute respiratory syndrome", "PROBLEM", 86, 119], ["SARS)", "PROBLEM", 121, 126], ["middle east respiratory syndrome", "PROBLEM", 128, 160], ["coronavirus", "OBSERVATION", 16, 27], ["most prominent", "OBSERVATION_MODIFIER", 59, 73], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory syndrome", "OBSERVATION", 99, 119], ["middle", "ANATOMY_MODIFIER", 128, 134], ["respiratory syndrome", "OBSERVATION", 140, 160]]], ["SARS-CoV is known as an infectious disease with high transmissibility that caused the global epidemic following the early cases of Guangdong, China [3] .", [["SARS-CoV", "DISEASE", 0, 8], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["an infectious disease", "PROBLEM", 21, 42], ["high transmissibility", "PROBLEM", 48, 69], ["infectious", "OBSERVATION", 24, 34]]], ["Within weeks, SARS-CoV reached almost all countries and peaked in March and April 2003 within a short time [4, 5] .", [["SARS", "DISEASE", 14, 18], ["SARS-CoV", "ORGANISM", 14, 22], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "PROBLEM", 14, 18], ["CoV", "PROBLEM", 19, 22]]], ["At first, the cause of the disease was unknown, but due to the rapid spread of the disease, it was considered as a potential infectious agent [6, 7] .", [["the disease", "PROBLEM", 23, 34], ["the rapid spread of the disease", "PROBLEM", 59, 90], ["disease", "OBSERVATION", 27, 34], ["disease", "OBSERVATION", 83, 90]]], ["With reports announced by the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), a viral agent belonging to the CoV group but with completely different genetic features than other CoVs, was isolated from infected patients [8] .", [["CoV", "ORGANISM", 154, 157], ["CoVs", "GENE_OR_GENE_PRODUCT", 222, 226], ["patients", "ORGANISM", 255, 263], ["patients", "SPECIES", 255, 263], ["Disease Control", "TREATMENT", 45, 60], ["a viral agent", "TREATMENT", 123, 136], ["other CoVs", "PROBLEM", 216, 226], ["infected", "OBSERVATION_MODIFIER", 246, 254]]], ["Given that the disease is a newly emerging disease and is likely to recur, understanding suspected clinical and laboratory symptoms, the treatment process, its transmission, some strategies for controlling the infection, and essential recommendations before traveling to and from infected areas were shown to be necessary [9, 10] .", [["infection", "DISEASE", 210, 219], ["the disease", "PROBLEM", 11, 22], ["a newly emerging disease", "PROBLEM", 26, 50], ["clinical and laboratory symptoms", "PROBLEM", 99, 131], ["the treatment process", "TREATMENT", 133, 154], ["the infection", "PROBLEM", 206, 219], ["infected areas", "PROBLEM", 280, 294], ["disease", "OBSERVATION", 15, 22], ["likely to", "UNCERTAINTY", 58, 67], ["infection", "OBSERVATION", 210, 219]]], ["Nearly ten years later at 2012, the CoV caused a SARS-like illness in Saudi Arabia that, unlike SARS-CoV, affected not only the respiratory system but also other vital organs such as the kidney and liver [11, 12] .", [["respiratory system", "ANATOMY", 128, 146], ["organs", "ANATOMY", 168, 174], ["kidney", "ANATOMY", 187, 193], ["liver", "ANATOMY", 198, 203], ["SARS-like illness", "DISEASE", 49, 66], ["SARS", "DISEASE", 96, 100], ["CoV", "ORGANISM", 36, 39], ["SARS-CoV", "ORGANISM", 96, 104], ["organs", "ORGAN", 168, 174], ["kidney", "ORGAN", 187, 193], ["liver", "ORGAN", 198, 203], ["SARS-CoV", "SPECIES", 96, 104], ["the CoV", "PROBLEM", 32, 39], ["a SARS", "PROBLEM", 47, 53], ["respiratory system", "ANATOMY", 128, 146], ["kidney", "ANATOMY", 187, 193], ["liver", "ANATOMY", 198, 203]]], ["As a result, its mortality rate was more than SARS-CoV and was named MERS-CoV [13, 14] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 69, 77], ["SARS-CoV", "SPECIES", 46, 54], ["MERS-CoV", "SPECIES", 69, 77], ["its mortality rate", "TEST", 13, 31]]], ["The clinical features of MERS-CoV infection were varied and ranged from asymptomatic or mild to acute respiratory syndrome and multiple organ failure and could lead to death, especially in people with underlying disease [15, 16] .", [["respiratory", "ANATOMY", 102, 113], ["organ", "ANATOMY", 136, 141], ["MERS-CoV infection", "DISEASE", 25, 43], ["acute respiratory syndrome", "DISEASE", 96, 122], ["multiple organ failure", "DISEASE", 127, 149], ["death", "DISEASE", 168, 173], ["MERS-CoV", "ORGANISM", 25, 33], ["organ", "ORGAN", 136, 141], ["people", "ORGANISM", 189, 195], ["people", "SPECIES", 189, 195], ["MERS-CoV", "SPECIES", 25, 33], ["MERS", "PROBLEM", 25, 29], ["CoV infection", "PROBLEM", 30, 43], ["acute respiratory syndrome", "PROBLEM", 96, 122], ["multiple organ failure", "PROBLEM", 127, 149], ["death", "PROBLEM", 168, 173], ["underlying disease", "PROBLEM", 201, 219], ["CoV", "OBSERVATION_MODIFIER", 30, 33], ["infection", "OBSERVATION", 34, 43], ["mild", "OBSERVATION_MODIFIER", 88, 92], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["respiratory syndrome", "OBSERVATION", 102, 122], ["multiple", "OBSERVATION_MODIFIER", 127, 135], ["organ", "ANATOMY", 136, 141], ["failure", "OBSERVATION", 142, 149]]], ["There is no specific drug for the treatment of MERS and preventive intensive care are needed to prevent the virus from spreading to health care centers [17] .IntroductionJ o u r n a l P r e -p r o o f SARS-CoV2 is known as a new variant of the CoV that has not been previously reported in humans [18, 19] .", [["MERS", "DISEASE", 47, 51], ["CoV", "ORGANISM", 244, 247], ["humans", "ORGANISM", 289, 295], ["CoV2", "DNA", 206, 210], ["humans", "SPECIES", 289, 295], ["humans", "SPECIES", 289, 295], ["MERS", "PROBLEM", 47, 51], ["preventive intensive care", "TREATMENT", 56, 81], ["the virus", "PROBLEM", 104, 113], ["IntroductionJ", "TEST", 158, 171], ["a l P r e -p r o o f", "TEST", 180, 200], ["SARS", "PROBLEM", 201, 205], ["a new variant of the CoV", "PROBLEM", 223, 247], ["no", "UNCERTAINTY", 9, 11], ["CoV", "ANATOMY", 244, 247]]], ["There is still much to be learned about how CoV diseases-19 (COVID-19) spreads, its severity, and other features of the virus.", [["CoV diseases", "DISEASE", 44, 56], ["CoV", "ORGANISM", 44, 47], ["how CoV diseases", "PROBLEM", 40, 56], ["COVID", "TEST", 61, 66], ["its severity", "PROBLEM", 80, 92], ["the virus", "PROBLEM", 116, 125], ["virus", "OBSERVATION", 120, 125]]], ["Indeed, epidemiological and clinical research are ongoing to determine the prevalence of CoV-19 infections among people as a public health concern.", [["CoV-19 infections", "DISEASE", 89, 106], ["CoV-19", "ORGANISM", 89, 95], ["people", "ORGANISM", 113, 119], ["people", "SPECIES", 113, 119], ["CoV-19", "SPECIES", 89, 95], ["CoV-19 infections", "PROBLEM", 89, 106]]], ["Bioinformatical and biophysical researches are underway to examine a number of drugs available to find the potential drug to inhibit the CoV protease.", [["CoV protease", "GENE_OR_GENE_PRODUCT", 137, 149], ["CoV protease", "PROTEIN", 137, 149], ["drugs", "TREATMENT", 79, 84], ["the CoV protease", "TREATMENT", 133, 149]]], ["Therefore, there is a great deal on interest in identifying potential drugs among the numerous compounds available in the treatment of viral or other diseases through the bioinformatics and biophysical approaches.", [["potential drugs", "TREATMENT", 60, 75], ["viral or other diseases", "PROBLEM", 135, 158]]], ["Drugs that have the ability to bind the RBD can be considered as potential inhibitors of the CoV-19 protease enzyme.IntroductionRapid access to CoV genomic data made it possible to produce first-generation homologous models for 3CLpro cysteine protease [20] .", [["cysteine", "CHEMICAL", 235, 243], ["RBD", "GENE_OR_GENE_PRODUCT", 40, 43], ["CoV-19", "GENE_OR_GENE_PRODUCT", 93, 99], ["3CLpro cysteine", "GENE_OR_GENE_PRODUCT", 228, 243], ["RBD", "PROTEIN", 40, 43], ["CoV-19 protease enzyme", "PROTEIN", 93, 115], ["3CLpro cysteine protease", "PROTEIN", 228, 252], ["Drugs", "TREATMENT", 0, 5], ["the CoV", "TEST", 89, 96], ["protease enzyme", "TEST", 100, 115], ["CoV genomic data", "TEST", 144, 160], ["first-generation homologous models", "TREATMENT", 189, 223], ["3CLpro cysteine protease", "TREATMENT", 228, 252]]], ["This enzyme is critical for CoV replication and has previously been studied as a target for antiviral therapies in the treatment of SARS-CoV [20, 21] .IntroductionThis version shows that although the viral genome closely resembles the bat CoV, the protease most closely resembles the corona protease of the SARS-CoV, indicating that the virus has entered the human population through another animal (civets) [22] .IntroductionHuang, et al. [23] used crystallographic and biophysical methods to identify the structural and functional properties of HKU9 (a bat CoV not transmitted to humans).", [["SARS-CoV", "DISEASE", 132, 140], ["SARS", "DISEASE", 307, 311], ["CoV", "GENE_OR_GENE_PRODUCT", 28, 31], ["SARS-CoV", "ORGANISM", 132, 140], ["bat CoV", "ORGANISM", 235, 242], ["SARS-CoV", "ORGANISM", 307, 315], ["human", "ORGANISM", 359, 364], ["HKU9", "GENE_OR_GENE_PRODUCT", 547, 551], ["bat CoV", "ORGANISM", 555, 562], ["humans", "ORGANISM", 582, 588], ["viral genome", "DNA", 200, 212], ["protease", "PROTEIN", 248, 256], ["corona protease", "PROTEIN", 284, 299], ["HKU9", "PROTEIN", 547, 551], ["human", "SPECIES", 359, 364], ["humans", "SPECIES", 582, 588], ["CoV", "SPECIES", 28, 31], ["SARS-CoV", "SPECIES", 132, 140], ["bat CoV", "SPECIES", 235, 242], ["SARS-CoV", "SPECIES", 307, 315], ["human", "SPECIES", 359, 364], ["humans", "SPECIES", 582, 588], ["This enzyme", "TEST", 0, 11], ["CoV replication", "TREATMENT", 28, 43], ["antiviral therapies", "TREATMENT", 92, 111], ["SARS", "PROBLEM", 132, 136], ["CoV", "TEST", 137, 140], ["This version", "TEST", 163, 175], ["the viral genome", "PROBLEM", 196, 212], ["the bat CoV", "PROBLEM", 231, 242], ["the protease", "TREATMENT", 244, 256], ["the virus", "PROBLEM", 333, 342], ["crystallographic and biophysical methods", "TREATMENT", 450, 490], ["a bat CoV", "PROBLEM", 553, 562], ["viral genome", "OBSERVATION", 200, 212]]], ["The main reason for these studies was that \u03b2-CoV (a type that includes SARS-CoV and MERS-CoV) should be well characterized if they lead to the next global epidemic.", [["\u03b2-CoV", "ORGANISM", 43, 48], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 71, 79], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 84, 92], ["\u03b2-CoV", "SPECIES", 43, 48], ["SARS-CoV", "SPECIES", 71, 79], ["MERS-CoV", "SPECIES", 84, 92], ["these studies", "TEST", 20, 33], ["CoV", "PROBLEM", 45, 48], ["SARS", "PROBLEM", 71, 75], ["main", "OBSERVATION_MODIFIER", 4, 8], ["epidemic", "OBSERVATION", 155, 163]]], ["After comparing the RBD of the virus with the existing structures of SARS-CoV, MERS-CoV, and HKU4-CoV (bat CoV), it was found that the recognition of receptor-ligand interaction is difficult despite the knowledge of the evolutionary history of RNA viruses [24] .J o u r n a l P r e -p r o o fExtensive research is ongoing to find disinfectants for previously known CoV as well as SARS-CoV2.", [["SARS", "DISEASE", 69, 73], ["SARS", "DISEASE", 380, 384], ["SARS-CoV", "ORGANISM", 69, 77], ["MERS-CoV", "ORGANISM", 79, 87], ["HKU4-CoV", "ORGANISM", 93, 101], ["bat CoV", "ORGANISM", 103, 110], ["receptor-ligand", "GENE_OR_GENE_PRODUCT", 150, 165], ["CoV", "ORGANISM", 365, 368], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 380, 389], ["RBD", "PROTEIN", 20, 23], ["HKU4", "PROTEIN", 93, 97], ["CoV", "DNA", 98, 101], ["SARS-CoV", "SPECIES", 69, 77], ["MERS-CoV", "SPECIES", 79, 87], ["HKU4-CoV (bat CoV", "SPECIES", 93, 110], ["the virus", "PROBLEM", 27, 36], ["SARS", "PROBLEM", 69, 73], ["CoV", "TEST", 74, 77], ["MERS", "TEST", 79, 83], ["CoV", "TEST", 84, 87], ["HKU4", "TEST", 93, 97], ["RNA viruses", "PROBLEM", 244, 255], ["fExtensive research", "TREATMENT", 291, 310], ["previously known CoV", "PROBLEM", 348, 368], ["virus", "OBSERVATION", 31, 36], ["SARS", "OBSERVATION", 69, 73]]], ["A review study by Liu, et al. [25] discusses the possible prevention and treatment options for SARS-CoV2.", [["SARS", "DISEASE", 95, 99], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 95, 104], ["A review study", "TEST", 0, 14], ["treatment options", "TREATMENT", 73, 90], ["SARS", "PROBLEM", 95, 99]]], ["There are four important enzymes that are essential for the pathogenesis: the S-protein that facilitates virus entry through the angiotensin-converting enzyme 2 (ACE2) to the host cell surface receptor, the major protease of CoV 3CLpro, and the papain-like protease (PLpro) involved in the assembly of new viruses, and RNA-dependent RNA polymerase (RdRp) that facilitates CoV RNA genome replication [25] .Discovery of new CoVA new variant of the CoV spread in Wuhan, China, last year, followed by Chinese authorities reporting an outbreak of pneumonia of unknown origin.", [["cell surface", "ANATOMY", 180, 192], ["angiotensin", "CHEMICAL", 129, 140], ["pneumonia", "DISEASE", 542, 551], ["S-protein", "GENE_OR_GENE_PRODUCT", 78, 87], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 129, 160], ["ACE2", "GENE_OR_GENE_PRODUCT", 162, 166], ["cell surface receptor", "GENE_OR_GENE_PRODUCT", 180, 201], ["CoV 3CLpro", "GENE_OR_GENE_PRODUCT", 225, 235], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 245, 265], ["PLpro", "GENE_OR_GENE_PRODUCT", 267, 272], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 319, 347], ["RdRp", "GENE_OR_GENE_PRODUCT", 349, 353], ["CoV", "GENE_OR_GENE_PRODUCT", 372, 375], ["CoVA", "CANCER", 422, 426], ["S-protein", "PROTEIN", 78, 87], ["angiotensin-converting enzyme 2", "PROTEIN", 129, 160], ["ACE2", "PROTEIN", 162, 166], ["host cell surface receptor", "PROTEIN", 175, 201], ["major protease", "PROTEIN", 207, 221], ["CoV 3CLpro", "PROTEIN", 225, 235], ["papain-like protease", "PROTEIN", 245, 265], ["PLpro", "PROTEIN", 267, 272], ["RNA-dependent RNA polymerase", "PROTEIN", 319, 347], ["RdRp", "PROTEIN", 349, 353], ["four important enzymes", "TEST", 10, 32], ["the pathogenesis", "PROBLEM", 56, 72], ["the S-protein", "PROBLEM", 74, 87], ["the angiotensin-converting enzyme", "TREATMENT", 125, 158], ["the host cell surface receptor", "TREATMENT", 171, 201], ["CoV 3CLpro", "TREATMENT", 225, 235], ["the papain", "TREATMENT", 241, 251], ["protease (PLpro)", "TREATMENT", 257, 273], ["new viruses", "PROBLEM", 302, 313], ["RNA-dependent RNA polymerase (RdRp", "TREATMENT", 319, 353], ["CoV RNA genome replication", "TREATMENT", 372, 398], ["pneumonia", "PROBLEM", 542, 551], ["new", "OBSERVATION_MODIFIER", 302, 305], ["viruses", "OBSERVATION", 306, 313], ["new", "OBSERVATION_MODIFIER", 418, 421], ["CoVA", "OBSERVATION", 422, 426], ["CoV", "OBSERVATION_MODIFIER", 446, 449], ["spread", "OBSERVATION_MODIFIER", 450, 456], ["pneumonia", "OBSERVATION", 542, 551], ["unknown origin", "OBSERVATION_MODIFIER", 555, 569]]], ["CoVs belong to the family Coronaviridae and \u03b1 and \u03b2 viruses normally infect mammals, while \u03b3 and \u03b4 CoVs usually infect birds and fish [26, 27] .", [["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 26, 39], ["\u03b1", "GENE_OR_GENE_PRODUCT", 44, 45], ["\u03b2 viruses", "ORGANISM", 50, 59], ["\u03b3", "GENE_OR_GENE_PRODUCT", 91, 92], ["\u03b4 CoVs", "GENE_OR_GENE_PRODUCT", 97, 103], ["birds", "ORGANISM", 119, 124], ["fish", "ORGANISM_SUBDIVISION", 129, 133], ["CoVs", "PROTEIN", 0, 4], ["Coronaviridae", "TREATMENT", 26, 39]]], ["Canine CoV, which can cause mild diarrhea, and cat CoV, which can cause infectious catfish peritoneal inflammation, are both \u03b1-CoVs.", [["peritoneal", "ANATOMY", 91, 101], ["diarrhea", "DISEASE", 33, 41], ["peritoneal inflammation", "DISEASE", 91, 114], ["Canine CoV", "ORGANISM", 0, 10], ["cat CoV", "ORGANISM", 47, 54], ["catfish", "ORGANISM", 83, 90], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 91, 101], ["\u03b1-CoVs", "GENE_OR_GENE_PRODUCT", 125, 131], ["Canine", "SPECIES", 0, 6], ["cat", "SPECIES", 47, 50], ["Canine CoV", "SPECIES", 0, 10], ["cat CoV", "SPECIES", 47, 54], ["Canine CoV", "PROBLEM", 0, 10], ["mild diarrhea", "PROBLEM", 28, 41], ["cat CoV", "PROBLEM", 47, 54], ["infectious catfish peritoneal inflammation", "PROBLEM", 72, 114], ["mild", "OBSERVATION_MODIFIER", 28, 32], ["diarrhea", "OBSERVATION", 33, 41], ["infectious", "OBSERVATION_MODIFIER", 72, 82], ["peritoneal", "ANATOMY", 91, 101], ["inflammation", "OBSERVATION", 102, 114]]], ["Until the appearance of SARS-CoV2, which belongs to \u03b2-CoV ( Figure 1A ), only six known CoV were capable of infecting humans and causing respiratory disease, including SARS and MERS.", [["respiratory", "ANATOMY", 137, 148], ["SARS", "DISEASE", 24, 28], ["respiratory disease", "DISEASE", 137, 156], ["SARS", "DISEASE", 168, 172], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 24, 33], ["\u03b2-CoV", "ORGANISM", 52, 57], ["Figure 1A", "ORGANISM", 60, 69], ["CoV", "ORGANISM", 88, 91], ["humans", "ORGANISM", 118, 124], ["CoV2", "DNA", 29, 33], ["\u03b2-CoV", "PROTEIN", 52, 57], ["humans", "SPECIES", 118, 124], ["\u03b2-CoV", "SPECIES", 52, 57], ["humans", "SPECIES", 118, 124], ["SARS", "PROBLEM", 24, 28], ["six known CoV", "PROBLEM", 78, 91], ["infecting humans", "PROBLEM", 108, 124], ["respiratory disease", "PROBLEM", 137, 156], ["SARS", "PROBLEM", 168, 172], ["MERS", "PROBLEM", 177, 181], ["SARS", "OBSERVATION", 24, 28], ["CoV", "OBSERVATION", 88, 91], ["infecting", "OBSERVATION", 108, 117], ["respiratory disease", "OBSERVATION", 137, 156]]], ["The new CoV is genetically more related to SARS-CoV than MERS-CoV, but both are \u03b2-Cov, originating from bats.", [["SARS", "DISEASE", 43, 47], ["CoV", "ORGANISM", 8, 11], ["SARS-CoV", "ORGANISM", 43, 51], ["MERS-CoV", "ORGANISM", 57, 65], ["\u03b2-Cov", "GENE_OR_GENE_PRODUCT", 80, 85], ["\u03b2-Cov", "DNA", 80, 85], ["SARS-CoV", "SPECIES", 43, 51], ["MERS-CoV", "SPECIES", 57, 65], ["The new CoV", "PROBLEM", 0, 11], ["SARS", "PROBLEM", 43, 47], ["Cov", "PROBLEM", 82, 85], ["new", "OBSERVATION_MODIFIER", 4, 7], ["CoV", "OBSERVATION", 8, 11], ["Cov", "OBSERVATION", 82, 85]]], ["While we don't know for sure if this virus will behave like SARS-CoV and MERS-CoV, we can use the information from both previous viruses for development of potential anti-viral agents [1, 26, 28] .RBD of SARS-CoV2The RBD in the S-protein has been shown to be the most flexible segment of the CoV structure [26, 29] .", [["SARS", "DISEASE", 60, 64], ["RBD", "DISEASE", 197, 200], ["SARS", "DISEASE", 204, 208], ["RBD", "DISEASE", 217, 220], ["S-protein", "CHEMICAL", 228, 237], ["SARS-CoV", "ORGANISM", 60, 68], ["MERS-CoV", "ORGANISM", 73, 81], ["S-protein", "GENE_OR_GENE_PRODUCT", 228, 237], ["RBD", "PROTEIN", 197, 200], ["RBD", "PROTEIN", 217, 220], ["S-protein", "PROTEIN", 228, 237], ["SARS-CoV", "SPECIES", 60, 68], ["MERS-CoV", "SPECIES", 73, 81], ["SARS-CoV2", "SPECIES", 204, 213], ["this virus", "PROBLEM", 32, 42], ["SARS", "PROBLEM", 60, 64], ["potential anti-viral agents", "TREATMENT", 156, 183], ["SARS", "PROBLEM", 204, 208], ["SARS", "OBSERVATION", 204, 208], ["RBD", "OBSERVATION", 217, 220], ["S-protein", "OBSERVATION", 228, 237], ["CoV structure", "OBSERVATION", 292, 305]]], ["Six RBD residues have been demonstrated to be crucial for interaction of S-J o u r n a l P r e -p r o o f protein with ACE2 as a receptor and for identifying the host range of SARS-CoV-mimicking viruses (Table 1) [30, 31] .RBD of SARS-CoV2As tabulated in Table 1 and Figure 1 (B), only one of these six amino acids are similar between SARS-CoV2 and SARS-CoV.RBD of SARS-CoV2While this data revealed that SARS-CoV2 may interact with human ACE2 with potential binding affinity, theoretical investigations demonstrated that the formation of this complex interaction is not favorable and that the RBD sequence is not similar with those in SARS-CoV to be potential for interaction with receptor [30, 33] .RBD of SARS-CoV2S-proteins present on the surface of the virus are a key factor in the detection of receptors and play an important role in the mechanism of membrane infiltration and infection.", [["surface", "ANATOMY", 742, 749], ["membrane", "ANATOMY", 857, 865], ["RBD", "DISEASE", 223, 226], ["SARS", "DISEASE", 230, 234], ["amino acids", "CHEMICAL", 303, 314], ["SARS", "DISEASE", 365, 369], ["SARS", "DISEASE", 404, 408], ["SARS", "DISEASE", 707, 711], ["infection", "DISEASE", 883, 892], ["amino acids", "CHEMICAL", 303, 314], ["ACE2", "GENE_OR_GENE_PRODUCT", 119, 123], ["SARS-CoV", "ORGANISM", 176, 184], ["amino acids", "AMINO_ACID", 303, 314], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 335, 344], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 349, 357], ["SARS-CoV2While", "GENE_OR_GENE_PRODUCT", 365, 379], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 404, 413], ["human", "ORGANISM", 432, 437], ["ACE2", "GENE_OR_GENE_PRODUCT", 438, 442], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 635, 643], ["SARS-CoV2S", "GENE_OR_GENE_PRODUCT", 707, 717], ["surface", "CELLULAR_COMPONENT", 742, 749], ["membrane", "CELLULAR_COMPONENT", 857, 865], ["RBD residues", "PROTEIN", 4, 16], ["S-J o u r n a l P r e -p r o o f protein", "PROTEIN", 73, 113], ["ACE2", "PROTEIN", 119, 123], ["RBD", "PROTEIN", 223, 226], ["RBD", "PROTEIN", 358, 361], ["CoV2", "PROTEIN", 409, 413], ["human ACE2", "PROTEIN", 432, 442], ["RBD", "PROTEIN", 593, 596], ["RBD", "PROTEIN", 700, 703], ["SARS-CoV2S-proteins", "PROTEIN", 707, 726], ["human", "SPECIES", 432, 437], ["SARS-CoV", "SPECIES", 176, 184], ["SARS-CoV", "SPECIES", 349, 357], ["human", "SPECIES", 432, 437], ["SARS-CoV", "SPECIES", 635, 643], ["Six RBD residues", "PROBLEM", 0, 16], ["ACE2", "PROBLEM", 119, 123], ["SARS", "PROBLEM", 176, 180], ["mimicking viruses", "PROBLEM", 185, 202], ["RBD of SARS", "TEST", 223, 234], ["amino acids", "TEST", 303, 314], ["SARS", "TEST", 335, 339], ["SARS", "PROBLEM", 349, 353], ["CoV", "PROBLEM", 354, 357], ["SARS", "TEST", 365, 369], ["this data", "TEST", 380, 389], ["SARS", "PROBLEM", 404, 408], ["potential binding affinity", "PROBLEM", 448, 474], ["theoretical investigations", "TEST", 476, 502], ["the RBD sequence", "TEST", 589, 605], ["SARS", "PROBLEM", 707, 711], ["CoV2S", "TEST", 712, 717], ["proteins", "PROBLEM", 718, 726], ["the virus", "PROBLEM", 753, 762], ["membrane infiltration", "PROBLEM", 857, 878], ["infection", "PROBLEM", 883, 892], ["RBD residues", "OBSERVATION", 4, 16], ["SARS", "OBSERVATION", 230, 234], ["SARS", "OBSERVATION", 365, 369], ["SARS", "OBSERVATION", 707, 711], ["virus", "OBSERVATION", 757, 762], ["membrane infiltration", "OBSERVATION", 857, 878], ["infection", "OBSERVATION", 883, 892]]], ["Researchers have found that S-protein from \u03b2-CoV originate from a common ancestor and evolve in the outer region of the RBD and this determines the virus's potential for transmission between species.", [["outer region", "ANATOMY", 100, 112], ["RBD", "DISEASE", 120, 123], ["S-protein", "GENE_OR_GENE_PRODUCT", 28, 37], ["\u03b2-CoV", "ORGANISM", 43, 48], ["outer region", "CELLULAR_COMPONENT", 100, 112], ["RBD", "GENE_OR_GENE_PRODUCT", 120, 123], ["S-protein", "PROTEIN", 28, 37], ["\u03b2-CoV", "PROTEIN", 43, 48], ["RBD", "PROTEIN", 120, 123], ["\u03b2-CoV", "SPECIES", 43, 48], ["S-protein from \u03b2-CoV", "PROBLEM", 28, 48], ["the RBD", "PROBLEM", 116, 123], ["the virus", "PROBLEM", 144, 153], ["transmission between species", "PROBLEM", 170, 198], ["S-protein", "OBSERVATION", 28, 37], ["outer", "ANATOMY_MODIFIER", 100, 105], ["region", "ANATOMY_MODIFIER", 106, 112], ["RBD", "OBSERVATION", 120, 123]]], ["An atomic model of a CoV S-protein has been introduced that facilitates the entry of CoV into host cells [34] .RBD of SARS-CoV2A number of strategies for development of ESV designs using only certain domains of the S-J o u r n a l P r e -p r o o f protein as antigen have been proposed through the analysis of this model.", [["cells", "ANATOMY", 99, 104], ["S-protein", "CHEMICAL", 25, 34], ["SARS", "DISEASE", 118, 122], ["CoV", "ORGANISM", 21, 24], ["CoV", "GENE_OR_GENE_PRODUCT", 85, 88], ["host cells", "CELL", 94, 104], ["CoV S-protein", "PROTEIN", 21, 34], ["CoV", "PROTEIN", 85, 88], ["host cells", "CELL_TYPE", 94, 104], ["RBD", "PROTEIN", 111, 114], ["P r e", "DNA", 231, 236], ["a CoV S-protein", "TREATMENT", 19, 34], ["SARS", "PROBLEM", 118, 122], ["ESV designs", "PROBLEM", 169, 180], ["the S", "TEST", 211, 216], ["a l P r e -p r o o f protein as antigen", "TEST", 227, 266], ["SARS", "OBSERVATION", 118, 122]]], ["These human viruses, which contain S-proteins, are responsible for one-third of the typical cold-like pseudo-pneumonia.RBD of SARS-CoV2The epidemic nature of deadly pneumonia reveals that animal CoV are capable of being transmitted from animals to humans.", [["RBD", "DISEASE", 119, 122], ["pneumonia", "DISEASE", 165, 174], ["human", "ORGANISM", 6, 11], ["S-proteins", "GENE_OR_GENE_PRODUCT", 35, 45], ["animal CoV", "ORGANISM", 188, 198], ["humans", "ORGANISM", 248, 254], ["S-proteins", "PROTEIN", 35, 45], ["RBD", "PROTEIN", 119, 122], ["SARS-CoV2", "PROTEIN", 126, 135], ["human", "SPECIES", 6, 11], ["humans", "SPECIES", 248, 254], ["human viruses", "SPECIES", 6, 19], ["humans", "SPECIES", 248, 254], ["These human viruses", "PROBLEM", 0, 19], ["pseudo-pneumonia", "PROBLEM", 102, 118], ["deadly pneumonia", "PROBLEM", 158, 174], ["animal CoV", "PROBLEM", 188, 198], ["viruses", "OBSERVATION", 12, 19], ["typical", "OBSERVATION_MODIFIER", 84, 91], ["cold", "OBSERVATION", 92, 96], ["pseudo-pneumonia", "OBSERVATION", 102, 118], ["deadly", "OBSERVATION_MODIFIER", 158, 164], ["pneumonia", "OBSERVATION", 165, 174], ["animal CoV", "OBSERVATION", 188, 198]]], ["Currently, it was assumed that a limited number of people could be infected by animal CoV; however, animals are infected by a large number of these kinds of viruses.", [["people", "ORGANISM", 51, 57], ["animal CoV", "ORGANISM", 79, 89], ["people", "SPECIES", 51, 57], ["CoV", "SPECIES", 86, 89], ["animal CoV", "PROBLEM", 79, 89], ["viruses", "PROBLEM", 157, 164], ["infected", "OBSERVATION", 67, 75], ["infected", "OBSERVATION", 112, 120], ["large", "OBSERVATION_MODIFIER", 126, 131], ["viruses", "OBSERVATION", 157, 164]]], ["The recent animal CoV outbreak is due to the overcoming inter-species barriers by this virus.", [["CoV", "ORGANISM", 18, 21], ["The recent animal CoV outbreak", "PROBLEM", 0, 30], ["this virus", "PROBLEM", 82, 92], ["CoV outbreak", "OBSERVATION", 18, 30]]], ["This indicates the inevitability of the new CoV with the potential to be contagious.", [["CoV", "ORGANISM", 44, 47], ["the new CoV", "PROBLEM", 36, 47], ["contagious", "PROBLEM", 73, 83], ["new", "OBSERVATION_MODIFIER", 40, 43], ["CoV", "OBSERVATION", 44, 47], ["contagious", "OBSERVATION", 73, 83]]], ["Antiviral treatments and approved ESV are not yet available for SARS-CoV2.RBD of SARS-CoV2S-proteins with a transparent membrane help the CoV to attach to specific cells and eventually enter them.", [["membrane", "ANATOMY", 120, 128], ["cells", "ANATOMY", 164, 169], ["SARS", "DISEASE", 64, 68], ["SARS", "DISEASE", 81, 85], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 64, 73], ["membrane", "CELLULAR_COMPONENT", 120, 128], ["CoV", "ORGANISM", 138, 141], ["cells", "CELL", 164, 169], ["RBD", "PROTEIN", 74, 77], ["SARS-CoV2S-proteins", "PROTEIN", 81, 100], ["Antiviral treatments", "TREATMENT", 0, 20], ["ESV", "TEST", 34, 37], ["SARS", "PROBLEM", 64, 68], ["SARS", "TEST", 81, 85], ["a transparent membrane", "TREATMENT", 106, 128], ["SARS", "OBSERVATION", 81, 85]]], ["The cryo-electron microscope and supercritical analysis has revealed the structure of the SARS-CoV2 trimeric S-protein.", [["SARS", "DISEASE", 90, 94], ["SARS-CoV2 trimeric S-protein", "PROTEIN", 90, 118], ["The cryo-electron microscope", "TEST", 0, 28], ["supercritical analysis", "TEST", 33, 55], ["the SARS", "PROBLEM", 86, 94], ["SARS", "OBSERVATION", 90, 94], ["S-protein", "OBSERVATION", 109, 118]]], ["Figure 2A Walls, et al. [35] showed that as both SARS-CoV and SARS-CoV2 has similar host cell surface binding domain, promising blocking compounds or approaches assayed to block SARS-CoV entry could be explored against SARS-CoV2.", [["cell surface", "ANATOMY", 89, 101], ["SARS", "DISEASE", 49, 53], ["SARS", "DISEASE", 62, 66], ["SARS", "DISEASE", 178, 182], ["SARS-CoV", "ORGANISM", 49, 57], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 62, 71], ["cell", "CELL", 89, 93], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 178, 186], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 219, 228], ["CoV2", "DNA", 67, 71], ["host cell surface binding domain", "PROTEIN", 84, 116], ["SARS-CoV", "SPECIES", 49, 57], ["SARS-CoV", "SPECIES", 178, 186], ["both SARS", "PROBLEM", 44, 53], ["SARS", "PROBLEM", 62, 66], ["CoV2", "PROBLEM", 67, 71], ["promising blocking compounds", "PROBLEM", 118, 146], ["block SARS", "PROBLEM", 172, 182], ["CoV entry", "TEST", 183, 192], ["SARS", "PROBLEM", 219, 223], ["host cell", "OBSERVATION", 84, 93]]], ["They studied two Abs isolated from human survivors targeting the S-protein RBD ( Figure 3A (Figures 3B (i, ii) ), which also mediates the interaction of S-protein and human ACE2 [39] .", [["human", "ORGANISM", 35, 40], ["Figures 3B (i, ii)", "GENE_OR_GENE_PRODUCT", 92, 110], ["S-protein", "GENE_OR_GENE_PRODUCT", 153, 162], ["human", "ORGANISM", 167, 172], ["ACE2", "GENE_OR_GENE_PRODUCT", 173, 177], ["Abs", "PROTEIN", 17, 20], ["S-protein RBD", "PROTEIN", 65, 78], ["Figure 3A", "PROTEIN", 81, 90], ["Figures 3B (i, ii)", "PROTEIN", 92, 110], ["S-protein", "PROTEIN", 153, 162], ["human ACE2", "PROTEIN", 167, 177], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 167, 172], ["the S-protein RBD", "PROBLEM", 61, 78]]], ["Comparison of the SARS-CoV S-protein-S230 complex conformation with the SARS-CoV B domain-ACE2 complex revealed that these proteins would compete upon interaction with SARS-CoV S (Figures 3B (iii, iv)) [35] .RBD of SARS-CoV2J o u r n a l P r e -p r o o f80RSui, et al. [40] probed the different recombinant single-chain variable region fragments (scFvs) against the S1 domain of S-protein of the SARS-CoV.", [["SARS", "DISEASE", 396, 400], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["S-protein", "GENE_OR_GENE_PRODUCT", 379, 388], ["SARS-CoV", "ORGANISM", 396, 404], ["SARS-CoV S-protein", "PROTEIN", 18, 36], ["S230 complex", "PROTEIN", 37, 49], ["SARS-CoV B domain", "PROTEIN", 72, 89], ["ACE2 complex", "PROTEIN", 90, 102], ["RBD", "PROTEIN", 208, 211], ["recombinant single-chain variable region fragments", "DNA", 295, 345], ["scFvs", "PROTEIN", 347, 352], ["S1 domain", "PROTEIN", 366, 375], ["S-protein", "PROTEIN", 379, 388], ["SARS-CoV", "PROTEIN", 396, 404], ["SARS-CoV", "SPECIES", 18, 26], ["SARS-CoV", "SPECIES", 168, 176], ["SARS-CoV", "SPECIES", 396, 404], ["the SARS", "TEST", 14, 22], ["CoV S-protein", "TEST", 23, 36], ["the SARS", "TEST", 68, 76], ["these proteins", "PROBLEM", 117, 131], ["SARS", "TEST", 168, 172], ["CoV S (Figures 3B (iii, iv)", "TREATMENT", 173, 200], ["RBD", "TEST", 208, 211], ["SARS-CoV2J", "TEST", 215, 225], ["RSui", "TEST", 256, 260], ["et al.", "TEST", 262, 268], ["the different recombinant single-chain variable region fragments (scFvs", "TREATMENT", 281, 352], ["S-protein", "OBSERVATION", 379, 388]]], ["Mapping of the 80R epitope demonstrated it binds the N-terminal residues of S-protein and relative to ACE2, they bind to S1 domain with high affinity.", [["N", "CHEMICAL", 53, 54], ["80R", "GENE_OR_GENE_PRODUCT", 15, 18], ["S-protein", "GENE_OR_GENE_PRODUCT", 76, 85], ["ACE2", "GENE_OR_GENE_PRODUCT", 102, 106], ["80R epitope", "PROTEIN", 15, 26], ["N-terminal residues", "PROTEIN", 53, 72], ["S-protein", "PROTEIN", 76, 85], ["ACE2", "PROTEIN", 102, 106], ["S1 domain", "PROTEIN", 121, 130], ["terminal residues of S-protein", "PROBLEM", 55, 85], ["ACE2", "TEST", 102, 106], ["high affinity", "PROBLEM", 136, 149], ["high affinity", "OBSERVATION", 136, 149]]], ["Sui, et al. [40] also investigated the antiviral activity of 80R mAb on SARS-CoV S-protein in vivo.", [["80R mAb", "SIMPLE_CHEMICAL", 61, 68], ["SARS-CoV S-protein", "GENE_OR_GENE_PRODUCT", 72, 90], ["80R mAb", "PROTEIN", 61, 68], ["SARS-CoV S-protein", "PROTEIN", 72, 90], ["SARS-CoV", "SPECIES", 72, 80], ["the antiviral activity", "TREATMENT", 35, 57], ["SARS", "PROBLEM", 72, 76], ["CoV S-protein in vivo", "TREATMENT", 77, 98]]], ["They found that 80R mAb at levels therapeutically permittable in humans, significantly decreased the virus infection.", [["infection", "DISEASE", 107, 116], ["80R mAb", "GENE_OR_GENE_PRODUCT", 16, 23], ["humans", "ORGANISM", 65, 71], ["80R mAb", "PROTEIN", 16, 23], ["humans", "SPECIES", 65, 71], ["humans", "SPECIES", 65, 71], ["80R mAb", "TREATMENT", 16, 23], ["the virus infection", "PROBLEM", 97, 116], ["significantly", "OBSERVATION_MODIFIER", 73, 86], ["decreased", "OBSERVATION_MODIFIER", 87, 96], ["virus infection", "OBSERVATION", 101, 116]]], ["They suggested that the crucial core domain of S-protein needed for 80R binding acts as a structurally sensitive segment to overlap the receptor ACE2-binding site [41] .F26G18 and F26G19Berry, et al. [42] reported the selectivity and affinity of chimeric versions of recombinant mAbs.", [["S-protein", "GENE_OR_GENE_PRODUCT", 47, 56], ["80R", "GENE_OR_GENE_PRODUCT", 68, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 145, 149], ["mAbs", "GENE_OR_GENE_PRODUCT", 279, 283], ["S-protein", "PROTEIN", 47, 56], ["80R", "PROTEIN", 68, 71], ["ACE2", "PROTEIN", 145, 149], ["chimeric versions", "PROTEIN", 246, 263], ["recombinant mAbs", "PROTEIN", 267, 283], ["the crucial core domain of S-protein", "TREATMENT", 20, 56], ["80R binding acts", "TREATMENT", 68, 84], ["recombinant mAbs", "TREATMENT", 267, 283]]], ["They showed that the F26G18 and F26G19 chimeric mAbs bind to the different domain of S-proteins [42] .", [["F26G18", "GENE_OR_GENE_PRODUCT", 21, 27], ["F26G18 and F26G19 chimeric mAbs", "PROTEIN", 21, 52], ["S-proteins", "PROTEIN", 85, 95], ["the F26G18 and F26G19 chimeric mAbs", "TREATMENT", 17, 52]]], ["Although, F26G18 mAb binds to the linear epitope (460-476) on S1 segment of SARS-CoV, F26G19 mAb binds to the different conformational epitope on S1 segment of SARS-CoV.", [["SARS", "DISEASE", 160, 164], ["F26G18 mAb", "GENE_OR_GENE_PRODUCT", 10, 20], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 76, 84], ["F26G19 mAb", "GENE_OR_GENE_PRODUCT", 86, 96], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 160, 168], ["F26G18 mAb", "PROTEIN", 10, 20], ["S1 segment", "PROTEIN", 62, 72], ["F26G19 mAb", "PROTEIN", 86, 96], ["conformational epitope", "PROTEIN", 120, 142], ["SARS-CoV", "SPECIES", 76, 84], ["SARS-CoV", "SPECIES", 160, 168], ["SARS", "PROBLEM", 76, 80], ["CoV", "PROBLEM", 81, 84], ["F26G19 mAb binds", "TREATMENT", 86, 102], ["CoV", "PROBLEM", 165, 168], ["S1 segment", "ANATOMY_MODIFIER", 146, 156], ["CoV", "ANATOMY", 165, 168]]], ["This data suggested that the specificity of chimeric mAbs to the S-protein is based on the interaction of mAb with residues 318-510 in the RBD.CR3014 and CR3022Ter Meulen, et al. [43] reported that prophylactic administration of the CR3014 mAb for the binding of the most efficient neutralizing MAb, namely CR3014 ( Figure 4B ) [44] .CR3014 and CR3022The combination of two mAbs CR3014 and CR3022 promisingly regulate the immune escape mechanism and also the potential synergistic effect between these mAbs may result in a lower mAb level to be used for passive immune prophylaxis of CoV infection ( Figure 4C ) [45] .M396 and S230.15Prabakaran, et al. [46] reported the structure of SARS-CoV RBD interacted with m396 mAb ( Figure 5 (i-iv)).", [["residues 318-510", "CHEMICAL", 115, 131], ["RBD", "DISEASE", 139, 142], ["CR3014", "CHEMICAL", 143, 149], ["CR3014", "CHEMICAL", 233, 239], ["CR3014", "CHEMICAL", 334, 340], ["CR3022", "CHEMICAL", 345, 351], ["CR3014", "CHEMICAL", 379, 385], ["CR3022", "CHEMICAL", 390, 396], ["CoV infection", "DISEASE", 584, 597], ["SARS", "DISEASE", 684, 688], ["CR3014", "CHEMICAL", 334, 340], ["CR3022", "CHEMICAL", 345, 351], ["CR3022", "CHEMICAL", 390, 396], ["S230", "CHEMICAL", 627, 631], ["mAbs", "GENE_OR_GENE_PRODUCT", 53, 57], ["S-protein", "GENE_OR_GENE_PRODUCT", 65, 74], ["mAb", "GENE_OR_GENE_PRODUCT", 106, 109], ["CR3014 mAb", "GENE_OR_GENE_PRODUCT", 233, 243], ["CR3022", "CELL", 345, 351], ["CR3014", "GENE_OR_GENE_PRODUCT", 379, 385], ["CR3022", "SIMPLE_CHEMICAL", 390, 396], ["mAbs", "GENE_OR_GENE_PRODUCT", 502, 506], ["CoV", "ORGANISM", 584, 587], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 684, 692], ["chimeric mAbs", "PROTEIN", 44, 57], ["S-protein", "PROTEIN", 65, 74], ["mAb", "PROTEIN", 106, 109], ["RBD", "PROTEIN", 139, 142], ["CR3014 mAb", "PROTEIN", 233, 243], ["neutralizing MAb", "PROTEIN", 282, 298], ["mAbs", "PROTEIN", 374, 378], ["mAbs", "PROTEIN", 502, 506], ["mAb", "PROTEIN", 529, 532], ["SARS-CoV RBD", "PROTEIN", 684, 696], ["m396 mAb", "PROTEIN", 713, 721], ["CoV", "SPECIES", 584, 587], ["SARS-CoV", "SPECIES", 684, 692], ["chimeric mAbs", "TREATMENT", 44, 57], ["prophylactic administration", "TREATMENT", 198, 225], ["the CR3014 mAb", "TREATMENT", 229, 243], ["two mAbs CR3014", "TEST", 370, 385], ["the immune escape mechanism", "PROBLEM", 418, 445], ["these mAbs", "TREATMENT", 496, 506], ["a lower mAb level", "TREATMENT", 521, 538], ["passive immune prophylaxis", "TREATMENT", 554, 580], ["CoV infection", "PROBLEM", 584, 597], ["SARS", "PROBLEM", 684, 688], ["CoV RBD", "PROBLEM", 689, 696], ["immune escape", "OBSERVATION", 422, 435]]], ["They found that there is a remarkable alteration in the elbow angle between the unliganded and RBD-bound conformations of the Fab 396 ( Figure 5i ).", [["elbow", "ANATOMY", 56, 61], ["elbow", "ORGANISM_SUBDIVISION", 56, 61], ["RBD", "PROTEIN", 95, 98], ["Fab 396", "PROTEIN", 126, 133], ["Figure 5i", "PROTEIN", 136, 145], ["a remarkable alteration in the elbow angle", "PROBLEM", 25, 67], ["the Fab", "TEST", 122, 129], ["remarkable", "OBSERVATION_MODIFIER", 27, 37], ["alteration", "OBSERVATION", 38, 48], ["elbow", "ANATOMY", 56, 61]]], ["The unliganded Fab, depicted in red, shows an undeviating elbow angle, whereas the RBD-interacted Fab, depicted in blue, is significantly turned.", [["Fab", "GENE_OR_GENE_PRODUCT", 15, 18], ["elbow", "ORGANISM_SUBDIVISION", 58, 63], ["Fab", "GENE_OR_GENE_PRODUCT", 98, 101], ["unliganded Fab", "PROTEIN", 4, 18], ["RBD", "PROTEIN", 83, 86], ["interacted Fab", "PROTEIN", 87, 101], ["The unliganded Fab", "TEST", 0, 18], ["an undeviating elbow angle", "PROBLEM", 43, 69], ["the RBD", "PROBLEM", 79, 86], ["Fab", "OBSERVATION", 15, 18], ["elbow angle", "ANATOMY", 58, 69], ["RBD", "OBSERVATION", 83, 86]]], ["The mAb and the ACE2 bind to common residues within RBD consisting Thr-484, Thr-486, Thr-487, Gly-488, Tyr-491, Arg-426.", [["Thr-484", "CHEMICAL", 67, 74], ["Thr-486", "CHEMICAL", 76, 83], ["Tyr-491, Arg-426", "CHEMICAL", 103, 119], ["Thr", "CHEMICAL", 67, 70], ["Thr", "CHEMICAL", 76, 79], ["Thr", "CHEMICAL", 85, 88], ["Gly-488", "CHEMICAL", 94, 101], ["Tyr-491, Arg-426", "CHEMICAL", 103, 119], ["mAb", "GENE_OR_GENE_PRODUCT", 4, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 16, 20], ["Thr-484", "AMINO_ACID", 67, 74], ["Thr-486", "AMINO_ACID", 76, 83], ["Thr-487", "AMINO_ACID", 85, 92], ["Gly-488", "AMINO_ACID", 94, 101], ["Tyr-491", "AMINO_ACID", 103, 110], ["Arg-426", "AMINO_ACID", 112, 119], ["mAb", "PROTEIN", 4, 7], ["ACE2", "PROTEIN", 16, 20], ["RBD", "PROTEIN", 52, 55], ["The mAb", "TREATMENT", 0, 7], ["the ACE2 bind", "TREATMENT", 12, 25], ["RBD", "TEST", 52, 55], ["Thr", "TEST", 67, 70], ["Thr", "TEST", 76, 79], ["Thr", "TEST", 85, 88], ["Gly", "TEST", 94, 97], ["Tyr-", "TEST", 103, 107], ["Arg", "TEST", 112, 115]]], ["Hence, this segment is crucial for the interaction of RBD to both the mAb and the ACE2.", [["RBD", "GENE_OR_GENE_PRODUCT", 54, 57], ["mAb", "GENE_OR_GENE_PRODUCT", 70, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["RBD", "PROTEIN", 54, 57], ["mAb", "PROTEIN", 70, 73], ["ACE2", "PROTEIN", 82, 86], ["the interaction of RBD", "PROBLEM", 35, 57], ["ACE2", "ANATOMY", 82, 86]]], ["Figure 5 (ii) displays a superimposed illustration of the RBD binding with mAb, shown in yellow and with ACE2, shown in cyan.", [["RBD", "DISEASE", 58, 61], ["mAb", "GENE_OR_GENE_PRODUCT", 75, 78], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["RBD", "PROTEIN", 58, 61], ["mAb", "PROTEIN", 75, 78], ["ACE2", "PROTEIN", 105, 109], ["a superimposed illustration of the RBD binding", "PROBLEM", 23, 69], ["mAb", "TREATMENT", 75, 78], ["RBD", "OBSERVATION", 58, 61]]], ["Figure 5 (iii-iv) presents the binding domain of the mAb and the ACE2, respectively [46] .J o u r n a l P r e -p r o o fZhu, et al. [47] reported that two human mAbs, m396 and S230.15, effectively neutralized related isolates from the SARS-CoV infection, namely Urbani, Tor2 and from palm civets, namely SZ3, SZ16.", [["SARS-CoV infection", "DISEASE", 235, 253], ["mAb", "GENE_OR_GENE_PRODUCT", 53, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["human", "ORGANISM", 155, 160], ["SARS-CoV", "ORGANISM", 235, 243], ["Tor2", "GENE_OR_GENE_PRODUCT", 270, 274], ["binding domain", "PROTEIN", 31, 45], ["mAb", "PROTEIN", 53, 56], ["ACE2", "PROTEIN", 65, 69], ["human mAbs", "PROTEIN", 155, 165], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160], ["SARS-CoV", "SPECIES", 235, 243], ["the ACE2", "TEST", 61, 69], ["effectively neutralized related isolates", "PROBLEM", 185, 225], ["the SARS", "PROBLEM", 231, 239], ["CoV infection", "PROBLEM", 240, 253], ["CoV", "ANATOMY", 240, 243], ["infection", "OBSERVATION", 244, 253]]], ["Both mAbs competed with ACE2 for interaction with the S-protein RBD ( Figure 5B ).Comparison between the mAbs and the mechanism of interactionCoughlin and Prabhakar [50] studied a number of human mAbs binding the S-protein RBD.Comparison between the mAbs and the mechanism of interactionThe interaction of SARS-CoV S-protein and mAbs are demonstrated in Figure 6A (i).", [["SARS", "DISEASE", 306, 310], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["human", "ORGANISM", 190, 195], ["mAbs", "GENE_OR_GENE_PRODUCT", 196, 200], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 306, 314], ["mAbs", "GENE_OR_GENE_PRODUCT", 329, 333], ["mAbs", "PROTEIN", 5, 9], ["ACE2", "PROTEIN", 24, 28], ["S-protein RBD", "PROTEIN", 54, 67], ["Figure 5B", "PROTEIN", 70, 79], ["mAbs", "PROTEIN", 105, 109], ["human mAbs", "PROTEIN", 190, 200], ["S-protein RBD", "PROTEIN", 213, 226], ["mAbs", "PROTEIN", 250, 254], ["SARS-CoV S-protein", "PROTEIN", 306, 324], ["mAbs", "PROTEIN", 329, 333], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 190, 195], ["SARS-CoV", "SPECIES", 306, 314], ["the S-protein RBD", "PROBLEM", 50, 67], ["the mAbs", "TREATMENT", 101, 109], ["the S-protein RBD", "PROBLEM", 209, 226], ["the mAbs", "TREATMENT", 246, 254], ["SARS", "TEST", 306, 310], ["CoV S-protein", "TEST", 311, 324], ["mAbs", "TEST", 329, 333]]], ["As both SARS-CoV and SARS-CoV2 used ACE2 as receptor, promising blocking compounds or approaches assayed to inhibit SARS-CoV entry could be explored against SARS-CoV2 [51] .Comparison between the mAbs and the mechanism of interactionIndeed, the S-protein RBD with 193 residue length is the crucial site for interaction of neutralizing mAbs.", [["SARS", "DISEASE", 116, 120], ["SARS-CoV", "ORGANISM", 8, 16], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 21, 30], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["SARS-CoV", "ORGANISM", 116, 124], ["S-protein RBD", "GENE_OR_GENE_PRODUCT", 245, 258], ["CoV2", "DNA", 26, 30], ["ACE2", "PROTEIN", 36, 40], ["mAbs", "PROTEIN", 196, 200], ["S-protein RBD", "PROTEIN", 245, 258], ["neutralizing mAbs", "PROTEIN", 322, 339], ["SARS-CoV", "SPECIES", 8, 16], ["SARS-CoV", "SPECIES", 116, 124], ["SARS", "PROBLEM", 21, 25], ["CoV2", "TREATMENT", 26, 30], ["ACE2 as receptor", "TREATMENT", 36, 52], ["promising blocking compounds", "TREATMENT", 54, 82], ["SARS", "PROBLEM", 116, 120], ["CoV entry", "TEST", 121, 130], ["SARS", "PROBLEM", 157, 161], ["the mAbs", "TEST", 192, 200], ["the S-protein RBD", "PROBLEM", 241, 258], ["neutralizing mAbs", "TREATMENT", 322, 339], ["length", "OBSERVATION_MODIFIER", 276, 282], ["neutralizing mAbs", "OBSERVATION", 322, 339]]], ["Several mAbs interact with various epitopes on RBD; e.g. the SARS-CoV neutralizing mAbs, namely CR3014 and CR3022 interacted with the SARS-CoV RBD in a noncompetitive manner and neutralized the CoV in a synergistic mode [41] .", [["CR3022", "CHEMICAL", 107, 113], ["mAbs", "GENE_OR_GENE_PRODUCT", 8, 12], ["RBD", "GENE_OR_GENE_PRODUCT", 47, 50], ["SARS-CoV", "ORGANISM", 61, 69], ["CR3014", "GENE_OR_GENE_PRODUCT", 96, 102], ["CR3022", "SIMPLE_CHEMICAL", 107, 113], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 134, 142], ["mAbs", "PROTEIN", 8, 12], ["epitopes", "PROTEIN", 35, 43], ["RBD", "PROTEIN", 47, 50], ["SARS-CoV neutralizing mAbs", "PROTEIN", 61, 87], ["CR3014", "PROTEIN", 96, 102], ["CR3022", "PROTEIN", 107, 113], ["SARS-CoV RBD", "PROTEIN", 134, 146], ["SARS-CoV", "SPECIES", 61, 69], ["SARS-CoV", "SPECIES", 134, 142], ["various epitopes on RBD", "PROBLEM", 27, 50], ["the SARS", "TEST", 57, 65], ["CoV neutralizing mAbs", "TEST", 66, 87], ["the SARS", "PROBLEM", 130, 138], ["CoV RBD", "PROBLEM", 139, 146]]], ["Tian, et al. [52] J o u r n a l P r e -p r o o f modeled the structure of SARS-CoV2 S-protein RBD and reported its interaction with a number of neutralizing mAbs, and displayed that the molecular dynamic outcomes complete the binding of SARS-CoV2 S-protein RBD and some SARS-CoV mAbs ( Figure 6A(ii) ).", [["SARS", "DISEASE", 74, 78], ["SARS-CoV mAbs", "GENE_OR_GENE_PRODUCT", 270, 283], ["SARS-CoV2 S-protein", "PROTEIN", 74, 93], ["RBD", "PROTEIN", 94, 97], ["neutralizing mAbs", "PROTEIN", 144, 161], ["SARS-CoV2 S-protein", "PROTEIN", 237, 256], ["RBD", "PROTEIN", 257, 260], ["SARS-CoV mAbs", "PROTEIN", 270, 283], ["Figure 6A(ii)", "PROTEIN", 286, 299], ["SARS-CoV", "SPECIES", 270, 278], ["the structure", "TEST", 57, 70], ["SARS", "PROBLEM", 74, 78], ["protein RBD", "PROBLEM", 86, 97], ["neutralizing mAbs", "TREATMENT", 144, 161], ["SARS", "PROBLEM", 237, 241], ["CoV2", "TEST", 242, 246], ["protein RBD", "PROBLEM", 249, 260], ["some SARS", "TEST", 265, 274], ["CoV mAbs", "TEST", 275, 283], ["SARS", "OBSERVATION", 74, 78]]], ["For example, amino acids in RBD of SARS-CoV that contribute in the formation of polar forces with a neutralizing mAb m396 are firmly conserved in SARS-CoV2 S-protein RBD ( Figure 6A(iii) ).", [["amino acids", "CHEMICAL", 13, 24], ["SARS", "DISEASE", 35, 39], ["amino acids", "CHEMICAL", 13, 24], ["amino acids", "AMINO_ACID", 13, 24], ["SARS-CoV", "ORGANISM", 35, 43], ["RBD", "PROTEIN", 28, 31], ["mAb m396", "PROTEIN", 113, 121], ["SARS-CoV2 S-protein", "PROTEIN", 146, 165], ["RBD", "PROTEIN", 166, 169], ["Figure 6A(iii)", "PROTEIN", 172, 186], ["SARS-CoV", "SPECIES", 35, 43], ["amino acids", "TEST", 13, 24], ["SARS", "PROBLEM", 35, 39], ["CoV", "PROBLEM", 40, 43], ["a neutralizing mAb m", "TEST", 98, 118], ["SARS", "TEST", 146, 150], ["protein RBD", "TEST", 158, 169], ["polar forces", "OBSERVATION", 80, 92]]], ["Afterwards ELISA assay was done to examine the binding ability of SARS-CoV-specific mAbs to SARS-CoV2 S-protein RBD ( Figure 6A(iv) ).", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 66, 74], ["SARS-CoV-specific mAbs", "PROTEIN", 66, 88], ["SARS-CoV2 S-protein RBD", "PROTEIN", 92, 115], ["Figure 6A(iv)", "PROTEIN", 118, 131], ["SARS-CoV", "SPECIES", 66, 74], ["ELISA assay", "TEST", 11, 22], ["SARS", "PROBLEM", 66, 70], ["CoV", "TEST", 71, 74], ["specific mAbs", "TEST", 75, 88], ["SARS", "TEST", 92, 96], ["CoV2 S", "TEST", 97, 103]]], ["Interestingly, it was shown that most of these mAbs failed to bind SARS-CoV2 S-protein RBD [52] .Comparison between the mAbs and the mechanism of interactionBased on the comparatively high identity of RBD in SARS-CoV2 and SARS-CoV, it is assumed to assay the cross-reactivity of anti-SARS-CoV mAbs with SARS-CoV2 S-protein RBD, which could show outstanding applications for rapid and sensitive advancement of ESV-based therapeutic systems against SARS-CoV2.", [["RBD", "DISEASE", 201, 204], ["SARS", "DISEASE", 208, 212], ["SARS", "DISEASE", 447, 451], ["mAbs", "GENE_OR_GENE_PRODUCT", 47, 51], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 208, 217], ["SARS-CoV", "ORGANISM", 222, 230], ["anti-SARS-CoV mAbs", "GENE_OR_GENE_PRODUCT", 279, 297], ["ESV", "SIMPLE_CHEMICAL", 409, 412], ["SARS-CoV2", "SIMPLE_CHEMICAL", 447, 456], ["mAbs", "PROTEIN", 47, 51], ["SARS-CoV2 S-protein", "PROTEIN", 67, 86], ["RBD", "PROTEIN", 87, 90], ["mAbs", "PROTEIN", 120, 124], ["RBD", "PROTEIN", 201, 204], ["anti-SARS-CoV mAbs", "PROTEIN", 279, 297], ["SARS-CoV2 S-protein RBD", "PROTEIN", 303, 326], ["SARS-CoV", "SPECIES", 222, 230], ["anti-SARS-CoV", "SPECIES", 279, 292], ["SARS-CoV2", "SPECIES", 447, 456], ["these mAbs", "PROBLEM", 41, 51], ["bind SARS", "TEST", 62, 71], ["CoV2 S-protein RBD", "TEST", 72, 90], ["the mAbs", "TEST", 116, 124], ["RBD", "PROBLEM", 201, 204], ["SARS", "PROBLEM", 208, 212], ["SARS", "PROBLEM", 222, 226], ["anti-SARS", "TEST", 279, 288], ["CoV mAbs", "TEST", 289, 297], ["SARS", "PROBLEM", 303, 307], ["protein RBD", "PROBLEM", 315, 326], ["ESV", "TEST", 409, 412], ["SARS", "PROBLEM", 447, 451], ["RBD", "OBSERVATION", 201, 204]]], ["It was revealed that SARS-CoV-specific human mAbs, namely CR3022, could potentially interact with SARS-CoV2 S-protein RBD ( Figure 6B ) [52] .", [["CR3022", "CHEMICAL", 58, 64], ["SARS-CoV", "ORGANISM", 21, 29], ["human", "ORGANISM", 39, 44], ["mAbs", "GENE_OR_GENE_PRODUCT", 45, 49], ["CR3022", "GENE_OR_GENE_PRODUCT", 58, 64], ["SARS-CoV-specific human mAbs", "PROTEIN", 21, 49], ["CR3022", "PROTEIN", 58, 64], ["SARS-CoV2 S-protein", "PROTEIN", 98, 117], ["RBD", "PROTEIN", 118, 121], ["Figure 6B", "PROTEIN", 124, 133], ["human", "SPECIES", 39, 44], ["SARS-CoV", "SPECIES", 21, 29], ["human", "SPECIES", 39, 44], ["SARS", "PROBLEM", 21, 25], ["CoV", "TEST", 26, 29], ["specific human mAbs", "TEST", 30, 49], ["SARS", "TEST", 98, 102], ["CoV2 S", "TEST", 103, 109]]], ["As, the epitope of this mAb does not overlap with the ACE2 binding domain, it may be indicated that CR3022 show the potential to be used as a potential candidate therapeutic, alone or in integration with other mAbs, for the inhibiting and treatment of COVID- 19 .", [["CR3022", "CHEMICAL", 100, 106], ["CR3022", "CHEMICAL", 100, 106], ["COVID- 19", "CHEMICAL", 252, 261], ["mAb", "GENE_OR_GENE_PRODUCT", 24, 27], ["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["CR3022", "SIMPLE_CHEMICAL", 100, 106], ["mAb", "PROTEIN", 24, 27], ["ACE2 binding domain", "PROTEIN", 54, 73], ["mAbs", "PROTEIN", 210, 214], ["this mAb", "TREATMENT", 19, 27], ["other mAbs", "TREATMENT", 204, 214], ["COVID", "TEST", 252, 257]]], ["Surprisingly, a number of the most efficient SARS-CoV-specific neutralizing mAbs such as S230, m396, CR3014 that bind the ACE2 binding domain do not show an ability to bind SARS-CoV2 S-protein, indicating that dissimilarity in the RBD of SARS-CoV and SARS-CoV2 shows a crucial effect for the crossreactivity of neutralizing mAbs, and that it is still important to design and develop potential mAbs that could interact specifically and selectively to SARS-CoV2 S-protein RBD.", [["SARS", "DISEASE", 238, 242], ["SARS", "DISEASE", 251, 255], ["SARS-CoV", "ORGANISM", 45, 53], ["S230", "GENE_OR_GENE_PRODUCT", 89, 93], ["m396", "GENE_OR_GENE_PRODUCT", 95, 99], ["CR3014", "GENE_OR_GENE_PRODUCT", 101, 107], ["ACE2", "GENE_OR_GENE_PRODUCT", 122, 126], ["SARS-CoV", "ORGANISM", 238, 246], ["SARS-CoV2", "ORGANISM", 251, 260], ["SARS-CoV2 S-", "GENE_OR_GENE_PRODUCT", 450, 462], ["SARS-CoV-specific neutralizing mAbs", "PROTEIN", 45, 80], ["S230", "PROTEIN", 89, 93], ["m396", "PROTEIN", 95, 99], ["CR3014", "PROTEIN", 101, 107], ["ACE2 binding domain", "PROTEIN", 122, 141], ["SARS-CoV2 S-protein", "PROTEIN", 173, 192], ["RBD", "PROTEIN", 231, 234], ["neutralizing mAbs", "PROTEIN", 311, 328], ["mAbs", "PROTEIN", 393, 397], ["SARS-CoV2 S-protein", "PROTEIN", 450, 469], ["RBD", "PROTEIN", 470, 473], ["SARS-CoV", "SPECIES", 238, 246], ["specific neutralizing mAbs", "TEST", 54, 80], ["the ACE2 binding domain", "TEST", 118, 141], ["bind SARS", "TEST", 168, 177], ["CoV2 S-protein", "TEST", 178, 192], ["dissimilarity in the RBD of SARS", "PROBLEM", 210, 242], ["CoV", "TEST", 243, 246], ["SARS", "PROBLEM", 251, 255], ["neutralizing mAbs", "TREATMENT", 311, 328], ["potential mAbs", "PROBLEM", 383, 397], ["protein RBD", "PROBLEM", 462, 473]]], ["However in-depth analysis has shown that the vaccine is not working for the SARS-CoV2 and cannot stop the outbreak and infection of this virus [52] .", [["SARS", "DISEASE", 76, 80], ["infection", "DISEASE", 119, 128], ["depth analysis", "TEST", 11, 25], ["the vaccine", "TREATMENT", 41, 52], ["this virus", "PROBLEM", 132, 142]]], ["Therefore, the development of potential ESV against SARS-CoV2 has received a great deal of interest in preventing CoV infection.", [["SARS", "DISEASE", 52, 56], ["CoV infection", "DISEASE", 114, 127], ["ESV", "SIMPLE_CHEMICAL", 40, 43], ["SARS-CoV2", "ORGANISM", 52, 61], ["CoV", "ORGANISM", 114, 117], ["ESV", "SPECIES", 40, 43], ["CoV", "SPECIES", 114, 117], ["SARS", "PROBLEM", 52, 56], ["CoV infection", "PROBLEM", 114, 127], ["preventing", "UNCERTAINTY", 103, 113], ["CoV infection", "OBSERVATION", 114, 127]]], ["The conventional vaccines are currently produced from weak or inactivated toxic of the virus or parts of the virus, including proteins, and the immune system recognizes the virus as an invader at the time of injection and generates Abs to prevent subsequent invasions.", [["Abs", "PROTEIN", 232, 235], ["The conventional vaccines", "TREATMENT", 0, 25], ["weak or inactivated toxic of the virus", "PROBLEM", 54, 92], ["the virus", "PROBLEM", 105, 114], ["proteins", "TEST", 126, 134], ["the virus", "PROBLEM", 169, 178], ["subsequent invasions", "PROBLEM", 247, 267], ["invasions", "OBSERVATION", 258, 267]]], ["However, the point is that growing enough viruses or purifying enough proteins to vaccinate millions of people against SARS-CoV2 can take months or even years.", [["SARS", "DISEASE", 119, 123], ["people", "ORGANISM", 104, 110], ["SARS-CoV2", "ORGANISM", 119, 128], ["people", "SPECIES", 104, 110], ["growing enough viruses", "PROBLEM", 27, 49], ["SARS", "PROBLEM", 119, 123], ["viruses", "OBSERVATION", 42, 49]]], ["Therefore, some other promising strategies should be considered to develop vaccine against SARS-CoV2 in a less labor and time-intensive manner.", [["SARS", "DISEASE", 91, 95], ["vaccine", "TREATMENT", 75, 82], ["SARS", "PROBLEM", 91, 95]]], ["One approach can be done thorough transformation of virus's RNA (SARS-CoV or MERS-CoV ESV) into DNA and determining some regions of the virus based on molecular simulations, which potentially stimulate the immune system to produce Abs [57] .", [["immune system", "ANATOMY", 206, 219], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 65, 73], ["MERS-CoV ESV", "GENE_OR_GENE_PRODUCT", 77, 89], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["Abs", "PROTEIN", 231, 234], ["SARS-CoV", "SPECIES", 65, 73], ["virus's RNA", "PROBLEM", 52, 63], ["MERS", "PROBLEM", 77, 81], ["DNA", "PROBLEM", 96, 99], ["the virus", "PROBLEM", 132, 141], ["molecular simulations", "TEST", 151, 172], ["virus", "OBSERVATION", 136, 141]]], ["Those identified segments of DNA are then introduced into the bacteria to produce large amounts of protein fragments for development of ESV.", [["DNA", "CELLULAR_COMPONENT", 29, 32], ["protein fragments", "PROTEIN", 99, 116], ["ESV", "PROTEIN", 136, 139], ["segments of DNA", "PROBLEM", 17, 32], ["the bacteria", "PROBLEM", 58, 70], ["large amounts of protein fragments", "PROBLEM", 82, 116], ["ESV", "TEST", 136, 139], ["segments", "OBSERVATION_MODIFIER", 17, 25], ["bacteria", "OBSERVATION", 62, 70], ["large", "OBSERVATION_MODIFIER", 82, 87], ["amounts", "OBSERVATION_MODIFIER", 88, 95], ["protein fragments", "OBSERVATION", 99, 116], ["ESV", "OBSERVATION", 136, 139]]], ["This method dramatically shortens the time needed to produce a potential ESV against SARS-CoV2.J o u r n a l P r e -p r o o fAnother approach is to develop a mRNA that stimulates the body to produce vaccine components [58] .", [["body", "ANATOMY", 183, 187], ["body", "ORGANISM_SUBDIVISION", 183, 187], ["mRNA", "RNA", 158, 162], ["fAnother approach", "TREATMENT", 124, 141], ["a mRNA", "PROBLEM", 156, 162]]], ["Scientists have selected parts of SARS-CoV2 that may trigger a severe immune response against the virus.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV2", "ORGANISM", 34, 43], ["a severe immune response", "PROBLEM", 61, 85], ["the virus", "PROBLEM", 94, 103]]], ["The mRNA vaccine dictates the human cells which viral proteins should be biosynthesized.", [["cells", "ANATOMY", 36, 41], ["human", "ORGANISM", 30, 35], ["cells", "CELL", 36, 41], ["human cells", "CELL_TYPE", 30, 41], ["viral proteins", "PROTEIN", 48, 62], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["The mRNA vaccine", "TREATMENT", 0, 16], ["the human cells", "TREATMENT", 26, 41], ["viral proteins", "PROBLEM", 48, 62]]], ["Since the body biosynthesize protein by vaccine mRNA, researchers can bypass the time-consuming and costly process of producing vaccine proteins.J o u r n a l P r e -p r o o fThis strategy can be used to design vaccines against future viruses or other infectious and contagious diseases.", [["body", "ANATOMY", 10, 14], ["infectious and contagious diseases", "DISEASE", 252, 286], ["body", "ORGANISM_SUBDIVISION", 10, 14], ["vaccine mRNA", "RNA", 40, 52], ["vaccine proteins", "PROTEIN", 128, 144], ["the body biosynthesize protein", "TREATMENT", 6, 36], ["vaccine mRNA", "TREATMENT", 40, 52], ["producing vaccine proteins", "TREATMENT", 118, 144], ["a l P r e -p r o o fThis strategy", "TREATMENT", 155, 188], ["design vaccines", "TREATMENT", 204, 219], ["future viruses", "PROBLEM", 228, 242], ["other infectious and contagious diseases", "PROBLEM", 246, 286], ["infectious", "OBSERVATION_MODIFIER", 252, 262], ["contagious", "OBSERVATION_MODIFIER", 267, 277]]], ["Meanwhile, other mRNA vaccines against SARS-CoV2 and other diseases are still being tested.J o u r n a l P r e -p r o o fThe mRNA vaccine can be ready for initial immunization testing within the next few months [58] .", [["SARS-CoV2", "DISEASE", 39, 48], ["SARS-CoV2", "ORGANISM", 39, 48], ["SARS-CoV2", "SPECIES", 39, 48], ["other mRNA vaccines", "TREATMENT", 11, 30], ["SARS", "PROBLEM", 39, 43], ["other diseases", "PROBLEM", 53, 67], ["The mRNA vaccine", "TREATMENT", 121, 137], ["initial immunization testing", "TEST", 155, 183], ["diseases", "OBSERVATION", 59, 67]]], ["However, researchers must find some pharmaceutical companies to produce the large amounts of mRNA that are essential for the general public.", [["mRNA", "RNA", 93, 97], ["large", "OBSERVATION_MODIFIER", 76, 81]]], ["Indeed, the experience with MERS vaccine is an example of how long it typically takes to make sure a vaccine is safe and effective.J o u r n a l P r e -p r o o fThe company conducted initial safety testing of the MERS vaccine in a phase I clinical trial from February 2016 to May 2017 [59] .", [["MERS vaccine", "TREATMENT", 28, 40], ["a vaccine", "TREATMENT", 99, 108], ["initial safety testing", "TEST", 183, 205], ["the MERS vaccine", "TREATMENT", 209, 225]]], ["The vaccine was switched to Phase II testing in August 2018 to test the safety of a larger number of people and to determine whether the vaccine stimulates the immune system to produce protective Abs [60] .", [["immune system", "ANATOMY", 160, 173], ["people", "ORGANISM", 101, 107], ["Abs", "PROTEIN", 196, 199], ["people", "SPECIES", 101, 107], ["The vaccine", "TREATMENT", 0, 11], ["Phase II testing", "TEST", 28, 44], ["the vaccine", "TREATMENT", 133, 144]]], ["Even if everything goes smoothly, the MERS vaccine must pass the phase III safety and efficacy test before being approved by the US Food and Drug Administration, and vaccines and medicines will then become publicly available [60] .", [["the MERS vaccine", "TREATMENT", 34, 50], ["efficacy test", "TEST", 86, 99], ["Drug Administration", "TREATMENT", 141, 160], ["vaccines", "TREATMENT", 166, 174], ["medicines", "TREATMENT", 179, 188]]], ["Using some well-developed devices, researchers can perform experiments over several weeks.", [["devices", "TREATMENT", 26, 33]]], ["The laboratory device may be improved in the next few weeks.", [["The laboratory device", "TREATMENT", 0, 21], ["improved", "OBSERVATION_MODIFIER", 29, 37]]], ["Indeed, the emergence of the SARS-CoV2 have forced the researchers to look into speeding up their efforts.", [["SARS", "DISEASE", 29, 33], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 29, 38], ["SARS-CoV2", "DNA", 29, 38]]], ["However, we estimate that it will take at least a year to prepare the SARS-CoV2 ESV.J o u r n a l P r e -p r o o fAlthough, vaccine helps people avoid becoming infected with pathogens, it may not help as soon as they become infected.", [["SARS", "DISEASE", 70, 74], ["people", "ORGANISM", 138, 144], ["people", "SPECIES", 138, 144], ["fAlthough", "PROBLEM", 113, 122], ["vaccine", "TREATMENT", 124, 131], ["pathogens", "PROBLEM", 174, 183], ["infected", "OBSERVATION", 160, 168], ["infected", "OBSERVATION", 224, 232]]], ["However, protective mAbs can both prevent and treat the infection.", [["infection", "DISEASE", 56, 65], ["protective mAbs", "PROTEIN", 9, 24], ["protective mAbs", "TREATMENT", 9, 24], ["the infection", "PROBLEM", 52, 65], ["infection", "OBSERVATION", 56, 65]]], ["Abs in the blood of people who have recovered from infection and become resistant to the virus or bacteria that cause the disease often stay in the body for several years or decades, and when mAbs later become infected, they can protect the person.", [["blood", "ANATOMY", 11, 16], ["body", "ANATOMY", 148, 152], ["infection", "DISEASE", 51, 60], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["people", "ORGANISM", 20, 26], ["body", "ORGANISM_SUBDIVISION", 148, 152], ["Abs", "PROTEIN", 0, 3], ["mAbs", "PROTEIN", 192, 196], ["people", "SPECIES", 20, 26], ["person", "SPECIES", 241, 247], ["infection", "PROBLEM", 51, 60], ["the virus", "PROBLEM", 85, 94], ["bacteria", "PROBLEM", 98, 106], ["the disease", "PROBLEM", 118, 129], ["infected", "PROBLEM", 210, 218], ["infection", "OBSERVATION", 51, 60], ["infected", "OBSERVATION", 210, 218]]], ["However, the important thing is that these mAbs can protect the individual against other pathogens as well.", [["mAbs", "GENE_OR_GENE_PRODUCT", 43, 47], ["mAbs", "PROTEIN", 43, 47], ["these mAbs", "TREATMENT", 37, 47], ["other pathogens", "PROBLEM", 83, 98], ["pathogens", "OBSERVATION", 89, 98]]], ["It takes weeks to months for the ESV to stimulate the immune system to produce a protective level of mAbs.", [["immune system", "ANATOMY", 54, 67], ["mAbs", "GENE_OR_GENE_PRODUCT", 101, 105], ["mAbs", "PROTEIN", 101, 105], ["the ESV", "TREATMENT", 29, 36]]], ["For example, Ebola vaccines take at least a week to stimulate Ab production, but in the end, they provide immediate protection.", [["Ebola", "DISEASE", 13, 18], ["Ebola", "ORGANISM", 13, 18], ["Ab", "GENE_OR_GENE_PRODUCT", 62, 64], ["Ebola", "SPECIES", 13, 18], ["Ebola vaccines", "TREATMENT", 13, 27]]], ["The companies are now producing potential mAbs to fight the SARS-CoV2 based on the information that they have learned from the SARS-CoV and MERS-CoV projects.ConclusionMost natural and synthetic compounds are involved in enhancing vaccine efficacy, but toxicity is the most important problem in introducing them for use in living organisms.", [["SARS", "DISEASE", 60, 64], ["SARS", "DISEASE", 127, 131], ["toxicity", "DISEASE", 253, 261], ["MERS-CoV", "ORGANISM", 140, 148], ["mAbs", "PROTEIN", 42, 46], ["SARS-CoV", "SPECIES", 127, 135], ["the SARS", "PROBLEM", 123, 131], ["enhancing vaccine efficacy", "TREATMENT", 221, 247], ["toxicity", "PROBLEM", 253, 261]]], ["Therefore, the design and development of potential platforms is based on their safety and efficacy, knowledge of the functional pathways, the activation of innate and acquired immune system, and the ability to conformational comparison between SARS-CoV2 S-protein and SARS-CoV S-protein, (i) Single protomer of SARS-CoV2 S-protein with the RBD, (ii) RBDs of SARS-CoV2 and SARS-CoV and the NTD of SARS-CoV2, (iii) Structural alignments of different domains from SARS-CoV2 Sprotein and SARS-CoV S-protein [34] .", [["SARS", "DISEASE", 358, 362], ["SARS", "DISEASE", 396, 400], ["SARS-CoV2 S-", "GENE_OR_GENE_PRODUCT", 244, 256], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 268, 276], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 311, 320], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 358, 367], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 372, 380], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 396, 405], ["SARS-CoV2 Sprotein", "GENE_OR_GENE_PRODUCT", 461, 479], ["SARS-CoV S-", "GENE_OR_GENE_PRODUCT", 484, 495], ["SARS-CoV2 S-protein", "PROTEIN", 244, 263], ["SARS-CoV S-protein", "PROTEIN", 268, 286], ["SARS-CoV2 S-protein", "PROTEIN", 311, 330], ["RBD", "PROTEIN", 340, 343], ["RBDs", "PROTEIN", 350, 354], ["CoV2", "PROTEIN", 363, 367], ["CoV", "PROTEIN", 377, 380], ["NTD", "PROTEIN", 389, 392], ["SARS-CoV2 Sprotein", "PROTEIN", 461, 479], ["SARS-CoV S-protein", "PROTEIN", 484, 502], ["SARS-CoV", "SPECIES", 268, 276], ["SARS-CoV", "SPECIES", 372, 380], ["SARS-CoV", "SPECIES", 484, 492], ["SARS", "TEST", 244, 248], ["protein", "TEST", 256, 263], ["SARS", "TEST", 268, 272], ["CoV S", "TEST", 273, 278], ["SARS", "TEST", 311, 315], ["CoV2 S", "TEST", 316, 322], ["the RBD", "TEST", 336, 343], ["SARS", "PROBLEM", 358, 362], ["CoV2", "TEST", 363, 367], ["SARS", "PROBLEM", 372, 376], ["CoV", "PROBLEM", 377, 380], ["SARS", "PROBLEM", 396, 400], ["different domains", "PROBLEM", 438, 455], ["SARS", "TEST", 461, 465], ["CoV2", "TEST", 466, 470], ["Sprotein", "TEST", 471, 479], ["SARS", "TEST", 484, 488], ["CoV S-protein", "TEST", 489, 502]]], ["(B) Titration of IgGs CR3006, CR3013, CR3014, and negative control IgG (Control) in an S565 fragment-coated ELISA [44] .", [["IgGs CR3006", "SIMPLE_CHEMICAL", 17, 28], ["CR3013", "SIMPLE_CHEMICAL", 30, 36], ["CR3014", "SIMPLE_CHEMICAL", 38, 44], ["IgG", "GENE_OR_GENE_PRODUCT", 67, 70], ["IgGs CR3006", "PROTEIN", 17, 28], ["CR3013", "PROTEIN", 30, 36], ["CR3014", "PROTEIN", 38, 44], ["IgG", "PROTEIN", 67, 70], ["IgGs", "TEST", 17, 21], ["CR3013", "TEST", 30, 36], ["CR3014", "TEST", 38, 44]]], ["(C) Wild-type SARS-CoV and a CR3014-neutralization escape variant (E6) with combined CR3014 and CR3022 mAbs [45] .", [["SARS-CoV", "ORGANISM", 14, 22], ["CR3014", "GENE_OR_GENE_PRODUCT", 29, 35], ["E6", "ORGANISM", 67, 69], ["CR3014", "PROTEIN", 29, 35], ["E6", "PROTEIN", 67, 69], ["CR3014", "PROTEIN", 85, 91], ["CR3022 mAbs", "PROTEIN", 96, 107], ["SARS-CoV", "SPECIES", 14, 22], ["Wild-type SARS", "PROBLEM", 4, 18], ["a CR3014", "TEST", 27, 35], ["CR3022 mAbs", "TEST", 96, 107]]], ["[43] [44] [45] .Figure 5.", [["[43] [44] [45]", "SIMPLE_CHEMICAL", 0, 14]]], ["(A)interaction of m396 and ACE2 with RBD, (i) Superimposed illustration of RBDunliganded (red) and RBD-interacted Fab (blue), (ii) Comparison of the RBD-Fab and the RBD-ACE2 interaction, (iii, iv) Conformational footprints of the mAb and ACE2 RBD, respectively demonstrated as red balls on the RBD surface [46] .", [["surface", "ANATOMY", 298, 305], ["m396", "GENE_OR_GENE_PRODUCT", 18, 22], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["RBD-Fab", "GENE_OR_GENE_PRODUCT", 149, 156], ["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["ACE2", "GENE_OR_GENE_PRODUCT", 238, 242], ["m396", "PROTEIN", 18, 22], ["ACE2", "PROTEIN", 27, 31], ["RBD", "PROTEIN", 37, 40], ["RBDunliganded (red)", "PROTEIN", 75, 94], ["RBD", "PROTEIN", 99, 102], ["Fab", "PROTEIN", 114, 117], ["RBD", "PROTEIN", 149, 152], ["Fab", "PROTEIN", 153, 156], ["RBD", "PROTEIN", 165, 168], ["ACE2", "PROTEIN", 169, 173], ["mAb", "PROTEIN", 230, 233], ["ACE2", "PROTEIN", 238, 242], ["RBD", "PROTEIN", 243, 246], ["RBD", "PROTEIN", 294, 297], ["RBD", "PROBLEM", 37, 40], ["RBDunliganded (red) and RBD", "PROBLEM", 75, 102], ["the RBD", "TEST", 145, 152], ["Fab", "TEST", 153, 156], ["ACE2 interaction", "PROBLEM", 169, 185], ["the mAb", "TREATMENT", 226, 233], ["ACE2 RBD", "PROBLEM", 238, 246], ["red balls", "TEST", 277, 286], ["balls", "OBSERVATION_MODIFIER", 281, 286]]], ["(B) M396 considerably neutralizes viruses pseudotyped with S-protein [47] .", [["M396", "CHEMICAL", 4, 8], ["(B) M396", "CHEMICAL", 0, 8], ["neutralizes viruses", "PROBLEM", 22, 41], ["S-protein", "TEST", 59, 68]]], ["[35, 46, 51, [53] [54] [55] , (ii) The docking of SARS-CoV2 Sprotein RBD binding to specific mAbs, (iii) The comparison of the residues involved in the interaction of two mAbs with SARS-CoV-RBD and SARS-CoV2 S-protein RBD, (iv) Binding of Table 1 .", [["[53] [54] [55]", "SIMPLE_CHEMICAL", 13, 27], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 181, 189], ["RBD", "PROTEIN", 69, 72], ["mAbs", "PROTEIN", 93, 97], ["mAbs", "PROTEIN", 171, 175], ["SARS-CoV-RBD and SARS-CoV2 S-protein RBD", "PROTEIN", 181, 221], ["SARS", "PROBLEM", 50, 54], ["Sprotein RBD binding", "PROBLEM", 60, 80], ["two mAbs", "TEST", 167, 175], ["SARS", "TEST", 181, 185], ["CoV", "TEST", 186, 189], ["RBD", "PROBLEM", 190, 193], ["SARS", "TEST", 198, 202]]], ["Six RBD residues of S-protein which are critical for the interaction of SARS-CoV and SARS-CoV2 with ACE2 [29, 31] .", [["SARS", "DISEASE", 72, 76], ["SARS", "DISEASE", 85, 89], ["S-protein", "GENE_OR_GENE_PRODUCT", 20, 29], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 72, 80], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 85, 94], ["ACE2", "GENE_OR_GENE_PRODUCT", 100, 104], ["RBD residues", "PROTEIN", 4, 16], ["S-protein", "PROTEIN", 20, 29], ["ACE2", "PROTEIN", 100, 104], ["SARS-CoV", "SPECIES", 72, 80], ["Six RBD residues of S-protein", "PROBLEM", 0, 29], ["SARS", "PROBLEM", 72, 76], ["SARS", "PROBLEM", 85, 89], ["ACE2", "TEST", 100, 104], ["RBD residues", "OBSERVATION", 4, 16], ["S-protein", "OBSERVATION", 20, 29]]]], "6918c10814e703ffeee070428c3a9334fbafe5e2": [["63Tuberculosis (TB) is a major public health concern worldwide representing the 64 principal cause of death from a single infectious agent, Mycobacterium tuberculosis.", [["63Tuberculosis", "CHEMICAL", 0, 14], ["TB", "DISEASE", 16, 18], ["death", "DISEASE", 102, 107], ["Mycobacterium tuberculosis", "DISEASE", 140, 166], ["Mycobacterium tuberculosis", "ORGANISM", 140, 166], ["Mycobacterium tuberculosis", "SPECIES", 140, 166], ["Mycobacterium tuberculosis", "SPECIES", 140, 166], ["death", "PROBLEM", 102, 107], ["a single infectious agent", "TREATMENT", 113, 138], ["Mycobacterium tuberculosis", "PROBLEM", 140, 166], ["Mycobacterium tuberculosis", "OBSERVATION", 140, 166]]], ["65 Each year, approximately 10 million people become ill with TB, with the prevailing 66 incidence in Southeast Asia and Africa.", [["TB", "DISEASE", 62, 64], ["people", "ORGANISM", 39, 45], ["people", "SPECIES", 39, 45], ["TB", "PROBLEM", 62, 64], ["Africa", "PROBLEM", 121, 127]]], ["The risk of developing TB is high, considering 67 an estimated 1.7 billion people globally infected with these mycobacteria [1, 2] .", [["TB", "DISEASE", 23, 25], ["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81], ["TB", "PROBLEM", 23, 25], ["these mycobacteria", "TEST", 105, 123], ["TB", "OBSERVATION", 23, 25], ["high", "OBSERVATION_MODIFIER", 29, 33], ["mycobacteria", "OBSERVATION", 111, 123]]], ["In 2018, 68 7 million of new cases and 11.1 million of the estimated incident cases were reported. for TB and are a major public health concern.", [["TB", "DISEASE", 103, 105], ["TB", "PROBLEM", 103, 105]]], ["MDR and XDR strains are often 85 associated with low cure and high mortality rates [1].", [["MDR", "PROBLEM", 0, 3], ["XDR strains", "PROBLEM", 8, 19], ["low cure", "PROBLEM", 49, 57], ["high mortality rates", "PROBLEM", 62, 82]]], ["In the last three years, synthetic methodologies to coupling selenium groups 134 involving direct selenilation of the quinone ring have been described through Rh-135 catalyzed C-H phenylselenation, as shown in Fig. 2 .", [["selenium", "CHEMICAL", 61, 69], ["quinone", "CHEMICAL", 118, 125], ["Rh-135", "CHEMICAL", 159, 165], ["C-H", "CHEMICAL", 176, 179], ["selenium", "CHEMICAL", 61, 69], ["quinone", "CHEMICAL", 118, 125], ["Rh-135", "CHEMICAL", 159, 165], ["C-H", "CHEMICAL", 176, 179], ["selenium", "SIMPLE_CHEMICAL", 61, 69], ["quinone ring", "SIMPLE_CHEMICAL", 118, 130], ["Rh-135", "SIMPLE_CHEMICAL", 159, 165], ["C-H phenylselenation", "SIMPLE_CHEMICAL", 176, 196], ["synthetic methodologies to coupling selenium groups", "TREATMENT", 25, 76], ["the quinone ring", "TREATMENT", 114, 130], ["Rh", "TEST", 159, 161], ["quinone ring", "OBSERVATION", 118, 130]]], ["For example, (phenylseleno)-phthalimide or phenyl hypochloroselenoites as an electrophile, the C-2 137 selenation of naphthoquinone can be performed, as well as the Rh-catalyzed selenation 138 of benzoquinone ( Fig. 2A ) [37] [38] [39] .", [["phenylseleno)-phthalimide", "CHEMICAL", 14, 39], ["phenyl hypochloroselenoites", "CHEMICAL", 43, 70], ["C-2 137", "CHEMICAL", 95, 102], ["naphthoquinone", "CHEMICAL", 117, 131], ["benzoquinone", "CHEMICAL", 196, 208], ["(phenylseleno)-phthalimide", "CHEMICAL", 13, 39], ["phenyl hypochloroselenoites", "CHEMICAL", 43, 70], ["naphthoquinone", "CHEMICAL", 117, 131], ["benzoquinone", "CHEMICAL", 196, 208], ["Fig. 2A ) [37] [38]", "CHEMICAL", 211, 230], ["(phenylseleno)-phthalimide", "SIMPLE_CHEMICAL", 13, 39], ["phenyl hypochloroselenoites", "SIMPLE_CHEMICAL", 43, 70], ["C-2 137", "SIMPLE_CHEMICAL", 95, 102], ["naphthoquinone", "SIMPLE_CHEMICAL", 117, 131], ["benzoquinone", "SIMPLE_CHEMICAL", 196, 208], ["Fig. 2A ) [37] [38] [39]", "SIMPLE_CHEMICAL", 211, 235], ["phthalimide", "TREATMENT", 28, 39], ["phenyl hypochloroselenoites", "TREATMENT", 43, 70], ["an electrophile", "TEST", 74, 89], ["the C", "TEST", 91, 96], ["naphthoquinone", "TREATMENT", 117, 131]]], ["139 We herein report on the synthesis of a new series of naphthoquinone derivatives The reagents were purchased from Sigma-Aldrich Brazil and were used without 154 further purification.", [["naphthoquinone", "CHEMICAL", 57, 71], ["naphthoquinone", "CHEMICAL", 57, 71], ["naphthoquinone derivatives", "SIMPLE_CHEMICAL", 57, 83], ["Sigma-Aldrich Brazil", "ORGANISM", 117, 137], ["a new series of naphthoquinone derivatives", "TREATMENT", 41, 83], ["further purification", "TREATMENT", 164, 184]]], ["Column chromatography was performed with silica gel 60 (Merck 155 70-230 mesh).", [["silica gel", "CHEMICAL", 41, 51], ["silica gel", "CHEMICAL", 41, 51], ["Column chromatography", "TEST", 0, 21], ["silica gel", "TEST", 41, 51], ["Merck", "TEST", 56, 61]]], ["Analytical thin layer chromatography was performed with silica gel 156 plates (Merck, TLC silica gel 60 F 254 ), and the plates were visualized using UV light.63coupling constants (J) are reported in hertz and refer to apparent peak multiplicities.63High-resolution mass spectra (HRMS) were recorded on a MICROMASS Q-TOF mass 168 spectrometer (Waters) and the deviation of the measured mass from the theoretical mass 169 (\u2206) was inserted in ppm.", [["silica gel", "CHEMICAL", 56, 66], ["silica gel", "CHEMICAL", 56, 66], ["silica", "CHEMICAL", 90, 96], ["Analytical thin layer chromatography", "TEST", 0, 36], ["silica gel 156 plates", "TREATMENT", 56, 77], ["Merck, TLC silica gel", "TREATMENT", 79, 100], ["the plates", "TREATMENT", 117, 127], ["UV light", "TREATMENT", 150, 158], ["resolution mass spectra (HRMS)", "PROBLEM", 255, 285], ["a MICROMASS", "TEST", 303, 314], ["the measured mass", "PROBLEM", 373, 390], ["the theoretical mass", "PROBLEM", 396, 416], ["UV light", "OBSERVATION", 150, 158], ["resolution", "OBSERVATION_MODIFIER", 255, 265], ["mass", "OBSERVATION", 266, 270], ["mass", "OBSERVATION", 386, 390], ["mass", "OBSERVATION", 412, 416]]], ["Intrinsic Phasing and refinement package using Least Squares Methods with the 175 SHELX programs [40] .", [["refinement package", "TREATMENT", 22, 40]]], ["Non-hydrogen atoms were refined with anisotropic 176 displacement parameters, and the hydrogen atoms were positioned geometrically using 177 the riding model.", [["hydrogen", "CHEMICAL", 86, 94], ["Non-hydrogen", "CHEMICAL", 0, 12], ["hydrogen", "CHEMICAL", 86, 94], ["Non-hydrogen atoms", "SIMPLE_CHEMICAL", 0, 18], ["hydrogen atoms", "SIMPLE_CHEMICAL", 86, 100], ["Non-hydrogen atoms", "PROBLEM", 0, 18], ["anisotropic 176 displacement parameters", "TEST", 37, 76], ["the hydrogen atoms", "TREATMENT", 82, 100], ["hydrogen atoms", "OBSERVATION", 86, 100]]], ["Molecular graphics draw using SHELXL [41] .178The protocol for preparing 2-(chloromethyl)-3-methylnaphthalene-1,4-dione (9) 179 was performed as described by Ferreira and cols.", [["2-(chloromethyl)-3-methylnaphthalene-1,4-dione (9) 179", "CHEMICAL", 73, 127], ["2-(chloromethyl)-3-methylnaphthalene-1,4-dione", "CHEMICAL", 73, 119], ["2-(chloromethyl)-3-methylnaphthalene-1,4-dione (9) 179", "SIMPLE_CHEMICAL", 73, 127], ["The protocol", "TREATMENT", 46, 58], ["preparing 2-(chloromethyl)", "TREATMENT", 63, 89], ["methylnaphthalene", "TREATMENT", 92, 109]]], ["91, 125.77, 19.81, 12.59 Se-( (3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl) 43, 185.04, 184.42, 145.15, 144.47, 144.25, 136.07, 205 133.84, 133.70, 132.40, 132.10, 129.75, 127.58, 126.66, 126.57, 21.92, 20.14, 13.22 51, 185.10, 184.49, 151.35, 144.53, 223 144.", [["12.59 Se-( (3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl", "CHEMICAL", 19, 76], ["Se", "CHEMICAL", 25, 27], ["(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)", "CHEMICAL", 30, 77], ["12.59 Se-( (3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl) 43", "SIMPLE_CHEMICAL", 19, 80], ["3-methyl", "TEST", 31, 39], ["-dioxo", "TEST", 43, 49]]], ["28, 133.88, 132.43, 132.13, 131.94, 128.83, 128.62, 127.71, 126.70, 126.61, 29.23, 224 20.16, 15.29, 13.25 CDCl 3 ) \u03b4 ppm: 200.92, 184.70, 183.99, 144.22, 143.78, 133.60, 133.47, 132.12, 131.81, 257 126.", [["CDCl", "TEST", 107, 111], ["ppm", "TEST", 118, 121]]], ["Metabolically active cells were assessed using the MTT reduction colorimetric 310 assay, as previously reported by Mosmann (1983) [45] and Alley (1988) [46] .", [["cells", "ANATOMY", 21, 26], ["MTT", "CHEMICAL", 51, 54], ["cells", "CELL", 21, 26], ["Metabolically active cells", "PROBLEM", 0, 26], ["the MTT reduction colorimetric", "TEST", 47, 77], ["active cells", "OBSERVATION", 14, 26]]], ["Cells multidrug resistance (Fig. 3) .", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells multidrug resistance", "TEST", 0, 26], ["multidrug resistance", "OBSERVATION", 6, 26]]], ["This selenofunctionalization of menadione is described344The synthetic approach used to obtain selenium-containing menadione 345 derivatives 8a-i initially provided some synthetic steps described in the literature [42] 346 and was based on a two-step pathway entailing the use of commercial menadione (7).347The synthetic route started with the first reaction of the insertion of the -CH 2 Cl group in 348 menadione, in excellent yield (95 %), through the reaction with formaldehyde, glacial 349 acetic acid and dry hydrogen chloride, obtaining 2-(chloromethyl)-3-350 methylnaphthalene-1,4-dione (7) (Fig. 3) .", [["menadione", "CHEMICAL", 32, 41], ["selenium", "CHEMICAL", 95, 103], ["menadione", "CHEMICAL", 115, 124], ["[42] 346", "CHEMICAL", 214, 222], ["menadione", "CHEMICAL", 291, 300], ["CH 2 Cl", "CHEMICAL", 385, 392], ["menadione", "CHEMICAL", 406, 415], ["formaldehyde", "CHEMICAL", 470, 482], ["glacial 349 acetic acid", "CHEMICAL", 484, 507], ["hydrogen chloride", "CHEMICAL", 516, 533], ["2-(chloromethyl)-3-350 methylnaphthalene-1,4-dione", "CHEMICAL", 545, 595], ["menadione", "CHEMICAL", 32, 41], ["selenium", "CHEMICAL", 95, 103], ["menadione 345", "CHEMICAL", 115, 128], ["menadione", "CHEMICAL", 291, 300], ["CH", "CHEMICAL", 385, 387], ["Cl", "CHEMICAL", 390, 392], ["menadione", "CHEMICAL", 406, 415], ["formaldehyde", "CHEMICAL", 470, 482], ["acetic acid", "CHEMICAL", 496, 507], ["hydrogen chloride", "CHEMICAL", 516, 533], ["2-(chloromethyl)-3-350 methylnaphthalene-1,4-dione", "CHEMICAL", 545, 595], ["menadione", "SIMPLE_CHEMICAL", 32, 41], ["selenium", "SIMPLE_CHEMICAL", 95, 103], ["menadione 345 derivatives 8a-i", "SIMPLE_CHEMICAL", 115, 145], ["menadione", "SIMPLE_CHEMICAL", 291, 300], ["menadione", "SIMPLE_CHEMICAL", 406, 415], ["formaldehyde", "SIMPLE_CHEMICAL", 470, 482], ["glacial 349 acetic acid", "SIMPLE_CHEMICAL", 484, 507], ["dry hydrogen chloride", "SIMPLE_CHEMICAL", 512, 533], ["2-(chloromethyl)-3-350 methylnaphthalene-1,4-dione (7)", "SIMPLE_CHEMICAL", 545, 599], ["The synthetic approach", "TREATMENT", 57, 79], ["selenium-containing menadione 345 derivatives", "TREATMENT", 95, 140], ["some synthetic steps", "TREATMENT", 165, 185], ["commercial menadione", "TREATMENT", 280, 300], ["The synthetic route", "TREATMENT", 308, 327], ["formaldehyde", "TREATMENT", 470, 482], ["glacial", "TREATMENT", 484, 491], ["acetic acid", "TEST", 496, 507], ["dry hydrogen chloride", "TREATMENT", 512, 533]]], ["351 Then, we promoted the selenofuncionalization of 9 through the reaction with the 352 respective selenocarboxylate that was generated in situ from benzoyl chloride and Se 0 353 (Fig. 3) .", [["selenocarboxylate", "CHEMICAL", 99, 116], ["benzoyl chloride", "CHEMICAL", 149, 165], ["Se 0 353", "CHEMICAL", 170, 178], ["selenocarboxylate", "CHEMICAL", 99, 116], ["benzoyl chloride", "CHEMICAL", 149, 165], ["Se 0 353", "CHEMICAL", 170, 178], ["selenocarboxylate", "SIMPLE_CHEMICAL", 99, 116], ["benzoyl chloride", "SIMPLE_CHEMICAL", 149, 165], ["Se 0 353", "SIMPLE_CHEMICAL", 170, 178], ["the selenofuncionalization", "TEST", 22, 48], ["the 352 respective selenocarboxylate", "TREATMENT", 80, 116], ["benzoyl chloride", "TREATMENT", 149, 165]]], ["Using different acyl chlorides and benzoylchlorides, a series of menadione-354 derived selenoesters in moderate to good yields ranged between 24-75 % was obtained, 355 as reported in Fig. 3 .356For example, compound 8b, with p-methylbenzoyl chloride, was obtained in 58 357 % yield, while the best yield was represented by compound 8a with 75 % (Fig. 3) .358Exchanging the aromatic for aliphatic selenocarboxylate led to a decrease in the yield, 359 as shown in Fig. 3 .", [["acyl chlorides", "CHEMICAL", 16, 30], ["benzoylchlorides", "CHEMICAL", 35, 51], ["menadione-354", "CHEMICAL", 65, 78], ["selenoesters", "CHEMICAL", 87, 99], ["compound 8b", "CHEMICAL", 207, 218], ["p-methylbenzoyl chloride", "CHEMICAL", 225, 249], ["aliphatic selenocarboxylate", "CHEMICAL", 386, 413], ["acyl chlorides", "CHEMICAL", 16, 30], ["benzoylchlorides", "CHEMICAL", 35, 51], ["menadione-354", "CHEMICAL", 65, 78], ["selenoesters", "CHEMICAL", 87, 99], ["p-methylbenzoyl chloride", "CHEMICAL", 225, 249], ["aliphatic selenocarboxylate", "CHEMICAL", 386, 413], ["acyl chlorides", "SIMPLE_CHEMICAL", 16, 30], ["benzoylchlorides", "SIMPLE_CHEMICAL", 35, 51], ["menadione-354 derived selenoesters", "SIMPLE_CHEMICAL", 65, 99], ["p-methylbenzoyl chloride", "SIMPLE_CHEMICAL", 225, 249], ["aliphatic selenocarboxylate", "SIMPLE_CHEMICAL", 386, 413], ["different acyl chlorides", "TREATMENT", 6, 30], ["benzoylchlorides", "TREATMENT", 35, 51], ["menadione", "TEST", 65, 74], ["aliphatic selenocarboxylate", "TREATMENT", 386, 413], ["moderate", "OBSERVATION_MODIFIER", 103, 111], ["decrease", "OBSERVATION_MODIFIER", 423, 431]]], ["Additionally, we found that a change in the electron-donating group 360 in the aromatic ring to an electron withdrawer group did not produce significant 361 variation in the product yield.", [["electron", "SIMPLE_CHEMICAL", 44, 52], ["electron", "SIMPLE_CHEMICAL", 99, 107], ["a change", "PROBLEM", 28, 36], ["change", "OBSERVATION_MODIFIER", 30, 36], ["significant", "OBSERVATION_MODIFIER", 141, 152], ["361 variation", "OBSERVATION", 153, 166]]], ["Synthesis of menadione-derived selenoesters 8a-i.367The structure of all products synthetized was confirmed by 1 H and 13 C nuclear permeate through M. tuberculosis cell wall [55] .", [["cell wall", "ANATOMY", 165, 174], ["menadione", "CHEMICAL", 13, 22], ["selenoesters 8a-i.367", "CHEMICAL", 31, 52], ["menadione", "CHEMICAL", 13, 22], ["selenoesters", "CHEMICAL", 31, 43], ["menadione", "SIMPLE_CHEMICAL", 13, 22], ["selenoesters 8a-i.367", "SIMPLE_CHEMICAL", 31, 52], ["M. tuberculosis", "SPECIES", 149, 164], ["M. tuberculosis", "SPECIES", 149, 164], ["Synthesis of menadione", "TREATMENT", 0, 22]]], ["As reported in Table 2 ClogP values consistent with the classic rule of five [56] .", [["Table 2 ClogP values", "TEST", 15, 35]]], ["In addition, the number of 462 hydrogen bonds donors (< 5) and hydrogen bonds acceptors (< 10) as well as the 463 molecular mass (< 500 D) were also respected, suggesting that these molecules may 464 have adequate bioavailability when orally administered. between toxicity in Vero cells, isolated renal tissue and nephrotoxicity in rats [57] . biological activity and toxicity, suggest the continuation of this study for in vivo tests, to phenomenon of resistance to multiple TB drugs.", [["Vero cells", "ANATOMY", 276, 286], ["renal tissue", "ANATOMY", 297, 309], ["toxicity", "DISEASE", 264, 272], ["nephrotoxicity", "DISEASE", 314, 328], ["toxicity", "DISEASE", 368, 376], ["TB", "DISEASE", 476, 478], ["hydrogen", "CHEMICAL", 31, 39], ["hydrogen", "CHEMICAL", 63, 71], ["hydrogen bonds acceptors", "SIMPLE_CHEMICAL", 63, 87], ["Vero cells", "CELL", 276, 286], ["renal tissue", "TISSUE", 297, 309], ["rats", "ORGANISM", 332, 336], ["Vero cells", "CELL_LINE", 276, 286], ["rats", "SPECIES", 332, 336], ["hydrogen bonds donors", "TEST", 31, 52], ["hydrogen bonds acceptors", "TEST", 63, 87], ["the 463 molecular mass", "PROBLEM", 106, 128], ["toxicity in Vero cells", "PROBLEM", 264, 286], ["isolated renal tissue", "PROBLEM", 288, 309], ["nephrotoxicity in rats", "PROBLEM", 314, 336], ["this study", "TEST", 406, 416], ["vivo tests", "TEST", 424, 434], ["multiple TB drugs", "TREATMENT", 467, 484], ["mass", "OBSERVATION", 124, 128], ["Vero cells", "OBSERVATION", 276, 286], ["renal tissue", "ANATOMY", 297, 309], ["nephrotoxicity", "OBSERVATION", 314, 328], ["multiple", "OBSERVATION_MODIFIER", 467, 475], ["TB", "OBSERVATION", 476, 478]]], ["The next steps to understand the mechanism of action and to determine the molecular target(s) of the selenium-506 containing naphthoquinones will include the selection of spontaneous mutants, the 507 whole-genome sequencing of the obtained mutants, and the use of genetic approaches to 508 validate the gene(s) involved in the mechanism of action and resistance.", [["selenium-506", "CHEMICAL", 101, 113], ["naphthoquinones", "CHEMICAL", 125, 140], ["selenium-506", "CHEMICAL", 101, 113], ["naphthoquinones", "CHEMICAL", 125, 140], ["selenium-506", "SIMPLE_CHEMICAL", 101, 113], ["naphthoquinones", "SIMPLE_CHEMICAL", 125, 140], ["naphthoquinones", "TREATMENT", 125, 140], ["spontaneous mutants", "PROBLEM", 171, 190], ["genetic approaches", "TREATMENT", 264, 282]]], ["Besides, 509 considering that ebselen is known to bind and inhibit the antigen 85 (Ag85) complex 510 activity, which is involved in the biosynthesis of trehalose dimycolate and 511 mycolylarabinogalactan, both essential components of the mycomembrane [28] , 512 attempts will be made to evaluate the capacity of our compounds to inhibit in vitro the", [["ebselen", "CHEMICAL", 30, 37], ["trehalose dimycolate", "CHEMICAL", 152, 172], ["mycolylarabinogalactan", "CHEMICAL", 181, 203], ["ebselen", "CHEMICAL", 30, 37], ["trehalose dimycolate", "CHEMICAL", 152, 172], ["mycolylarabinogalactan", "CHEMICAL", 181, 203], ["ebselen", "SIMPLE_CHEMICAL", 30, 37], ["antigen 85", "GENE_OR_GENE_PRODUCT", 71, 81], ["Ag85", "GENE_OR_GENE_PRODUCT", 83, 87], ["trehalose dimycolate", "SIMPLE_CHEMICAL", 152, 172], ["511 mycolylarabinogalactan", "SIMPLE_CHEMICAL", 177, 203], ["antigen 85 (Ag85) complex 510", "PROTEIN", 71, 100], ["the antigen", "TEST", 67, 78], ["trehalose dimycolate", "TREATMENT", 152, 172], ["mycolylarabinogalactan", "TREATMENT", 181, 203]]]], "PMC6957694": [["IntroductionSepsis is triggered by an overwhelming systemic inflammatory response to pathogenic microorganisms, and may lead to multiple organ dysfunction syndrome (MODS) and death.", [["organ", "ANATOMY", 137, 142], ["multiple organ dysfunction syndrome", "DISEASE", 128, 163], ["MODS", "DISEASE", 165, 169], ["death", "DISEASE", 175, 180], ["organ", "ORGAN", 137, 142], ["an overwhelming systemic inflammatory response", "PROBLEM", 35, 81], ["pathogenic microorganisms", "PROBLEM", 85, 110], ["multiple organ dysfunction syndrome", "PROBLEM", 128, 163], ["MODS", "PROBLEM", 165, 169], ["death", "PROBLEM", 175, 180], ["overwhelming", "OBSERVATION_MODIFIER", 38, 50], ["systemic", "OBSERVATION_MODIFIER", 51, 59], ["inflammatory", "OBSERVATION", 60, 72], ["multiple", "OBSERVATION_MODIFIER", 128, 136], ["organ", "ANATOMY", 137, 142], ["dysfunction", "OBSERVATION", 143, 154]]], ["Sepsis is associated with high morbidity and mortality, even under optimal conditions of critical care.", [["Sepsis", "DISEASE", 0, 6], ["Sepsis", "PROBLEM", 0, 6], ["high morbidity", "PROBLEM", 26, 40], ["associated with", "UNCERTAINTY", 10, 25], ["high", "OBSERVATION_MODIFIER", 26, 30], ["morbidity", "OBSERVATION", 31, 40]]], ["It is the leading cause of death in non-coronary intensive care units1.", [["death", "DISEASE", 27, 32], ["death", "PROBLEM", 27, 32]]], ["The hospital case-fatality rate of severe sepsis patients has been estimated at approximately 25%, while close to 50% of septic shock patients die2.", [["sepsis", "DISEASE", 42, 48], ["septic shock", "DISEASE", 121, 133], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 134, 142], ["severe sepsis", "PROBLEM", 35, 48], ["septic shock patients die2", "PROBLEM", 121, 147], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["sepsis", "OBSERVATION", 42, 48], ["septic shock", "OBSERVATION", 121, 133]]], ["Most importantly, the incidence of sepsis has risen by nearly 30% in the past decade3.", [["sepsis", "DISEASE", 35, 41], ["sepsis", "PROBLEM", 35, 41], ["sepsis", "OBSERVATION", 35, 41], ["risen", "OBSERVATION_MODIFIER", 46, 51]]], ["Because sepsis can be induced by different microorganisms, vaccine development is difficult to impossible.", [["sepsis", "DISEASE", 8, 14], ["sepsis", "PROBLEM", 8, 14], ["different microorganisms", "PROBLEM", 33, 57], ["vaccine", "TREATMENT", 59, 66], ["sepsis", "OBSERVATION", 8, 14]]], ["Moreover, the abuse of antibiotics in the hospital setting has induced drug resistance in common pathogens.", [["antibiotics", "TREATMENT", 23, 34], ["drug resistance in common pathogens", "PROBLEM", 71, 106], ["drug resistance", "OBSERVATION", 71, 86]]], ["Therefore, despite enormous advancements in understanding the pathogenesis of sepsis, drug treatment remains largely ineffective.", [["sepsis", "DISEASE", 78, 84], ["sepsis", "PROBLEM", 78, 84], ["drug treatment", "TREATMENT", 86, 100], ["sepsis", "OBSERVATION", 78, 84], ["ineffective", "OBSERVATION_MODIFIER", 117, 128]]], ["The identification, validation, and development of more effective drug treatments is extremely important.IntroductionWhile sepsis can be induced by a number of traumatic and/or pathogenic events, it is commonly induced by a host inflammatory reaction to a number of different microbes and their products3\u20136.", [["sepsis", "DISEASE", 123, 129], ["traumatic", "DISEASE", 160, 169], ["The identification", "TEST", 0, 18], ["validation", "TEST", 20, 30], ["more effective drug treatments", "TREATMENT", 51, 81], ["sepsis", "PROBLEM", 123, 129], ["traumatic and/or pathogenic events", "PROBLEM", 160, 194], ["a host inflammatory reaction", "PROBLEM", 222, 250], ["different microbes", "TREATMENT", 266, 284], ["their products", "TREATMENT", 289, 303], ["sepsis", "OBSERVATION", 123, 129], ["traumatic", "OBSERVATION", 160, 169], ["inflammatory", "OBSERVATION_MODIFIER", 229, 241]]], ["Gram-negative bacteria are the leading cause of infection in both hospital-acquired and community-acquired infections.", [["infection", "DISEASE", 48, 57], ["infections", "DISEASE", 107, 117], ["Gram", "TEST", 0, 4], ["negative bacteria", "PROBLEM", 5, 22], ["infection", "PROBLEM", 48, 57], ["community-acquired infections", "PROBLEM", 88, 117], ["negative bacteria", "OBSERVATION_MODIFIER", 5, 22], ["leading cause of", "UNCERTAINTY", 31, 47], ["infection", "OBSERVATION", 48, 57], ["infections", "OBSERVATION", 107, 117]]], ["Lipopolysaccharide (LPS) is a major component of the gram-negative bacterial cell wall, and is itself the biggest player in induction of this antibacterial immune response7.", [["cell wall", "ANATOMY", 77, 86], ["Lipopolysaccharide", "CHEMICAL", 0, 18], ["LPS", "CHEMICAL", 20, 23], ["Lipopolysaccharide", "SIMPLE_CHEMICAL", 0, 18], ["LPS", "SIMPLE_CHEMICAL", 20, 23], ["Lipopolysaccharide (LPS", "TEST", 0, 23], ["the gram", "TEST", 49, 57], ["negative bacterial cell wall", "PROBLEM", 58, 86], ["this antibacterial immune response7", "TREATMENT", 137, 172], ["gram", "OBSERVATION_MODIFIER", 53, 57], ["negative bacterial cell wall", "OBSERVATION", 58, 86], ["biggest", "OBSERVATION_MODIFIER", 106, 113]]], ["LPS induces inflammation by binding to Toll-like receptor 4 on the host cell surface.", [["cell surface", "ANATOMY", 72, 84], ["LPS", "CHEMICAL", 0, 3], ["inflammation", "DISEASE", 12, 24], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["Toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 39, 59], ["cell surface", "CELLULAR_COMPONENT", 72, 84], ["Toll-like receptor 4", "PROTEIN", 39, 59], ["LPS", "PROBLEM", 0, 3], ["inflammation", "PROBLEM", 12, 24], ["inflammation", "OBSERVATION", 12, 24], ["host cell", "OBSERVATION_MODIFIER", 67, 76], ["surface", "OBSERVATION_MODIFIER", 77, 84]]], ["Upon activation of this receptor, the adaptor protein MyD88 is recruited to the receptor, which in turn triggers a cascade of signaling events that leads to the transcription of the transcription factor NF-\u03baB and the mitogen-activated protein (MAP) kinases.", [["MyD88", "GENE_OR_GENE_PRODUCT", 54, 59], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 203, 208], ["mitogen-activated protein (MAP) kinases", "GENE_OR_GENE_PRODUCT", 217, 256], ["adaptor protein", "PROTEIN", 38, 53], ["MyD88", "PROTEIN", 54, 59], ["transcription factor", "PROTEIN", 182, 202], ["NF-\u03baB", "PROTEIN", 203, 208], ["mitogen-activated protein (MAP) kinases", "PROTEIN", 217, 256], ["this receptor", "TREATMENT", 19, 32], ["the adaptor protein MyD88", "TREATMENT", 34, 59], ["signaling events", "PROBLEM", 126, 142], ["the transcription factor NF", "TEST", 178, 205], ["the mitogen", "TEST", 213, 224]]], ["A subsequent series of downstream pro-inflammatory reactions leads to the expression of cytokines, chemokines, stress-responsive proteins, and other inflammatory elements8.IntroductionNF-\u03baB plays a pivotal role in the transcription of pro-inflammatory cytokines, including tumor necrosis factor \u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), and IL-6.", [["IntroductionNF-\u03baB", "CHEMICAL", 172, 189], ["tumor necrosis", "DISEASE", 273, 287], ["IntroductionNF-\u03baB", "GENE_OR_GENE_PRODUCT", 172, 189], ["tumor necrosis factor \u03b1", "GENE_OR_GENE_PRODUCT", 273, 296], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 298, 303], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 306, 320], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 322, 327], ["IL-6", "GENE_OR_GENE_PRODUCT", 334, 338], ["cytokines", "PROTEIN", 88, 97], ["chemokines", "PROTEIN", 99, 109], ["stress-responsive proteins", "PROTEIN", 111, 137], ["inflammatory elements8", "DNA", 149, 171], ["\u03baB", "PROTEIN", 187, 189], ["pro-inflammatory cytokines", "PROTEIN", 235, 261], ["tumor necrosis factor \u03b1", "PROTEIN", 273, 296], ["TNF", "PROTEIN", 298, 301], ["interleukin-1\u03b2 (IL-1\u03b2", "PROTEIN", 306, 327], ["IL-6", "PROTEIN", 334, 338], ["downstream pro-inflammatory reactions", "PROBLEM", 23, 60], ["cytokines", "PROBLEM", 88, 97], ["chemokines", "PROBLEM", 99, 109], ["stress-responsive proteins", "PROBLEM", 111, 137], ["other inflammatory elements", "PROBLEM", 143, 170], ["pro-inflammatory cytokines", "PROBLEM", 235, 261], ["tumor necrosis factor", "TEST", 273, 294], ["TNF", "TEST", 298, 301], ["interleukin", "TEST", 306, 317], ["IL", "TEST", 322, 324], ["cytokines", "OBSERVATION", 88, 97], ["responsive proteins", "OBSERVATION", 118, 137], ["inflammatory elements", "OBSERVATION", 149, 170]]], ["MAP kinases, including extracellular signal-related kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38, also modulate cytokine expression at multiple levels.", [["NH2", "CHEMICAL", 72, 75], ["MAP kinases", "GENE_OR_GENE_PRODUCT", 0, 11], ["extracellular signal-related kinase", "GENE_OR_GENE_PRODUCT", 23, 58], ["ERK", "GENE_OR_GENE_PRODUCT", 60, 63], ["c-Jun NH2-terminal kinase", "GENE_OR_GENE_PRODUCT", 66, 91], ["JNK", "GENE_OR_GENE_PRODUCT", 93, 96], ["p38", "GENE_OR_GENE_PRODUCT", 103, 106], ["MAP kinases", "PROTEIN", 0, 11], ["extracellular signal-related kinase", "PROTEIN", 23, 58], ["ERK", "PROTEIN", 60, 63], ["Jun NH2-terminal kinase", "PROTEIN", 68, 91], ["JNK", "PROTEIN", 93, 96], ["p38", "PROTEIN", 103, 106], ["cytokine", "PROTEIN", 122, 130], ["MAP kinases", "TEST", 0, 11], ["extracellular signal", "TEST", 23, 43], ["kinase", "TEST", 52, 58], ["ERK", "TEST", 60, 63], ["c-Jun NH2-terminal kinase (JNK)", "TEST", 66, 97], ["p38", "TEST", 103, 106], ["modulate cytokine expression at multiple levels", "PROBLEM", 113, 160], ["terminal kinase", "ANATOMY", 76, 91], ["cytokine expression", "OBSERVATION", 122, 141]]], ["ERK is required for the transportation of TNF-\u03b1 mRNA from the nucleus to the cytoplasm9. p38 is a critical mediator of the production of pro-inflammatory cytokines, and has been identified as the target of a class of small-molecule inhibitors capable of inhibiting this process10,11.", [["nucleus", "ANATOMY", 62, 69], ["ERK", "GENE_OR_GENE_PRODUCT", 0, 3], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 42, 47], ["nucleus", "CELLULAR_COMPONENT", 62, 69], ["cytoplasm9", "GENE_OR_GENE_PRODUCT", 77, 87], ["p38", "GENE_OR_GENE_PRODUCT", 89, 92], ["ERK", "PROTEIN", 0, 3], ["TNF-\u03b1 mRNA", "RNA", 42, 52], ["cytoplasm9", "PROTEIN", 77, 87], ["p38", "PROTEIN", 89, 92], ["pro-inflammatory cytokines", "PROTEIN", 137, 163], ["ERK", "TEST", 0, 3], ["the transportation of TNF", "TREATMENT", 20, 45], ["pro-inflammatory cytokines", "PROBLEM", 137, 163], ["small-molecule inhibitors", "TREATMENT", 217, 242], ["nucleus", "ANATOMY", 62, 69], ["pro-inflammatory cytokines", "OBSERVATION", 137, 163]]], ["LPS-induced transcription and translation of inflammatory mediators leads to inflammatory reactions, organ damage, and ultimately shock in the host12.IntroductionRolipram is a typical phosphodiesterase-4 (PDE-4) inhibitor, which can inhibit TNF production in activated mouse macrophages.", [["organ", "ANATOMY", 101, 106], ["macrophages", "ANATOMY", 275, 286], ["LPS", "CHEMICAL", 0, 3], ["organ damage", "DISEASE", 101, 113], ["shock", "DISEASE", 130, 135], ["IntroductionRolipram", "CHEMICAL", 150, 170], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["organ", "ORGAN", 101, 106], ["IntroductionRolipram", "SIMPLE_CHEMICAL", 150, 170], ["phosphodiesterase-4", "GENE_OR_GENE_PRODUCT", 184, 203], ["PDE-4", "GENE_OR_GENE_PRODUCT", 205, 210], ["TNF", "GENE_OR_GENE_PRODUCT", 241, 244], ["mouse", "ORGANISM", 269, 274], ["macrophages", "CELL", 275, 286], ["inflammatory mediators", "PROTEIN", 45, 67], ["TNF", "PROTEIN", 241, 244], ["activated mouse macrophages", "CELL_TYPE", 259, 286], ["mouse", "SPECIES", 269, 274], ["mouse", "SPECIES", 269, 274], ["LPS", "TEST", 0, 3], ["inflammatory mediators", "PROBLEM", 45, 67], ["inflammatory reactions", "PROBLEM", 77, 99], ["organ damage", "PROBLEM", 101, 113], ["IntroductionRolipram", "TREATMENT", 150, 170], ["a typical phosphodiesterase", "TREATMENT", 174, 201], ["PDE-4) inhibitor", "TREATMENT", 205, 221], ["TNF production in activated mouse macrophages", "PROBLEM", 241, 286], ["inflammatory", "OBSERVATION_MODIFIER", 45, 57], ["inflammatory", "OBSERVATION_MODIFIER", 77, 89], ["shock", "OBSERVATION", 130, 135], ["mouse macrophages", "OBSERVATION", 269, 286]]], ["Furthermore, studies have shown that rolipram markedly restrains carrageenan-induced acute inflammatory responses in mice13.", [["rolipram", "CHEMICAL", 37, 45], ["carrageenan", "CHEMICAL", 65, 76], ["rolipram", "CHEMICAL", 37, 45], ["rolipram", "SIMPLE_CHEMICAL", 37, 45], ["carrageenan", "SIMPLE_CHEMICAL", 65, 76], ["studies", "TEST", 13, 20], ["rolipram markedly restrains carrageenan", "TREATMENT", 37, 76], ["acute inflammatory responses", "PROBLEM", 85, 113], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["inflammatory", "OBSERVATION", 91, 103]]], ["Both human and animal experiments have shown that rolipram is also an effective antidepressant, indicating significant bioavailability and effectiveness in the blood14,15.", [["blood", "ANATOMY", 160, 165], ["rolipram", "CHEMICAL", 50, 58], ["antidepressant", "CHEMICAL", 80, 94], ["rolipram", "CHEMICAL", 50, 58], ["human", "ORGANISM", 5, 10], ["rolipram", "SIMPLE_CHEMICAL", 50, 58], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["rolipram", "TREATMENT", 50, 58], ["an effective antidepressant", "TREATMENT", 67, 94], ["the blood", "TEST", 156, 165], ["significant", "OBSERVATION_MODIFIER", 107, 118], ["bioavailability", "OBSERVATION", 119, 134]]], ["However, rolipram has never been studied as a sepsis treatment.", [["rolipram", "CHEMICAL", 9, 17], ["sepsis", "DISEASE", 46, 52], ["rolipram", "CHEMICAL", 9, 17], ["rolipram", "SIMPLE_CHEMICAL", 9, 17], ["rolipram", "TREATMENT", 9, 17], ["a sepsis treatment", "TREATMENT", 44, 62], ["sepsis", "OBSERVATION", 46, 52]]], ["We therefore hypothesized, based on preliminary results, that rolipram may protect mice from E. coli induced septic shock and E. coli derived LPS resultant massive inflammatory response.", [["rolipram", "CHEMICAL", 62, 70], ["septic shock", "DISEASE", 109, 121], ["LPS", "CHEMICAL", 142, 145], ["rolipram", "CHEMICAL", 62, 70], ["rolipram", "SIMPLE_CHEMICAL", 62, 70], ["mice", "ORGANISM", 83, 87], ["E. coli", "ORGANISM", 93, 100], ["E. coli", "ORGANISM", 126, 133], ["mice", "SPECIES", 83, 87], ["E. coli", "SPECIES", 93, 100], ["E. coli", "SPECIES", 126, 133], ["mice", "SPECIES", 83, 87], ["E. coli", "SPECIES", 93, 100], ["E. coli", "SPECIES", 126, 133], ["rolipram", "TREATMENT", 62, 70], ["E. coli", "PROBLEM", 93, 100], ["septic shock", "PROBLEM", 109, 121], ["E. coli", "PROBLEM", 126, 133], ["LPS resultant massive inflammatory response", "PROBLEM", 142, 185], ["E. coli", "OBSERVATION_MODIFIER", 93, 100], ["septic shock", "OBSERVATION", 109, 121], ["massive", "OBSERVATION_MODIFIER", 156, 163], ["inflammatory response", "OBSERVATION", 164, 185]]], ["Our findings indicate that rolipram may protect mice from sepsis and septic shock-like symptoms induced by E. coli, CLP, or E. coli derived LPS, through inhibition of the NF-\u03baB and MAP kinase signaling pathways.", [["rolipram", "CHEMICAL", 27, 35], ["sepsis", "DISEASE", 58, 64], ["septic shock", "DISEASE", 69, 81], ["LPS", "CHEMICAL", 140, 143], ["rolipram", "CHEMICAL", 27, 35], ["rolipram", "SIMPLE_CHEMICAL", 27, 35], ["mice", "ORGANISM", 48, 52], ["E. coli", "ORGANISM", 107, 114], ["CLP", "GENE_OR_GENE_PRODUCT", 116, 119], ["E. coli", "ORGANISM", 124, 131], ["LPS", "GENE_OR_GENE_PRODUCT", 140, 143], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 171, 176], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 181, 191], ["NF-\u03baB", "PROTEIN", 171, 176], ["MAP kinase", "PROTEIN", 181, 191], ["mice", "SPECIES", 48, 52], ["E. coli", "SPECIES", 107, 114], ["E. coli", "SPECIES", 124, 131], ["mice", "SPECIES", 48, 52], ["E. coli", "SPECIES", 107, 114], ["E. coli", "SPECIES", 124, 131], ["rolipram", "TREATMENT", 27, 35], ["sepsis", "PROBLEM", 58, 64], ["septic shock", "PROBLEM", 69, 81], ["symptoms", "PROBLEM", 87, 95], ["E. coli", "PROBLEM", 107, 114], ["CLP", "PROBLEM", 116, 119], ["E. coli derived LPS", "PROBLEM", 124, 143], ["the NF", "TEST", 167, 173], ["MAP kinase signaling pathways", "TEST", 181, 210], ["sepsis", "OBSERVATION", 58, 64], ["septic shock", "OBSERVATION", 69, 81], ["E. coli", "OBSERVATION", 124, 131]]], ["Rolipram is already approved and in use for chronic obstructive pulmonary disorder in the United States.", [["pulmonary", "ANATOMY", 64, 73], ["Rolipram", "CHEMICAL", 0, 8], ["chronic obstructive pulmonary disorder", "DISEASE", 44, 82], ["Rolipram", "CHEMICAL", 0, 8], ["Rolipram", "SIMPLE_CHEMICAL", 0, 8], ["pulmonary", "ORGAN", 64, 73], ["Rolipram", "TREATMENT", 0, 8], ["chronic obstructive pulmonary disorder", "PROBLEM", 44, 82], ["chronic", "OBSERVATION_MODIFIER", 44, 51], ["obstructive", "OBSERVATION", 52, 63], ["pulmonary", "ANATOMY", 64, 73], ["disorder", "OBSERVATION", 74, 82]]], ["As a result, if rolipram is shown to be a viable sepsis treatment in future experiments, significant time and money that would otherwise be spent on the drug-discovery process may be avoided altogether.Rolipram significantly reduces the mortality rates in multiple mice septic models ::: ResultsTo assess the protective effect of rolipram on sepsis induced by E. coli, CLP, or E. coli derived LPS, we investigated the effect of the drug on survival rate.", [["rolipram", "CHEMICAL", 16, 24], ["sepsis", "DISEASE", 49, 55], ["Rolipram", "CHEMICAL", 202, 210], ["septic", "DISEASE", 270, 276], ["rolipram", "CHEMICAL", 330, 338], ["sepsis", "DISEASE", 342, 348], ["LPS", "CHEMICAL", 393, 396], ["rolipram", "CHEMICAL", 16, 24], ["Rolipram", "CHEMICAL", 202, 210], ["rolipram", "CHEMICAL", 330, 338], ["rolipram", "SIMPLE_CHEMICAL", 16, 24], ["Rolipram", "SIMPLE_CHEMICAL", 202, 210], ["mice", "ORGANISM", 265, 269], ["rolipram", "SIMPLE_CHEMICAL", 330, 338], ["E. coli", "ORGANISM", 360, 367], ["CLP", "GENE_OR_GENE_PRODUCT", 369, 372], ["E. coli", "ORGANISM", 377, 384], ["LPS", "SIMPLE_CHEMICAL", 393, 396], ["mice", "SPECIES", 265, 269], ["E. coli", "SPECIES", 360, 367], ["E. coli", "SPECIES", 377, 384], ["mice", "SPECIES", 265, 269], ["E. coli", "SPECIES", 360, 367], ["E. coli", "SPECIES", 377, 384], ["rolipram", "TREATMENT", 16, 24], ["a viable sepsis treatment", "TREATMENT", 40, 65], ["Rolipram", "TREATMENT", 202, 210], ["the mortality rates", "TREATMENT", 233, 252], ["rolipram", "TREATMENT", 330, 338], ["sepsis", "PROBLEM", 342, 348], ["E. coli", "PROBLEM", 360, 367], ["CLP", "PROBLEM", 369, 372], ["E. coli derived LPS", "PROBLEM", 377, 396], ["survival rate", "TREATMENT", 440, 453], ["sepsis", "OBSERVATION", 49, 55], ["septic models", "OBSERVATION", 270, 283], ["sepsis", "OBSERVATION", 342, 348], ["E. coli", "OBSERVATION_MODIFIER", 360, 367]]], ["First, mice were injected intraperitoneally (i.p.) with rolipram or vehicle 6 hr before E. coli injection.", [["rolipram", "CHEMICAL", 56, 64], ["rolipram", "CHEMICAL", 56, 64], ["mice", "ORGANISM", 7, 11], ["rolipram", "SIMPLE_CHEMICAL", 56, 64], ["E. coli", "ORGANISM", 88, 95], ["mice", "SPECIES", 7, 11], ["E. coli", "SPECIES", 88, 95], ["mice", "SPECIES", 7, 11], ["E. coli", "SPECIES", 88, 95], ["rolipram", "TREATMENT", 56, 64], ["vehicle", "TREATMENT", 68, 75], ["E. coli injection", "TREATMENT", 88, 105]]], ["In the absence of rolipram, 62% of infected mice died within 60 hr of E. coli injection (Fig. 1A).", [["rolipram", "CHEMICAL", 18, 26], ["rolipram", "CHEMICAL", 18, 26], ["rolipram", "SIMPLE_CHEMICAL", 18, 26], ["mice", "ORGANISM", 44, 48], ["E. coli", "ORGANISM", 70, 77], ["mice", "SPECIES", 44, 48], ["E. coli", "SPECIES", 70, 77], ["mice", "SPECIES", 44, 48], ["E. coli", "SPECIES", 70, 77], ["rolipram", "TREATMENT", 18, 26], ["E. coli injection", "TREATMENT", 70, 87]]], ["In contrast, injection with rolipram resulted in 15% mortality over 7 days, suggesting that rolipram pretreatment can prevent E. coli -induced septic shock in mice.", [["rolipram", "CHEMICAL", 28, 36], ["rolipram", "CHEMICAL", 92, 100], ["septic shock", "DISEASE", 143, 155], ["rolipram", "CHEMICAL", 28, 36], ["rolipram", "CHEMICAL", 92, 100], ["rolipram", "SIMPLE_CHEMICAL", 28, 36], ["rolipram", "SIMPLE_CHEMICAL", 92, 100], ["E. coli", "ORGANISM", 126, 133], ["mice", "ORGANISM", 159, 163], ["E. coli", "SPECIES", 126, 133], ["mice", "SPECIES", 159, 163], ["E. coli", "SPECIES", 126, 133], ["mice", "SPECIES", 159, 163], ["rolipram", "TREATMENT", 28, 36], ["rolipram pretreatment", "TREATMENT", 92, 113], ["E. coli", "PROBLEM", 126, 133], ["septic shock", "PROBLEM", 143, 155], ["E. coli", "OBSERVATION_MODIFIER", 126, 133], ["septic shock", "OBSERVATION", 143, 155]]], ["Pretreat the CLP model mice can also significant improve the mice survival rate, from 44% to 69% (Fig. 1B).", [["mice", "ORGANISM", 23, 27], ["mice", "ORGANISM", 61, 65], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 61, 65], ["CLP", "OBSERVATION", 13, 16], ["significant", "OBSERVATION_MODIFIER", 37, 48]]], ["To confirm the protective effect of rolipram both in E. coli-induced and CLP-induced septic mice, we assessed the role of rolipram in mouse sepsis induced by lipopolysaccharide (LPS) derived from E. coli.", [["rolipram", "CHEMICAL", 36, 44], ["septic", "DISEASE", 85, 91], ["rolipram", "CHEMICAL", 122, 130], ["sepsis", "DISEASE", 140, 146], ["lipopolysaccharide", "CHEMICAL", 158, 176], ["LPS", "CHEMICAL", 178, 181], ["rolipram", "CHEMICAL", 36, 44], ["rolipram", "CHEMICAL", 122, 130], ["rolipram", "SIMPLE_CHEMICAL", 36, 44], ["E. coli-induced", "ORGANISM", 53, 68], ["CLP", "ORGANISM", 73, 76], ["mice", "ORGANISM", 92, 96], ["rolipram", "SIMPLE_CHEMICAL", 122, 130], ["mouse", "ORGANISM", 134, 139], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 158, 176], ["LPS", "SIMPLE_CHEMICAL", 178, 181], ["E. coli", "ORGANISM", 196, 203], ["mice", "SPECIES", 92, 96], ["mouse", "SPECIES", 134, 139], ["E. coli", "SPECIES", 196, 203], ["mice", "SPECIES", 92, 96], ["mouse", "SPECIES", 134, 139], ["E. coli", "SPECIES", 196, 203], ["rolipram", "TREATMENT", 36, 44], ["CLP", "PROBLEM", 73, 76], ["septic mice", "PROBLEM", 85, 96], ["rolipram", "TREATMENT", 122, 130], ["mouse sepsis", "PROBLEM", 134, 146], ["lipopolysaccharide (LPS)", "TREATMENT", 158, 182], ["E. coli", "PROBLEM", 196, 203], ["septic mice", "OBSERVATION", 85, 96], ["sepsis", "OBSERVATION", 140, 146], ["E. coli", "OBSERVATION", 196, 203]]], ["Mice were i.p. injected with rolipram 1 hr before LPS injection.", [["rolipram", "CHEMICAL", 29, 37], ["LPS", "CHEMICAL", 50, 53], ["rolipram", "CHEMICAL", 29, 37], ["Mice", "ORGANISM", 0, 4], ["rolipram", "SIMPLE_CHEMICAL", 29, 37], ["LPS", "SIMPLE_CHEMICAL", 50, 53], ["Mice", "SPECIES", 0, 4], ["rolipram", "TREATMENT", 29, 37], ["LPS injection", "TREATMENT", 50, 63]]], ["In the absence of rolipram, 73% of endotoxic mice died within 48 hr of LPS injection, but 100% mice survival in the rolipram pretreated group (Fig. 1C).", [["rolipram", "CHEMICAL", 18, 26], ["endotoxic", "DISEASE", 35, 44], ["LPS", "CHEMICAL", 71, 74], ["rolipram", "CHEMICAL", 116, 124], ["rolipram", "CHEMICAL", 18, 26], ["rolipram", "CHEMICAL", 116, 124], ["rolipram", "SIMPLE_CHEMICAL", 18, 26], ["mice", "ORGANISM", 45, 49], ["LPS", "SIMPLE_CHEMICAL", 71, 74], ["mice", "ORGANISM", 95, 99], ["rolipram", "SIMPLE_CHEMICAL", 116, 124], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 95, 99], ["rolipram", "TREATMENT", 18, 26], ["LPS injection", "TREATMENT", 71, 84], ["the rolipram pretreated", "TREATMENT", 112, 135]]], ["These results suggest that rolipram may have a protective effect in sepsis.Rolipram significantly reduces the mortality rates in multiple mice septic models ::: ResultsThe survival dose-response curve for rolipram indicates that the mice receiving the highest dose, 10 mg/kg rolipram, experienced the most benefit (Fig. 1D).", [["rolipram", "CHEMICAL", 27, 35], ["sepsis", "DISEASE", 68, 74], ["Rolipram", "CHEMICAL", 75, 83], ["septic", "DISEASE", 143, 149], ["rolipram", "CHEMICAL", 205, 213], ["rolipram", "CHEMICAL", 275, 283], ["rolipram", "CHEMICAL", 27, 35], ["Rolipram", "CHEMICAL", 75, 83], ["rolipram", "CHEMICAL", 205, 213], ["rolipram", "CHEMICAL", 275, 283], ["rolipram", "SIMPLE_CHEMICAL", 27, 35], ["Rolipram", "SIMPLE_CHEMICAL", 75, 83], ["mice", "ORGANISM", 138, 142], ["rolipram", "SIMPLE_CHEMICAL", 205, 213], ["mice", "ORGANISM", 233, 237], ["rolipram", "SIMPLE_CHEMICAL", 275, 283], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 233, 237], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 233, 237], ["rolipram", "TREATMENT", 27, 35], ["sepsis", "PROBLEM", 68, 74], ["Rolipram", "TREATMENT", 75, 83], ["the mortality rates", "TREATMENT", 106, 125], ["The survival dose", "TREATMENT", 168, 185], ["rolipram", "TREATMENT", 205, 213], ["rolipram", "TREATMENT", 275, 283], ["sepsis", "OBSERVATION", 68, 74], ["septic models", "OBSERVATION", 143, 156]]], ["Taking into account the differential survival rates and occurrence of first mortality, 10 mg/kg rolipram showed the highest efficacy of all tested concentrations.", [["rolipram", "CHEMICAL", 96, 104], ["rolipram", "CHEMICAL", 96, 104], ["rolipram", "SIMPLE_CHEMICAL", 96, 104], ["rolipram", "TREATMENT", 96, 104]]], ["Rolipram at 5 mg/kg significantly improved the survival rate to 71% as opposed to 36% (p < 0.05).", [["Rolipram", "CHEMICAL", 0, 8], ["Rolipram", "CHEMICAL", 0, 8], ["Rolipram", "SIMPLE_CHEMICAL", 0, 8], ["Rolipram", "TREATMENT", 0, 8], ["the survival rate", "TEST", 43, 60]]], ["1 mg/kg rolipram did not significantly improve the survival rate (33%) compared to the LPS-only group.Rolipram significantly reduces E. coli derived lipopolysaccharide-induced release of serum pro-inflammatory cytokines in mice ::: ResultsThe overwhelming release of pro-inflammatory cytokines plays an important role in the pathology of sepsis.", [["serum", "ANATOMY", 187, 192], ["rolipram", "CHEMICAL", 8, 16], ["LPS", "CHEMICAL", 87, 90], ["Rolipram", "CHEMICAL", 102, 110], ["lipopolysaccharide", "CHEMICAL", 149, 167], ["sepsis", "DISEASE", 338, 344], ["rolipram", "CHEMICAL", 8, 16], ["Rolipram", "CHEMICAL", 102, 110], ["rolipram", "SIMPLE_CHEMICAL", 8, 16], ["LPS", "SIMPLE_CHEMICAL", 87, 90], ["Rolipram", "SIMPLE_CHEMICAL", 102, 110], ["E. coli", "ORGANISM", 133, 140], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 149, 167], ["serum", "ORGANISM_SUBSTANCE", 187, 192], ["mice", "ORGANISM", 223, 227], ["serum pro-inflammatory cytokines", "PROTEIN", 187, 219], ["pro-inflammatory cytokines", "PROTEIN", 267, 293], ["E. coli", "SPECIES", 133, 140], ["mice", "SPECIES", 223, 227], ["E. coli", "SPECIES", 133, 140], ["mice", "SPECIES", 223, 227], ["rolipram", "TREATMENT", 8, 16], ["the survival rate", "TEST", 47, 64], ["the LPS", "TEST", 83, 90], ["Rolipram", "TREATMENT", 102, 110], ["E. coli derived lipopolysaccharide", "TREATMENT", 133, 167], ["pro-inflammatory cytokines", "TREATMENT", 267, 293], ["sepsis", "PROBLEM", 338, 344], ["coli", "OBSERVATION", 136, 140], ["pro-inflammatory cytokines", "OBSERVATION", 267, 293], ["sepsis", "OBSERVATION", 338, 344]]], ["Therefore, the serum levels of multiple pro-inflammatory cytokines were examined.", [["serum", "ANATOMY", 15, 20], ["serum", "ORGANISM_SUBSTANCE", 15, 20], ["pro-inflammatory cytokines", "PROTEIN", 40, 66], ["the serum levels", "TEST", 11, 27], ["multiple pro-inflammatory cytokines", "TEST", 31, 66], ["multiple", "OBSERVATION_MODIFIER", 31, 39], ["pro-inflammatory cytokines", "OBSERVATION", 40, 66]]], ["Results show that the concentrations of IL-1\u03b2, IL-5, IL-6, IL-12 (p40), TNF-\u03b1, MCP-1, MIP-2, eotaxin, KC, MIG, LIF, and VEGF, as well as the anti-inflammatory cytokine IL-10, were all significantly elevated in serum after 3 hr and 12 hr of LPS challenge (Fig. 2).", [["serum", "ANATOMY", 210, 215], ["LPS", "CHEMICAL", 240, 243], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 40, 45], ["IL-5", "GENE_OR_GENE_PRODUCT", 47, 51], ["IL-6", "GENE_OR_GENE_PRODUCT", 53, 57], ["IL-12 (p40", "GENE_OR_GENE_PRODUCT", 59, 69], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 72, 77], ["MCP-1", "GENE_OR_GENE_PRODUCT", 79, 84], ["MIP-2", "GENE_OR_GENE_PRODUCT", 86, 91], ["eotaxin", "GENE_OR_GENE_PRODUCT", 93, 100], ["KC", "GENE_OR_GENE_PRODUCT", 102, 104], ["MIG", "GENE_OR_GENE_PRODUCT", 106, 109], ["LIF", "GENE_OR_GENE_PRODUCT", 111, 114], ["VEGF", "GENE_OR_GENE_PRODUCT", 120, 124], ["IL-10", "GENE_OR_GENE_PRODUCT", 168, 173], ["serum", "ORGANISM_SUBSTANCE", 210, 215], ["LPS", "SIMPLE_CHEMICAL", 240, 243], ["IL", "PROTEIN", 40, 42], ["TNF", "PROTEIN", 72, 75], ["MCP", "PROTEIN", 79, 82], ["eotaxin", "PROTEIN", 93, 100], ["KC", "PROTEIN", 102, 104], ["MIG", "PROTEIN", 106, 109], ["LIF", "PROTEIN", 111, 114], ["VEGF", "PROTEIN", 120, 124], ["anti-inflammatory cytokine IL-10", "PROTEIN", 141, 173], ["the concentrations", "TEST", 18, 36], ["IL", "TEST", 40, 42], ["IL", "TEST", 47, 49], ["IL", "TEST", 53, 55], ["IL", "TEST", 59, 61], ["TNF", "TEST", 72, 75], ["MCP", "TEST", 79, 82], ["MIP", "TEST", 86, 89], ["eotaxin", "TREATMENT", 93, 100], ["MIG", "TREATMENT", 106, 109], ["LIF", "TREATMENT", 111, 114], ["VEGF", "TREATMENT", 120, 124], ["the anti-inflammatory cytokine IL", "TREATMENT", 137, 170], ["LPS challenge", "TREATMENT", 240, 253]]], ["In contrast, administration of rolipram effectively reduced the production of pro-inflammatory cytokines and chemokines, and further increased the levels of IL-10.Rolipram prevents E. coli derived lipopolysaccharide-induced lung injury in mice ::: ResultsLPS-induced endotoxic shock is known to cause a number of effects in the murine host, including severe lung injury.", [["lung", "ANATOMY", 224, 228], ["lung", "ANATOMY", 358, 362], ["rolipram", "CHEMICAL", 31, 39], ["Rolipram", "CHEMICAL", 163, 171], ["lipopolysaccharide", "CHEMICAL", 197, 215], ["lung injury", "DISEASE", 224, 235], ["ResultsLPS", "CHEMICAL", 248, 258], ["endotoxic shock", "DISEASE", 267, 282], ["lung injury", "DISEASE", 358, 369], ["rolipram", "CHEMICAL", 31, 39], ["Rolipram", "CHEMICAL", 163, 171], ["rolipram", "SIMPLE_CHEMICAL", 31, 39], ["IL-10", "GENE_OR_GENE_PRODUCT", 157, 162], ["Rolipram", "SIMPLE_CHEMICAL", 163, 171], ["E. coli", "ORGANISM", 181, 188], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 197, 215], ["lung", "ORGAN", 224, 228], ["mice", "ORGANISM", 239, 243], ["ResultsLPS", "SIMPLE_CHEMICAL", 248, 258], ["murine", "ORGANISM", 328, 334], ["lung", "ORGAN", 358, 362], ["pro-inflammatory cytokines", "PROTEIN", 78, 104], ["chemokines", "PROTEIN", 109, 119], ["IL", "PROTEIN", 157, 159], ["E. coli", "SPECIES", 181, 188], ["mice", "SPECIES", 239, 243], ["murine", "SPECIES", 328, 334], ["E. coli", "SPECIES", 181, 188], ["mice", "SPECIES", 239, 243], ["rolipram", "TREATMENT", 31, 39], ["pro-inflammatory cytokines", "TREATMENT", 78, 104], ["chemokines", "TREATMENT", 109, 119], ["Rolipram", "TREATMENT", 163, 171], ["E. coli derived lipopolysaccharide", "PROBLEM", 181, 215], ["lung injury", "PROBLEM", 224, 235], ["ResultsLPS", "TEST", 248, 258], ["endotoxic shock", "PROBLEM", 267, 282], ["severe lung injury", "PROBLEM", 351, 369], ["pro-inflammatory cytokines", "OBSERVATION", 78, 104], ["E. coli", "OBSERVATION_MODIFIER", 181, 188], ["lipopolysaccharide", "OBSERVATION_MODIFIER", 197, 215], ["lung", "ANATOMY", 224, 228], ["injury", "OBSERVATION", 229, 235], ["endotoxic shock", "OBSERVATION", 267, 282], ["severe", "OBSERVATION_MODIFIER", 351, 357], ["lung", "ANATOMY", 358, 362], ["injury", "OBSERVATION", 363, 369]]], ["Histopathological analysis, consisting of hematoxylin and eosin (H&E) staining of lung sections from LPS-only mice, revealed signs of extreme inflammation.", [["lung sections", "ANATOMY", 82, 95], ["inflammation", "DISEASE", 142, 154], ["hematoxylin", "CHEMICAL", 42, 53], ["eosin", "CHEMICAL", 58, 63], ["hematoxylin", "SIMPLE_CHEMICAL", 42, 53], ["lung sections", "MULTI-TISSUE_STRUCTURE", 82, 95], ["LPS", "SIMPLE_CHEMICAL", 101, 104], ["mice", "ORGANISM", 110, 114], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 110, 114], ["Histopathological analysis", "TEST", 0, 26], ["hematoxylin", "TREATMENT", 42, 53], ["eosin", "TREATMENT", 58, 63], ["lung sections", "TEST", 82, 95], ["LPS", "TEST", 101, 104], ["extreme inflammation", "PROBLEM", 134, 154], ["lung", "ANATOMY", 82, 86], ["signs of", "UNCERTAINTY", 125, 133], ["extreme", "OBSERVATION_MODIFIER", 134, 141], ["inflammation", "OBSERVATION", 142, 154]]], ["Edema, neutrophil recruitment, and hemorrhage in the lung samples were also seen (Fig. 3A).", [["Edema", "ANATOMY", 0, 5], ["neutrophil", "ANATOMY", 7, 17], ["lung samples", "ANATOMY", 53, 65], ["Edema", "DISEASE", 0, 5], ["hemorrhage", "DISEASE", 35, 45], ["neutrophil", "CELL", 7, 17], ["lung samples", "CANCER", 53, 65], ["Edema", "PROBLEM", 0, 5], ["neutrophil recruitment", "PROBLEM", 7, 29], ["hemorrhage in the lung samples", "PROBLEM", 35, 65], ["neutrophil recruitment", "OBSERVATION", 7, 29], ["hemorrhage", "OBSERVATION", 35, 45], ["lung", "ANATOMY", 53, 57]]], ["Lung injury in the LPS group was visibly increased in comparison with the control group.", [["Lung", "ANATOMY", 0, 4], ["Lung injury", "DISEASE", 0, 11], ["LPS", "CHEMICAL", 19, 22], ["Lung", "ORGAN", 0, 4], ["LPS", "SIMPLE_CHEMICAL", 19, 22], ["Lung injury", "PROBLEM", 0, 11], ["injury", "OBSERVATION", 5, 11], ["increased", "OBSERVATION_MODIFIER", 41, 50]]], ["Rolipram treatment, however, markedly attenuated LPS-induced lung injury.", [["lung", "ANATOMY", 61, 65], ["Rolipram", "CHEMICAL", 0, 8], ["LPS", "CHEMICAL", 49, 52], ["lung injury", "DISEASE", 61, 72], ["Rolipram", "CHEMICAL", 0, 8], ["Rolipram", "SIMPLE_CHEMICAL", 0, 8], ["LPS", "SIMPLE_CHEMICAL", 49, 52], ["lung", "ORGAN", 61, 65], ["Rolipram treatment", "TREATMENT", 0, 18], ["markedly attenuated LPS", "PROBLEM", 29, 52], ["lung injury", "PROBLEM", 61, 72], ["markedly", "OBSERVATION_MODIFIER", 29, 37], ["attenuated", "OBSERVATION_MODIFIER", 38, 48], ["LPS", "OBSERVATION", 49, 52], ["lung", "ANATOMY", 61, 65], ["injury", "OBSERVATION", 66, 72]]], ["In bronchiolar lavage fluid, total protein (Fig. 3B), absolute neutrophil count (Fig. 3C), and total cells count (Fig. 3D) were significantly reduced.Rolipram alleviates E. coli derived lipopolysaccharide-induced liver and kidney damage ::: ResultsH&E staining of liver tissue from control mice showed that the liver plate was radially arranged around the central vein in normal hepatic lobules.", [["bronchiolar lavage fluid", "ANATOMY", 3, 27], ["neutrophil", "ANATOMY", 63, 73], ["cells", "ANATOMY", 101, 106], ["liver", "ANATOMY", 213, 218], ["kidney", "ANATOMY", 223, 229], ["liver tissue", "ANATOMY", 264, 276], ["liver plate", "ANATOMY", 311, 322], ["central vein", "ANATOMY", 356, 368], ["hepatic lobules", "ANATOMY", 379, 394], ["Rolipram", "CHEMICAL", 150, 158], ["lipopolysaccharide", "CHEMICAL", 186, 204], ["liver and kidney damage", "DISEASE", 213, 236], ["Rolipram", "CHEMICAL", 150, 158], ["bronchiolar lavage fluid", "ORGANISM_SUBSTANCE", 3, 27], ["neutrophil", "CELL", 63, 73], ["cells", "CELL", 101, 106], ["Rolipram", "SIMPLE_CHEMICAL", 150, 158], ["E. coli", "ORGANISM", 170, 177], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 186, 204], ["liver", "ORGAN", 213, 218], ["kidney", "ORGAN", 223, 229], ["liver tissue", "TISSUE", 264, 276], ["mice", "ORGANISM", 290, 294], ["liver", "ORGAN", 311, 316], ["central vein", "MULTI-TISSUE_STRUCTURE", 356, 368], ["hepatic lobules", "MULTI-TISSUE_STRUCTURE", 379, 394], ["total protein", "PROTEIN", 29, 42], ["E. coli", "SPECIES", 170, 177], ["mice", "SPECIES", 290, 294], ["E. coli", "SPECIES", 170, 177], ["mice", "SPECIES", 290, 294], ["bronchiolar lavage fluid", "TEST", 3, 27], ["total protein", "TEST", 29, 42], ["absolute neutrophil count", "TEST", 54, 79], ["Fig. 3C", "TEST", 81, 88], ["total cells count", "TEST", 95, 112], ["Rolipram", "TREATMENT", 150, 158], ["E. coli derived lipopolysaccharide", "TREATMENT", 170, 204], ["liver and kidney damage", "PROBLEM", 213, 236], ["liver tissue", "TEST", 264, 276], ["the liver plate", "PROBLEM", 307, 322], ["bronchiolar", "ANATOMY", 3, 14], ["lavage fluid", "OBSERVATION", 15, 27], ["neutrophil count", "OBSERVATION", 63, 79], ["liver", "ANATOMY", 213, 218], ["kidney", "ANATOMY", 223, 229], ["damage", "OBSERVATION", 230, 236], ["liver", "ANATOMY", 264, 269], ["liver", "ANATOMY", 311, 316], ["plate", "ANATOMY_MODIFIER", 317, 322], ["radially", "OBSERVATION_MODIFIER", 327, 335], ["central vein", "ANATOMY", 356, 368], ["normal", "OBSERVATION", 372, 378], ["hepatic", "ANATOMY", 379, 386], ["lobules", "ANATOMY_MODIFIER", 387, 394]]], ["The livers of LPS-only mice sacrificed at the 24-hr time point showed structural disorder of the hepatic lobule, narrowing or even disappearance of the hepatic sinusoidal space, vacuolar degeneration of hepatocytes, and nuclear pyknosis.", [["livers", "ANATOMY", 4, 10], ["hepatic lobule", "ANATOMY", 97, 111], ["hepatic sinusoidal space", "ANATOMY", 152, 176], ["vacuolar", "ANATOMY", 178, 186], ["hepatocytes", "ANATOMY", 203, 214], ["nuclear", "ANATOMY", 220, 227], ["LPS", "CHEMICAL", 14, 17], ["disorder of the hepatic lobule", "DISEASE", 81, 111], ["livers", "ORGAN", 4, 10], ["LPS", "SIMPLE_CHEMICAL", 14, 17], ["mice", "ORGANISM", 23, 27], ["hepatic lobule", "MULTI-TISSUE_STRUCTURE", 97, 111], ["hepatic sinusoidal", "MULTI-TISSUE_STRUCTURE", 152, 170], ["vacuolar", "CELLULAR_COMPONENT", 178, 186], ["hepatocytes", "CELL", 203, 214], ["nuclear", "CELLULAR_COMPONENT", 220, 227], ["hepatocytes", "CELL_TYPE", 203, 214], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["LPS", "TEST", 14, 17], ["structural disorder of the hepatic lobule", "PROBLEM", 70, 111], ["narrowing", "PROBLEM", 113, 122], ["disappearance of the hepatic sinusoidal space", "PROBLEM", 131, 176], ["vacuolar degeneration of hepatocytes", "PROBLEM", 178, 214], ["nuclear pyknosis", "PROBLEM", 220, 236], ["livers", "ANATOMY", 4, 10], ["LPS", "ANATOMY", 14, 17], ["disorder", "OBSERVATION", 81, 89], ["hepatic", "ANATOMY", 97, 104], ["lobule", "ANATOMY_MODIFIER", 105, 111], ["narrowing", "OBSERVATION", 113, 122], ["disappearance", "OBSERVATION_MODIFIER", 131, 144], ["hepatic", "ANATOMY", 152, 159], ["sinusoidal space", "OBSERVATION", 160, 176], ["vacuolar degeneration", "OBSERVATION", 178, 199], ["hepatocytes", "ANATOMY", 203, 214], ["nuclear pyknosis", "OBSERVATION", 220, 236]]], ["However, rolipram pre-treatment for 1 hr significantly reduced these changes (Fig. 4A).", [["rolipram", "CHEMICAL", 9, 17], ["rolipram", "CHEMICAL", 9, 17], ["rolipram", "SIMPLE_CHEMICAL", 9, 17], ["rolipram pre-treatment", "TREATMENT", 9, 31]]], ["Renal tissue H&E staining (Fig. 4B) clearly showed normal structure and morphology in glomeruli, renal tubules, and renal tubular epithelial cells in control mice.", [["Renal tissue", "ANATOMY", 0, 12], ["glomeruli", "ANATOMY", 86, 95], ["renal tubules", "ANATOMY", 97, 110], ["renal tubular epithelial cells", "ANATOMY", 116, 146], ["Renal tissue", "TISSUE", 0, 12], ["glomeruli", "TISSUE", 86, 95], ["renal tubules", "TISSUE", 97, 110], ["renal tubular epithelial cells", "CELL", 116, 146], ["mice", "ORGANISM", 158, 162], ["renal tubular epithelial cells", "CELL_TYPE", 116, 146], ["mice", "SPECIES", 158, 162], ["mice", "SPECIES", 158, 162], ["Renal tissue H&E staining", "TEST", 0, 25], ["Fig. 4B", "TEST", 27, 34], ["renal tubules", "PROBLEM", 97, 110], ["renal tubular epithelial cells", "PROBLEM", 116, 146], ["tissue", "ANATOMY", 6, 12], ["normal structure", "OBSERVATION", 51, 67], ["morphology", "OBSERVATION_MODIFIER", 72, 82], ["glomeruli", "ANATOMY_MODIFIER", 86, 95], ["renal tubules", "ANATOMY", 97, 110], ["renal", "ANATOMY", 116, 121], ["tubular", "ANATOMY_MODIFIER", 122, 129], ["epithelial cells", "OBSERVATION", 130, 146]]], ["The renal lumen was regular, and no inflammatory cells infiltrated the renal interstitial cells.", [["renal lumen", "ANATOMY", 4, 15], ["inflammatory cells", "ANATOMY", 36, 54], ["renal interstitial cells", "ANATOMY", 71, 95], ["renal lumen", "MULTI-TISSUE_STRUCTURE", 4, 15], ["cells", "CELL", 49, 54], ["renal interstitial cells", "CELL", 71, 95], ["inflammatory cells", "CELL_TYPE", 36, 54], ["renal interstitial cells", "CELL_TYPE", 71, 95], ["inflammatory cells", "PROBLEM", 36, 54], ["renal", "ANATOMY", 4, 9], ["lumen", "ANATOMY_MODIFIER", 10, 15], ["no", "UNCERTAINTY", 33, 35], ["inflammatory cells", "OBSERVATION", 36, 54], ["renal", "ANATOMY", 71, 76], ["interstitial cells", "OBSERVATION", 77, 95]]], ["The kidneys of LPS-only mice at the 24-hr time point showed inflammatory infiltrate in the renal interstitial cells, swelling of renal tubular epithelial cells, and an unclear cell gap.", [["kidneys", "ANATOMY", 4, 11], ["renal interstitial cells", "ANATOMY", 91, 115], ["renal tubular epithelial cells", "ANATOMY", 129, 159], ["cell", "ANATOMY", 176, 180], ["LPS", "CHEMICAL", 15, 18], ["kidneys", "ORGAN", 4, 11], ["LPS", "SIMPLE_CHEMICAL", 15, 18], ["mice", "ORGANISM", 24, 28], ["renal interstitial cells", "CELL", 91, 115], ["renal tubular epithelial cells", "CELL", 129, 159], ["cell", "CELL", 176, 180], ["renal interstitial cells", "CELL_TYPE", 91, 115], ["renal tubular epithelial cells", "CELL_TYPE", 129, 159], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28], ["LPS", "TEST", 15, 18], ["inflammatory infiltrate", "PROBLEM", 60, 83], ["the renal interstitial cells", "PROBLEM", 87, 115], ["swelling of renal tubular epithelial cells", "PROBLEM", 117, 159], ["an unclear cell gap", "PROBLEM", 165, 184], ["kidneys", "ANATOMY", 4, 11], ["LPS", "ANATOMY", 15, 18], ["inflammatory", "OBSERVATION_MODIFIER", 60, 72], ["infiltrate", "OBSERVATION", 73, 83], ["renal", "ANATOMY_MODIFIER", 91, 96], ["interstitial cells", "ANATOMY", 97, 115], ["swelling", "OBSERVATION", 117, 125], ["renal", "ANATOMY_MODIFIER", 129, 134], ["tubular", "ANATOMY_MODIFIER", 135, 142], ["epithelial cells", "OBSERVATION", 143, 159], ["unclear", "UNCERTAINTY", 168, 175], ["cell gap", "OBSERVATION", 176, 184]]], ["Rolipram pretreatment for 1 hr significantly reduced these changes.", [["Rolipram", "CHEMICAL", 0, 8], ["Rolipram", "CHEMICAL", 0, 8], ["Rolipram", "SIMPLE_CHEMICAL", 0, 8], ["Rolipram pretreatment", "TREATMENT", 0, 21]]], ["We also examined biochemical markers for liver and kidney injury in serum from each group of mice treated with LPS for 24 hr.", [["liver", "ANATOMY", 41, 46], ["kidney", "ANATOMY", 51, 57], ["serum", "ANATOMY", 68, 73], ["liver and kidney injury", "DISEASE", 41, 64], ["LPS", "CHEMICAL", 111, 114], ["liver", "ORGAN", 41, 46], ["kidney", "ORGAN", 51, 57], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["mice", "ORGANISM", 93, 97], ["LPS", "SIMPLE_CHEMICAL", 111, 114], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 93, 97], ["biochemical markers", "TEST", 17, 36], ["liver and kidney injury", "PROBLEM", 41, 64], ["LPS", "TREATMENT", 111, 114], ["liver", "ANATOMY", 41, 46], ["kidney", "ANATOMY", 51, 57], ["injury", "OBSERVATION", 58, 64]]], ["Rolipram inhibited levels of aspartate and alanine aminotransferases (AST and ALT), creatinine (Cr), and brain natriuretic peptide (BUN) in serum.", [["serum", "ANATOMY", 140, 145], ["Rolipram", "CHEMICAL", 0, 8], ["aspartate", "CHEMICAL", 29, 38], ["alanine", "CHEMICAL", 43, 50], ["creatinine", "CHEMICAL", 84, 94], ["Cr", "CHEMICAL", 96, 98], ["Rolipram", "CHEMICAL", 0, 8], ["aspartate", "CHEMICAL", 29, 38], ["alanine", "CHEMICAL", 43, 50], ["creatinine", "CHEMICAL", 84, 94], ["Cr", "CHEMICAL", 96, 98], ["Rolipram", "SIMPLE_CHEMICAL", 0, 8], ["aspartate", "SIMPLE_CHEMICAL", 29, 38], ["alanine", "AMINO_ACID", 43, 50], ["aminotransferases", "GENE_OR_GENE_PRODUCT", 51, 68], ["AST", "SIMPLE_CHEMICAL", 70, 73], ["ALT", "SIMPLE_CHEMICAL", 78, 81], ["creatinine", "SIMPLE_CHEMICAL", 84, 94], ["Cr", "SIMPLE_CHEMICAL", 96, 98], ["brain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 105, 130], ["BUN", "SIMPLE_CHEMICAL", 132, 135], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["alanine aminotransferases", "PROTEIN", 43, 68], ["AST", "PROTEIN", 70, 73], ["ALT", "PROTEIN", 78, 81], ["Rolipram", "TREATMENT", 0, 8], ["aspartate", "TEST", 29, 38], ["alanine aminotransferases", "TEST", 43, 68], ["AST", "TEST", 70, 73], ["ALT", "TEST", 78, 81], ["creatinine", "TEST", 84, 94], ["Cr", "TEST", 96, 98], ["brain natriuretic peptide", "TEST", 105, 130], ["BUN", "TEST", 132, 135], ["serum", "TEST", 140, 145]]], ["This indicates that rolipram can ameliorate liver and kidney injury induced by LPS (Fig. 4C\u2013F).Rolipram inhibits E. coli derived lipopolysaccharide-induced activation of the NF-\u03baB and MAPK signaling pathways in mouse lungs ::: ResultsImmunofluorescence microscopy using anti-NF-\u03baB/p65 antibody, revealed that LPS induces NF-\u03baB/p65 nuclear translocation in the mouse lung 3 hr after injection.", [["liver", "ANATOMY", 44, 49], ["kidney", "ANATOMY", 54, 60], ["lungs", "ANATOMY", 217, 222], ["nuclear", "ANATOMY", 331, 338], ["lung", "ANATOMY", 366, 370], ["rolipram", "CHEMICAL", 20, 28], ["liver and kidney injury", "DISEASE", 44, 67], ["LPS", "CHEMICAL", 79, 82], ["Rolipram", "CHEMICAL", 95, 103], ["lipopolysaccharide", "CHEMICAL", 129, 147], ["LPS", "CHEMICAL", 309, 312], ["rolipram", "CHEMICAL", 20, 28], ["Rolipram", "CHEMICAL", 95, 103], ["rolipram", "SIMPLE_CHEMICAL", 20, 28], ["liver", "ORGAN", 44, 49], ["kidney", "ORGAN", 54, 60], ["LPS", "SIMPLE_CHEMICAL", 79, 82], ["Rolipram", "SIMPLE_CHEMICAL", 95, 103], ["E. coli", "ORGANISM", 113, 120], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 129, 147], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 174, 179], ["MAPK", "GENE_OR_GENE_PRODUCT", 184, 188], ["mouse", "ORGANISM", 211, 216], ["lungs", "ORGAN", 217, 222], ["anti-NF-\u03baB", "GENE_OR_GENE_PRODUCT", 270, 280], ["p65", "GENE_OR_GENE_PRODUCT", 281, 284], ["LPS", "SIMPLE_CHEMICAL", 309, 312], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 321, 326], ["p65", "GENE_OR_GENE_PRODUCT", 327, 330], ["mouse", "ORGANISM", 360, 365], ["lung", "ORGAN", 366, 370], ["NF-\u03baB", "PROTEIN", 174, 179], ["MAPK", "PROTEIN", 184, 188], ["anti-NF", "PROTEIN", 270, 277], ["\u03baB", "PROTEIN", 278, 280], ["p65 antibody", "PROTEIN", 281, 293], ["NF-\u03baB", "PROTEIN", 321, 326], ["p65", "PROTEIN", 327, 330], ["E. coli", "SPECIES", 113, 120], ["mouse", "SPECIES", 211, 216], ["mouse", "SPECIES", 360, 365], ["E. coli", "SPECIES", 113, 120], ["mouse", "SPECIES", 211, 216], ["mouse", "SPECIES", 360, 365], ["rolipram", "TREATMENT", 20, 28], ["liver and kidney injury", "PROBLEM", 44, 67], ["Rolipram", "TREATMENT", 95, 103], ["E. coli", "PROBLEM", 113, 120], ["lipopolysaccharide", "TEST", 129, 147], ["the NF", "TEST", 170, 176], ["ResultsImmunofluorescence microscopy", "TEST", 227, 263], ["anti-NF", "TEST", 270, 277], ["B/p65 antibody", "TEST", 279, 293], ["LPS", "TEST", 309, 312], ["NF", "TEST", 321, 323], ["rolipram", "OBSERVATION", 20, 28], ["liver", "ANATOMY", 44, 49], ["kidney", "ANATOMY", 54, 60], ["injury", "OBSERVATION", 61, 67], ["E. coli", "OBSERVATION_MODIFIER", 113, 120], ["lungs", "ANATOMY", 217, 222], ["lung", "ANATOMY", 366, 370]]], ["However, rolipram markedly inhibited this translocation (Fig. 5A).", [["rolipram", "CHEMICAL", 9, 17], ["rolipram", "CHEMICAL", 9, 17], ["rolipram", "SIMPLE_CHEMICAL", 9, 17], ["rolipram", "TREATMENT", 9, 17]]], ["Three hours after LPS treatment, phosphorylation of NF-\u03baB/p65 significantly increased in the mouse lung as compared to controls.", [["lung", "ANATOMY", 99, 103], ["LPS", "CHEMICAL", 18, 21], ["LPS", "SIMPLE_CHEMICAL", 18, 21], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 52, 57], ["p65", "GENE_OR_GENE_PRODUCT", 58, 61], ["mouse", "ORGANISM", 93, 98], ["lung", "ORGAN", 99, 103], ["NF-\u03baB", "PROTEIN", 52, 57], ["p65", "PROTEIN", 58, 61], ["mouse", "SPECIES", 93, 98], ["mouse", "SPECIES", 93, 98], ["LPS treatment", "TREATMENT", 18, 31], ["phosphorylation of NF", "TREATMENT", 33, 54], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["lung", "ANATOMY", 99, 103]]], ["Rolipram markedly suppressed phosphorylation of this molecule (Fig. 5B).", [["Rolipram", "CHEMICAL", 0, 8], ["Rolipram", "CHEMICAL", 0, 8], ["Rolipram", "SIMPLE_CHEMICAL", 0, 8], ["Fig. 5B", "GENE_OR_GENE_PRODUCT", 63, 70], ["Fig. 5B", "PROTEIN", 63, 70], ["Rolipram", "TREATMENT", 0, 8], ["suppressed phosphorylation", "OBSERVATION", 18, 44]]], ["Western blot results showed that LPS treatment induced the phosphorylation of ERK1/2, JNK, and p38 MAPK (Fig. 5B\u2013D).", [["LPS", "CHEMICAL", 33, 36], ["LPS", "SIMPLE_CHEMICAL", 33, 36], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 78, 84], ["JNK", "GENE_OR_GENE_PRODUCT", 86, 89], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 95, 103], ["Fig. 5B\u2013D", "GENE_OR_GENE_PRODUCT", 105, 114], ["ERK1/2", "PROTEIN", 78, 84], ["JNK", "PROTEIN", 86, 89], ["p38 MAPK", "PROTEIN", 95, 103], ["Fig. 5B\u2013D", "PROTEIN", 105, 114], ["Western blot", "TEST", 0, 12], ["LPS treatment", "TREATMENT", 33, 46], ["the phosphorylation", "TEST", 55, 74], ["ERK1", "TEST", 78, 82], ["JNK", "TEST", 86, 89], ["p38 MAPK", "TEST", 95, 103]]], ["Rolipram significantly suppressed the phosphorylation of all three molecules in mouse lungs 3 hr after administration.DiscussionWe demonstrate that rolipram may protect against LPS-induced inflammation and shock in mice, likely through the inhibition of the NF-\u03baB and MAPK signaling pathways.", [["lungs", "ANATOMY", 86, 91], ["Rolipram", "CHEMICAL", 0, 8], ["rolipram", "CHEMICAL", 148, 156], ["LPS", "CHEMICAL", 177, 180], ["inflammation", "DISEASE", 189, 201], ["shock", "DISEASE", 206, 211], ["Rolipram", "CHEMICAL", 0, 8], ["rolipram", "CHEMICAL", 148, 156], ["Rolipram", "SIMPLE_CHEMICAL", 0, 8], ["mouse", "ORGANISM", 80, 85], ["lungs", "ORGAN", 86, 91], ["rolipram", "SIMPLE_CHEMICAL", 148, 156], ["LPS", "SIMPLE_CHEMICAL", 177, 180], ["mice", "ORGANISM", 215, 219], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 258, 263], ["MAPK", "GENE_OR_GENE_PRODUCT", 268, 272], ["NF-\u03baB", "PROTEIN", 258, 263], ["MAPK", "PROTEIN", 268, 272], ["mouse", "SPECIES", 80, 85], ["mice", "SPECIES", 215, 219], ["mouse", "SPECIES", 80, 85], ["mice", "SPECIES", 215, 219], ["Rolipram", "TREATMENT", 0, 8], ["rolipram", "TREATMENT", 148, 156], ["LPS", "PROBLEM", 177, 180], ["inflammation", "PROBLEM", 189, 201], ["shock in mice", "PROBLEM", 206, 219], ["the NF", "TEST", 254, 260], ["lungs", "ANATOMY", 86, 91], ["inflammation", "OBSERVATION", 189, 201], ["shock", "OBSERVATION", 206, 211]]], ["We found that rolipram significantly improved animal survival, decreased inflammatory cytokines essential to the process of shock, alleviated organ injury, and dephosphorylated critical inflammatory pathways.", [["organ", "ANATOMY", 142, 147], ["rolipram", "CHEMICAL", 14, 22], ["shock", "DISEASE", 124, 129], ["organ injury", "DISEASE", 142, 154], ["rolipram", "CHEMICAL", 14, 22], ["rolipram", "SIMPLE_CHEMICAL", 14, 22], ["organ", "ORGAN", 142, 147], ["inflammatory cytokines", "PROTEIN", 73, 95], ["rolipram", "TREATMENT", 14, 22], ["decreased inflammatory cytokines", "PROBLEM", 63, 95], ["shock", "PROBLEM", 124, 129], ["alleviated organ injury", "PROBLEM", 131, 154], ["dephosphorylated critical inflammatory pathways", "PROBLEM", 160, 207], ["decreased", "OBSERVATION_MODIFIER", 63, 72], ["inflammatory cytokines", "OBSERVATION", 73, 95], ["shock", "OBSERVATION", 124, 129], ["organ", "ANATOMY", 142, 147], ["injury", "OBSERVATION", 148, 154], ["critical", "OBSERVATION_MODIFIER", 177, 185], ["inflammatory", "OBSERVATION_MODIFIER", 186, 198]]], ["These results indicate that rolipram suppresses inflammatory responses that are essential to the process of sepsis, and thus may be protective against sepsis.", [["rolipram", "CHEMICAL", 28, 36], ["sepsis", "DISEASE", 108, 114], ["sepsis", "DISEASE", 151, 157], ["rolipram", "CHEMICAL", 28, 36], ["rolipram", "SIMPLE_CHEMICAL", 28, 36], ["rolipram suppresses inflammatory responses", "PROBLEM", 28, 70], ["sepsis", "PROBLEM", 108, 114], ["sepsis", "PROBLEM", 151, 157], ["sepsis", "OBSERVATION", 108, 114], ["may be", "UNCERTAINTY", 125, 131], ["sepsis", "OBSERVATION", 151, 157]]], ["Therefore, rolipram may serve as a novel drug treatment for inflammatory disease, such as septic shock.DiscussionSepsis is induced by a dysregulated innate immune reaction, leading to a harmful host response to pathogens.", [["rolipram", "CHEMICAL", 11, 19], ["inflammatory disease", "DISEASE", 60, 80], ["septic shock", "DISEASE", 90, 102], ["DiscussionSepsis", "DISEASE", 103, 119], ["rolipram", "CHEMICAL", 11, 19], ["rolipram", "SIMPLE_CHEMICAL", 11, 19], ["rolipram", "TREATMENT", 11, 19], ["a novel drug treatment", "TREATMENT", 33, 55], ["inflammatory disease", "PROBLEM", 60, 80], ["septic shock", "PROBLEM", 90, 102], ["a dysregulated innate immune reaction", "PROBLEM", 134, 171], ["pathogens", "PROBLEM", 211, 220], ["inflammatory", "OBSERVATION_MODIFIER", 60, 72], ["septic shock", "OBSERVATION", 90, 102]]], ["This is includes excessive amounts of pro-inflammatory cytokines, such as TNF-\u03b1 and IL-1\u03b216,17, as well as other inflammatory mediators.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 74, 79], ["IL-1\u03b216,17", "GENE_OR_GENE_PRODUCT", 84, 94], ["pro-inflammatory cytokines", "PROTEIN", 38, 64], ["TNF", "PROTEIN", 74, 77], ["IL-1\u03b216,17", "PROTEIN", 84, 94], ["inflammatory mediators", "PROTEIN", 113, 135], ["pro-inflammatory cytokines", "PROBLEM", 38, 64], ["TNF", "TEST", 74, 77], ["IL", "TREATMENT", 84, 86], ["excessive", "OBSERVATION_MODIFIER", 17, 26], ["amounts", "OBSERVATION_MODIFIER", 27, 34], ["pro-inflammatory cytokines", "OBSERVATION", 38, 64], ["inflammatory", "OBSERVATION", 113, 125]]], ["These molecules can in turn trigger secondary inflammatory processes, leading to inflammatory pathology and life-threatening organ damage.", [["organ", "ANATOMY", 125, 130], ["organ damage", "DISEASE", 125, 137], ["organ", "ORGAN", 125, 130], ["inflammatory processes", "PROBLEM", 46, 68], ["inflammatory pathology", "PROBLEM", 81, 103], ["life-threatening organ damage", "PROBLEM", 108, 137], ["inflammatory", "OBSERVATION_MODIFIER", 46, 58], ["inflammatory", "OBSERVATION_MODIFIER", 81, 93], ["organ", "ANATOMY", 125, 130], ["damage", "OBSERVATION", 131, 137]]], ["Proteins that induce the migration of inflammatory cells into tissue are also upregulated.", [["inflammatory cells", "ANATOMY", 38, 56], ["tissue", "ANATOMY", 62, 68], ["inflammatory cells", "CELL", 38, 56], ["tissue", "TISSUE", 62, 68], ["inflammatory cells", "CELL_TYPE", 38, 56], ["Proteins", "TREATMENT", 0, 8], ["inflammatory cells into tissue", "PROBLEM", 38, 68], ["migration", "OBSERVATION_MODIFIER", 25, 34], ["inflammatory cells", "OBSERVATION", 38, 56], ["upregulated", "OBSERVATION_MODIFIER", 78, 89]]], ["We have found that rolipram inhibits pro-inflammatory cytokines and chemokines released by the administration of LPS, leading to the suppression of excessive inflammatory responses, cell adhesion and migration, and the further sequelae of shock and multiple organ failure in the mouse host.", [["cell", "ANATOMY", 182, 186], ["organ", "ANATOMY", 258, 263], ["rolipram", "CHEMICAL", 19, 27], ["LPS", "CHEMICAL", 113, 116], ["shock", "DISEASE", 239, 244], ["organ failure", "DISEASE", 258, 271], ["rolipram", "CHEMICAL", 19, 27], ["rolipram", "SIMPLE_CHEMICAL", 19, 27], ["LPS", "SIMPLE_CHEMICAL", 113, 116], ["cell", "CELL", 182, 186], ["organ", "ORGAN", 258, 263], ["mouse", "ORGANISM", 279, 284], ["pro-inflammatory cytokines", "PROTEIN", 37, 63], ["chemokines", "PROTEIN", 68, 78], ["mouse", "SPECIES", 279, 284], ["mouse", "SPECIES", 279, 284], ["rolipram", "TREATMENT", 19, 27], ["pro-inflammatory cytokines", "TREATMENT", 37, 63], ["chemokines", "TREATMENT", 68, 78], ["LPS", "TREATMENT", 113, 116], ["excessive inflammatory responses", "PROBLEM", 148, 180], ["cell adhesion", "PROBLEM", 182, 195], ["shock", "PROBLEM", 239, 244], ["multiple organ failure", "PROBLEM", 249, 271], ["rolipram", "OBSERVATION", 19, 27], ["pro-inflammatory cytokines", "OBSERVATION", 37, 63], ["excessive", "OBSERVATION_MODIFIER", 148, 157], ["inflammatory", "OBSERVATION_MODIFIER", 158, 170], ["cell adhesion", "OBSERVATION", 182, 195], ["migration", "OBSERVATION_MODIFIER", 200, 209], ["sequelae", "OBSERVATION_MODIFIER", 227, 235], ["shock", "OBSERVATION", 239, 244], ["multiple", "OBSERVATION_MODIFIER", 249, 257], ["organ", "ANATOMY", 258, 263], ["failure", "OBSERVATION", 264, 271]]], ["Sepsis-induced multi-organ dysfunction and injury are the main mechanisms of patient shock and death.", [["multi-organ", "ANATOMY", 15, 26], ["Sepsis", "DISEASE", 0, 6], ["multi-organ dysfunction", "DISEASE", 15, 38], ["shock", "DISEASE", 85, 90], ["death", "DISEASE", 95, 100], ["multi-organ", "ORGAN", 15, 26], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["Sepsis", "PROBLEM", 0, 6], ["multi-organ dysfunction", "PROBLEM", 15, 38], ["injury", "PROBLEM", 43, 49], ["patient shock", "PROBLEM", 77, 90], ["death", "PROBLEM", 95, 100], ["multi-organ dysfunction", "OBSERVATION", 15, 38], ["injury", "OBSERVATION", 43, 49], ["shock", "OBSERVATION", 85, 90]]], ["Therefore, sepsis treatment guidelines consider multi-organ dysfunction a key point of attack in sepsis treatment18.", [["multi-organ", "ANATOMY", 48, 59], ["sepsis", "DISEASE", 11, 17], ["multi-organ dysfunction", "DISEASE", 48, 71], ["sepsis", "DISEASE", 97, 103], ["multi-organ", "ORGAN", 48, 59], ["sepsis treatment guidelines", "TREATMENT", 11, 38], ["multi-organ dysfunction", "PROBLEM", 48, 71], ["attack", "PROBLEM", 87, 93], ["sepsis treatment", "TREATMENT", 97, 113], ["sepsis", "OBSERVATION", 11, 17], ["sepsis", "OBSERVATION", 97, 103]]], ["It has previously been reported that rolipram significantly decreased hyperoxia-induced neutrophil numbers in BALF and inhibits IL-6 and MCP-1 transcription in rat lungs19.", [["neutrophil", "ANATOMY", 88, 98], ["BALF", "ANATOMY", 110, 114], ["lungs", "ANATOMY", 164, 169], ["rolipram", "CHEMICAL", 37, 45], ["hyperoxia", "CHEMICAL", 70, 79], ["rolipram", "CHEMICAL", 37, 45], ["rolipram", "SIMPLE_CHEMICAL", 37, 45], ["neutrophil", "CELL", 88, 98], ["BALF", "CELL", 110, 114], ["IL-6", "GENE_OR_GENE_PRODUCT", 128, 132], ["MCP-1", "GENE_OR_GENE_PRODUCT", 137, 142], ["rat", "ORGANISM", 160, 163], ["lungs", "ORGAN", 164, 169], ["BALF", "CELL_TYPE", 110, 114], ["MCP", "PROTEIN", 137, 140], ["rat", "SPECIES", 160, 163], ["rat", "SPECIES", 160, 163], ["rolipram significantly decreased hyperoxia", "PROBLEM", 37, 79], ["neutrophil numbers", "TEST", 88, 106], ["BALF", "TEST", 110, 114], ["IL", "TEST", 128, 130], ["MCP", "TEST", 137, 140], ["decreased", "OBSERVATION_MODIFIER", 60, 69], ["hyperoxia", "OBSERVATION", 70, 79], ["neutrophil numbers", "OBSERVATION", 88, 106], ["BALF", "ANATOMY", 110, 114], ["lungs", "ANATOMY", 164, 169]]], ["Rolipram also alleviates pulmonary edema and reduces neutrophil numbers in BALF during chlorine-induced mouse shock20.", [["pulmonary", "ANATOMY", 25, 34], ["neutrophil", "ANATOMY", 53, 63], ["BALF", "ANATOMY", 75, 79], ["Rolipram", "CHEMICAL", 0, 8], ["pulmonary edema", "DISEASE", 25, 40], ["chlorine", "CHEMICAL", 87, 95], ["Rolipram", "CHEMICAL", 0, 8], ["chlorine", "CHEMICAL", 87, 95], ["Rolipram", "SIMPLE_CHEMICAL", 0, 8], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 25, 40], ["neutrophil", "CELL", 53, 63], ["BALF", "ORGANISM_SUBSTANCE", 75, 79], ["chlorine", "SIMPLE_CHEMICAL", 87, 95], ["mouse", "ORGANISM", 104, 109], ["neutrophil", "CELL_TYPE", 53, 63], ["BALF", "CELL_TYPE", 75, 79], ["mouse", "SPECIES", 104, 109], ["mouse", "SPECIES", 104, 109], ["Rolipram", "TREATMENT", 0, 8], ["pulmonary edema", "PROBLEM", 25, 40], ["reduces neutrophil numbers", "PROBLEM", 45, 71], ["chlorine-induced mouse shock20", "TREATMENT", 87, 117], ["pulmonary", "ANATOMY", 25, 34], ["edema", "OBSERVATION", 35, 40], ["reduces", "OBSERVATION_MODIFIER", 45, 52], ["neutrophil numbers", "OBSERVATION", 53, 71]]], ["Our results go further in showing that rolipram inhibits pulmonary edema, neutrophil infiltration in alveoli, and protein concentrations and neutrophil numbers in BALF.", [["pulmonary", "ANATOMY", 57, 66], ["neutrophil", "ANATOMY", 74, 84], ["alveoli", "ANATOMY", 101, 108], ["neutrophil", "ANATOMY", 141, 151], ["BALF", "ANATOMY", 163, 167], ["rolipram", "CHEMICAL", 39, 47], ["pulmonary edema", "DISEASE", 57, 72], ["rolipram", "CHEMICAL", 39, 47], ["rolipram", "SIMPLE_CHEMICAL", 39, 47], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 57, 72], ["neutrophil", "CELL", 74, 84], ["alveoli", "MULTI-TISSUE_STRUCTURE", 101, 108], ["neutrophil", "CELL", 141, 151], ["BALF", "CELL", 163, 167], ["BALF", "CELL_TYPE", 163, 167], ["rolipram", "TREATMENT", 39, 47], ["pulmonary edema", "PROBLEM", 57, 72], ["neutrophil infiltration in alveoli", "PROBLEM", 74, 108], ["protein concentrations", "TEST", 114, 136], ["neutrophil numbers", "TEST", 141, 159], ["pulmonary", "ANATOMY", 57, 66], ["edema", "OBSERVATION", 67, 72], ["neutrophil infiltration", "OBSERVATION", 74, 97], ["alveoli", "ANATOMY", 101, 108], ["neutrophil numbers", "OBSERVATION", 141, 159], ["BALF", "ANATOMY", 163, 167]]], ["Liver and kidney function is also improved, indicating that rolipram can prevent LPS-induced multi-organ failure.", [["Liver", "ANATOMY", 0, 5], ["kidney", "ANATOMY", 10, 16], ["multi-organ", "ANATOMY", 93, 104], ["rolipram", "CHEMICAL", 60, 68], ["LPS", "CHEMICAL", 81, 84], ["multi-organ failure", "DISEASE", 93, 112], ["rolipram", "CHEMICAL", 60, 68], ["Liver", "ORGAN", 0, 5], ["kidney", "ORGAN", 10, 16], ["rolipram", "SIMPLE_CHEMICAL", 60, 68], ["LPS", "SIMPLE_CHEMICAL", 81, 84], ["multi-organ", "ORGAN", 93, 104], ["Liver and kidney function", "TEST", 0, 25], ["rolipram", "TREATMENT", 60, 68], ["LPS", "PROBLEM", 81, 84], ["multi-organ failure", "PROBLEM", 93, 112], ["kidney", "ANATOMY", 10, 16], ["improved", "OBSERVATION_MODIFIER", 34, 42], ["multi-organ", "ANATOMY", 93, 104], ["failure", "OBSERVATION", 105, 112]]], ["The exact mechanism by which rolipram controls the inflammatory cascade, thereby preventing shock and multiple organ failure in the host, is unknown.", [["organ", "ANATOMY", 111, 116], ["rolipram", "CHEMICAL", 29, 37], ["shock", "DISEASE", 92, 97], ["organ failure", "DISEASE", 111, 124], ["rolipram", "CHEMICAL", 29, 37], ["rolipram", "SIMPLE_CHEMICAL", 29, 37], ["organ", "ORGAN", 111, 116], ["the inflammatory cascade", "PROBLEM", 47, 71], ["shock", "PROBLEM", 92, 97], ["multiple organ failure", "PROBLEM", 102, 124], ["inflammatory cascade", "OBSERVATION", 51, 71], ["multiple", "OBSERVATION_MODIFIER", 102, 110], ["organ", "ANATOMY", 111, 116], ["failure", "OBSERVATION", 117, 124]]], ["However, it is known that the NF-\u03baB pathway is crucial in the regulation of inflammatory gene expression.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 30, 35], ["NF-\u03baB", "PROTEIN", 30, 35], ["inflammatory gene expression", "PROBLEM", 76, 104], ["inflammatory gene expression", "OBSERVATION", 76, 104]]], ["Nuclear translocation activates the transcription and expression of a variety of cytokines and adhesion molecules, all of which are closely associated with inflammation and the immune response21.", [["Nuclear", "ANATOMY", 0, 7], ["inflammation", "DISEASE", 156, 168], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["cytokines", "PROTEIN", 81, 90], ["adhesion molecules", "PROTEIN", 95, 113], ["Nuclear translocation", "PROBLEM", 0, 21], ["cytokines and adhesion molecules", "PROBLEM", 81, 113], ["inflammation", "PROBLEM", 156, 168], ["inflammation", "OBSERVATION", 156, 168]]], ["The NF-\u03baB family, including p65 (RelA), p50/p105 (NF-\u03baB1), p52/p100 (NF-\u03baB2), RelB, and c-Rel, exist in the cytoplasm in homo- or heterodimers that can bind with I\u03baB.", [["cytoplasm", "ANATOMY", 108, 117], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 4, 9], ["p65", "GENE_OR_GENE_PRODUCT", 28, 31], ["RelA", "GENE_OR_GENE_PRODUCT", 33, 37], ["p50/p105", "GENE_OR_GENE_PRODUCT", 40, 48], ["NF-\u03baB1", "GENE_OR_GENE_PRODUCT", 50, 56], ["p52/p100", "GENE_OR_GENE_PRODUCT", 59, 67], ["NF-\u03baB2", "GENE_OR_GENE_PRODUCT", 69, 75], ["RelB", "GENE_OR_GENE_PRODUCT", 78, 82], ["c-Rel", "GENE_OR_GENE_PRODUCT", 88, 93], ["cytoplasm", "ORGANISM_SUBSTANCE", 108, 117], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 162, 165], ["NF-\u03baB family", "PROTEIN", 4, 16], ["p65", "PROTEIN", 28, 31], ["RelA", "PROTEIN", 33, 37], ["p50", "PROTEIN", 40, 43], ["p105", "PROTEIN", 44, 48], ["NF-\u03baB1", "PROTEIN", 50, 56], ["p52", "PROTEIN", 59, 62], ["p100", "PROTEIN", 63, 67], ["NF-\u03baB2", "PROTEIN", 69, 75], ["RelB", "PROTEIN", 78, 82], ["c", "PROTEIN", 88, 89], ["Rel", "PROTEIN", 90, 93], ["heterodimers", "PROTEIN", 130, 142], ["I\u03baB", "PROTEIN", 162, 165], ["p50", "TEST", 40, 43], ["NF", "TEST", 50, 52], ["p52", "TEST", 59, 62], ["NF", "TEST", 69, 71], ["RelB", "TEST", 78, 82], ["heterodimers", "TREATMENT", 130, 142], ["RelB", "ANATOMY", 78, 82]]], ["During conditions of stimulation by LPS or other pro-inflammatory factors, I\u03baB kinase (IKK) phosphorylates I\u03baB, leading to NF-\u03baB nuclear translocation and further activation of inflammatory genes22.", [["nuclear", "ANATOMY", 129, 136], ["LPS", "CHEMICAL", 36, 39], ["LPS", "SIMPLE_CHEMICAL", 36, 39], ["I\u03baB kinase", "GENE_OR_GENE_PRODUCT", 75, 85], ["IKK", "GENE_OR_GENE_PRODUCT", 87, 90], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 107, 110], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 123, 128], ["pro-inflammatory factors", "PROTEIN", 49, 73], ["I\u03baB kinase", "PROTEIN", 75, 85], ["IKK", "PROTEIN", 87, 90], ["I\u03baB", "PROTEIN", 107, 110], ["NF-\u03baB", "PROTEIN", 123, 128], ["inflammatory genes22", "DNA", 177, 197], ["stimulation", "TREATMENT", 21, 32], ["LPS", "PROBLEM", 36, 39], ["other pro-inflammatory factors", "PROBLEM", 43, 73], ["I\u03baB kinase (IKK) phosphorylates I", "TEST", 75, 108], ["NF", "TEST", 123, 125], ["B nuclear translocation", "PROBLEM", 127, 150], ["inflammatory genes", "PROBLEM", 177, 195], ["inflammatory", "OBSERVATION", 177, 189]]], ["It has been confirmed that toll-like receptor 4 -NF\u03baB signaling plays a key role in acute lung injury23.", [["lung", "ANATOMY", 90, 94], ["toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 27, 47], ["NF\u03ba", "GENE_OR_GENE_PRODUCT", 49, 52], ["B", "GENE_OR_GENE_PRODUCT", 52, 53], ["lung", "ORGAN", 90, 94], ["toll-like receptor 4", "PROTEIN", 27, 47], ["NF\u03ba", "PROTEIN", 49, 52], ["acute lung injury23", "PROBLEM", 84, 103], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["lung", "ANATOMY", 90, 94], ["injury23", "OBSERVATION", 95, 103]]], ["Our studies show that LPS activates NF-\u03baB and its signaling pathways, while rolipram restrains activation.", [["LPS", "CHEMICAL", 22, 25], ["rolipram", "CHEMICAL", 76, 84], ["rolipram", "CHEMICAL", 76, 84], ["LPS", "SIMPLE_CHEMICAL", 22, 25], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 36, 41], ["rolipram", "SIMPLE_CHEMICAL", 76, 84], ["NF-\u03baB", "PROTEIN", 36, 41], ["Our studies", "TEST", 0, 11], ["LPS", "TEST", 22, 25], ["NF", "TEST", 36, 38], ["rolipram restrains activation", "TREATMENT", 76, 105]]], ["This indicates that the NF-\u03baB may be part of the mechanism by which rolipram exerts its effects.DiscussionThe MAPK signaling pathway also plays a critical role in regulating inflammation and the immune response.", [["rolipram", "CHEMICAL", 68, 76], ["inflammation", "DISEASE", 174, 186], ["rolipram", "CHEMICAL", 68, 76], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 24, 29], ["rolipram", "SIMPLE_CHEMICAL", 68, 76], ["MAPK", "GENE_OR_GENE_PRODUCT", 110, 114], ["NF-\u03baB", "PROTEIN", 24, 29], ["MAPK", "PROTEIN", 110, 114], ["regulating inflammation", "PROBLEM", 163, 186], ["inflammation", "OBSERVATION", 174, 186]]], ["As a conserved signaling cascade, the MAPK pathway exists in almost all eukaryotic cells.", [["cells", "ANATOMY", 83, 88], ["MAPK", "GENE_OR_GENE_PRODUCT", 38, 42], ["cells", "CELL", 83, 88], ["MAPK", "PROTEIN", 38, 42], ["eukaryotic cells", "CELL_TYPE", 72, 88], ["a conserved signaling cascade", "PROBLEM", 3, 32], ["the MAPK pathway", "TEST", 34, 50], ["eukaryotic cells", "OBSERVATION", 72, 88]]], ["MAPKs can regulate target protein function through phosphorylation, thus participating in cell proliferation, growth, differentiation, and function.", [["cell", "ANATOMY", 90, 94], ["MAPKs", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 90, 94], ["MAPKs", "PROTEIN", 0, 5], ["cell proliferation", "OBSERVATION", 90, 108]]], ["MAPK signaling is activated through three levels, including MAP3K, MAPKK, and MAPK.", [["MAPK", "GENE_OR_GENE_PRODUCT", 0, 4], ["MAP3K", "GENE_OR_GENE_PRODUCT", 60, 65], ["MAPKK", "GENE_OR_GENE_PRODUCT", 67, 72], ["MAPK", "GENE_OR_GENE_PRODUCT", 78, 82], ["MAPK", "PROTEIN", 0, 4], ["MAP3K", "PROTEIN", 60, 65], ["MAPKK", "PROTEIN", 67, 72], ["MAPK", "PROTEIN", 78, 82], ["MAPK signaling", "TEST", 0, 14], ["MAP3K", "TEST", 60, 65], ["MAPKK", "TEST", 67, 72], ["MAPK", "TEST", 78, 82]]], ["At present, four MAPK signaling pathways have been identified: ERK1/2, ERK5, p38 MAPK, and JNK24.", [["MAPK", "GENE_OR_GENE_PRODUCT", 17, 21], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 63, 69], ["ERK5", "GENE_OR_GENE_PRODUCT", 71, 75], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 77, 85], ["JNK24", "GENE_OR_GENE_PRODUCT", 91, 96], ["MAPK", "PROTEIN", 17, 21], ["ERK1/2", "PROTEIN", 63, 69], ["ERK5", "PROTEIN", 71, 75], ["p38 MAPK", "PROTEIN", 77, 85], ["JNK24", "PROTEIN", 91, 96], ["ERK1", "TEST", 63, 67], ["ERK5", "TEST", 71, 75], ["p38 MAPK", "TEST", 77, 85], ["JNK24", "TEST", 91, 96]]], ["It has been found that rolipram promotes the maturation of glial progenitor cells and regeneration of myelin through enhancement of ERK phosphorylation25.", [["glial progenitor cells", "ANATOMY", 59, 81], ["myelin", "ANATOMY", 102, 108], ["rolipram", "CHEMICAL", 23, 31], ["rolipram", "CHEMICAL", 23, 31], ["rolipram", "SIMPLE_CHEMICAL", 23, 31], ["glial progenitor cells", "CELL", 59, 81], ["myelin", "GENE_OR_GENE_PRODUCT", 102, 108], ["ERK", "GENE_OR_GENE_PRODUCT", 132, 135], ["glial progenitor cells", "CELL_TYPE", 59, 81], ["ERK phosphorylation25", "PROTEIN", 132, 153], ["rolipram", "TREATMENT", 23, 31], ["glial progenitor cells", "TREATMENT", 59, 81], ["regeneration of myelin", "PROBLEM", 86, 108], ["ERK phosphorylation25", "TREATMENT", 132, 153], ["rolipram", "OBSERVATION", 23, 31], ["glial progenitor cells", "OBSERVATION", 59, 81]]], ["Studies have also found that rolipram restrains bone cancer pain through inhibition of the JNK signaling pathway in the bone marrow, suppressing neuron-stellate cell activation26.", [["bone cancer", "ANATOMY", 48, 59], ["bone marrow", "ANATOMY", 120, 131], ["neuron-stellate cell", "ANATOMY", 145, 165], ["rolipram", "CHEMICAL", 29, 37], ["cancer pain", "DISEASE", 53, 64], ["rolipram", "CHEMICAL", 29, 37], ["rolipram", "SIMPLE_CHEMICAL", 29, 37], ["bone cancer", "CANCER", 48, 59], ["JNK", "GENE_OR_GENE_PRODUCT", 91, 94], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 120, 131], ["neuron-stellate cell", "CELL", 145, 165], ["JNK", "PROTEIN", 91, 94], ["Studies", "TEST", 0, 7], ["rolipram restrains", "TREATMENT", 29, 47], ["bone cancer pain", "PROBLEM", 48, 64], ["the JNK signaling pathway", "TEST", 87, 112], ["bone", "ANATOMY", 48, 52], ["cancer", "OBSERVATION", 53, 59], ["bone marrow", "ANATOMY", 120, 131], ["stellate cell", "OBSERVATION", 152, 165]]], ["In addition, rolipram can inhibit LPS-induced p38 MAPK phosphorylation in J774 cells13.", [["J774 cells", "ANATOMY", 74, 84], ["rolipram", "CHEMICAL", 13, 21], ["LPS", "CHEMICAL", 34, 37], ["rolipram", "CHEMICAL", 13, 21], ["rolipram", "SIMPLE_CHEMICAL", 13, 21], ["LPS", "SIMPLE_CHEMICAL", 34, 37], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 46, 54], ["J774 cells", "CELL", 74, 84], ["p38 MAPK", "PROTEIN", 46, 54], ["J774 cells13", "CELL_LINE", 74, 86], ["rolipram", "TREATMENT", 13, 21], ["LPS", "TEST", 34, 37], ["MAPK phosphorylation", "TEST", 50, 70], ["J774 cells", "TEST", 74, 84]]], ["However, the role of rolipram on phosphorylation of the MAPK downstream signaling pathways has not yet been reported.", [["rolipram", "CHEMICAL", 21, 29], ["rolipram", "CHEMICAL", 21, 29], ["rolipram", "SIMPLE_CHEMICAL", 21, 29], ["MAPK", "GENE_OR_GENE_PRODUCT", 56, 60], ["MAPK", "PROTEIN", 56, 60], ["rolipram", "TREATMENT", 21, 29], ["the MAPK downstream signaling pathways", "TEST", 52, 90]]], ["Our results indicated that rolipram suppresses LPS-induced ERK, JNK, and p38 MAPK phosphorylation in lung tissue, suggesting that the MAPK signaling pathway \u2013 as well as NF-\u03baB \u2013 may mediate the anti-inflammatory actions of rolipram.DiscussionIn conclusion, we have found that rolipram protects mice from massive inflammatory responses and endotoxic shock through inhibition of NF-\u03baB and MAPK signaling pathway activation.", [["lung tissue", "ANATOMY", 101, 112], ["rolipram", "CHEMICAL", 27, 35], ["LPS", "CHEMICAL", 47, 50], ["rolipram", "CHEMICAL", 223, 231], ["rolipram", "CHEMICAL", 276, 284], ["shock", "DISEASE", 349, 354], ["rolipram", "CHEMICAL", 27, 35], ["rolipram", "CHEMICAL", 223, 231], ["rolipram", "CHEMICAL", 276, 284], ["rolipram", "SIMPLE_CHEMICAL", 27, 35], ["LPS", "SIMPLE_CHEMICAL", 47, 50], ["ERK", "GENE_OR_GENE_PRODUCT", 59, 62], ["JNK", "GENE_OR_GENE_PRODUCT", 64, 67], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 73, 81], ["lung tissue", "TISSUE", 101, 112], ["MAPK", "GENE_OR_GENE_PRODUCT", 134, 138], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 170, 175], ["rolipram", "SIMPLE_CHEMICAL", 223, 231], ["rolipram", "SIMPLE_CHEMICAL", 276, 284], ["mice", "ORGANISM", 294, 298], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 377, 382], ["MAPK", "GENE_OR_GENE_PRODUCT", 387, 391], ["ERK", "PROTEIN", 59, 62], ["JNK", "PROTEIN", 64, 67], ["p38 MAPK", "PROTEIN", 73, 81], ["MAPK", "PROTEIN", 134, 138], ["NF-\u03baB", "PROTEIN", 170, 175], ["NF-\u03baB", "PROTEIN", 377, 382], ["MAPK", "PROTEIN", 387, 391], ["mice", "SPECIES", 294, 298], ["mice", "SPECIES", 294, 298], ["rolipram suppresses", "TREATMENT", 27, 46], ["LPS", "TEST", 47, 50], ["ERK", "TEST", 59, 62], ["JNK", "TEST", 64, 67], ["p38 MAPK phosphorylation in lung tissue", "PROBLEM", 73, 112], ["the MAPK signaling pathway", "TEST", 130, 156], ["rolipram", "TREATMENT", 223, 231], ["rolipram", "TREATMENT", 276, 284], ["massive inflammatory responses", "PROBLEM", 304, 334], ["endotoxic shock", "TREATMENT", 339, 354], ["NF", "TEST", 377, 379], ["lung", "ANATOMY", 101, 105], ["massive", "OBSERVATION_MODIFIER", 304, 311], ["inflammatory", "OBSERVATION", 312, 324], ["endotoxic shock", "OBSERVATION", 339, 354]]], ["Rolipram may thus serve as a novel drug treatment for inflammatory disease, namely sepsis and septic shock.", [["Rolipram", "CHEMICAL", 0, 8], ["inflammatory disease", "DISEASE", 54, 74], ["sepsis", "DISEASE", 83, 89], ["septic shock", "DISEASE", 94, 106], ["Rolipram", "CHEMICAL", 0, 8], ["Rolipram", "SIMPLE_CHEMICAL", 0, 8], ["Rolipram", "TREATMENT", 0, 8], ["a novel drug treatment", "TREATMENT", 27, 49], ["inflammatory disease", "PROBLEM", 54, 74], ["sepsis", "PROBLEM", 83, 89], ["septic shock", "PROBLEM", 94, 106], ["inflammatory", "OBSERVATION_MODIFIER", 54, 66], ["sepsis", "OBSERVATION", 83, 89], ["septic shock", "OBSERVATION", 94, 106]]], ["As rolipram is an approved drug in the United States for chronic obstructive pulmonary disorder, this drug repositioning strategy may circumvent the lengthy and expensive drug discovery process, and allow faster and better treatment for sepsis patients.Reagents ::: MethodsEscherichia coli 0127:B8 was obtained from ATCC (12740).", [["pulmonary", "ANATOMY", 77, 86], ["rolipram", "CHEMICAL", 3, 11], ["chronic obstructive pulmonary disorder", "DISEASE", 57, 95], ["sepsis", "DISEASE", 237, 243], ["rolipram", "CHEMICAL", 3, 11], ["rolipram", "SIMPLE_CHEMICAL", 3, 11], ["pulmonary", "ORGAN", 77, 86], ["patients", "ORGANISM", 244, 252], ["MethodsEscherichia coli", "ORGANISM", 266, 289], ["patients", "SPECIES", 244, 252], ["MethodsEscherichia coli", "SPECIES", 266, 289], ["MethodsEscherichia coli", "SPECIES", 266, 289], ["rolipram", "TREATMENT", 3, 11], ["chronic obstructive pulmonary disorder", "PROBLEM", 57, 95], ["this drug repositioning strategy", "TREATMENT", 97, 129], ["sepsis", "PROBLEM", 237, 243], ["chronic", "OBSERVATION_MODIFIER", 57, 64], ["obstructive", "OBSERVATION_MODIFIER", 65, 76], ["pulmonary", "ANATOMY", 77, 86], ["disorder", "OBSERVATION", 87, 95]]], ["LPS (Escherichia coli 0127:B8) was purchased from Sigma-Aldrich (St. Louis, MO, USA).", [["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["Escherichia coli", "ORGANISM", 5, 21], ["Sigma-Aldrich", "ORGANISM", 50, 63], ["St. Louis", "ORGANISM", 65, 74], ["Escherichia coli", "SPECIES", 5, 21], ["Escherichia coli", "SPECIES", 5, 21], ["LPS", "TEST", 0, 3], ["Escherichia coli", "TEST", 5, 21], ["Escherichia coli", "OBSERVATION", 5, 21]]], ["Rolipram was obtained from Enzo Life Science (Farmingdale, NY, USA).", [["Rolipram", "CHEMICAL", 0, 8], ["Rolipram", "CHEMICAL", 0, 8], ["Rolipram", "SIMPLE_CHEMICAL", 0, 8], ["Rolipram", "TREATMENT", 0, 8]]], ["Rabbit anti-p38, anti-phospho-p38, anti-ERK1/2, anti-phospho-ERK1/2, anti-JNK, anti-phospho-JNK, and horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG were procured from Bioworld Technology (St. Louis, MN, USA).", [["Rabbit", "ORGANISM", 0, 6], ["anti-p38", "GENE_OR_GENE_PRODUCT", 7, 15], ["anti-phospho-p38", "GENE_OR_GENE_PRODUCT", 17, 33], ["anti-ERK1/2", "GENE_OR_GENE_PRODUCT", 35, 46], ["anti-phospho-ERK1/2", "GENE_OR_GENE_PRODUCT", 48, 67], ["anti-JNK", "GENE_OR_GENE_PRODUCT", 69, 77], ["anti-phospho-JNK", "GENE_OR_GENE_PRODUCT", 79, 95], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 101, 123], ["HRP", "SIMPLE_CHEMICAL", 125, 128], ["Rabbit anti-p38", "PROTEIN", 0, 15], ["p38", "PROTEIN", 30, 33], ["anti-ERK1/2", "PROTEIN", 35, 46], ["anti-phospho-ERK1/2", "PROTEIN", 48, 67], ["anti-JNK", "PROTEIN", 69, 77], ["anti-phospho", "PROTEIN", 79, 91], ["JNK", "PROTEIN", 92, 95], ["horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG", "PROTEIN", 101, 161], ["Rabbit", "SPECIES", 0, 6], ["horseradish", "SPECIES", 101, 112], ["goat", "SPECIES", 141, 145], ["anti-rabbit", "SPECIES", 146, 157], ["Rabbit", "SPECIES", 0, 6], ["goat", "SPECIES", 141, 145], ["anti-rabbit", "SPECIES", 146, 157], ["Rabbit", "TEST", 0, 6], ["anti-phospho", "TEST", 17, 29], ["anti-ERK1", "TEST", 35, 44], ["anti-phospho", "TEST", 48, 60], ["ERK1", "TEST", 61, 65], ["anti-JNK", "TEST", 69, 77], ["anti-phospho", "TEST", 79, 91], ["JNK", "TEST", 92, 95], ["horseradish peroxidase", "TEST", 101, 123], ["HRP", "TEST", 125, 128], ["conjugated goat anti-rabbit IgG", "TREATMENT", 130, 161], ["JNK", "ANATOMY", 92, 95]]], ["Rabbit anti-NF\u03baB p65 and anti-phospho-NF\u03baB p65 antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA).", [["Cell", "ANATOMY", 77, 81], ["Rabbit", "ORGANISM", 0, 6], ["anti-NF\u03baB p65", "GENE_OR_GENE_PRODUCT", 7, 20], ["anti-phospho-NF\u03baB p65", "GENE_OR_GENE_PRODUCT", 25, 46], ["Cell", "CELL", 77, 81], ["Rabbit anti-NF\u03baB p65", "PROTEIN", 0, 20], ["anti-phospho-NF\u03baB p65 antibodies", "PROTEIN", 25, 57], ["Rabbit", "SPECIES", 0, 6], ["Rabbit", "SPECIES", 0, 6], ["Rabbit anti-NF", "TEST", 0, 14], ["anti-phospho", "TEST", 25, 37], ["NF\u03baB p65 antibodies", "TEST", 38, 57]]], ["Alexa Fluor\u00ae 488 goat anti-rabbit IgG (H + L) was purchased from Molecular Probes (Eugene, OR, USA).", [["H + L", "SIMPLE_CHEMICAL", 39, 44], ["Alexa Fluor\u00ae 488 goat anti-rabbit IgG", "PROTEIN", 0, 37], ["H + L", "PROTEIN", 39, 44], ["goat", "SPECIES", 17, 21], ["anti-rabbit", "SPECIES", 22, 33], ["goat", "SPECIES", 17, 21], ["Alexa Fluor\u00ae", "TEST", 0, 12], ["anti-rabbit IgG", "TEST", 22, 37]]], ["MILLIPLEX\u00ae MAP Mouse Cytokine/Chemokine Magnetic Bead Panel Kit for 96-Well Plate Assay was purchased from EMD Millipore (Darmstadt, Germany).Animals ::: MethodsMale C57BL/6 mice, weighing 20\u201325 g, all 8\u201310 weeks old, were used for experiments.", [["C57BL/6 mice", "ORGANISM", 166, 178], ["Cytokine", "PROTEIN", 21, 29], ["Chemokine", "PROTEIN", 30, 39], ["Mouse", "SPECIES", 15, 20], ["mice", "SPECIES", 174, 178], ["Mouse", "SPECIES", 15, 20], ["mice", "SPECIES", 174, 178], ["MAP", "TEST", 11, 14], ["Cytokine", "TEST", 21, 29], ["Bead Panel", "TEST", 49, 59], ["Kit", "TEST", 60, 63], ["Plate Assay", "TEST", 76, 87]]], ["The mice were purchased from the Department of Laboratory Animal Science of Southern Medical University (Guangzhou, China).", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8]]], ["All animals were housed with free access to food and water under conditions of optimal light, temperature, and humidity (12:12-hr light-dark cycle, approximately 24 degrees Celsius, 50\u201360% humidity).", [["temperature", "TEST", 94, 105], ["humidity", "TEST", 111, 119]]], ["All experimental procedures were approved by the Ethics Committee of Animal Research at the College of Medicine, Southern Medical University, and were conducted in accordance with the international guidelines for care and use of laboratory animals.Animal model ::: MethodsLipopolysaccharide was dissolved in phosphate-buffered saline (PBS) and stored at \u221220 degrees Celsius.", [["MethodsLipopolysaccharide", "CHEMICAL", 265, 290], ["phosphate", "CHEMICAL", 308, 317], ["phosphate", "CHEMICAL", 308, 317], ["MethodsLipopolysaccharide", "SIMPLE_CHEMICAL", 265, 290], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 308, 333], ["MethodsLipopolysaccharide", "TREATMENT", 265, 290], ["phosphate-buffered saline (PBS", "TREATMENT", 308, 338]]], ["Rolipram was dissolved in dimethyl sulfoxide (DMSO) and further diluted in PBS (final DMSO concentration: <0.05%).", [["Rolipram", "CHEMICAL", 0, 8], ["dimethyl sulfoxide", "CHEMICAL", 26, 44], ["DMSO", "CHEMICAL", 46, 50], ["DMSO", "CHEMICAL", 86, 90], ["Rolipram", "CHEMICAL", 0, 8], ["dimethyl sulfoxide", "CHEMICAL", 26, 44], ["DMSO", "CHEMICAL", 46, 50], ["DMSO", "CHEMICAL", 86, 90], ["Rolipram", "SIMPLE_CHEMICAL", 0, 8], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 26, 44], ["DMSO", "SIMPLE_CHEMICAL", 46, 50], ["PBS", "SIMPLE_CHEMICAL", 75, 78], ["DMSO", "SIMPLE_CHEMICAL", 86, 90], ["Rolipram", "TREATMENT", 0, 8], ["dimethyl sulfoxide (DMSO", "TREATMENT", 26, 50], ["further diluted in PBS (final DMSO concentration", "TREATMENT", 56, 104]]], ["First, male C57BL/6 mice were intraperitoneally (i.p.) injected with 200 \u00b5L rolipram (10 mg/kg) 1 hr before, 1 hr after, or at the same time as LPS (15 mg/kg in 200 \u00b5L).", [["intraperitoneally", "ANATOMY", 30, 47], ["rolipram", "CHEMICAL", 76, 84], ["LPS", "CHEMICAL", 144, 147], ["rolipram", "CHEMICAL", 76, 84], ["C57BL/6 mice", "ORGANISM", 12, 24], ["rolipram", "SIMPLE_CHEMICAL", 76, 84], ["LPS", "SIMPLE_CHEMICAL", 144, 147], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["male C57BL/6 mice", "TREATMENT", 7, 24], ["200 \u00b5L rolipram", "TREATMENT", 69, 84]]], ["Survival rate was monitored for 7 days.", [["Survival rate", "TEST", 0, 13]]], ["The experiments were repeated using variable doses of rolipram (1, 5, and 10 mg/kg).", [["rolipram", "CHEMICAL", 54, 62], ["rolipram", "CHEMICAL", 54, 62], ["rolipram", "SIMPLE_CHEMICAL", 54, 62], ["variable doses of rolipram", "TREATMENT", 36, 62]]], ["At 0, 3, 12, 24, and 48 hr after LPS injection, mice were anesthetized and sacrificed.", [["LPS", "CHEMICAL", 33, 36], ["LPS", "SIMPLE_CHEMICAL", 33, 36], ["mice", "ORGANISM", 48, 52], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["LPS injection", "TREATMENT", 33, 46]]], ["Blood was collected for analysis of serum cytokines.", [["Blood", "ANATOMY", 0, 5], ["serum", "ANATOMY", 36, 41], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["serum cytokines", "PROTEIN", 36, 51], ["Blood", "TEST", 0, 5], ["analysis of serum cytokines", "TEST", 24, 51]]], ["For histological analysis, normal saline (10 mL) was perfused through the right heart ventricle.", [["right heart ventricle", "ANATOMY", 74, 95], ["saline", "SIMPLE_CHEMICAL", 34, 40], ["heart ventricle", "MULTI-TISSUE_STRUCTURE", 80, 95], ["histological analysis", "TEST", 4, 25], ["normal saline", "TREATMENT", 27, 40], ["right", "ANATOMY_MODIFIER", 74, 79], ["heart ventricle", "ANATOMY", 80, 95]]], ["Lung, liver, and kidney samples were collected and processed as described later.", [["Lung", "ANATOMY", 0, 4], ["liver", "ANATOMY", 6, 11], ["kidney samples", "ANATOMY", 17, 31], ["Lung", "ORGAN", 0, 4], ["liver", "ORGAN", 6, 11], ["kidney samples", "CANCER", 17, 31], ["Lung, liver, and kidney samples", "TEST", 0, 31], ["liver", "ANATOMY", 6, 11], ["kidney", "ANATOMY", 17, 23]]], ["Mouse blood samples were left at room temperature for 1 hr, then spun at 1000 \u00d7 g for 15 minutes at 4 degrees C. Serum was obtained and stored at \u221280 degrees C until required.Cytokine assays ::: MethodsCytokines from mouse serum were measured using the MILLIPLEX\u00ae MAP Mouse Cytokine/Chemokine Magnetic Bead Panel Kit for 96-Well Plate Assay, run on a Luminex platform.", [["blood samples", "ANATOMY", 6, 19], ["Serum", "ANATOMY", 113, 118], ["serum", "ANATOMY", 223, 228], ["Mouse", "ORGANISM", 0, 5], ["blood samples", "ORGANISM_SUBSTANCE", 6, 19], ["Serum", "ORGANISM_SUBSTANCE", 113, 118], ["MethodsCytokines", "SIMPLE_CHEMICAL", 195, 211], ["mouse", "ORGANISM", 217, 222], ["serum", "ORGANISM_SUBSTANCE", 223, 228], ["Cytokine", "PROTEIN", 175, 183], ["Cytokine", "PROTEIN", 274, 282], ["Chemokine", "PROTEIN", 283, 292], ["Mouse", "SPECIES", 0, 5], ["mouse", "SPECIES", 217, 222], ["Mouse", "SPECIES", 268, 273], ["Mouse", "SPECIES", 0, 5], ["mouse", "SPECIES", 217, 222], ["Mouse", "SPECIES", 268, 273], ["Mouse blood samples", "TEST", 0, 19], ["Serum", "TEST", 113, 118], ["Cytokine assays", "TEST", 175, 190], ["MethodsCytokines from mouse serum", "TEST", 195, 228], ["MAP", "TEST", 264, 267], ["Bead Panel", "TEST", 302, 312], ["Kit", "TEST", 313, 316], ["Plate Assay", "TEST", 329, 340], ["a Luminex platform", "TREATMENT", 349, 367]]], ["Cytokines include the three primary cytokines of interest: tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1-\u03b2 (IL-1\u03b2), and IL-6.", [["tumor", "DISEASE", 59, 64], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 59, 82], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 84, 89], ["interleukin-1-\u03b2", "GENE_OR_GENE_PRODUCT", 92, 107], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 109, 114], ["IL-6", "GENE_OR_GENE_PRODUCT", 121, 125], ["Cytokines", "PROTEIN", 0, 9], ["cytokines", "PROTEIN", 36, 45], ["tumor necrosis factor-\u03b1 (TNF-\u03b1", "PROTEIN", 59, 89], ["interleukin-1-\u03b2 (IL-1\u03b2", "PROTEIN", 92, 114], ["IL-6", "PROTEIN", 121, 125], ["Cytokines", "TREATMENT", 0, 9], ["tumor necrosis factor", "PROBLEM", 59, 80], ["TNF", "TEST", 84, 87], ["interleukin", "TEST", 92, 103], ["IL", "TEST", 109, 111], ["IL", "TEST", 121, 123], ["tumor", "OBSERVATION_MODIFIER", 59, 64], ["necrosis", "OBSERVATION", 65, 73]]], ["Multiple cytokines were also explored: IL-1\u03b1, IL-2, IL-5, IL-7, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IFN-\u03b3 inducible protein 10 (IP-10), eotaxin, interferon-\u03b3 (IFN-\u03b3), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1\u03b1 (MIP-1\u03b1), MIP-1\u03b2, MIP-2, migration-inducing protein (MIG), keratinocyte chemoattractant (KC), leukemia inhibitory factor (LIF), lipopolysaccharide-induced CXC chemokine (LIX), lipopolysaccharide-induced CXC chemokine (RANTGES), granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF, M-CSF, and vascular endothelial growth factor (VEGF).", [["lipopolysaccharide", "CHEMICAL", 396, 414], ["lipopolysaccharide", "CHEMICAL", 444, 462], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 39, 44], ["IL-2", "GENE_OR_GENE_PRODUCT", 46, 50], ["IL-5", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL-7", "GENE_OR_GENE_PRODUCT", 58, 62], ["IL-9", "GENE_OR_GENE_PRODUCT", 64, 68], ["IL-10", "GENE_OR_GENE_PRODUCT", 70, 75], ["IL-12", "GENE_OR_GENE_PRODUCT", 77, 82], ["p40", "GENE_OR_GENE_PRODUCT", 83, 86], ["IL-12", "GENE_OR_GENE_PRODUCT", 89, 94], ["p70", "GENE_OR_GENE_PRODUCT", 95, 98], ["IL-13", "GENE_OR_GENE_PRODUCT", 101, 106], ["IL-15", "GENE_OR_GENE_PRODUCT", 108, 113], ["IL-17", "GENE_OR_GENE_PRODUCT", 115, 120], ["IFN-\u03b3 inducible protein 10", "GENE_OR_GENE_PRODUCT", 122, 148], ["IP-10", "GENE_OR_GENE_PRODUCT", 150, 155], ["eotaxin", "GENE_OR_GENE_PRODUCT", 158, 165], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 167, 179], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 181, 186], ["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 189, 223], ["MCP-1", "GENE_OR_GENE_PRODUCT", 225, 230], ["macrophage inflammatory protein-1\u03b1", "GENE_OR_GENE_PRODUCT", 233, 267], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 269, 275], ["MIP-1\u03b2", "GENE_OR_GENE_PRODUCT", 278, 284], ["MIP-2", "GENE_OR_GENE_PRODUCT", 286, 291], ["migration-inducing protein", "GENE_OR_GENE_PRODUCT", 293, 319], ["MIG", "GENE_OR_GENE_PRODUCT", 321, 324], ["keratinocyte chemoattractant", "GENE_OR_GENE_PRODUCT", 327, 355], ["KC", "GENE_OR_GENE_PRODUCT", 357, 359], ["leukemia inhibitory factor", "GENE_OR_GENE_PRODUCT", 362, 388], ["LIF", "GENE_OR_GENE_PRODUCT", 390, 393], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 396, 414], ["CXC chemokine", "GENE_OR_GENE_PRODUCT", 423, 436], ["LIX", "GENE_OR_GENE_PRODUCT", 438, 441], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 444, 462], ["CXC chemokine", "GENE_OR_GENE_PRODUCT", 471, 484], ["RANTGES", "GENE_OR_GENE_PRODUCT", 486, 493], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 496, 544], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 546, 552], ["G-CSF", "GENE_OR_GENE_PRODUCT", 555, 560], ["M-CSF", "GENE_OR_GENE_PRODUCT", 562, 567], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 573, 607], ["VEGF", "GENE_OR_GENE_PRODUCT", 609, 613], ["cytokines", "PROTEIN", 9, 18], ["p40", "PROTEIN", 83, 86], ["p70", "PROTEIN", 95, 98], ["IFN-\u03b3 inducible protein 10", "PROTEIN", 122, 148], ["IP-10", "PROTEIN", 150, 155], ["eotaxin", "PROTEIN", 158, 165], ["interferon-\u03b3", "PROTEIN", 167, 179], ["IFN-\u03b3", "PROTEIN", 181, 186], ["monocyte chemoattractant protein-1 (MCP-1", "PROTEIN", 189, 230], ["macrophage inflammatory protein-1\u03b1 (MIP-1\u03b1", "PROTEIN", 233, 275], ["MIP-1\u03b2", "PROTEIN", 278, 284], ["MIP-2, migration-inducing protein", "PROTEIN", 286, 319], ["MIG", "PROTEIN", 321, 324], ["keratinocyte chemoattractant", "PROTEIN", 327, 355], ["KC", "PROTEIN", 357, 359], ["leukemia inhibitory factor", "PROTEIN", 362, 388], ["LIF", "PROTEIN", 390, 393], ["CXC chemokine", "PROTEIN", 423, 436], ["LIX", "PROTEIN", 438, 441], ["CXC chemokine", "PROTEIN", 471, 484], ["RANTGES", "PROTEIN", 486, 493], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 496, 544], ["GM", "PROTEIN", 546, 548], ["CSF", "PROTEIN", 549, 552], ["CSF", "PROTEIN", 557, 560], ["CSF", "PROTEIN", 564, 567], ["vascular endothelial growth factor", "PROTEIN", 573, 607], ["VEGF", "PROTEIN", 609, 613], ["Multiple cytokines", "TEST", 0, 18], ["IL", "TEST", 39, 41], ["IL", "TEST", 46, 48], ["IL", "TEST", 52, 54], ["IL", "TEST", 58, 60], ["IL", "TEST", 64, 66], ["IL", "TEST", 70, 72], ["IL", "TEST", 77, 79], ["IL", "TEST", 89, 91], ["IL", "TEST", 101, 103], ["IL", "TEST", 108, 110], ["IL", "TEST", 115, 117], ["IFN", "TEST", 122, 125], ["inducible protein", "TEST", 128, 145], ["IP", "TEST", 150, 152], ["eotaxin", "TEST", 158, 165], ["interferon", "TEST", 167, 177], ["IFN", "TEST", 181, 184], ["monocyte chemoattractant protein", "TEST", 189, 221], ["MCP", "TEST", 225, 228], ["macrophage inflammatory protein", "TEST", 233, 264], ["MIP", "TEST", 269, 272], ["MIP", "TEST", 278, 281], ["MIP", "TEST", 286, 289], ["migration", "TEST", 293, 302], ["protein", "TEST", 312, 319], ["MIG", "TEST", 321, 324], ["keratinocyte chemoattractant (KC)", "TREATMENT", 327, 360], ["leukemia inhibitory factor", "PROBLEM", 362, 388], ["lipopolysaccharide", "TEST", 396, 414], ["CXC chemokine", "TEST", 423, 436], ["LIX", "TEST", 438, 441], ["lipopolysaccharide", "TEST", 444, 462], ["CXC chemokine", "TEST", 471, 484], ["RANTGES", "TEST", 486, 493], ["granulocyte", "TEST", 496, 507], ["macrophage colony", "TEST", 508, 525], ["stimulating factor", "TEST", 526, 544], ["GM", "TEST", 546, 548], ["CSF", "TEST", 549, 552], ["G-CSF", "TEST", 555, 560], ["M-CSF", "TEST", 562, 567], ["vascular endothelial growth factor", "PROBLEM", 573, 607], ["cytokines", "OBSERVATION", 9, 18], ["granulocyte", "ANATOMY", 496, 507], ["macrophage", "ANATOMY", 508, 518], ["vascular endothelial", "ANATOMY", 573, 593]]], ["For quality assurance, each sample was run twice.Liver and renal function tests ::: MethodsSerum activity of aspartate aminotransferase (AST, a nonspecific marker for hepatic injury), alanine aminotransferase (ALT, a specific marker for hepatic parenchymal injury), blood urea nitrogen (BUN, a marker for glomerular renal function), and creatinine (Cr, a marker for glomerular filtration rate and renal failure) were measured by Fengrui Biotechnology Company kits (Hunan, China).Broncheoalveolar lavage (BAL) fluid collection and analysis ::: MethodsBAL was performed immediately after 24 hr of LPS challenge.", [["Liver", "ANATOMY", 49, 54], ["renal", "ANATOMY", 59, 64], ["hepatic", "ANATOMY", 167, 174], ["hepatic parenchymal", "ANATOMY", 237, 256], ["blood", "ANATOMY", 266, 271], ["glomerular renal", "ANATOMY", 305, 321], ["glomerular", "ANATOMY", 366, 376], ["renal", "ANATOMY", 397, 402], ["Broncheoalveolar lavage", "ANATOMY", 479, 502], ["BAL", "ANATOMY", 504, 507], ["aspartate", "CHEMICAL", 109, 118], ["hepatic injury", "DISEASE", 167, 181], ["alanine", "CHEMICAL", 184, 191], ["blood urea nitrogen", "CHEMICAL", 266, 285], ["creatinine", "CHEMICAL", 337, 347], ["Cr", "CHEMICAL", 349, 351], ["renal failure", "DISEASE", 397, 410], ["LPS", "CHEMICAL", 595, 598], ["aspartate", "CHEMICAL", 109, 118], ["alanine", "CHEMICAL", 184, 191], ["urea", "CHEMICAL", 272, 276], ["nitrogen", "CHEMICAL", 277, 285], ["creatinine", "CHEMICAL", 337, 347], ["Cr", "CHEMICAL", 349, 351], ["Liver", "ORGAN", 49, 54], ["renal", "ORGAN", 59, 64], ["MethodsSerum", "SIMPLE_CHEMICAL", 84, 96], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 109, 135], ["AST", "SIMPLE_CHEMICAL", 137, 140], ["hepatic", "ORGAN", 167, 174], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 184, 208], ["ALT", "SIMPLE_CHEMICAL", 210, 213], ["hepatic parenchymal", "MULTI-TISSUE_STRUCTURE", 237, 256], ["blood", "ORGANISM_SUBSTANCE", 266, 271], ["urea nitrogen", "SIMPLE_CHEMICAL", 272, 285], ["BUN", "SIMPLE_CHEMICAL", 287, 290], ["glomerular renal", "MULTI-TISSUE_STRUCTURE", 305, 321], ["creatinine", "SIMPLE_CHEMICAL", 337, 347], ["Cr", "SIMPLE_CHEMICAL", 349, 351], ["glomerular", "TISSUE", 366, 376], ["renal", "ORGAN", 397, 402], ["BAL", "MULTI-TISSUE_STRUCTURE", 504, 507], ["MethodsBAL", "SIMPLE_CHEMICAL", 543, 553], ["LPS", "SIMPLE_CHEMICAL", 595, 598], ["aspartate aminotransferase", "PROTEIN", 109, 135], ["AST", "PROTEIN", 137, 140], ["alanine aminotransferase", "PROTEIN", 184, 208], ["ALT", "PROTEIN", 210, 213], ["Liver and renal function tests", "TEST", 49, 79], ["aspartate aminotransferase", "TEST", 109, 135], ["AST", "TEST", 137, 140], ["a nonspecific marker", "TEST", 142, 162], ["hepatic injury", "PROBLEM", 167, 181], ["alanine aminotransferase", "TEST", 184, 208], ["ALT", "TEST", 210, 213], ["hepatic parenchymal injury", "PROBLEM", 237, 263], ["blood urea nitrogen", "TEST", 266, 285], ["BUN", "TEST", 287, 290], ["a marker", "TEST", 292, 300], ["glomerular renal function", "TEST", 305, 330], ["creatinine", "TEST", 337, 347], ["Cr", "TEST", 349, 351], ["a marker", "TEST", 353, 361], ["glomerular filtration rate", "TEST", 366, 392], ["renal failure", "PROBLEM", 397, 410], ["Broncheoalveolar lavage (BAL) fluid collection", "TEST", 479, 525], ["MethodsBAL", "TREATMENT", 543, 553], ["LPS challenge", "TREATMENT", 595, 608], ["renal", "ANATOMY", 59, 64], ["hepatic", "ANATOMY", 167, 174], ["injury", "OBSERVATION", 175, 181], ["hepatic", "ANATOMY", 237, 244], ["parenchymal", "ANATOMY_MODIFIER", 245, 256], ["injury", "OBSERVATION", 257, 263], ["renal", "ANATOMY", 316, 321], ["renal", "ANATOMY", 397, 402], ["failure", "OBSERVATION", 403, 410], ["lavage", "OBSERVATION", 496, 502], ["fluid collection", "OBSERVATION", 509, 525]]], ["Lungs were lavaged with PBS (0.5 mL \u00d7 3).", [["Lungs", "ANATOMY", 0, 5], ["Lungs", "ORGAN", 0, 5], ["PBS", "TREATMENT", 24, 27], ["lavaged", "OBSERVATION", 11, 18]]], ["The recovery rate of BAL fluid (BALF) was approximately 80%.", [["BAL fluid", "ANATOMY", 21, 30], ["BALF", "ANATOMY", 32, 36], ["BAL fluid", "ORGANISM_SUBSTANCE", 21, 30], ["BALF", "ORGANISM_SUBSTANCE", 32, 36], ["BAL fluid (BALF", "TEST", 21, 36], ["BAL fluid", "OBSERVATION", 21, 30]]], ["Cells were isolated from the BALF by centrifugation of 500 x g for 5 minutes, and the cell pellets were resuspended.", [["Cells", "ANATOMY", 0, 5], ["BALF", "ANATOMY", 29, 33], ["cell", "ANATOMY", 86, 90], ["Cells", "CELL", 0, 5], ["BALF", "ORGANISM_SUBSTANCE", 29, 33], ["cell", "CELL", 86, 90], ["BALF", "CELL_TYPE", 29, 33], ["Cells", "TEST", 0, 5], ["the cell pellets", "TREATMENT", 82, 98]]], ["The total cells in the BALF were counted using a hemocytometer.", [["cells", "ANATOMY", 10, 15], ["BALF", "ANATOMY", 23, 27], ["cells", "CELL", 10, 15], ["BALF", "CELL", 23, 27], ["BALF", "CELL_TYPE", 23, 27], ["The total cells", "TEST", 0, 15], ["the BALF", "TEST", 19, 27], ["a hemocytometer", "TEST", 47, 62], ["total cells", "OBSERVATION", 4, 15], ["BALF", "ANATOMY", 23, 27]]], ["Subsequently, the cell suspension was cytospin-centrifuged onto microscope slides and stained using Liu Stain (Baso, China).", [["cell", "ANATOMY", 18, 22], ["cell", "CELL", 18, 22], ["the cell suspension", "TREATMENT", 14, 33], ["cytospin", "TEST", 38, 46], ["microscope slides", "TEST", 64, 81], ["Liu Stain", "TEST", 100, 109]]], ["The percentage of neutrophils was determined by counting 400 cells.", [["neutrophils", "ANATOMY", 18, 29], ["cells", "ANATOMY", 61, 66], ["neutrophils", "CELL", 18, 29], ["cells", "CELL", 61, 66], ["neutrophils", "CELL_TYPE", 18, 29], ["The percentage of neutrophils", "TEST", 0, 29], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["neutrophils", "OBSERVATION", 18, 29]]], ["The BALF supernatant was analysed for total protein concentration by using bicinchonic acid (BCA) assay, according to the manufacturer\u2019s instructions.Histology ::: MethodsLungs, livers, and kidneys were fixed in 4% paraformaldehyde (pH 7.4).", [["BALF supernatant", "ANATOMY", 4, 20], ["livers", "ANATOMY", 178, 184], ["kidneys", "ANATOMY", 190, 197], ["bicinchonic acid", "CHEMICAL", 75, 91], ["bicinchonic acid", "CHEMICAL", 75, 91], ["BCA", "CHEMICAL", 93, 96], ["paraformaldehyde", "CHEMICAL", 215, 231], ["BALF", "ORGANISM_SUBSTANCE", 4, 8], ["bicinchonic acid", "SIMPLE_CHEMICAL", 75, 91], ["BCA", "SIMPLE_CHEMICAL", 93, 96], ["livers", "ORGAN", 178, 184], ["kidneys", "ORGAN", 190, 197], ["paraformaldehyde", "SIMPLE_CHEMICAL", 215, 231], ["The BALF supernatant", "TREATMENT", 0, 20], ["total protein concentration", "TREATMENT", 38, 65], ["bicinchonic acid (BCA", "TREATMENT", 75, 96], ["pH", "TEST", 233, 235], ["livers", "ANATOMY", 178, 184], ["kidneys", "ANATOMY", 190, 197], ["fixed", "OBSERVATION_MODIFIER", 203, 208]]], ["The organs were then dehydrated and embedded in paraffin.", [["organs", "ANATOMY", 4, 10], ["paraffin", "CHEMICAL", 48, 56], ["organs", "ORGAN", 4, 10], ["dehydrated", "PROBLEM", 21, 31], ["organs", "ANATOMY", 4, 10]]], ["The slides were then stained with hematoxylin and eosin (H&E), and examined by a light microscope.Western blot analysis ::: MethodsTotal protein was extracted from the frozen lung tissue using T-PER Tissue Protein Extraction Reagent (Pierce, IL, USA).", [["lung tissue", "ANATOMY", 175, 186], ["hematoxylin", "CHEMICAL", 34, 45], ["eosin", "CHEMICAL", 50, 55], ["hematoxylin", "SIMPLE_CHEMICAL", 34, 45], ["eosin", "SIMPLE_CHEMICAL", 50, 55], ["lung tissue", "TISSUE", 175, 186], ["hematoxylin", "TREATMENT", 34, 45], ["a light microscope", "TEST", 79, 97], ["Methods", "TREATMENT", 124, 131], ["Total protein", "TEST", 131, 144], ["T-PER Tissue Protein Extraction", "TREATMENT", 193, 224], ["protein", "OBSERVATION", 137, 144], ["lung", "ANATOMY", 175, 179]]], ["Protein concentrations were determined using a BCA Assay Kit (KeyGEN, China).", [["Protein concentrations", "PROBLEM", 0, 22], ["a BCA", "TEST", 45, 50]]], ["Equal amounts of lung tissue protein (100 \u00b5g per animal) were run on a 10% SDS-PAGE gel and transferred onto polyvinylidene difluoride (PVDF) membranes.", [["lung tissue", "ANATOMY", 17, 28], ["polyvinylidene difluoride", "CHEMICAL", 109, 134], ["PVDF", "CHEMICAL", 136, 140], ["lung tissue", "TISSUE", 17, 28], ["lung tissue protein", "PROTEIN", 17, 36], ["lung tissue protein", "TEST", 17, 36], ["a 10% SDS", "TREATMENT", 69, 78], ["PAGE gel", "TREATMENT", 79, 87], ["polyvinylidene difluoride (PVDF) membranes", "TREATMENT", 109, 151], ["amounts", "OBSERVATION_MODIFIER", 6, 13], ["lung", "ANATOMY", 17, 21], ["tissue", "ANATOMY_MODIFIER", 22, 28]]], ["The membranes were blocked with 5% bovine serum albumin (BSA) in TBST at room temperature for 2 hr, and then incubated with primary antibody against mouse ERK1/2, p-ERK1/2, JNK, p-JNK, p38, p-p38, or p65 (all at a 1:1000 antibody:BSA ratio) at 4 degrees C overnight.", [["membranes", "ANATOMY", 4, 13], ["serum", "ANATOMY", 42, 47], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["bovine", "ORGANISM", 35, 41], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["albumin", "SIMPLE_CHEMICAL", 48, 55], ["BSA", "SIMPLE_CHEMICAL", 57, 60], ["mouse", "ORGANISM", 149, 154], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 155, 161], ["p-ERK1/2", "GENE_OR_GENE_PRODUCT", 163, 171], ["JNK", "GENE_OR_GENE_PRODUCT", 173, 176], ["p-JNK", "GENE_OR_GENE_PRODUCT", 178, 183], ["p38", "GENE_OR_GENE_PRODUCT", 185, 188], ["p-p38", "GENE_OR_GENE_PRODUCT", 190, 195], ["p65", "GENE_OR_GENE_PRODUCT", 200, 203], ["BSA", "SIMPLE_CHEMICAL", 230, 233], ["ERK1", "PROTEIN", 155, 159], ["ERK1/2", "PROTEIN", 165, 171], ["JNK", "PROTEIN", 173, 176], ["JNK", "PROTEIN", 180, 183], ["p38", "PROTEIN", 185, 188], ["p38", "PROTEIN", 192, 195], ["p65", "PROTEIN", 200, 203], ["1:1000 antibody", "PROTEIN", 214, 229], ["bovine", "SPECIES", 35, 41], ["mouse", "SPECIES", 149, 154], ["mouse", "SPECIES", 149, 154], ["5% bovine serum albumin (BSA", "TREATMENT", 32, 60], ["primary antibody", "TEST", 124, 140], ["mouse ERK1", "TEST", 149, 159], ["p", "TEST", 163, 164], ["ERK1/", "TEST", 165, 170], ["JNK", "TEST", 173, 176], ["p", "TEST", 178, 179], ["JNK", "TEST", 180, 183], ["p38", "TEST", 185, 188], ["p", "TEST", 190, 191], ["p65", "TEST", 200, 203], ["BSA ratio", "TEST", 230, 239]]], ["After 3 washes with TBST, the membranes were incubated in secondary HRP-conjugated anti-rabbit IgG at room temperature for 1 hr.", [["membranes", "ANATOMY", 30, 39], ["membranes", "CELLULAR_COMPONENT", 30, 39], ["HRP", "SIMPLE_CHEMICAL", 68, 71], ["secondary HRP", "PROTEIN", 58, 71], ["anti-rabbit IgG", "PROTEIN", 83, 98], ["anti-rabbit", "SPECIES", 83, 94], ["anti-rabbit", "SPECIES", 83, 94], ["TBST", "TREATMENT", 20, 24], ["the membranes", "TREATMENT", 26, 39]]], ["The membranes were then washed with TBST, processed with an ECL detection kit (Pierce, IL, USA), and measured on film in a darkroom.Immunofluorescence ::: MethodsAll tissue stainings were performed on frozen 8 \u00b5M-thick OCT-embedded mouse lung tissue sections.", [["membranes", "ANATOMY", 4, 13], ["tissue", "ANATOMY", 166, 172], ["lung tissue sections", "ANATOMY", 238, 258], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["tissue", "TISSUE", 166, 172], ["mouse", "ORGANISM", 232, 237], ["lung tissue sections", "MULTI-TISSUE_STRUCTURE", 238, 258], ["mouse", "SPECIES", 232, 237], ["mouse", "SPECIES", 232, 237], ["film", "TEST", 113, 117], ["All tissue stainings", "TEST", 162, 182], ["frozen", "TEST", 201, 207], ["thick OCT", "TEST", 213, 222], ["lung tissue", "ANATOMY", 238, 249]]], ["Sections were blocked to eliminate non-specific binding with 0.5% BSA in PBS for 1 hr, then incubated with primary antibody against mouse phosphorylated p65 (1:100) at 4 degrees overnight.", [["BSA", "CHEMICAL", 66, 69], ["BSA", "SIMPLE_CHEMICAL", 66, 69], ["mouse", "ORGANISM", 132, 137], ["p65", "GENE_OR_GENE_PRODUCT", 153, 156], ["primary antibody", "PROTEIN", 107, 123], ["mouse phosphorylated p65", "PROTEIN", 132, 156], ["mouse", "SPECIES", 132, 137], ["mouse", "SPECIES", 132, 137], ["non-specific binding", "PROBLEM", 35, 55], ["0.5% BSA in PBS", "TREATMENT", 61, 76], ["primary antibody", "TEST", 107, 123], ["mouse phosphorylated p65", "TEST", 132, 156]]], ["After subsequent washes with PBS, the sections were incubated with Alexa Fluor\u00ae 488 goat anti-rabbit IgG (H + L) for 1 hr at 37 degrees C, then washed with PBS.", [["sections", "ANATOMY", 38, 46], ["Alexa Fluor\u00ae 488 goat anti-rabbit IgG", "PROTEIN", 67, 104], ["H + L", "PROTEIN", 106, 111], ["goat", "SPECIES", 84, 88], ["anti-rabbit", "SPECIES", 89, 100], ["Alexa Fluor\u00ae 488", "SPECIES", 67, 83], ["goat", "SPECIES", 84, 88], ["PBS", "TREATMENT", 29, 32], ["the sections", "TEST", 34, 46], ["Alexa Fluor\u00ae", "TEST", 67, 79], ["anti-rabbit IgG", "TEST", 89, 104], ["PBS", "TREATMENT", 156, 159]]], ["The slides were stained with DAPI (Santa Cruz Biotechnology, CA, USA) for 5 min.", [["DAPI", "CHEMICAL", 29, 33], ["DAPI", "SIMPLE_CHEMICAL", 29, 33]]], ["Coverslips were mounted onto the slides using anti-fade reagent (Beyotime Biotechnology, China).", [["anti-fade reagent", "TREATMENT", 46, 63]]], ["The images were acquired using a Zeiss LSM 710 confocal microscope (Zeiss, Germany).Statistical analysis ::: MethodsData are expressed as the mean plus or minus standard deviations.", [["The images", "TEST", 0, 10], ["confocal microscope", "TEST", 47, 66], ["MethodsData", "TREATMENT", 109, 120], ["minus standard deviations", "PROBLEM", 155, 180], ["minus", "OBSERVATION", 155, 160], ["standard deviations", "OBSERVATION", 161, 180]]], ["Statistical evaluation was performed with SPSS software (Version 20.0).", [["Statistical evaluation", "TEST", 0, 22], ["SPSS software", "TEST", 42, 55], ["Version", "TEST", 57, 64]]], ["Kaplan-Meier analysis, followed by a log-rank test, was used for survival time analysis.", [["Meier analysis", "TEST", 7, 21], ["a log-rank test", "TEST", 35, 50], ["survival time analysis", "TEST", 65, 87]]]], "eab864c28b61d92f3fa719ad7a8de29d074fd984": [["INTRODUCTIONframes (ORFs), ORF1a and ORF1b.", [["ORF1a", "GENE_OR_GENE_PRODUCT", 27, 32], ["ORF1b", "GENE_OR_GENE_PRODUCT", 37, 42], ["INTRODUCTIONframes", "PROTEIN", 0, 18], ["ORFs", "DNA", 20, 24], ["ORF1a", "DNA", 27, 32], ["ORF1b", "DNA", 37, 42]]], ["1 ORF1a encodes the polyprotein pp1a with a calculated molecular mass of 454 kDa.", [["ORF1a", "GENE_OR_GENE_PRODUCT", 2, 7], ["pp1a", "GENE_OR_GENE_PRODUCT", 32, 36], ["ORF1a", "DNA", 2, 7], ["polyprotein pp1a", "PROTEIN", 20, 36], ["the polyprotein pp1a", "TREATMENT", 16, 36], ["a calculated molecular mass", "PROBLEM", 42, 69], ["mass", "OBSERVATION", 65, 69]]], ["The downstream ORF1b is expressed as a fusion protein with pp1a by a mechanism involving a ( 1) ribosomal frame shift during translation.", [["ribosomal", "ANATOMY", 96, 105], ["ORF1b", "GENE_OR_GENE_PRODUCT", 15, 20], ["pp1a", "GENE_OR_GENE_PRODUCT", 59, 63], ["ORF1b", "PROTEIN", 15, 20], ["fusion protein", "PROTEIN", 39, 53], ["pp1a", "PROTEIN", 59, 63], ["a fusion protein", "TREATMENT", 37, 53]]], ["1, 2 The ORF1a/1b gene product has a calculated molecular mass of 754 kDa and is referred to as polyprotein 1ab (pp1ab). pp1a and pp1ab are processed by two virusencoded, papain-like proteases and the main protease M pro , resulting in at least 16 non structural proteins (Nsps).", [["ORF1a/1b", "GENE_OR_GENE_PRODUCT", 9, 17], ["polyprotein 1ab", "GENE_OR_GENE_PRODUCT", 96, 111], ["pp1ab", "GENE_OR_GENE_PRODUCT", 113, 118], ["pp1a", "GENE_OR_GENE_PRODUCT", 121, 125], ["pp1ab", "GENE_OR_GENE_PRODUCT", 130, 135], ["papain", "GENE_OR_GENE_PRODUCT", 171, 177], ["Nsps", "GENE_OR_GENE_PRODUCT", 273, 277], ["ORF1a/1b gene product", "PROTEIN", 9, 30], ["pp1ab", "PROTEIN", 113, 118], ["pp1a", "PROTEIN", 121, 125], ["pp1ab", "PROTEIN", 130, 135], ["virusencoded, papain-like proteases", "PROTEIN", 157, 192], ["protease M pro", "PROTEIN", 206, 220], ["structural proteins", "PROTEIN", 252, 271], ["Nsps", "PROTEIN", 273, 277], ["a calculated molecular mass", "PROBLEM", 35, 62], ["pp1a", "TEST", 121, 125], ["papain", "TREATMENT", 171, 177], ["the main protease M pro", "TREATMENT", 197, 220], ["mass", "OBSERVATION", 58, 62]]], ["3 Several or all of these nonstructural proteins build the replicase complex, probably mediating all the functions necessary for polyprotein processing, viral transcription, and replication.", [["nonstructural proteins", "PROTEIN", 26, 48], ["replicase complex", "PROTEIN", 59, 76], ["polyprotein processing", "TREATMENT", 129, 151], ["viral transcription", "TREATMENT", 153, 172]]], ["4 The 3\u00b4 region of the coronaviral ORF1a encodes a set of relatively small polypeptides (Nsp6 to Nsp11), of which only SARS-CoV Nsp9 has had a function assigned, i.e., as ssDNA/RNA-binding protein.", [["3\u00b4 region", "CELLULAR_COMPONENT", 6, 15], ["ORF1a", "GENE_OR_GENE_PRODUCT", 35, 40], ["Nsp6", "GENE_OR_GENE_PRODUCT", 89, 93], ["Nsp11", "GENE_OR_GENE_PRODUCT", 97, 102], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 119, 127], ["Nsp9", "GENE_OR_GENE_PRODUCT", 128, 132], ["ssDNA", "CELLULAR_COMPONENT", 171, 176], ["RNA-binding protein", "GENE_OR_GENE_PRODUCT", 177, 196], ["3\u00b4 region", "DNA", 6, 15], ["coronaviral ORF1a", "DNA", 23, 40], ["Nsp6", "PROTEIN", 89, 93], ["Nsp11", "PROTEIN", 97, 102], ["SARS-CoV Nsp9", "PROTEIN", 119, 132], ["ssDNA/RNA-binding protein", "PROTEIN", 171, 196], ["SARS-CoV", "SPECIES", 119, 127], ["relatively small polypeptides", "PROBLEM", 58, 87], ["ssDNA/RNA", "TEST", 171, 180], ["small", "OBSERVATION_MODIFIER", 69, 74], ["polypeptides", "OBSERVATION", 75, 87]]], ["5, 6 In mouse hepatitis CoV, several of these polypeptides colocalize with other components of the viral replication complex in the perinuclear region of the infected cell.", [["perinuclear region", "ANATOMY", 132, 150], ["cell", "ANATOMY", 167, 171], ["hepatitis CoV", "DISEASE", 14, 27], ["mouse", "ORGANISM", 8, 13], ["hepatitis CoV", "ORGANISM", 14, 27], ["perinuclear region", "CELLULAR_COMPONENT", 132, 150], ["cell", "CELL", 167, 171], ["viral replication complex", "PROTEIN", 99, 124], ["infected cell", "CELL_TYPE", 158, 171], ["mouse", "SPECIES", 8, 13], ["mouse hepatitis CoV", "SPECIES", 8, 27], ["mouse hepatitis CoV", "PROBLEM", 8, 27], ["these polypeptides", "TREATMENT", 40, 58], ["the viral replication complex", "PROBLEM", 95, 124], ["hepatitis CoV", "OBSERVATION", 14, 27], ["viral replication", "OBSERVATION", 99, 116], ["complex", "OBSERVATION_MODIFIER", 117, 124], ["perinuclear", "ANATOMY_MODIFIER", 132, 143], ["region", "ANATOMY_MODIFIER", 144, 150], ["infected cell", "OBSERVATION", 158, 171]]], ["7 Thus, the HCoV-229E polypeptides Nsp 6, 7, 8, and 10 are probably involved, directly or indirectly, in the viral replication complex.", [["HCoV-229E", "GENE_OR_GENE_PRODUCT", 12, 21], ["Nsp 6", "GENE_OR_GENE_PRODUCT", 35, 40], ["7", "GENE_OR_GENE_PRODUCT", 42, 43], ["8", "GENE_OR_GENE_PRODUCT", 45, 46], ["10", "GENE_OR_GENE_PRODUCT", 52, 54], ["HCoV", "PROTEIN", 12, 16], ["Nsp 6, 7, 8, and 10", "PROTEIN", 35, 54], ["viral replication complex", "PROTEIN", 109, 134], ["the HCoV", "TEST", 8, 16], ["viral replication", "OBSERVATION", 109, 126]]], ["In this communication, we will describe the expression of genes coding for HCoV-229E Nsp8 and Nsp9, as well as the purification and biophysical characterization of the proteins.", [["HCoV-229E Nsp8", "GENE_OR_GENE_PRODUCT", 75, 89], ["Nsp9", "GENE_OR_GENE_PRODUCT", 94, 98], ["HCoV", "PROTEIN", 75, 79], ["229E", "PROTEIN", 80, 84], ["Nsp8", "PROTEIN", 85, 89], ["Nsp9", "PROTEIN", 94, 98], ["HCoV", "TEST", 75, 79], ["Nsp9", "TREATMENT", 94, 98], ["the purification", "TEST", 111, 127], ["biophysical characterization", "TEST", 132, 160]]], ["The two proteins are shown to bind tRNA using zoneinterference electrophoresis and fluorescence spectroscopy.CloningGenes coding for Nsp8 and Nsp9 of HCoV-229E were amplified by polymerase chain reaction from virus-derived cDNA fragments.", [["fragments", "ANATOMY", 228, 237], ["zoneinterference", "SIMPLE_CHEMICAL", 46, 62], ["Nsp8", "GENE_OR_GENE_PRODUCT", 133, 137], ["Nsp9", "GENE_OR_GENE_PRODUCT", 142, 146], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 150, 159], ["Nsp8", "DNA", 133, 137], ["Nsp9", "DNA", 142, 146], ["HCoV", "DNA", 150, 154], ["229E", "DNA", 155, 159], ["cDNA fragments", "DNA", 223, 237], ["HCoV-229E", "SPECIES", 150, 159], ["zoneinterference electrophoresis", "TREATMENT", 46, 78], ["fluorescence spectroscopy", "TEST", 83, 108], ["Nsp8", "TEST", 133, 137], ["HCoV", "TEST", 150, 154], ["polymerase chain reaction", "PROBLEM", 178, 203], ["virus", "PROBLEM", 209, 214], ["cDNA fragments", "PROBLEM", 223, 237], ["cDNA fragments", "OBSERVATION", 223, 237]]], ["The amino-acid sequences encompass pp1a residues 3630-3824 for Nsp8, with an additional methionine at the Nterminus and six histidines at the C-terminus, and residues 3825-3933 for Nsp9, with an additional methionine, six histidines and a His-tag cleavage site for M pro at the Nterminus.", [["amino-acid", "CHEMICAL", 4, 14], ["methionine", "CHEMICAL", 88, 98], ["methionine", "CHEMICAL", 206, 216], ["amino-acid", "CHEMICAL", 4, 14], ["methionine", "CHEMICAL", 88, 98], ["histidines", "CHEMICAL", 124, 134], ["C", "CHEMICAL", 142, 143], ["methionine", "CHEMICAL", 206, 216], ["histidines", "CHEMICAL", 222, 232], ["His", "CHEMICAL", 239, 242], ["amino-acid", "AMINO_ACID", 4, 14], ["Nsp8", "GENE_OR_GENE_PRODUCT", 63, 67], ["methionine", "AMINO_ACID", 88, 98], ["Nsp9", "GENE_OR_GENE_PRODUCT", 181, 185], ["methionine", "SIMPLE_CHEMICAL", 206, 216], ["amino-acid sequences", "PROTEIN", 4, 24], ["Nsp8", "PROTEIN", 63, 67], ["Nterminus", "PROTEIN", 106, 115], ["C-terminus", "PROTEIN", 142, 152], ["Nsp9", "PROTEIN", 181, 185], ["His-tag cleavage site", "PROTEIN", 239, 260], ["M pro", "PROTEIN", 265, 270], ["Nterminus", "PROTEIN", 278, 287], ["The amino-acid sequences", "TEST", 0, 24], ["an additional methionine", "TREATMENT", 74, 98], ["an additional methionine", "TREATMENT", 192, 216], ["six histidines", "TREATMENT", 218, 232], ["a His-tag cleavage site", "TREATMENT", 237, 260]]], ["The nsp8 PCR product was cloned into the pET11a expression vector resulting in pETHCoV-229E/nsp8.", [["nsp8", "GENE_OR_GENE_PRODUCT", 4, 8], ["pET11a", "GENE_OR_GENE_PRODUCT", 41, 47], ["pETHCoV-229E", "GENE_OR_GENE_PRODUCT", 79, 91], ["nsp8", "GENE_OR_GENE_PRODUCT", 92, 96], ["nsp8 PCR product", "PROTEIN", 4, 20], ["pET11a expression vector", "DNA", 41, 65], ["pETHCoV", "PROTEIN", 79, 86], ["229E", "PROTEIN", 87, 91], ["nsp8", "DNA", 92, 96], ["The nsp8 PCR product", "TEST", 0, 20], ["pETHCoV", "TEST", 79, 86]]], ["The nsp9 PCR product was cloned into pET15b resulting in pETHCoV-229E/nsp9.Protein Production, Purification, and CharacterizationNsp8-and Nsp9-encoding plasmids were transformed in competent E. coli B834 (DE3) and E. coli Tuner (DE3) pLacI strains, respectively (Novagen).", [["nsp9", "GENE_OR_GENE_PRODUCT", 4, 8], ["pET15b", "GENE_OR_GENE_PRODUCT", 37, 43], ["pETHCoV-229E", "GENE_OR_GENE_PRODUCT", 57, 69], ["nsp9", "GENE_OR_GENE_PRODUCT", 70, 74], ["Nsp9", "GENE_OR_GENE_PRODUCT", 138, 142], ["E. coli B834", "ORGANISM", 191, 203], ["DE3", "GENE_OR_GENE_PRODUCT", 205, 208], ["E. coli Tuner", "ORGANISM", 214, 227], ["DE3) pLacI", "GENE_OR_GENE_PRODUCT", 229, 239], ["Novagen", "GENE_OR_GENE_PRODUCT", 263, 270], ["nsp9 PCR product", "PROTEIN", 4, 20], ["pET15b", "DNA", 37, 43], ["pETHCoV", "PROTEIN", 57, 64], ["229E", "PROTEIN", 65, 69], ["nsp9", "PROTEIN", 70, 74], ["CharacterizationNsp8-and Nsp9-encoding plasmids", "DNA", 113, 160], ["E. coli", "SPECIES", 191, 198], ["E. coli", "SPECIES", 214, 221], ["E. coli", "SPECIES", 191, 198], ["E. coli", "SPECIES", 214, 221], ["The nsp9 PCR product", "TEST", 0, 20], ["pETHCoV", "TEST", 57, 64], ["Protein Production", "TEST", 75, 93], ["Purification", "TEST", 95, 107], ["CharacterizationNsp8", "TEST", 113, 133], ["encoding plasmids", "TREATMENT", 143, 160], ["E. coli Tuner (DE3) pLacI strains", "TREATMENT", 214, 247], ["coli Tuner", "OBSERVATION", 217, 227]]], ["Cultures were grown in TY medium at 37\u00b0C until cells reached an O.D. of 0.4 at 660 nm.", [["cells", "ANATOMY", 47, 52], ["cells", "CELL", 47, 52], ["Cultures", "TEST", 0, 8], ["cells", "TEST", 47, 52]]], ["Cells were then induced with 1 mM IPTG and grew for a further 5 h for Nsp8 and 4 h for Nsp9 at 37\u00b0C. The cells were then harvested by centrifugation at 5500 rpm for 30 min at 4\u00b0C. The resulting pellets were frozen at -20\u00b0C. For lysis, the cell pellets were resuspended in 50 mM Tris-HCl and 300 mM NaCl pH 7.5 (25\u00b0C).", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 105, 110], ["cell", "ANATOMY", 239, 243], ["IPTG", "CHEMICAL", 34, 38], ["Tris-HCl", "CHEMICAL", 278, 286], ["NaCl", "CHEMICAL", 298, 302], ["IPTG", "CHEMICAL", 34, 38], ["Tris-HCl", "CHEMICAL", 278, 286], ["NaCl", "CHEMICAL", 298, 302], ["Cells", "CELL", 0, 5], ["IPTG", "SIMPLE_CHEMICAL", 34, 38], ["Nsp9", "GENE_OR_GENE_PRODUCT", 87, 91], ["cells", "CELL", 105, 110], ["cell", "CELL", 239, 243], ["Tris-HCl", "SIMPLE_CHEMICAL", 278, 286], ["Nsp8", "PROTEIN", 70, 74], ["Nsp9", "PROTEIN", 87, 91], ["1 mM IPTG", "TREATMENT", 29, 38], ["Nsp9", "TEST", 87, 91], ["The resulting pellets", "TREATMENT", 180, 201], ["lysis", "TREATMENT", 228, 233], ["the cell pellets", "TREATMENT", 235, 251], ["mM NaCl pH", "TEST", 295, 305], ["pellets", "OBSERVATION_MODIFIER", 194, 201]]], ["Cells were broken by ultrasonification on ice after adding glycerol (1%, v/v, for Nsp8, and 10%, v/v, for Nsp9), 20 mM imidazole, 0.01% (w/v) n-octyl-\u03b2-glucoside (Bachem) (final concentrations).", [["Cells", "ANATOMY", 0, 5], ["glycerol", "CHEMICAL", 59, 67], ["imidazole", "CHEMICAL", 119, 128], ["n-octyl-\u03b2-glucoside", "CHEMICAL", 142, 161], ["glycerol", "CHEMICAL", 59, 67], ["imidazole", "CHEMICAL", 119, 128], ["(w/v) n-octyl-\u03b2-glucoside", "CHEMICAL", 136, 161], ["Cells", "CELL", 0, 5], ["glycerol", "SIMPLE_CHEMICAL", 59, 67], ["Nsp8", "SIMPLE_CHEMICAL", 82, 86], ["Nsp9", "SIMPLE_CHEMICAL", 106, 110], ["imidazole", "SIMPLE_CHEMICAL", 119, 128], ["(w/v) n-octyl-\u03b2-glucoside", "SIMPLE_CHEMICAL", 136, 161], ["Bachem", "SIMPLE_CHEMICAL", 163, 169], ["glycerol", "TREATMENT", 59, 67], ["Nsp8", "TREATMENT", 82, 86], ["20 mM imidazole", "TREATMENT", 113, 128], ["n-octyl", "TREATMENT", 142, 149], ["glucoside (Bachem", "TREATMENT", 152, 169]]], ["To optimize the solubilization of overproduced Nsp8 and Nsp9, a sparse matrix screen of buffer composition was applied.", [["Nsp8", "GENE_OR_GENE_PRODUCT", 47, 51], ["Nsp9", "GENE_OR_GENE_PRODUCT", 56, 60], ["matrix", "CELLULAR_COMPONENT", 71, 77], ["Nsp8", "PROTEIN", 47, 51], ["Nsp9", "PROTEIN", 56, 60], ["Nsp9", "TREATMENT", 56, 60], ["a sparse matrix screen", "TEST", 62, 84], ["buffer composition", "TREATMENT", 88, 106]]], ["8 The sample was ultracentrifuged at 30,000 rpm for 1 h at 4 \u00b0C (Kontron TGA centrifuge, TFT 45.94 rotor).", [["sample", "ANATOMY", 6, 12], ["The sample", "TEST", 2, 12], ["TFT", "TEST", 89, 92]]], ["The supernatant was applied to a His Trap HP column (1 ml, Amersham Pharmacia) with a flow rate of 1 ml/min.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15], ["a His Trap HP column", "TREATMENT", 31, 51], ["Amersham Pharmacia", "TREATMENT", 59, 77], ["a flow rate", "TREATMENT", 84, 95]]], ["After washing with 50 mM Tris-HCl, 20 mM imidazole, 300 mM NaCl, pH 7.5 (25\u00b0C), the protein was eluted with a linear gradient ranging from 20 mM up to 500 mM imidazole.", [["Tris-HCl", "CHEMICAL", 25, 33], ["imidazole", "CHEMICAL", 41, 50], ["NaCl", "CHEMICAL", 59, 63], ["imidazole", "CHEMICAL", 158, 167], ["Tris-HCl", "CHEMICAL", 25, 33], ["imidazole", "CHEMICAL", 41, 50], ["NaCl", "CHEMICAL", 59, 63], ["imidazole", "CHEMICAL", 158, 167], ["Tris-HCl", "SIMPLE_CHEMICAL", 25, 33], ["imidazole", "SIMPLE_CHEMICAL", 41, 50], ["imidazole", "SIMPLE_CHEMICAL", 158, 167], ["20 mM imidazole", "TREATMENT", 35, 50], ["pH", "TEST", 65, 67], ["the protein", "TEST", 80, 91], ["a linear gradient", "TEST", 108, 125], ["linear", "OBSERVATION_MODIFIER", 110, 116], ["gradient", "OBSERVATION_MODIFIER", 117, 125]]], ["The engineered N-terminal His-tag contained a SARS-CoV M pro cleavage site.", [["His", "CHEMICAL", 26, 29], ["engineered N-terminal His-tag", "PROTEIN", 4, 33], ["SARS-CoV M pro cleavage site", "DNA", 46, 74], ["a SARS", "PROBLEM", 44, 50], ["CoV M pro cleavage site", "TREATMENT", 51, 74]]], ["Therefore, by incubating Nsp9 with M pro in a molar ratio of 100:1 for 16 h at 37\u00b0C in a reduced state (5mM DTT), the His tag was cleaved off from the Nsp9.", [["DTT", "CHEMICAL", 108, 111], ["His", "CHEMICAL", 118, 121], ["Nsp9", "GENE_OR_GENE_PRODUCT", 25, 29], ["His tag", "GENE_OR_GENE_PRODUCT", 118, 125], ["Nsp9", "GENE_OR_GENE_PRODUCT", 151, 155], ["Nsp9", "PROTEIN", 25, 29], ["M pro", "PROTEIN", 35, 40], ["His tag", "PROTEIN", 118, 125], ["Nsp9", "PROTEIN", 151, 155], ["a molar ratio", "TEST", 44, 57], ["the His tag", "TREATMENT", 114, 125]]], ["Protein was blotted and detected with anti-tetra-histidine antibodies (Dianova) and anti-mouse IgG-alkaline phosphatase conjugate (Sigma).Zone-Interference Gel ElectrophoresisThe zone-interference gel electrophoresis device was constructed as described.", [["anti-tetra-histidine", "CHEMICAL", 38, 58], ["anti-tetra-histidine", "CHEMICAL", 38, 58], ["anti-tetra-histidine antibodies", "SIMPLE_CHEMICAL", 38, 69], ["alkaline phosphatase conjugate", "SIMPLE_CHEMICAL", 99, 129], ["anti-tetra-histidine antibodies", "PROTEIN", 38, 69], ["Dianova", "PROTEIN", 71, 78], ["anti-mouse IgG", "PROTEIN", 84, 98], ["alkaline phosphatase conjugate", "PROTEIN", 99, 129], ["anti-mouse", "SPECIES", 84, 94], ["Protein", "TEST", 0, 7], ["anti-tetra-histidine antibodies", "TREATMENT", 38, 69], ["Dianova", "TEST", 71, 78], ["anti-mouse IgG", "TEST", 84, 98], ["alkaline phosphatase conjugate", "TEST", 99, 129], ["Zone-Interference Gel Electrophoresis", "TREATMENT", 138, 175], ["The zone-interference gel electrophoresis device", "TREATMENT", 175, 223], ["zone", "OBSERVATION_MODIFIER", 179, 183]]], ["9 The 1% (w/v) agarose gel was prepared in 20 mM Tris acetate, pH 8.3, 50 mM NaCl, and 3.5 2 concentration were applied to the extended zone slot (sample buffer: 10% DMSO in sample buffer was loaded into the small slot of the device.", [["Tris acetate", "CHEMICAL", 49, 61], ["NaCl", "CHEMICAL", 77, 81], ["DMSO", "CHEMICAL", 166, 170], ["Tris acetate", "CHEMICAL", 49, 61], ["NaCl", "CHEMICAL", 77, 81], ["DMSO", "CHEMICAL", 166, 170], ["agarose", "SIMPLE_CHEMICAL", 15, 22], ["Tris acetate", "SIMPLE_CHEMICAL", 49, 61], ["DMSO", "SIMPLE_CHEMICAL", 166, 170], ["The 1% (w/v) agarose gel", "TREATMENT", 2, 26], ["20 mM Tris acetate", "TREATMENT", 43, 61], ["pH", "TEST", 63, 65], ["50 mM NaCl", "TREATMENT", 71, 81], ["the extended zone slot (sample buffer", "TREATMENT", 123, 160], ["10% DMSO in sample buffer", "TREATMENT", 162, 187], ["the device", "TREATMENT", 222, 232], ["small slot", "OBSERVATION", 208, 218]]], ["Gels were run at 200 mA for 2 h at 4\u00b0C in electrophoresis buffer.", [["Gels", "SIMPLE_CHEMICAL", 0, 4], ["C", "SIMPLE_CHEMICAL", 37, 38], ["C in electrophoresis buffer", "TREATMENT", 37, 64]]], ["9 K d values were calculated using the equation: The zone-interference gel electrophoresis apparatus was reconstructed for HCoV-229E Nsp9.", [["HCoV", "PROTEIN", 123, 127], ["229E Nsp9", "PROTEIN", 128, 137], ["HCoV-229E Nsp9", "SPECIES", 123, 137], ["K d values", "TEST", 2, 12], ["interference gel electrophoresis apparatus", "TEST", 58, 100], ["HCoV", "TEST", 123, 127]]], ["The protein was positively charged at pH 8.3.", [["The protein", "TEST", 0, 11], ["pH", "TEST", 38, 40]]], ["So, protein was loaded at the anodic side into the small slot and tRNA was loaded at the cathodic side into the extended slot.", [["protein", "TREATMENT", 4, 11], ["tRNA", "TREATMENT", 66, 70], ["small slot", "OBSERVATION", 51, 61], ["extended slot", "OBSERVATION", 112, 125]]], ["During the run, protein and tRNA migrated in opposite directions and crossed each other in the gel.Fluorescence MeasurementFluorescence emission spectra were recorded in 50 mM Tris, 100 mM NaCl, pH 8.5, at room temperature, using a Cary Eclipse fluorescence spectrometer.", [["NaCl", "CHEMICAL", 189, 193], ["Tris", "CHEMICAL", 176, 180], ["NaCl", "CHEMICAL", 189, 193], ["tRNA", "CELLULAR_COMPONENT", 28, 32], ["protein and tRNA", "TREATMENT", 16, 32], ["Fluorescence Measurement", "TEST", 99, 123], ["Fluorescence emission spectra", "TEST", 123, 152], ["Tris", "TEST", 176, 180], ["NaCl", "TEST", 189, 193], ["pH", "TEST", 195, 197], ["a Cary Eclipse fluorescence spectrometer", "TREATMENT", 230, 270], ["tRNA migrated", "OBSERVATION", 28, 41]]], ["Proteins were added to final concentrations of 5 \u00b5M.", [["Proteins", "TREATMENT", 0, 8]]], ["Spectra were recorded under identical spectrometer settings using an excitation wavelength of 280 nm.", [["an excitation wavelength", "TREATMENT", 66, 90], ["280 nm", "OBSERVATION_MODIFIER", 94, 100]]], ["Fluorescence titration experiments were carried out using the excitation wavelength of 280 nm and emission wavelengths of 330 nm (for Nsp8) or 350 nm (for Nsp9).", [["Nsp8", "PROTEIN", 134, 138], ["Nsp9", "PROTEIN", 155, 159], ["Fluorescence titration experiments", "TEST", 0, 34], ["the excitation wavelength", "TREATMENT", 58, 83]]], ["Fluorescence was measured in the presence of increasing concentrations of E. coli tRNA.Expression of HCoV-229E nsp8 and nsp9HCoV-229E Nsp8 and Nsp9 were successfully produced under heterologous conditions at about 10-20 mg protein per liter expression culture.", [["E. coli", "ORGANISM", 74, 81], ["HCoV-229E nsp8", "GENE_OR_GENE_PRODUCT", 101, 115], ["nsp9HCoV-229E Nsp8", "GENE_OR_GENE_PRODUCT", 120, 138], ["Nsp9", "GENE_OR_GENE_PRODUCT", 143, 147], ["HCoV-229E nsp8", "DNA", 101, 115], ["nsp9HCoV-229E Nsp8", "DNA", 120, 138], ["Nsp9", "DNA", 143, 147], ["E. coli", "SPECIES", 74, 81], ["E. coli", "SPECIES", 74, 81], ["HCoV-229E", "SPECIES", 101, 110], ["Fluorescence", "TEST", 0, 12], ["E. coli tRNA", "TREATMENT", 74, 86], ["HCoV", "TEST", 101, 105], ["nsp9HCoV", "TEST", 120, 128], ["Nsp9", "TREATMENT", 143, 147], ["expression culture", "TEST", 241, 259], ["increasing", "OBSERVATION_MODIFIER", 45, 55], ["concentrations", "OBSERVATION_MODIFIER", 56, 70], ["E. coli tRNA", "OBSERVATION", 74, 86]]], ["The proteins exhibited apparent molecular masses of about 23 kDa and 15 kDa, respectively, under denaturing conditions in SDS-PAGE (Fig. 1, A1 and B1 ).", [["A1", "PROTEIN", 140, 142], ["B1", "PROTEIN", 147, 149], ["molecular masses", "PROBLEM", 32, 48], ["SDS", "TEST", 122, 125], ["masses", "OBSERVATION", 42, 48], ["23 kDa", "OBSERVATION_MODIFIER", 58, 64]]], ["Owing to the attached hexahistidine tag, the Nsp8 and Nsp9 could be readily detected in immunoblots using an anti-histidine antibody (Fig. 1, A2 and B2 ).", [["anti-histidine", "CHEMICAL", 109, 123], ["hexahistidine", "GENE_OR_GENE_PRODUCT", 22, 35], ["Nsp8", "GENE_OR_GENE_PRODUCT", 45, 49], ["Nsp9", "GENE_OR_GENE_PRODUCT", 54, 58], ["A2", "GENE_OR_GENE_PRODUCT", 142, 144], ["B2", "GENE_OR_GENE_PRODUCT", 149, 151], ["hexahistidine tag", "PROTEIN", 22, 39], ["Nsp8", "PROTEIN", 45, 49], ["Nsp9", "PROTEIN", 54, 58], ["anti-histidine antibody", "PROTEIN", 109, 132], ["A2", "PROTEIN", 142, 144], ["B2", "PROTEIN", 149, 151], ["the attached hexahistidine tag", "TREATMENT", 9, 39], ["the Nsp8", "TEST", 41, 49], ["immunoblots", "TEST", 88, 99], ["an anti-histidine antibody", "TEST", 106, 132]]], ["Around 90% of HCoV-229E Nsp9 molecules had their Nterminal His tag removed using SARS-CoV M pro (Lane 5, Fig. 1, B1 and B2 ).RNA Binding Using Zone-Interference Gel ElectrophoresisHCoV-229E Nsp8 and Nsp9 bind to deacetylated tRNA.", [["His", "CHEMICAL", 59, 62], ["B1", "GENE_OR_GENE_PRODUCT", 113, 115], ["B2", "GENE_OR_GENE_PRODUCT", 120, 122], ["Nsp9", "GENE_OR_GENE_PRODUCT", 199, 203], ["HCoV-229E Nsp9 molecules", "PROTEIN", 14, 38], ["Nterminal His tag", "PROTEIN", 49, 66], ["B1", "PROTEIN", 113, 115], ["B2", "PROTEIN", 120, 122], ["ElectrophoresisHCoV-229E Nsp8", "DNA", 165, 194], ["Nsp9", "PROTEIN", 199, 203], ["deacetylated tRNA", "PROTEIN", 212, 229], ["HCoV-229E", "SPECIES", 14, 23], ["HCoV", "TEST", 14, 18], ["SARS-CoV M pro (Lane", "TREATMENT", 81, 101], ["Zone-Interference Gel ElectrophoresisHCoV", "TREATMENT", 143, 184], ["Nsp8", "TREATMENT", 190, 194], ["deacetylated tRNA", "TREATMENT", 212, 229], ["deacetylated tRNA", "OBSERVATION", 212, 229]]], ["The zone-interference gel pattern showed that the Nsp8 binding to the negatively charged tRNA increased considerably the electrophoretic mobility of the Nsp8 in a complex with tRNA, which is formed in a concentration-dependent manner ( Fig. 2A) .", [["Nsp8", "GENE_OR_GENE_PRODUCT", 50, 54], ["Nsp8", "GENE_OR_GENE_PRODUCT", 153, 157], ["Nsp8", "PROTEIN", 50, 54], ["negatively charged tRNA", "PROTEIN", 70, 93], ["Nsp8", "PROTEIN", 153, 157], ["The zone-interference gel pattern", "TEST", 0, 33], ["the Nsp8 binding", "PROBLEM", 46, 62], ["the negatively charged tRNA", "PROBLEM", 66, 93], ["the electrophoretic mobility", "PROBLEM", 117, 145], ["tRNA", "TREATMENT", 176, 180], ["electrophoretic mobility", "OBSERVATION_MODIFIER", 121, 145]]], ["E. coli elongation factor EF-Tu was used as negative control and dissociated rapidly from deacetylated tRNA, resulting in no net increase of electrophoretic mobility.", [["E. coli", "ORGANISM", 0, 7], ["EF-Tu", "GENE_OR_GENE_PRODUCT", 26, 31], ["E. coli elongation factor", "PROTEIN", 0, 25], ["EF", "PROTEIN", 26, 28], ["Tu", "PROTEIN", 29, 31], ["deacetylated tRNA", "PROTEIN", 90, 107], ["E. coli", "SPECIES", 0, 7], ["E. coli", "SPECIES", 0, 7], ["E. coli elongation factor EF", "PROBLEM", 0, 28], ["deacetylated tRNA", "TREATMENT", 90, 107], ["net increase of electrophoretic mobility", "PROBLEM", 125, 165], ["coli elongation", "OBSERVATION", 3, 18], ["deacetylated tRNA", "OBSERVATION", 90, 107], ["no", "UNCERTAINTY", 122, 124], ["net", "OBSERVATION_MODIFIER", 125, 128], ["increase", "OBSERVATION_MODIFIER", 129, 137], ["electrophoretic mobility", "OBSERVATION", 141, 165]]], ["9 The K d value for the Nsp8/tRNA complex was determined as 4 \u00b5M (Fig. 2B) .", [["K", "CHEMICAL", 6, 7], ["K d", "GENE_OR_GENE_PRODUCT", 6, 9], ["Nsp8", "GENE_OR_GENE_PRODUCT", 24, 28], ["Nsp8", "PROTEIN", 24, 28], ["tRNA complex", "PROTEIN", 29, 41], ["The K d value", "TEST", 2, 15], ["the Nsp8/tRNA complex", "TEST", 20, 41]]], ["HCoV-229E Nsp8 also showed binding to different polyribonucleotides (figure not shown).RNA Binding Using Zone-Interference Gel ElectrophoresisHCoV-229E Nsp9 also interacted with tRNA.", [["HCoV-229E Nsp8", "GENE_OR_GENE_PRODUCT", 0, 14], ["HCoV-229E Nsp8", "DNA", 0, 14], ["polyribonucleotides", "PROTEIN", 48, 67], ["Nsp9", "PROTEIN", 152, 156], ["HCoV-229E", "SPECIES", 0, 9], ["HCoV", "TEST", 0, 4], ["different polyribonucleotides", "PROBLEM", 38, 67]]], ["In this case, the protein is positively charged at pH 8.3 in the electrophoresis buffer.", [["the protein", "TEST", 14, 25], ["pH", "TEST", 51, 53], ["the electrophoresis buffer", "TREATMENT", 61, 87]]], ["Therefore, it was loaded at the anodic side and the tRNA loaded at the cathodic side.", [["the tRNA", "TREATMENT", 48, 56]]], ["The protein and tRNA migrated in the opposite direction.", [["tRNA", "CELLULAR_COMPONENT", 16, 20], ["The protein", "TEST", 0, 11], ["tRNA", "TREATMENT", 16, 20], ["tRNA migrated", "OBSERVATION", 16, 29]]], ["Nsp9 binding to the negatively charged tRNA decreased the migration of the protein to the cathodic side.", [["Nsp9", "CHEMICAL", 0, 4], ["Nsp9", "GENE_OR_GENE_PRODUCT", 0, 4], ["Nsp9", "PROTEIN", 0, 4], ["Nsp9 binding", "PROBLEM", 0, 12], ["migration", "OBSERVATION_MODIFIER", 58, 67]]], ["Hence, the Nsp9 electrophoretic mobility was increasingly retarded with increasing tRNA concentrations (Fig. 3) .Fluorescence QuenchingThe HCoV-229E Nsp8 protein displayed an emission maximum around 332 nm due to its tryptophan fluorescence (Fig. 4 A) .", [["tryptophan", "CHEMICAL", 217, 227], ["tryptophan", "CHEMICAL", 217, 227], ["Nsp9", "GENE_OR_GENE_PRODUCT", 11, 15], ["tryptophan", "SIMPLE_CHEMICAL", 217, 227], ["Nsp9", "PROTEIN", 11, 15], ["HCoV-229E Nsp8 protein", "PROTEIN", 139, 161], ["HCoV-229E", "SPECIES", 139, 148], ["the Nsp9 electrophoretic mobility", "PROBLEM", 7, 40], ["increasing tRNA concentrations", "TREATMENT", 72, 102], ["Fluorescence", "TEST", 113, 125], ["The HCoV", "TEST", 135, 143], ["Nsp8 protein", "TEST", 149, 161], ["its tryptophan fluorescence", "PROBLEM", 213, 240], ["mobility", "OBSERVATION_MODIFIER", 32, 40]]], ["In comparison, the HCoV-229E Nsp9 emission maximum is red-shifted to 350 nm by excitation at 280 nm.", [["HCoV", "PROTEIN", 19, 23], ["229E", "PROTEIN", 24, 28], ["the HCoV", "TEST", 15, 23], ["350 nm", "OBSERVATION_MODIFIER", 69, 75]]], ["Therefore, the single tryptophan in Nsp9 is more exposed to the hydrophilic environment than the two tryptophans in Nsp8.", [["tryptophan", "CHEMICAL", 22, 32], ["Nsp9", "CHEMICAL", 36, 40], ["tryptophan", "CHEMICAL", 22, 32], ["tryptophans", "CHEMICAL", 101, 112], ["tryptophan", "AMINO_ACID", 22, 32], ["Nsp9", "GENE_OR_GENE_PRODUCT", 36, 40], ["Nsp8", "GENE_OR_GENE_PRODUCT", 116, 120], ["Nsp9", "PROTEIN", 36, 40], ["Nsp8", "PROTEIN", 116, 120], ["the single tryptophan in Nsp9", "PROBLEM", 11, 40]]], ["Remarkably, the tryptophan fluorescence of the two nonstructural proteins was quenched by increasing concentrations of E. coli tRNA (Fig. 4 B) .", [["tryptophan", "CHEMICAL", 16, 26], ["tryptophan", "CHEMICAL", 16, 26], ["tryptophan", "SIMPLE_CHEMICAL", 16, 26], ["E. coli", "ORGANISM", 119, 126], ["Fig. 4 B", "GENE_OR_GENE_PRODUCT", 133, 141], ["nonstructural proteins", "PROTEIN", 51, 73], ["E. coli", "SPECIES", 119, 126], ["E. coli", "SPECIES", 119, 126], ["the tryptophan fluorescence", "TEST", 12, 39], ["the two nonstructural proteins", "PROBLEM", 43, 73], ["E. coli tRNA", "TREATMENT", 119, 131], ["coli tRNA", "OBSERVATION", 122, 131]]], ["At 5 \u00b5M tRNA, the intensity of the emitted light was only 20% of the fluorescence in the absence of tRNA.", [["tRNA", "TREATMENT", 8, 12], ["the fluorescence", "TEST", 65, 81], ["tRNA", "TREATMENT", 100, 104]]], ["The tryptophan fluorescence quenching clearly demonstrated binding of the two proteins to tRNA in the lower micromolar range.", [["tryptophan", "CHEMICAL", 4, 14], ["tryptophan", "CHEMICAL", 4, 14], ["tryptophan", "SIMPLE_CHEMICAL", 4, 14], ["The tryptophan fluorescence quenching", "TEST", 0, 37], ["lower micromolar", "ANATOMY_MODIFIER", 102, 118]]], ["Due to the obvious decrease of the tryptophan fluorescence it might be speculated that these residues in the two proteins are involved in complex formation.", [["tryptophan", "CHEMICAL", 35, 45], ["tryptophan", "CHEMICAL", 35, 45], ["tryptophan", "SIMPLE_CHEMICAL", 35, 45], ["the tryptophan fluorescence", "PROBLEM", 31, 58], ["these residues in the two proteins", "PROBLEM", 87, 121], ["decrease", "OBSERVATION_MODIFIER", 19, 27]]], ["This interaction study strongly supports results deduced from the gel shift experiment outlined above.DISCUSSIONHuman coronavirus 229E Nsp8 and Nsp9 were overproduced in a highly purified soluble form.", [["Nsp8", "GENE_OR_GENE_PRODUCT", 135, 139], ["Nsp9", "GENE_OR_GENE_PRODUCT", 144, 148], ["coronavirus 229E Nsp8", "PROTEIN", 118, 139], ["Nsp9", "PROTEIN", 144, 148], ["coronavirus", "SPECIES", 118, 129], ["This interaction study", "TEST", 0, 22]]], ["The nonstructural proteins exhibited unspecific interaction with tRNA as shown by zone-interference gel electrophoresis and fluorescence spectroscopy.", [["nonstructural proteins", "PROTEIN", 4, 26], ["tRNA", "TREATMENT", 65, 69], ["gel electrophoresis", "TEST", 100, 119], ["fluorescence spectroscopy", "TEST", 124, 149]]], ["Nsp8 has an affinity in the low micromolar range.", [["Nsp8", "CHEMICAL", 0, 4], ["Nsp8", "GENE_OR_GENE_PRODUCT", 0, 4], ["Nsp8", "PROTEIN", 0, 4], ["an affinity", "TEST", 9, 20], ["affinity", "OBSERVATION_MODIFIER", 12, 20], ["low micromolar", "OBSERVATION_MODIFIER", 28, 42]]], ["It is also tempting to speculate that tRNAs of the host cell might interact with these non structural proteins, which would suggest virusinduced modifications in the host\u00b4s translational processes.", [["cell", "ANATOMY", 56, 60], ["host cell", "CELL", 51, 60], ["structural proteins", "PROTEIN", 91, 110], ["these non structural proteins", "PROBLEM", 81, 110], ["virusinduced modifications in the host\u00b4s translational processes", "PROBLEM", 132, 196], ["host cell", "OBSERVATION", 51, 60], ["virusinduced modifications", "OBSERVATION", 132, 158]]]], "PMC7148202": [["IntroductionNowadays, people tend to acquire more information from online social media platforms than traditional media channels.", [["people", "ORGANISM", 22, 28], ["people", "SPECIES", 22, 28]]], ["In this paper, rumours refer to any unconfirmed information, including misinformation, regardless of the intention of the information source.IntroductionTo assess the truthfulness of rumours and combat misinformation, manual fact checking websites such as snopes.com and emergent.info heavily rely on human observers to report potential rumors and employ professional journalists to fact-check their truthfulness, which is costly and time consuming.", [["human", "ORGANISM", 301, 306], ["human", "SPECIES", 301, 306], ["human", "SPECIES", 301, 306], ["the truthfulness of rumours", "PROBLEM", 163, 190]]], ["Automatic rumour detection is thus desirable to reduce the time and human cost [11, 28].IntroductionAutomatic rumour detection has attracted significant research [28].", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["Automatic rumour detection", "TEST", 0, 26], ["IntroductionAutomatic rumour detection", "PROBLEM", 88, 126], ["significant", "OBSERVATION_MODIFIER", 141, 152]]], ["There are mainly three types of rumour detection approaches based on the type of data used.", [["rumour detection approaches", "TREATMENT", 32, 59]]], ["Content-based methods focus on rumour detection using the textual contents of tweets and their user comments [12, 25, 30].", [["rumour detection", "TEST", 31, 47]]], ["Generally tweet contents have direct signals for misinformation and content analysis for rumour detection is desirable.", [["content analysis", "TEST", 68, 84], ["rumour detection", "TEST", 89, 105]]], ["Feature-based models exploit features other than tweet contents such as author profile information for rumour detection [3, 9, 10, 13, 23].", [["tweet contents", "PROBLEM", 49, 63], ["rumour detection", "TEST", 103, 119]]], ["Propagation-based methods exploit patterns in tweet propagation for rumour detection [14, 16, 18, 27].", [["rumour detection", "TEST", 68, 84]]], ["Most existing approaches rely on large volumes of training data that are only possible when users have shown sufficient usage or tweets have been propagated for a while, and therefore are not designed for early detection.IntroductionEarly detection of rumours is most desirable, as it can trigger efforts for effective mitigation of rumours and misinformation at an early stage.", [["training data", "TEST", 50, 63], ["rumours", "PROBLEM", 252, 259], ["effective mitigation of rumours", "TREATMENT", 309, 340]]], ["But early rumour detection is a challenging task due to the lack of prominent signals in propagation and user metadata within the short period after tweet publication.", [["early rumour detection", "PROBLEM", 4, 26]]], ["\u201cIs this true?\u201d or \u201cReally?\u201d) that can be exploited for early detection of rumours.", [["rumours", "PROBLEM", 75, 82]]], ["But the reliance on fixed expressions implies low recall for the approach.IntroductionIn this paper, we propose early rumour detection based on only tweet contents and their immediate user comments that are readily available at the early stage.", [["early rumour detection", "TEST", 112, 134]]], ["Our main idea is to exploit the wisdom of the public crowd.", [["public", "ANATOMY", 46, 52], ["crowd", "OBSERVATION", 53, 58]]], ["As shown in previous studies [11, 30], the crowd shows attitudes such as disagreeing and questioning toward rumours.", [["previous studies", "TEST", 12, 28]]], ["We therefore hypothesize that attitudes of the crowd to a tweet contains signals for identifying rumour tweets.", [["rumour tweets", "OBSERVATION", 97, 110]]], ["We specifically address the following research questions:Can crowd attitudes be exploited for effective early rumour detection?How to learn attitude representation from tweet comments without costly human annotation?", [["human", "ORGANISM", 199, 204], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 199, 204], ["effective early rumour detection", "PROBLEM", 94, 126]]]], "PMC6824042": [["BackgroundMammalian fertilization is underpinned by a number of sequential interactions between sperm and oocytes that culminate in a complex process of membrane adhesion and fusion [1].", [["sperm", "ANATOMY", 96, 101], ["oocytes", "ANATOMY", 106, 113], ["membrane", "ANATOMY", 153, 161], ["sperm", "CELLULAR_COMPONENT", 96, 101], ["oocytes", "CELLULAR_COMPONENT", 106, 113], ["membrane", "CELLULAR_COMPONENT", 153, 161], ["sperm", "CELL_TYPE", 96, 101], ["BackgroundMammalian fertilization", "PROBLEM", 0, 33], ["sequential interactions between sperm and oocytes", "PROBLEM", 64, 113], ["membrane adhesion and fusion", "TREATMENT", 153, 181], ["Mammalian fertilization", "OBSERVATION", 10, 33], ["membrane adhesion", "OBSERVATION", 153, 170]]], ["The understanding of the molecular basis of gamete interactions has been advanced by an elegant series of transgenic and biochemical studies focusing on the sperm protein IZUMO1, and its oolemmal binding partner, IZUMO1R (sperm-egg fusion protein Juno) [2].", [["gamete", "ANATOMY", 44, 50], ["sperm", "ANATOMY", 157, 162], ["oolemmal", "ANATOMY", 187, 195], ["sperm", "CELLULAR_COMPONENT", 157, 162], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 171, 177], ["IZUMO1R", "GENE_OR_GENE_PRODUCT", 213, 220], ["sperm-egg", "GENE_OR_GENE_PRODUCT", 222, 231], ["sperm protein", "PROTEIN", 157, 170], ["IZUMO1", "PROTEIN", 171, 177], ["oolemmal binding partner", "PROTEIN", 187, 211], ["IZUMO1R", "PROTEIN", 213, 220], ["sperm-egg fusion protein", "PROTEIN", 222, 246], ["Juno", "PROTEIN", 247, 251], ["biochemical studies", "TEST", 121, 140], ["the sperm protein IZUMO1", "TREATMENT", 153, 177], ["IZUMO1R (sperm-egg fusion protein Juno)", "TREATMENT", 213, 252]]], ["IZUMO1 is a type 1 transmembrane protein [3] that localizes to both the inner and outer acrosomal membranes of spermatozoa before undergoing dynamic relocalization to the cell surface upon completion of an acrosome reaction [4].", [["inner", "ANATOMY", 72, 77], ["acrosomal membranes", "ANATOMY", 88, 107], ["spermatozoa", "ANATOMY", 111, 122], ["cell surface", "ANATOMY", 171, 183], ["acrosome", "ANATOMY", 206, 214], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 0, 6], ["type 1 transmembrane protein [3", "GENE_OR_GENE_PRODUCT", 12, 43], ["inner", "CELLULAR_COMPONENT", 72, 77], ["outer acrosomal membranes", "CELLULAR_COMPONENT", 82, 107], ["spermatozoa", "CELLULAR_COMPONENT", 111, 122], ["cell surface", "CELLULAR_COMPONENT", 171, 183], ["acrosome", "CELLULAR_COMPONENT", 206, 214], ["IZUMO1", "PROTEIN", 0, 6], ["type 1 transmembrane protein", "PROTEIN", 12, 40], ["spermatozoa", "CELL_TYPE", 111, 122], ["a type 1 transmembrane protein", "PROBLEM", 10, 40], ["dynamic relocalization", "TREATMENT", 141, 163], ["an acrosome reaction", "PROBLEM", 203, 223], ["inner", "ANATOMY_MODIFIER", 72, 77], ["outer", "ANATOMY_MODIFIER", 82, 87], ["acrosomal membranes", "ANATOMY", 88, 107]]], ["From this latter position, IZUMO1 directs gamete recognition and adhesion via multiple low-affinity interactions with IZUMO1R, a GPI-linked receptor that resides on the surface of the oolemma [5].", [["gamete", "ANATOMY", 42, 48], ["surface", "ANATOMY", 169, 176], ["oolemma", "ANATOMY", 184, 191], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 27, 33], ["gamete", "CELLULAR_COMPONENT", 42, 48], ["IZUMO1R", "GENE_OR_GENE_PRODUCT", 118, 125], ["surface", "CELLULAR_COMPONENT", 169, 176], ["IZUMO1", "PROTEIN", 27, 33], ["IZUMO1R", "PROTEIN", 118, 125], ["GPI-linked receptor", "PROTEIN", 129, 148], ["IZUMO1 directs gamete recognition", "TREATMENT", 27, 60], ["IZUMO1R", "TREATMENT", 118, 125], ["surface", "ANATOMY_MODIFIER", 169, 176], ["oolemma", "ANATOMY", 184, 191]]], ["The indispensable nature of this interaction has been confirmed through complementary in vitro antibody inhibition and in vivo knockout studies targeting Izumo1 and Izumo1r, all of which effectively block the fertilization cascade at the level of gamete adhesion/fusion [2].", [["gamete", "ANATOMY", 247, 253], ["Izumo1", "GENE_OR_GENE_PRODUCT", 154, 160], ["Izumo1r", "GENE_OR_GENE_PRODUCT", 165, 172], ["Izumo1", "PROTEIN", 154, 160], ["Izumo1r", "PROTEIN", 165, 172], ["vitro antibody inhibition", "TREATMENT", 89, 114], ["Izumo1r", "TREATMENT", 165, 172], ["the fertilization cascade", "TREATMENT", 205, 230], ["gamete adhesion/fusion", "TREATMENT", 247, 269]]], ["Bianchi and colleagues [6] have, however, shown that the IZUMO1-IZUMO1R interaction does not directly promote membrane fusion.", [["membrane", "ANATOMY", 110, 118], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 57, 63], ["IZUMO1R", "GENE_OR_GENE_PRODUCT", 64, 71], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["IZUMO1", "PROTEIN", 57, 63], ["IZUMO1R", "PROTEIN", 64, 71], ["membrane fusion", "TREATMENT", 110, 125], ["membrane fusion", "OBSERVATION", 110, 125]]], ["Indeed, while the ectopic expression of IZUMO1R in HEK293 cells is successful in promoting their adhesion, it fails to induce the formation of syncytia among these cells [6, 7].", [["HEK293 cells", "ANATOMY", 51, 63], ["syncytia", "ANATOMY", 143, 151], ["cells", "ANATOMY", 164, 169], ["IZUMO1R", "GENE_OR_GENE_PRODUCT", 40, 47], ["HEK293 cells", "CELL", 51, 63], ["syncytia", "CELL", 143, 151], ["cells", "CELL", 164, 169], ["IZUMO1R", "PROTEIN", 40, 47], ["HEK293 cells", "CELL_LINE", 51, 63], ["IZUMO1R in HEK293 cells", "TREATMENT", 40, 63], ["syncytia among these cells", "PROBLEM", 143, 169]]], ["Similarly, cultured cells expressing mouse IZUMO1 can bind to oocytes, but fail to fuse with them [8\u201310].", [["cells", "ANATOMY", 20, 25], ["oocytes", "ANATOMY", 62, 69], ["cells", "CELL", 20, 25], ["mouse", "ORGANISM", 37, 42], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 43, 49], ["oocytes", "CELL", 62, 69], ["cultured cells", "CELL_LINE", 11, 25], ["mouse IZUMO1", "PROTEIN", 37, 49], ["mouse", "SPECIES", 37, 42], ["mouse", "SPECIES", 37, 42]]], ["Such findings are seemingly at odds with the demonstration that sperm from Izumo1 null males are capable of binding to but not fusing with the oolemma [3].BackgroundThese apparently contradictory results may be reconciled by the existence of alternative IZUMO1 receptor(s) that mediate gamete membrane fusion [7] or by the propensity of IZUMO1 to associate with other, as yet unidentified sperm surface proteins, leading to the formation of several higher-order multiprotein complexes [11].", [["sperm", "ANATOMY", 64, 69], ["gamete membrane", "ANATOMY", 286, 301], ["sperm surface", "ANATOMY", 389, 402], ["sperm", "CELLULAR_COMPONENT", 64, 69], ["Izumo1 null males", "ORGANISM", 75, 92], ["IZUMO1 receptor", "GENE_OR_GENE_PRODUCT", 254, 269], ["gamete membrane", "CELLULAR_COMPONENT", 286, 301], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 337, 343], ["sperm surface", "CELLULAR_COMPONENT", 389, 402], ["sperm", "CELL_TYPE", 64, 69], ["IZUMO1 receptor", "PROTEIN", 254, 269], ["IZUMO1", "PROTEIN", 337, 343], ["sperm surface proteins", "PROTEIN", 389, 411], ["multiprotein complexes", "PROTEIN", 462, 484], ["alternative IZUMO1 receptor(s)", "TREATMENT", 242, 272], ["mediate gamete membrane fusion", "TREATMENT", 278, 308], ["IZUMO1", "TREATMENT", 337, 343], ["sperm surface proteins", "PROBLEM", 389, 411]]], ["Thus, in addition to its direct binding to IZUMO1R, it has been suggested that IZUMO1 may play a secondary role in gamete fusion by virtue of its ability to organize and/or stabilize fusogenic proteins within the sperm membrane [12].", [["gamete", "ANATOMY", 115, 121], ["sperm membrane", "ANATOMY", 213, 227], ["IZUMO1", "CHEMICAL", 79, 85], ["IZUMO1R", "GENE_OR_GENE_PRODUCT", 43, 50], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 79, 85], ["gamete", "CELLULAR_COMPONENT", 115, 121], ["sperm membrane", "CELLULAR_COMPONENT", 213, 227], ["IZUMO1R", "PROTEIN", 43, 50], ["IZUMO1", "PROTEIN", 79, 85], ["fusogenic proteins", "PROTEIN", 183, 201], ["sperm", "CELL_TYPE", 213, 218], ["IZUMO1", "TREATMENT", 79, 85], ["a secondary role in gamete fusion", "TREATMENT", 95, 128], ["fusogenic proteins", "PROBLEM", 183, 201]]], ["Alternatively, and as explored herein, IZUMO1 may be associated with other key regulators of sperm receptor organization and fusion.", [["sperm", "ANATOMY", 93, 98], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 39, 45], ["sperm receptor", "GENE_OR_GENE_PRODUCT", 93, 107], ["IZUMO1", "PROTEIN", 39, 45], ["IZUMO1", "TREATMENT", 39, 45], ["sperm receptor organization and fusion", "PROBLEM", 93, 131]]], ["Such models of gamete fusion share analogy with the mechanisms that underpin membrane fusion in many other biological systems where the concerted action of multiprotein complexes is a well-established paradigm.", [["membrane", "ANATOMY", 77, 85], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["multiprotein complexes", "PROTEIN", 156, 178], ["gamete fusion", "TREATMENT", 15, 28], ["membrane fusion", "TREATMENT", 77, 92], ["gamete fusion", "OBSERVATION", 15, 28], ["membrane fusion", "OBSERVATION", 77, 92], ["multiprotein complexes", "OBSERVATION", 156, 178]]], ["For instance, it is widely accepted that a majority of enveloped viruses use protein complexes to regulate their progression through the sequential phases of fusion with a suitable target cell membrane, i.e., receptor recognition, triggering of fusion, and fusion execution [13, 14].", [["cell membrane", "ANATOMY", 188, 201], ["cell membrane", "CELLULAR_COMPONENT", 188, 201], ["protein complexes", "PROTEIN", 77, 94], ["protein complexes", "TREATMENT", 77, 94], ["fusion", "TREATMENT", 158, 164], ["fusion", "TREATMENT", 245, 251], ["fusion", "OBSERVATION", 158, 164], ["fusion", "OBSERVATION", 245, 251]]], ["The complexity of this membrane fusion machinery ranges from the use of multiple copies of a single glycoprotein for the entire fusion reaction [15], through to the segregation of the activities responsible for membrane attachment and membrane fusion into different proteins and separate multimeric complexes [16].BackgroundAnalysis of the protein domains that are required for IZUMO1 complex formation has identified two distinct regions, each putatively involved in the formation of unique complexes [11].", [["membrane", "ANATOMY", 23, 31], ["membrane", "ANATOMY", 211, 219], ["membrane", "ANATOMY", 235, 243], ["membrane", "CELLULAR_COMPONENT", 23, 31], ["membrane", "CELLULAR_COMPONENT", 211, 219], ["membrane", "CELLULAR_COMPONENT", 235, 243], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 378, 384], ["glycoprotein", "PROTEIN", 100, 112], ["multimeric complexes", "PROTEIN", 288, 308], ["protein domains", "PROTEIN", 340, 355], ["IZUMO1 complex", "PROTEIN", 378, 392], ["this membrane fusion machinery", "TREATMENT", 18, 48], ["a single glycoprotein", "TREATMENT", 91, 112], ["the entire fusion reaction", "PROBLEM", 117, 143], ["membrane attachment", "PROBLEM", 211, 230], ["membrane fusion", "TREATMENT", 235, 250], ["the protein domains", "PROBLEM", 336, 355], ["IZUMO1 complex formation", "PROBLEM", 378, 402], ["complexity", "OBSERVATION_MODIFIER", 4, 14], ["membrane fusion", "OBSERVATION", 23, 38], ["two", "OBSERVATION_MODIFIER", 418, 421], ["distinct", "OBSERVATION_MODIFIER", 422, 430]]], ["It is proposed that the N-terminal IZUMO domain participates in formation of smaller complexes, whereas the transmembrane domain and/or the cytoplasmic tail direct the formation of larger complexes.", [["transmembrane", "ANATOMY", 108, 121], ["cytoplasmic tail", "ANATOMY", 140, 156], ["transmembrane", "CELLULAR_COMPONENT", 108, 121], ["cytoplasmic", "ORGANISM_SUBSTANCE", 140, 151], ["N-terminal IZUMO domain", "PROTEIN", 24, 47], ["transmembrane domain", "PROTEIN", 108, 128], ["cytoplasmic tail", "PROTEIN", 140, 156], ["the N-terminal IZUMO domain", "PROBLEM", 20, 47], ["smaller complexes", "PROBLEM", 77, 94], ["the transmembrane domain", "TEST", 104, 128], ["smaller", "OBSERVATION_MODIFIER", 77, 84], ["complexes", "OBSERVATION", 85, 94], ["cytoplasmic tail", "OBSERVATION", 140, 156], ["larger complexes", "OBSERVATION", 181, 197]]], ["The existence of unique pools of IZUMO1 complexes is further supported by the demonstration that different IZUMO1 antibodies localize the protein either exclusively within the equatorial segment [17] or, alternatively, on the entire/anterior acrosomal region of acrosome-reacted sperm [3, 11].", [["acrosomal region", "ANATOMY", 242, 258], ["acrosome", "ANATOMY", 262, 270], ["sperm", "ANATOMY", 279, 284], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 33, 39], ["IZUMO1 antibodies", "GENE_OR_GENE_PRODUCT", 107, 124], ["anterior acrosomal", "CELLULAR_COMPONENT", 233, 251], ["acrosome", "CELLULAR_COMPONENT", 262, 270], ["sperm", "CELLULAR_COMPONENT", 279, 284], ["IZUMO1 complexes", "PROTEIN", 33, 49], ["IZUMO1 antibodies", "PROTEIN", 107, 124], ["acrosome-reacted sperm", "CELL_TYPE", 262, 284], ["IZUMO1 complexes", "TREATMENT", 33, 49], ["different IZUMO1 antibodies", "TEST", 97, 124], ["equatorial", "ANATOMY_MODIFIER", 176, 186], ["segment", "ANATOMY_MODIFIER", 187, 194], ["anterior", "ANATOMY_MODIFIER", 233, 241], ["acrosomal", "ANATOMY_MODIFIER", 242, 251], ["region", "ANATOMY_MODIFIER", 252, 258], ["acrosome", "ANATOMY_MODIFIER", 262, 270], ["reacted sperm", "OBSERVATION", 271, 284]]], ["While the identity of the putative IZUMO1-interacting proteins has yet to be established, the use of genomic and proteomic techniques has uncovered several candidate molecules with putative roles in sperm-oocyte interaction [18], including various members of the ADAM (a disintegrin and metalloprotease domain) [19] and CAP (cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins) superfamily of enzymes [20].BackgroundThe aim of the current study was to investigate whether mouse spermatozoa harbor multimeric complexes that participate in oolemma interactions and, if so, identify some of the key proteins in these complexes.", [["sperm", "ANATOMY", 199, 204], ["oocyte", "ANATOMY", 205, 211], ["spermatozoa", "ANATOMY", 507, 518], ["oolemma", "ANATOMY", 567, 574], ["cysteine", "CHEMICAL", 325, 333], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 35, 41], ["sperm", "CELL", 199, 204], ["oocyte", "DEVELOPING_ANATOMICAL_STRUCTURE", 205, 211], ["ADAM", "GENE_OR_GENE_PRODUCT", 263, 267], ["disintegrin and metalloprotease domain) [19]", "GENE_OR_GENE_PRODUCT", 271, 315], ["CAP", "GENE_OR_GENE_PRODUCT", 320, 323], ["cysteine-rich secretory proteins", "GENE_OR_GENE_PRODUCT", 325, 357], ["antigen 5", "GENE_OR_GENE_PRODUCT", 359, 368], ["pathogenesis-related 1 proteins", "GENE_OR_GENE_PRODUCT", 374, 405], ["mouse", "ORGANISM", 501, 506], ["spermatozoa", "CELL", 507, 518], ["oolemma", "GENE_OR_GENE_PRODUCT", 567, 574], ["IZUMO1", "PROTEIN", 35, 41], ["interacting proteins", "PROTEIN", 42, 62], ["sperm", "CELL_TYPE", 199, 204], ["ADAM", "PROTEIN", 263, 267], ["disintegrin and metalloprotease domain", "PROTEIN", 271, 309], ["CAP", "PROTEIN", 320, 323], ["cysteine-rich secretory proteins", "PROTEIN", 325, 357], ["antigen 5", "PROTEIN", 359, 368], ["pathogenesis-related 1 proteins", "PROTEIN", 374, 405], ["enzymes", "PROTEIN", 422, 429], ["mouse spermatozoa", "CELL_TYPE", 501, 518], ["multimeric complexes", "PROTEIN", 526, 546], ["mouse", "SPECIES", 501, 506], ["mouse", "SPECIES", 501, 506], ["genomic and proteomic techniques", "TREATMENT", 101, 133], ["a disintegrin and metalloprotease domain)", "TREATMENT", 269, 310], ["CAP (cysteine-rich secretory proteins", "TEST", 320, 357], ["antigen", "TEST", 359, 366], ["enzymes", "TEST", 422, 429], ["the current study", "TEST", 456, 473], ["mouse spermatozoa harbor multimeric complexes", "PROBLEM", 501, 546]]], ["Using the combined techniques of blue native PAGE and far-western blotting, we successfully demonstrated that mouse spermatozoa do possess multimeric protein complexes that readily bind solubilized oolemmal proteins.", [["spermatozoa", "ANATOMY", 116, 127], ["mouse", "ORGANISM", 110, 115], ["spermatozoa", "CELL", 116, 127], ["mouse spermatozoa", "CELL_TYPE", 110, 127], ["multimeric protein complexes", "PROTEIN", 139, 167], ["solubilized oolemmal proteins", "PROTEIN", 186, 215], ["mouse", "SPECIES", 110, 115], ["mouse", "SPECIES", 110, 115], ["blue native PAGE", "TREATMENT", 33, 49], ["mouse spermatozoa", "PROBLEM", 110, 127], ["multimeric protein complexes", "PROBLEM", 139, 167], ["protein complexes", "OBSERVATION", 150, 167]]], ["A subset of these complexes contain IZUMO1 and the CAP proteins GLI pathogenesis-related 1 like 1 (GLIPR1L1).", [["IZUMO1", "GENE_OR_GENE_PRODUCT", 36, 42], ["GLI pathogenesis-related 1 like 1", "GENE_OR_GENE_PRODUCT", 64, 97], ["GLIPR1L1", "GENE_OR_GENE_PRODUCT", 99, 107], ["IZUMO1", "PROTEIN", 36, 42], ["CAP proteins", "PROTEIN", 51, 63], ["GLI pathogenesis-related 1 like 1", "PROTEIN", 64, 97], ["GLIPR1L1", "PROTEIN", 99, 107], ["IZUMO1", "TREATMENT", 36, 42], ["the CAP proteins GLI pathogenesis", "PROBLEM", 47, 80], ["CAP", "OBSERVATION_MODIFIER", 51, 54], ["GLI pathogenesis", "OBSERVATION", 64, 80]]], ["Indeed, the analysis of a knockout mouse model revealed that GLIPR1L1 is required for optimal fertilization, with the loss of this protein leading to the dysregulation of acrosomal exocytosis, a failure of IZUMO1 relocalization and poor in vitro fertilization rates.Identification of oolemmal binding complexes in mouse spermatozoa ::: ResultsMouse spermatozoa harbor at least four putative solubilized oolemmal protein-binding complexes that range in molecular weight from 260 to 750 kDa (complexes I\u2013IV; Fig. 1a).", [["acrosomal", "ANATOMY", 171, 180], ["oolemmal", "ANATOMY", 284, 292], ["spermatozoa", "ANATOMY", 320, 331], ["spermatozoa", "ANATOMY", 349, 360], ["mouse", "ORGANISM", 35, 40], ["GLIPR1L1", "GENE_OR_GENE_PRODUCT", 61, 69], ["acrosomal", "CELLULAR_COMPONENT", 171, 180], ["IZUMO1", "GENE_OR_GENE_PRODUCT", 206, 212], ["oolemmal binding complexes", "GENE_OR_GENE_PRODUCT", 284, 310], ["mouse", "ORGANISM", 314, 319], ["spermatozoa", "CELL", 320, 331], ["spermatozoa", "ORGANISM_SUBSTANCE", 349, 360], ["GLIPR1L1", "PROTEIN", 61, 69], ["IZUMO1", "PROTEIN", 206, 212], ["oolemmal binding complexes", "PROTEIN", 284, 310], ["mouse spermatozoa", "CELL_TYPE", 314, 331], ["oolemmal protein-binding complexes", "PROTEIN", 403, 437], ["complexes I\u2013IV", "PROTEIN", 490, 504], ["Fig. 1a", "PROTEIN", 506, 513], ["mouse", "SPECIES", 35, 40], ["mouse", "SPECIES", 314, 319], ["mouse", "SPECIES", 35, 40], ["mouse", "SPECIES", 314, 319], ["the analysis", "TEST", 8, 20], ["a knockout mouse model", "TEST", 24, 46], ["GLIPR1L1", "TREATMENT", 61, 69], ["the loss of this protein", "PROBLEM", 114, 138], ["acrosomal exocytosis", "PROBLEM", 171, 191], ["IZUMO1 relocalization", "TREATMENT", 206, 227], ["poor in vitro fertilization rates", "PROBLEM", 232, 265], ["oolemmal binding complexes", "PROBLEM", 284, 310], ["molecular weight", "TEST", 452, 468], ["acrosomal exocytosis", "OBSERVATION", 171, 191], ["oolemmal binding complexes", "OBSERVATION", 284, 310], ["mouse spermatozoa", "OBSERVATION", 314, 331]]], ["Of note, a similar profile of labeled complexes was observed irrespective of whether lysates were prepared from non-capacitated, capacitated, or capacitated sperm that were treated with the calcium ionophore, A23187, under conditions that robustly stimulate acrosomal exocytosis in approximately 70% of the cells.", [["lysates", "ANATOMY", 85, 92], ["sperm", "ANATOMY", 157, 162], ["acrosomal", "ANATOMY", 258, 267], ["cells", "ANATOMY", 307, 312], ["calcium", "CHEMICAL", 190, 197], ["A23187", "CHEMICAL", 209, 215], ["calcium", "CHEMICAL", 190, 197], ["A23187", "CHEMICAL", 209, 215], ["lysates", "ORGANISM_SUBSTANCE", 85, 92], ["sperm", "CELL", 157, 162], ["calcium ionophore", "SIMPLE_CHEMICAL", 190, 207], ["A23187", "SIMPLE_CHEMICAL", 209, 215], ["acrosomal", "CELLULAR_COMPONENT", 258, 267], ["cells", "CELL", 307, 312], ["labeled complexes", "PROTEIN", 30, 47], ["non-capacitated, capacitated, or capacitated sperm", "CELL_LINE", 112, 162], ["lysates", "TEST", 85, 92], ["capacitated sperm", "PROBLEM", 145, 162], ["the calcium ionophore", "TREATMENT", 186, 207], ["acrosomal exocytosis", "PROBLEM", 258, 278], ["acrosomal exocytosis", "OBSERVATION", 258, 278]]], ["However, lysates from the latter two samples appeared to bind more oolemmal proteins than that of non-capacitated spermatozoa.", [["lysates", "ANATOMY", 9, 16], ["samples", "ANATOMY", 37, 44], ["spermatozoa", "ANATOMY", 114, 125], ["lysates", "ORGANISM_SUBSTANCE", 9, 16], ["spermatozoa", "CELL", 114, 125], ["oolemmal proteins", "PROTEIN", 67, 84], ["non-capacitated spermatozoa", "CELL_TYPE", 98, 125], ["lysates", "TEST", 9, 16], ["non-capacitated spermatozoa", "PROBLEM", 98, 125], ["non-capacitated spermatozoa", "OBSERVATION", 98, 125]]]], "cafc17b98a6dcabe30e20827d68269fadceefe82": [["It partitions an image in terms of pixel-based features into several homogeneous and disjoint regions so that the members within the same region share the same characteristics.", [["an image", "TEST", 14, 22], ["several", "OBSERVATION_MODIFIER", 61, 68], ["homogeneous", "OBSERVATION_MODIFIER", 69, 80], ["disjoint", "OBSERVATION_MODIFIER", 85, 93]]], ["Image segmentation is employed as a pre-processing step in many applications such as medical image processing [4, 15] or modelling of microstructures [16] .IntroductionClustering is one of the most commonly employed approaches for image segmentation.", [["Image segmentation", "TEST", 0, 18], ["a pre-processing step", "TREATMENT", 34, 55], ["medical image processing", "TEST", 85, 109], ["image segmentation", "TEST", 231, 249]]], ["It divides an image into clusters (groups) so that the members located in the same cluster have more resemblance to each other than to those in others clusters.", [["clusters", "OBSERVATION_MODIFIER", 25, 33]]], ["However, k-means suffers from some drawbacks such as dependence on initialisation and getting stuck in local optima.IntroductionPopulation-based metaheuristics are problem-independent optimisation algorithms with stochastic characteristics and can be used to overcome these drawbacks.", [["some drawbacks", "TREATMENT", 30, 44], ["these drawbacks", "TREATMENT", 268, 283], ["local optima", "OBSERVATION", 103, 115]]], ["They typically create a random population of candidate solutions which are then iteratively updated based on operations that are stochastic and share information within the population.IntroductionPopular population-based metaheuristics that have been used for clusteringbased image segmentation include particle swarm optimisation (PSO) [12, 17] , differential evolution (DE) [2, 7] , artificial bee colony (ABC) [13] and harmony search (HS) [20] among others.IntroductionHuman mental search (HMS) [11] is a relatively new population-based metaheuristic that has shown competitive performance in solving optimisation problems [11] .", [["IntroductionPopular population", "TREATMENT", 184, 214], ["clusteringbased image segmentation", "TEST", 260, 294], ["artificial bee colony (ABC)", "TREATMENT", 385, 412]]], ["Mental search seeks around a candidate solution based on Levy flight, grouping clusters the population to find a promising region, and movement steers candidate solutions towards the promising area.IntroductionIn this paper, we propose a novel image segmentation based on clustering and HMS.", [["a novel image segmentation", "TEST", 236, 262]]], ["To this end, our encoding strategy is an array to define the cluster centres and we employ an objective function based on the mean squared error.", [["an objective function", "TEST", 91, 112]]], ["An extensive set of experiments demonstrates very good segmentation performance and superiority over other methods.IntroductionThe remainder of the paper is organised as follows.", [["very", "OBSERVATION_MODIFIER", 45, 49], ["good", "OBSERVATION_MODIFIER", 50, 54], ["segmentation", "OBSERVATION_MODIFIER", 55, 67]]], ["Section 2 summarises the human mental search algorithm, while Sect.", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30]]], ["3 details our proposed image segmentation algorithm.", [["image segmentation algorithm", "TEST", 23, 51]]], ["5 concludes the paper.Human Mental SearchHuman mental search (HMS) [11] is a recent population-based metaheuristic algorithm where candidate solutions are bids in the space of online auctions.Human Mental SearchThe workings of HMS are detailed in Algorithm 1 in terms of pseudo-code.", [["Human", "ORGANISM", 22, 27], ["Human", "ORGANISM", 192, 197], ["Human", "SPECIES", 22, 27], ["Human", "SPECIES", 192, 197], ["a recent population", "PROBLEM", 75, 94], ["based metaheuristic algorithm", "TREATMENT", 95, 124]]], ["Candidate solutions try to move towards the optimum using mental search (to explore the vicinity of bids), grouping (to find the promising area), and movement (to steer bids toward the promising area) operators.", [["Candidate solutions", "TREATMENT", 0, 19]]], ["In the following, we briefly explain these three operators. for j from 1 to qi do 16: x + = find best bid in current bids 39:Human Mental Searchif cost(x + ) < cost(x * ) then 40:Human Mental Searchx * = x + 41: end if 42: end whileMental SearchHere, each bid explores its vicinity based on a Levy flight distribution, resulting in both small and long jumps to enhance both exploration and exploitation ability of the algorithm simultaneously.Mental SearchA bid x i is updated asMental Searchwith S calculated asMental Searchwhere NF E is the number of objective function evaluations so far, NF E max is the maximum number of function evaluations, x * is the best bid found so far, and u and v are two random numbers calculated asMental SearchwithMental Searchwhere \u0393 is a standard gamma function.GroupingA clustering approach is used to group the current population of bids.", [["Human", "ORGANISM", 125, 130], ["Human", "ORGANISM", 179, 184], ["NF E", "GENE_OR_GENE_PRODUCT", 592, 596], ["Human", "SPECIES", 125, 130], ["Human", "SPECIES", 179, 184], ["Human Mental Searchif cost(x + )", "TREATMENT", 125, 157], ["both small and long jumps", "PROBLEM", 332, 357], ["both exploration", "TEST", 369, 385], ["objective function evaluations", "TEST", 553, 583], ["random numbers", "TEST", 702, 716], ["small", "OBSERVATION_MODIFIER", 337, 342]]], ["After clustering, which is performed using the k-means algorithm, similar bids are located in the same group.", [["the k-means algorithm", "TEST", 43, 64]]], ["Then, the mean objective function value is calculated for each group, and the group with the lowest value selected as the winner group.MovementHere, bids move towards the best bid in the winner cluster asMovementwhere x t+1 n is the n-th bid element at iteration t+1, winner t n is the n-th element of the best bid in the winner group, t is the current iteration, C is a constant, and r is a number in [0; 1] taken from a normal distribution.Proposed Segmentation AlgorithmThis paper introduces a novel clustering-based image segmentation algorithm based on clustering and HMS.Proposed Segmentation AlgorithmAssume that a dataset has N objects, O 1 , O 2 , ..., O N .", [["N", "CHEMICAL", 634, 635], ["O 1 , O 2", "CHEMICAL", 645, 654], ["O N", "CHEMICAL", 662, 665], ["n-th bid element", "DNA", 233, 249], ["n-th element", "DNA", 286, 298], ["the mean objective function value", "TEST", 6, 39], ["segmentation algorithm", "TEST", 526, 548], ["normal", "OBSERVATION", 422, 428]]], ["A clustering algorithm tries to find K cluster centres, C 1 , C 2 , ..., C K with the following conditions: 1.", [["K", "CHEMICAL", 37, 38], ["C K", "SIMPLE_CHEMICAL", 73, 76], ["K cluster centres", "TEST", 37, 54], ["C", "TEST", 56, 57], ["C", "TEST", 62, 63]]], ["Each cluster contains at least one object.", [["at least", "OBSERVATION_MODIFIER", 22, 30], ["one object", "OBSERVATION", 31, 41]]], ["Distinct clusters have no objects in common.", [["clusters", "OBSERVATION", 9, 17], ["no", "UNCERTAINTY", 23, 25], ["objects", "OBSERVATION", 26, 33], ["common", "ANATOMY_MODIFIER", 37, 43]]], ["The total number of cluster members is equal to the total number of objects in the dataset.Proposed Segmentation AlgorithmFor our application of HMS, two issues need to be taken into account: encoding strategy and objective function.", [["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["The encoding strategy determines the structure of each bid in HMS.", [["The encoding strategy", "TREATMENT", 0, 21]]], ["Also, the upper and lower bound of the array is set to the maximum and minimum of pixel values in the image.", [["upper", "ORGANISM_SUBDIVISION", 10, 15], ["upper", "ANATOMY_MODIFIER", 10, 15], ["lower", "ANATOMY_MODIFIER", 20, 25]]], ["As objective function, we use the mean squared error (MSE) defined asProposed Segmentation Algorithmwhere d(P i , c j ) is the Euclidean distance between pixel P i and its cluster centre C j , and n is the total number of pixels in the image.", [["P i", "DNA", 160, 163], ["total", "OBSERVATION_MODIFIER", 206, 211]]], ["Our image segmentation algorithm proceeds in the following steps:Proposed Segmentation AlgorithmStep 1: Parameter initialisation: population size N pop , minimum M l and maximum M h number of mental searches, number of clusters for bid grouping N , number of objective function evaluations NF E, and number of clusters for image segmentation K.Proposed Segmentation AlgorithmStep 2: Generate an initial random set of bids.Proposed Segmentation AlgorithmStep 3: Calculate the objective function value for each bid using Eq.", [["NF E", "PROTEIN", 290, 294], ["Our image segmentation algorithm", "TEST", 0, 32], ["mental searches", "TEST", 192, 207], ["objective function evaluations", "TEST", 259, 289], ["image segmentation", "TEST", 323, 341], ["size", "OBSERVATION_MODIFIER", 141, 145]]], ["(6).Proposed Segmentation AlgorithmStep 4: Create a random integer number for each bid in [M l ; M h ] indicating the number of mental searches for the bid.Proposed Segmentation AlgorithmStep 5: Mental search: generate new bids based on Levy flight distribution in the vicinity of each bid.Proposed Segmentation AlgorithmStep 6: Replacement: in case a newly produced bid is better than the old one, it will replace the latter.Proposed Segmentation AlgorithmStep 7: Bid grouping: all bids in the search space are clustered using the k-means algorithm.", [["Bid", "GENE_OR_GENE_PRODUCT", 465, 468], ["Bid", "PROTEIN", 465, 468], ["Replacement", "TREATMENT", 329, 340], ["the k-means algorithm", "TEST", 528, 549], ["Replacement", "OBSERVATION", 329, 340]]], ["Step 8: Calculate the mean objective function value for each cluster.Proposed Segmentation AlgorithmStep 9: The cluster with the minimum mean objective function value is selected as the winner cluster.Proposed Segmentation AlgorithmStep 10: Other bids move towards the best bid in the winner cluster based on Eq.", [["the minimum mean objective function value", "TEST", 125, 166]]], ["(5).Proposed Segmentation AlgorithmStep 11: Find the best bid in the current population and if it is better than the previous best bid, substitute the latter with it.Proposed Segmentation AlgorithmStep 12: If the stopping condition is not met, go back to Step 3.Experimental ResultsIn our experiments, we select 10 images, shown in Fig. 1 , which are commonly used in the literature: Lenna, House, Airplane, Peppers, and MRI, and five images from Berkeley image segmentation dataset [9] , namely 12003, 42049, 181079, 198054, and 385028.", [["the stopping condition", "PROBLEM", 209, 231], ["MRI", "TEST", 421, 424], ["Berkeley image segmentation dataset", "TEST", 447, 482]]], ["We compare our algorithm with other populationbased algorithms that have been previously used for image segmentation.Experimental ResultsThe population size and the number of objective function evaluations for all algorithms are set to 50 and 6000, respectively, and all results are run for K = 5.", [["our algorithm", "TEST", 11, 24], ["other populationbased algorithms", "TEST", 30, 62], ["image segmentation", "TEST", 98, 116], ["objective function evaluations", "TEST", 175, 205], ["all algorithms", "TEST", 210, 224], ["K", "TEST", 291, 292], ["population", "OBSERVATION_MODIFIER", 141, 151], ["size", "OBSERVATION_MODIFIER", 152, 156]]], ["For HMS, we set the number of clusters used during grouping to 5 and C to 2, while M l = 2, M h = 10, L = 0.3, and U = 1.99.", [["M h", "TEST", 92, 95], ["U", "TEST", 115, 116]]], ["For the other algorithms, we adapt default values previously employed in this context, listed in Table 1 .", [["the other algorithms", "TEST", 4, 24]]], ["Since the algorithms are stochastic, we run each algorithm 25 times on each image, and report the average over these runs.", [["stochastic", "OBSERVATION", 25, 35]]], ["We also rank the algorithms for each image and calculate Friedmann ranks which are obtained by averaging the ranks over the image set.", [["each image", "TEST", 32, 42]]], ["Table 2 compares the results in terms of objective function values.", [["objective function values", "TEST", 41, 66]]], ["As we can see, HMS is ranked first for 5 of the 10 images, and second for the other ones, leading to a clear best overall rank, followed by DE and PSO.Experimental ResultsWe also perform a statistical analysis, using the Wilcoxon signed rank test to compare our HMS-based algorithm with the other techniques.", [["a statistical analysis", "TEST", 187, 209], ["the Wilcoxon signed rank test", "TEST", 217, 246], ["clear", "OBSERVATION", 103, 108]]], ["The null hypothesis H 0 here indicates no statistical difference between two algorithms, while the alternative hypothesis H 1 points to a statistically significant difference.", [["statistical difference between two algorithms", "PROBLEM", 42, 87], ["a statistically significant difference", "PROBLEM", 136, 174], ["no", "UNCERTAINTY", 39, 41], ["significant", "OBSERVATION_MODIFIER", 152, 163], ["difference", "OBSERVATION", 164, 174]]], ["The obtained p-values are 0.0020 for ABC, 0.0039 for HS, 0.0273 for PSO, 0.0488 for DE, and 0.0020 for GA and are thus all below 0.05 demonstrating statistical superiority of HMS.Experimental ResultsWe further assess our proposed algorithm using several image segmentation criteria, in particular: -Borsotti criterion (BOR) [1] : an unsupervised criterion based on the number, the variance, and the area of segmented image regions.", [["ABC", "GENE_OR_GENE_PRODUCT", 37, 40], ["p-values", "TEST", 13, 21], ["ABC", "TEST", 37, 40], ["HS", "TEST", 53, 55], ["PSO", "TEST", 68, 71], ["GA", "TEST", 103, 105], ["our proposed algorithm", "TEST", 217, 239], ["several image segmentation criteria", "TEST", 246, 281]]], ["A lower BOR indicates a better segmentation performance. -Levine and Nazif interclass contrast (LNIC) [8] : an unsupervised criterion based on the sum of region contrasts weighted by their areas.", [["BOR", "DNA", 8, 11], ["A lower BOR", "PROBLEM", 0, 11], ["Levine and Nazif interclass contrast (LNIC)", "TREATMENT", 58, 101], ["lower", "ANATOMY_MODIFIER", 2, 7]]], ["A higher LNIC indicates a better segmentation performance. -Levine and Nazif intra-class uniformity (LNIU) [8] : an unsupervised criterion based on the sum of normalised standard deviations of image areas.", [["LNIC", "DNA", 9, 13], ["A higher LNIC", "PROBLEM", 0, 13], ["Levine", "TREATMENT", 60, 66], ["higher LNIC", "OBSERVATION", 2, 13]]], ["A higher LNIU indicates a better segmentation performance. -Variation of information (VoI) [10] : a supervised criterion that calculates the information shared between a ground truth and a segmented image.", [["LNIU", "DNA", 9, 13], ["A higher LNIU", "PROBLEM", 0, 13], ["a segmented image", "TEST", 187, 204]]], ["A lower VoI indicates better segmentation performance. -Probabilistic Rand index (PRI) [14] : a supervised criterion that computes the fraction of pairs of pixels whose labels are consistent between computed and ground truth segmentations.", [["VoI", "DNA", 8, 11], ["A lower VoI", "PROBLEM", 0, 11], ["better segmentation", "OBSERVATION", 22, 41], ["ground truth", "OBSERVATION", 212, 224]]], ["A higher PRI indicates better segmentation performance.Experimental ResultsSince the latter two require a ground truth, we can only evaluate these measures on the images of the Berkeley dataset.", [["PRI", "PROTEIN", 9, 12], ["A higher PRI", "PROBLEM", 0, 12], ["better segmentation", "OBSERVATION", 23, 42]]], ["The BOR results in Table 3 show that HMS performs best for all but one image and is thus clearly ranked first overall with PSO coming second.Experimental ResultsFor LNIC, reported in Table 4 , HMS yields the first rank for 5 images and second for a further 4, while similar results can be seen for LNIU in Table 5 .", [["BOR", "DNA", 4, 7]]], ["For all images, HMS ranks first or second, resulting in an overall first rank.Experimental ResultsLast not least, we show an example of the obtained results in Fig. 2 which also demonstrates the superiority of HMS.Experimental ResultsOverall, it is clear that our proposed HMS approach outperforms all other algorithms based on all employed measures.ConclusionsThis paper proposes a novel clustering-based image segmentation based on human mental search (HMS).", [["human", "ORGANISM", 434, 439], ["human", "SPECIES", 434, 439], ["human", "SPECIES", 434, 439], ["all images", "TEST", 4, 14], ["all employed measures", "TREATMENT", 328, 349], ["a novel clustering-based image segmentation", "PROBLEM", 381, 424]]], ["Our proposed algorithm encodes cluster centres as the candidate solutions, uses the mean squared error as objective function and employs HMS for optimisation of the latter.", [["objective function", "TEST", 106, 124]]], ["The proposed algorithm is compared with five other metaheuristic algorithms and the obtained experimental results verify the efficacy of the proposed algorithm for image segmentation and show it to outperform the other approaches.", [["image segmentation", "TEST", 164, 182]]], ["We also currently explore our algorithm in the context of video analysis [6] .", [["our algorithm", "TEST", 26, 39], ["video analysis", "TEST", 58, 72]]]], "PMC7366954": [["ETHICAL ASPECTS OF RECEIVING DONATED HUMAN BODY FOR ANATOMICAL DISSECTION ::: INTRODUCTIONThe practice of human dissection is more than two and half centuries old and this ever evolving learning medium has witnessed multiple changes in the manner in which it is carried out.", [["human", "ORGANISM", 106, 111], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["human dissection", "TREATMENT", 106, 122], ["DISSECTION", "OBSERVATION", 63, 73], ["human", "OBSERVATION_MODIFIER", 106, 111], ["dissection", "OBSERVATION", 112, 122]]], ["The most significant among them is regarding the availability of human bodies for dissection.", [["human", "ORGANISM", 65, 70], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["dissection", "PROBLEM", 82, 92], ["most significant", "OBSERVATION_MODIFIER", 4, 20], ["dissection", "OBSERVATION", 82, 92]]], ["The history of human dissection presents many instances where the ethical norms were flouted to ensure the adequacy of human bodies for dissection (Ghosh, 2015).", [["human", "ORGANISM", 15, 20], ["human", "ORGANISM", 119, 124], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 119, 124], ["human dissection", "PROBLEM", 15, 31], ["dissection", "PROBLEM", 136, 146], ["human", "OBSERVATION_MODIFIER", 15, 20], ["dissection", "OBSERVATION", 21, 31], ["dissection", "OBSERVATION", 136, 146]]], ["Even in the last century (during Third Reich) there were serious breaches in the boundaries of ethical practice regarding the use of human remains for the purpose of anatomical dissection (Hildebrandt, 2009).", [["human", "ORGANISM", 133, 138], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["anatomical dissection", "PROBLEM", 166, 187], ["serious", "OBSERVATION_MODIFIER", 57, 64], ["breaches", "OBSERVATION", 65, 73], ["dissection", "OBSERVATION", 177, 187]]], ["The key area for ethical concern towards the source of human bodies for academic activities is whether the concerned person whose body is being explored has actually consented for the same (Winkelmann, 2016).", [["body", "ANATOMY", 130, 134], ["human", "ORGANISM", 55, 60], ["body", "ORGANISM_SUBDIVISION", 130, 134], ["human", "SPECIES", 55, 60], ["person", "SPECIES", 117, 123], ["human", "SPECIES", 55, 60]]], ["However in all these cases the autonomy of the person concerned was overlooked in favour of scientific advancement thus raising pressing ethical concerns in the entire process (Habicht et al., 2018).", [["person", "SPECIES", 47, 53], ["scientific advancement", "TREATMENT", 92, 114]]], ["The concept of body donation whereby an individual wilfully during life bequeaths his/her mortal remains for anatomical dissection after death, rose to prominence towards the later part of 20th century and has emerged as the sole source of human bodies for dissection in most medical schools in the 21st century (Garment et al., 2007; Riederer, 2016).", [["body", "ANATOMY", 15, 19], ["death", "DISEASE", 137, 142], ["body", "ORGANISM_SUBDIVISION", 15, 19], ["human", "ORGANISM", 240, 245], ["human", "SPECIES", 240, 245], ["human", "SPECIES", 240, 245], ["body donation", "TREATMENT", 15, 28], ["anatomical dissection", "PROBLEM", 109, 130], ["death", "PROBLEM", 137, 142], ["dissection", "PROBLEM", 257, 267], ["body donation", "OBSERVATION", 15, 28], ["dissection", "OBSERVATION", 120, 130], ["prominence", "OBSERVATION", 152, 162], ["dissection", "OBSERVATION", 257, 267]]], ["The concept of body donation provides an acceptable solution to ethical loopholes that plagued anatomical sciences previously (Gangata et al., 2010; Jones and Whitaker, 2012).", [["body", "ANATOMY", 15, 19], ["body", "ORGANISM_SUBDIVISION", 15, 19], ["body donation", "TREATMENT", 15, 28]]], ["Rather the rising popularity of body donation programs among the general population and anatomists as such provides strength to the notion that this is the most acceptable manner through which availability of human remains can be ensured by ethical means (Zhang et al., 2008; Manyacka Ma Nyemb et al., 2014; Jones, 2016).", [["body", "ANATOMY", 32, 36], ["body", "ORGANISM_SUBDIVISION", 32, 36], ["human", "ORGANISM", 209, 214], ["human", "SPECIES", 209, 214], ["human", "SPECIES", 209, 214], ["body donation programs", "TREATMENT", 32, 54], ["rising", "OBSERVATION_MODIFIER", 11, 17]]], ["In fact the International Federation of Association of Anatomists (IFAA) in 2012 has recommended that only human bodies through donation programs be used for academic purpose (FICEM, 2012) (Table 1).", [["human", "ORGANISM", 107, 112], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["human bodies through donation programs", "TREATMENT", 107, 145]]], ["However the existing scenario is far from ideal as a recent study has documented that medical schools in major parts of Asia, Africa and South America till date depends on mostly unclaimed bodies or even exclusively unclaimed bodies for anatomical dissection (Habicht et al., 2018).", [["a recent study", "TEST", 51, 65], ["anatomical dissection", "OBSERVATION", 237, 258]]], ["Unfortunately this trend is also prevalent in some pockets of Europe and North America (Habicht et al., 2018; Caplan and DeCamp, 2019).", [["pockets", "OBSERVATION_MODIFIER", 51, 58]]], ["However the silver lining is that at least a few of these medical schools have either transitioned to a bequest system or are in the midst of the ongoing process (Habicht et al., 2018; Hutchinson et al., 2019).", [["silver", "CHEMICAL", 12, 18], ["silver", "CHEMICAL", 12, 18], ["silver", "OBSERVATION_MODIFIER", 12, 18], ["lining", "OBSERVATION_MODIFIER", 19, 25], ["few", "OBSERVATION_MODIFIER", 45, 48]]], ["Elsewhere anatomists are raising serious concerns regarding the improper practice of accepting unclaimed human bodies, which could be indicative of a better future in this regard (G\u00fcrses et al., 2018).", [["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["unclaimed human bodies", "PROBLEM", 95, 117], ["could be indicative", "UNCERTAINTY", 125, 144]]], ["It may be mentioned here that ethical issues are being raised even on the ongoing body donation programs (Champney, 2011).", [["body", "ANATOMY", 82, 86], ["body", "ORGANISM_SUBDIVISION", 82, 86], ["ethical issues", "PROBLEM", 30, 44]]], ["Recent literature emphasizes on adherence with particular norms for body donation to allay possible ethical concern (Riederer and Bueno-L\u00f3pez, 2014).", [["body", "ANATOMY", 68, 72], ["body", "ORGANISM_SUBDIVISION", 68, 72], ["body donation", "TREATMENT", 68, 81]]], ["These include obtaining written informed consent from the donors before accepting bequest, abstaining from commercialization in any form with relation to bequest of human remains and existence of institute oversight committee to review the functional program at regular intervals.", [["donors", "ORGANISM", 58, 64], ["human", "ORGANISM", 165, 170], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 165, 170]]], ["All these recommendations are included in IFAA guidelines issued in 2012 and are being followed in most medical schools across the globe (FICEM, 2012; Jones, 2016).Informed Consent From Donor is Mandatory ::: INTRODUCTIONFor all body bequeathal programs it is absolutely essential to have a written informed consent from every potential donor (Table 1).", [["body", "ANATOMY", 229, 233], ["body", "ORGANISM_SUBDIVISION", 229, 233], ["all body bequeathal programs", "TREATMENT", 225, 253], ["globe", "ANATOMY", 131, 136]]], ["This serves as a vital legal deed which acts as a guarantee that the donation confirms to the existing legislation in place for a country/ region.", [["legislation", "OBSERVATION", 103, 114]]], ["Moreover the consent is a testimony to the wilful act of the person concerned and also provides legal buffer to the concerned institute while utilizing the human remains for teaching and research (Riederer and Bueno-L\u00f3pez, 2014).", [["human", "ORGANISM", 156, 161], ["person", "SPECIES", 61, 67], ["human", "SPECIES", 156, 161], ["human", "SPECIES", 156, 161]]], ["It is to be explicitly stated as to the purpose for which the human remains to be used, details including financial implications (if any) with regards to the transportation and cremation, followed by an estimate regarding the time frame within which the human tissues will be used (FICEM, 2012).", [["tissues", "ANATOMY", 260, 267], ["human", "ORGANISM", 62, 67], ["human", "ORGANISM", 254, 259], ["tissues", "TISSUE", 260, 267], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 254, 259], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 254, 259], ["human tissues", "ANATOMY", 254, 267]]], ["Most medical schools avoid accepting donation when written consent cannot be given by the person concerned and one has to rely on proxy consent such as for foetuses and children as well as for person who are mentally ill or in coma (Riederer and Bueno-L\u00f3pez, 2014).", [["mentally ill", "DISEASE", 208, 220], ["coma", "DISEASE", 227, 231], ["foetuses", "ORGANISM", 156, 164], ["children", "ORGANISM", 169, 177], ["person", "SPECIES", 90, 96], ["children", "SPECIES", 169, 177], ["person", "SPECIES", 193, 199]]], ["Another interesting scenario is that of implied consent, which not granted in written form but rather inferred from the actions of a person concerned.", [["person", "SPECIES", 133, 139]]], ["Presently the legislative framework is not clearly established for whole body donation in these cases in most parts of the world and is handled on the basis of facts and circumstances of the situation at the institutional level (Rajasekhar et al., 2016; Prabhu, 2019).", [["body", "ANATOMY", 73, 77], ["body", "ORGANISM_SUBDIVISION", 73, 77], ["whole body donation", "TREATMENT", 67, 86]]], ["However in some countries such as the United Kingdom implied consent is not accepted with regards to body donation programs (Riederer and Bueno-L\u00f3pez, 2014).Donated Bodies are not Meant for Making Financial Gains ::: INTRODUCTIONInternational organizations in the domain of anatomical sciences have clearly mentioned in their guidelines for ethical practice that there should be no financial gain arising from either the human body or its parts (FICEM, 2012; AACA, 2017; AAA, 2018) (Table 1).", [["body", "ANATOMY", 101, 105], ["body", "ANATOMY", 427, 431], ["body", "ORGANISM_SUBDIVISION", 101, 105], ["human", "ORGANISM", 421, 426], ["body", "ORGANISM_SUBDIVISION", 427, 431], ["human", "SPECIES", 421, 426], ["human", "SPECIES", 421, 426], ["ethical practice", "TREATMENT", 341, 357]]], ["A major area of concern in this context is the emergence of commercial firms, who are often referred to as \u2018body brokers\u2019 (Goodwin, 2006; Shimazono, 2007).", [["body", "ANATOMY", 108, 112], ["body", "ORGANISM_SUBDIVISION", 108, 112], ["major", "OBSERVATION_MODIFIER", 2, 7], ["area", "OBSERVATION_MODIFIER", 8, 12], ["concern", "OBSERVATION", 16, 23]]], ["They are operational particularly in the United States (however these farms have been spreading their footprints globally) and are permitted within the legal framework to receive the bodies of altruistic donors followed by distribution to academic institutions (Champney, 2016; Nie and Jones, 2019).", [["donors", "ORGANISM", 204, 210]]], ["These entities are gaining prominence in those regions where body donation programs are either not functional or not been able to ensure adequate number or facing hindrance due to religious/cultural factors (Champney, 2016; Paul et al., 2017).", [["body", "ANATOMY", 61, 65], ["body", "ORGANISM_SUBDIVISION", 61, 65], ["body donation programs", "TREATMENT", 61, 83], ["gaining", "OBSERVATION_MODIFIER", 19, 26], ["prominence", "OBSERVATION", 27, 37]]], ["In a way their ongoing activities may possibly be in favour of ethical supply of human remains as these farms are acting as liaison between wilful donors and academic institutions.", [["human", "ORGANISM", 81, 86], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86]]], ["However lack of regulation both at administrative level as well as institutional level could lead to serious lacunae in terms of financial connotation thereby channelling these farms into potential profit making bodies (Nie and Jones, 2019).", [["serious lacunae", "PROBLEM", 101, 116], ["serious", "OBSERVATION_MODIFIER", 101, 108], ["lacunae", "OBSERVATION", 109, 116]]], ["Such a scenario would be a grave deviation from the ethical guidelines and would be no different from the misdeeds of the \u2018body snatchers/resurrectionists\u2019 in the 17th & 18th centuries (Ghosh, 2015).", [["body", "ANATOMY", 123, 127], ["body", "ORGANISM_SUBDIVISION", 123, 127], ["a grave deviation", "PROBLEM", 25, 42]]], ["In this context, it may also be mentioned that in the United States (possibly elsewhere also) there are companies which provide human body parts for dissection activities and this constitutes a potential grey zone in terms of practice of ethics (Bard, 2008).", [["body", "ANATOMY", 134, 138], ["human", "ORGANISM", 128, 133], ["body", "ORGANISM_SUBDIVISION", 134, 138], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["human body parts", "TREATMENT", 128, 144], ["dissection activities", "TREATMENT", 149, 170], ["dissection", "OBSERVATION", 149, 159]]], ["Under the prevailing situation it becomes imperative for the institute oversight committee (responsible to oversee that ethical guidelines are followed in every stage of human dissection course) to ensure that these farms/agencies/companies should not make any financial profits from providing donated bodies for academic purpose (Jones, 2016) (Table 1).", [["human", "ORGANISM", 170, 175], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["ethical guidelines", "TREATMENT", 120, 138], ["human dissection course", "TREATMENT", 170, 193]]], ["In other words care should be taken such that the overall process does not degrade to ulterior selling of human body or its parts.", [["body", "ANATOMY", 112, 116], ["human", "ORGANISM", 106, 111], ["body", "ORGANISM_SUBDIVISION", 112, 116], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111]]], ["This could be achieved through regulation of the remuneration paid to these farms/agencies at regular intervals such that the amount strictly includes only costs regarding transport, preparation (chemicals if any/labour charges if any) and cremation of the bodies (Table 1).Plastination of Donated Body Needs Prior Consent ::: INTRODUCTIONAnother aspect which merits discussion in this context is the trend of public exhibitions of plastinated bodies which have been gaining popularity of late (Nie and Jones, 2019).", [["any/labour charges", "PROBLEM", 209, 227], ["plastinated bodies", "PROBLEM", 432, 450], ["bodies", "ANATOMY_MODIFIER", 257, 263]]], ["Firstly since plastinated bodies are subjected to long time preservation, hence if the human remains is to be used for this purpose then this information should be communicated to the donor in the consent form in a transparent manner with a possible upper limit of the time duration for preservation (FICEM, 2018) (Table 1).", [["plastinated bodies", "ANATOMY", 14, 32], ["human", "ORGANISM", 87, 92], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["plastinated bodies", "TREATMENT", 14, 32], ["long time", "OBSERVATION_MODIFIER", 50, 59], ["upper limit", "OBSERVATION_MODIFIER", 250, 261]]], ["Moreover the financial connotation should be regulated whereby the events should be restricted strictly for academic purpose and to be run on a \u2018no profit no loss\u2019 basis whereby only the expenditure pertaining to logistics and other essentials could be recovered through sponsorships or issue of passes (Table 1).Regulation Obligatory for Donated Bodies from Physician Assisted Death ::: INTRODUCTIONA very recent development which justifies argument is the availability of donated human bodies of persons who have opted for medical assistance in dying (MAID) or to put it in a broader perspective physician assisted death (PAD) (Li et al., 2017).", [["Death", "DISEASE", 378, 383], ["death", "DISEASE", 617, 622], ["PAD", "DISEASE", 624, 627], ["human", "ORGANISM", 482, 487], ["persons", "ORGANISM", 498, 505], ["human", "SPECIES", 482, 487], ["persons", "SPECIES", 498, 505], ["human", "SPECIES", 482, 487]]], ["In recent times the authorization granted within judicial framework of some countries have meant that persons residing there now have the option to embrace MAID or PAD and subsequently donate their mortal remains for academic activities (Jones, 2019).", [["PAD", "DISEASE", 164, 167], ["persons", "ORGANISM", 102, 109], ["persons", "SPECIES", 102, 109], ["PAD", "TREATMENT", 164, 167]]], ["It is no surprise then that this has opened a novel avenue for ongoing body donation programs to receive donated human bodies (Nuhn et al., 2018; Grant, 2019).", [["body", "ANATOMY", 71, 75], ["body", "ORGANISM_SUBDIVISION", 71, 75], ["human", "ORGANISM", 113, 118], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["ongoing body donation programs", "TREATMENT", 63, 93], ["no", "UNCERTAINTY", 6, 8]]], ["However this new horizon has presented anatomists with its very own ethical challenges.", [["new", "OBSERVATION_MODIFIER", 13, 16]]], ["First whether the institutions should accept body donations coming through MAID/ PAD and the criteria for decision.", [["body", "ANATOMY", 45, 49], ["PAD", "DISEASE", 81, 84], ["body", "ORGANISM_SUBDIVISION", 45, 49], ["body donations", "TREATMENT", 45, 59], ["MAID/ PAD", "TREATMENT", 75, 84], ["PAD", "ANATOMY", 81, 84]]], ["Touching this debate, both Wainman and Cornwall (2019) as well as Jones (2019) have documented some core recommendations, whereby the decision to receive or not to receive MAID/PAD donated bodies has been left entirely to the concerned institution with a reiteration that donated bodies coming through MAID/PAD are appropriate for academic activities provided the death is legal in context of the country/region as per existing laws (Table 1).", [["PAD", "DISEASE", 177, 180], ["PAD", "DISEASE", 307, 310], ["death", "DISEASE", 364, 369], ["MAID/PAD donated bodies", "TREATMENT", 172, 195], ["a reiteration that donated bodies", "TREATMENT", 253, 286], ["MAID/PAD", "TREATMENT", 302, 310], ["the death", "PROBLEM", 360, 369], ["PAD", "ANATOMY", 307, 310]]], ["Regarding the second concern it has been noted that for human remains to be accepted through body donation, the potential donor should provide fully informed written consent with absolutely no persuasion from anyone involved in the process from MAID/PAD to body donation.", [["body", "ANATOMY", 93, 97], ["body", "ANATOMY", 257, 261], ["PAD", "DISEASE", 250, 253], ["human", "ORGANISM", 56, 61], ["body", "ORGANISM_SUBDIVISION", 93, 97], ["body", "ORGANISM_SUBDIVISION", 257, 261], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["MAID/PAD to body donation", "TREATMENT", 245, 270]]], ["Further it has to be ensured that there should be zero level solicitation from personnel responsible for MAID/PAD towards body donation (Jones, 2019; Wainman and Cornwall, 2019) (Table 1).", [["body", "ANATOMY", 122, 126], ["PAD", "DISEASE", 110, 113], ["body", "ORGANISM_SUBDIVISION", 122, 126], ["MAID/PAD", "TREATMENT", 105, 113]]], ["These recommendations should be considered as working guidelines pertaining to these cases and accordingly donated bodies may be accepted at the institutional level.Regulation Obligatory for Donated Bodies from Physician Assisted Death ::: INTRODUCTIONAn ethical dilemma arises when there is lack of storage space for human bodies particularly in case of countries having very popular body bequeathal programs.", [["body", "ANATOMY", 385, 389], ["Death", "DISEASE", 230, 235], ["human", "ORGANISM", 318, 323], ["body", "ORGANISM_SUBDIVISION", 385, 389], ["human", "SPECIES", 318, 323], ["human", "SPECIES", 318, 323], ["human bodies", "PROBLEM", 318, 330]]], ["In such a scenario it is never an option to refuse accepting even a single donation.", [["a single donation", "TREATMENT", 66, 83]]], ["As noted in one particular published literature, it is better advised to explore options such as developing exchange programs between anatomy departments within a region/country and channelize the precious resource as per availability of incoming donations (Riederer and Bueno-L\u00f3pez, 2014) (Table 1).Embalming Process Should Follow Quality Standards and May be Guided by Code of Ethics ::: DONATED HUMAN BODY SHOULD BE PRESERVED AS PER ETHICAL NORMSThe different embalming techniques followed by medical schools across the globe have been described in an elaborate manner by Brenner (2014).", [["exchange programs", "TREATMENT", 108, 125], ["The different embalming techniques", "TREATMENT", 449, 483], ["PRESERVED", "OBSERVATION", 419, 428], ["globe", "ANATOMY", 523, 528]]], ["Ideally an appropriately embalmed human body should be able to withstand changes attributed to putrefaction, should not be infested by insects/ maggots at any stage and should be deemed as safe for human handling without fear of infection (Macdonald and MacGregor, 1997).", [["body", "ANATOMY", 40, 44], ["infection", "DISEASE", 229, 238], ["human", "ORGANISM", 34, 39], ["body", "ORGANISM_SUBDIVISION", 40, 44], ["maggots", "ORGANISM_SUBDIVISION", 144, 151], ["human", "ORGANISM", 198, 203], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 198, 203], ["an appropriately embalmed human body", "TREATMENT", 8, 44], ["putrefaction", "PROBLEM", 95, 107], ["infection", "PROBLEM", 229, 238], ["infection", "OBSERVATION", 229, 238]]], ["On the dissection table a human body could be judged as properly embalmed if the tissues are fixed to a permissible level, colour and texture of muscles and organs make them readily identifiable, flexibility and colour of arteries maintained to a level such that they easily stand out from the surrounding anatomy (Balta et al., 2015b) (Table 2).", [["body", "ANATOMY", 32, 36], ["tissues", "ANATOMY", 81, 88], ["muscles", "ANATOMY", 145, 152], ["organs", "ANATOMY", 157, 163], ["arteries", "ANATOMY", 222, 230], ["human", "ORGANISM", 26, 31], ["body", "ORGANISM_SUBDIVISION", 32, 36], ["tissues", "TISSUE", 81, 88], ["muscles", "ORGAN", 145, 152], ["organs", "ORGAN", 157, 163], ["arteries", "MULTI-TISSUE_STRUCTURE", 222, 230], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["a human body", "TREATMENT", 24, 36], ["dissection", "OBSERVATION", 7, 17], ["muscles", "ANATOMY", 145, 152], ["arteries", "ANATOMY", 222, 230]]], ["Medical schools involved in handling donated human remains may consider to have Institute Code of Ethics (similar to the one adopted by The British Institute of Embalmers/ BIE) whereby all personnel involved in the embalming process should strictly abide by the contents (British Institute of Embalmers, 2017) (Table 2).", [["human", "ORGANISM", 45, 50], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50]]], ["The core idea of such an exercise would be aimed to convey the message that the human body being embalmed is a precious scientific resource, which deserves to be treated respectfully and that giving their best effort would be a worthy contribution towards fulfilment of last wish of the deceased as well as scientific advancement.", [["body", "ANATOMY", 86, 90], ["human", "ORGANISM", 80, 85], ["body", "ORGANISM_SUBDIVISION", 86, 90], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["scientific advancement", "TREATMENT", 307, 329]]], ["The Code of Ethics would also be applicable towards maintaining confidentiality regarding any information related to identity of the donor/ family or otherwise and that any issue arising during the process of embalming should be dealt with as per guidelines established by the concerned institute.Embalming and Storage Areas to be Separate and Sovereign ::: DONATED HUMAN BODY SHOULD BE PRESERVED AS PER ETHICAL NORMSDesignated areas used for embalming and storage of human remains should be separate individually and also independent from the area devoted to dissection (Chan and Pawlina, 2015) (Table 2).", [["human", "ORGANISM", 468, 473], ["human", "SPECIES", 468, 473], ["human", "SPECIES", 468, 473], ["Embalming and Storage Areas", "TREATMENT", 297, 324], ["embalming", "TREATMENT", 443, 452], ["PRESERVED", "OBSERVATION", 387, 396], ["dissection", "OBSERVATION", 560, 570]]], ["It may be opined that this is a critical ethical intervention as it would prevent unnecessary breach of privacy with regards to the mortal remains of a person.", [["person", "SPECIES", 152, 158], ["a critical ethical intervention", "TREATMENT", 30, 61]]], ["Nevertheless sanctity of the embalming premises (just like the dissection room) should be maintained at all times.", [["the embalming premises", "PROBLEM", 25, 47]]], ["The area should be clean and well ventilated with all necessary chemicals kept in covered containers and instruments arranged in organized manner being washed after every use (Bajracharya and Magar, 2006).", [["all necessary chemicals", "TREATMENT", 50, 73], ["clean", "OBSERVATION", 19, 24]]], ["While undertaking embalming the personnel involved should be in dress code (as per respective institutions) and should adopt all necessary protective measures as established at institute/department level.Embalming and Storage Areas to be Separate and Sovereign ::: DONATED HUMAN BODY SHOULD BE PRESERVED AS PER ETHICAL NORMSOnce embalming of the human body is completed it needs to be shifted to the storage area.", [["body", "ANATOMY", 352, 356], ["human", "ORGANISM", 346, 351], ["body", "ORGANISM_SUBDIVISION", 352, 356], ["human", "SPECIES", 346, 351], ["human", "SPECIES", 346, 351], ["all necessary protective measures", "TREATMENT", 125, 158], ["Embalming and Storage Areas", "TREATMENT", 204, 231], ["PRESERVED", "OBSERVATION", 294, 303], ["human body", "ANATOMY", 346, 356]]], ["Proper storage of human remains is a key component of the preservation chain and is also an avenue to demonstrate respect that sensitive materials such as these should be accorded (Macdonald and MacGregor, 1997).", [["human", "ORGANISM", 18, 23], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23]]], ["Maintenance of segregated working areas at every stage of preservation/conservation is a part of respect shown to the act of body donation and comprise of ethical handling of human remains.", [["body", "ANATOMY", 125, 129], ["body", "ORGANISM_SUBDIVISION", 125, 129], ["human", "ORGANISM", 175, 180], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 175, 180], ["segregated", "OBSERVATION_MODIFIER", 15, 25], ["working", "OBSERVATION_MODIFIER", 26, 33], ["areas", "OBSERVATION_MODIFIER", 34, 39]]], ["Ethical guidelines suggest that each body should be treated as an autonomous entity and thereby needs to be stored in separate boxes or compartments (Brady, 1998) (Table 2).", [["body", "ANATOMY", 37, 41], ["body", "ORGANISM_SUBDIVISION", 37, 41], ["Ethical guidelines", "TREATMENT", 0, 18]]], ["In other words contacts between bodies, wrappings, artefacts and other materials as applicable should be best avoided.", [["bodies", "ANATOMY", 32, 38], ["artefacts and other materials", "PROBLEM", 51, 80]]], ["Under ideal storage conditions, human bodies are best preserved in cool, dark, dry conditions while wrapped in acid-free tissue and packing materials (Pouliot, 2000).", [["bodies", "ANATOMY", 38, 44], ["tissue", "ANATOMY", 121, 127], ["human", "ORGANISM", 32, 37], ["tissue", "TISSUE", 121, 127], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["human bodies", "TREATMENT", 32, 44], ["acid-free tissue and packing materials", "TREATMENT", 111, 149], ["free tissue", "OBSERVATION", 116, 127]]], ["As mentioned previously preservation of human body by ethical means should be aimed at preventing any damage/destruction of any parts during the process.", [["body", "ANATOMY", 46, 50], ["human", "ORGANISM", 40, 45], ["body", "ORGANISM_SUBDIVISION", 46, 50], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["any damage/destruction", "PROBLEM", 98, 120], ["human body", "ANATOMY", 40, 50], ["destruction", "OBSERVATION", 109, 120]]], ["Hence unnecessary exposure to light should be avoided to prevent damage to tissues particularly the bones.", [["tissues", "ANATOMY", 75, 82], ["bones", "ANATOMY", 100, 105], ["tissues", "TISSUE", 75, 82], ["bones", "ORGAN", 100, 105], ["damage to tissues particularly the bones", "PROBLEM", 65, 105], ["bones", "ANATOMY", 100, 105]]], ["Moreover the human body being as organic material is adversely influenced by rise in temperature and changes in moisture level of the surroundings (Pouliot, 2000).", [["body", "ANATOMY", 19, 23], ["human", "ORGANISM", 13, 18], ["body", "ORGANISM_SUBDIVISION", 19, 23], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["organic material", "PROBLEM", 33, 49], ["human body", "OBSERVATION_MODIFIER", 13, 23]]], ["Overly moist conditions promote fungal growth, whereas low-humidity conditions can cause damage to the protein components resulting in cracks, split and shrinkage of the body (Ghosh and Sharma, 2015).", [["body", "ANATOMY", 170, 174], ["body", "ORGANISM_SUBDIVISION", 170, 174], ["fungal growth", "PROBLEM", 32, 45], ["low-humidity conditions", "PROBLEM", 55, 78], ["damage to the protein components", "PROBLEM", 89, 121], ["cracks", "PROBLEM", 135, 141], ["fungal", "OBSERVATION_MODIFIER", 32, 38], ["growth", "OBSERVATION_MODIFIER", 39, 45], ["cracks", "OBSERVATION_MODIFIER", 135, 141], ["split", "OBSERVATION_MODIFIER", 143, 148], ["shrinkage", "OBSERVATION_MODIFIER", 153, 162], ["body", "ANATOMY", 170, 174]]], ["Subsequently the established parameters should be adhered to round the clock throughout the preservation period.Duration of Preservation Should Honour Terms of Consent ::: DONATED HUMAN BODY SHOULD BE PRESERVED AS PER ETHICAL NORMSA significant aspect of ethical preservation of donated human bodies is the duration for which they are kept in storage (FICEM, 2012) (Table 2).", [["human", "ORGANISM", 287, 292], ["human", "SPECIES", 287, 292], ["human", "SPECIES", 287, 292], ["donated human bodies", "PROBLEM", 279, 299], ["BODY", "ANATOMY_MODIFIER", 186, 190], ["PRESERVED", "OBSERVATION", 201, 210], ["significant", "OBSERVATION_MODIFIER", 233, 244], ["ethical preservation", "OBSERVATION", 255, 275], ["donated human bodies", "OBSERVATION", 279, 299]]], ["In case of some extraordinary circumstances when the donated body is required to be preserved beyond the committed time duration, the matter should be brought under the purview of institute oversight committee and opinion/views of family members should be solicited and needful be done.", [["body", "ANATOMY", 61, 65], ["body", "ORGANISM_SUBDIVISION", 61, 65], ["extraordinary", "OBSERVATION_MODIFIER", 16, 29], ["circumstances", "OBSERVATION", 30, 43]]], ["However there should be no compromise policy with regards to the second point and at all cost the human remains is to be used for dissection activities post preservation and before cremation (Table 2).", [["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["dissection activities post preservation", "TREATMENT", 130, 169]]], ["Any deviation in this context would seriously defeat the very purpose of voluntary body donation programs and would be an act of disrespect to the last wish of the donor (Champney, 2011).", [["body", "ANATOMY", 83, 87], ["body", "ORGANISM_SUBDIVISION", 83, 87], ["Any deviation", "PROBLEM", 0, 13], ["voluntary body donation programs", "TREATMENT", 73, 105], ["deviation", "OBSERVATION", 4, 13]]], ["It may not be an overstatement that such ethical sacrilege is absolutely undesirable and policies regulating preservation and subsequent usage of donated human bodies should essentially be in line with the expectations of the society.Mandatory Practices for Dissection Room Activities ::: IDEAL ETHICAL BEHAVIOUR EXPECTED IN DISSECTION ROOMStudents should be guided to follow some mandatory practices from the point of entry to the point of exit like putting on the laboratory coat all the time in the dissection room, wearing covered shoes with enclosed heels and latex/vinyl gloves while touching the wet specimens.", [["wet specimens", "ANATOMY", 603, 616], ["latex/vinyl", "CHEMICAL", 565, 576], ["vinyl", "CHEMICAL", 571, 576], ["human", "ORGANISM", 154, 159], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["donated human bodies", "TREATMENT", 146, 166], ["DISSECTION ROOMStudents", "TREATMENT", 325, 348], ["enclosed heels", "TREATMENT", 546, 560], ["latex/vinyl gloves", "TREATMENT", 565, 583], ["the wet specimens", "TEST", 599, 616], ["may not be", "UNCERTAINTY", 3, 13], ["Dissection", "OBSERVATION", 258, 268], ["DISSECTION", "OBSERVATION", 325, 335], ["dissection", "ANATOMY", 502, 512], ["heels", "ANATOMY", 555, 560], ["vinyl gloves", "OBSERVATION", 571, 583]]], ["Similarly, they should also remember to remove the gloves at the end of the dissection session for a particular day and dispose the same in designated bio-waste bins, wash their hands and instruments with soap followed by drying and finally remove their laboratory coats when leaving the dissection room (University of Bristol, 2014\u20132015; University of New South Wales, 2015; Semmelweis University, 2016) (Table 3).", [["the gloves", "TREATMENT", 47, 57], ["the dissection session", "TREATMENT", 72, 94], ["soap", "TREATMENT", 205, 209], ["dissection", "OBSERVATION", 76, 86]]], ["These small steps when followed on a daily basis will gradually develop as a habit and it is very much likely that the students will follow the same during clinical postings (albeit with some modifications as applied) and later on as a practising physician.", [["small", "OBSERVATION_MODIFIER", 6, 11], ["steps", "OBSERVATION", 12, 17]]], ["Hence it would be prudent that during their stay in the dissection room, they should be advised against putting any object like stationary items or as applicable into their mouth.", [["mouth", "ANATOMY", 173, 178], ["mouth", "ORGANISM_SUBDIVISION", 173, 178], ["mouth", "ANATOMY", 173, 178]]], ["Information regarding potential toxicity of preservative solutions should be circulated among the students at the very onset of dissection based training.", [["toxicity", "DISEASE", 32, 40], ["preservative solutions", "TREATMENT", 44, 66], ["dissection based training", "TREATMENT", 128, 153], ["dissection", "OBSERVATION", 128, 138]]], ["Subsequently they should be instructed properly as to how they could prevent themselves from inhaling toxic fumes from harmful chemicals.", [["inhaling toxic fumes", "PROBLEM", 93, 113]]], ["As there is possible risk of injuries from sharp objects/needles during human dissection hence it should be mandatory to report such incidents to the staff/faculty for immediate assessment and management as per standard norms (University of Bristol, 2014\u20132015; University of New South Wales, 2015; Semmelweis University, 2016) (Table 3).", [["injuries", "DISEASE", 29, 37], ["human", "ORGANISM", 72, 77], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["injuries", "PROBLEM", 29, 37], ["sharp objects/needles", "TREATMENT", 43, 64], ["human dissection", "TREATMENT", 72, 88], ["immediate assessment", "TEST", 168, 188], ["management", "TREATMENT", 193, 203], ["possible risk of", "UNCERTAINTY", 12, 28], ["injuries", "OBSERVATION", 29, 37], ["dissection", "OBSERVATION", 78, 88]]], ["It may be opined that execution of these measures on regular basis essentially prepares them to adopt standard safety measures as per ethical norms later on as a physician.Respectful Handling of Human Tissues Every Time ::: IDEAL ETHICAL BEHAVIOUR EXPECTED IN DISSECTION ROOMDuring the act of dissection priority should be placed on maintaining cleanliness of the dissection area pertaining to the table on which the human body is being explored.", [["body", "ANATOMY", 423, 427], ["Human", "ORGANISM", 195, 200], ["human", "ORGANISM", 417, 422], ["body", "ORGANISM_SUBDIVISION", 423, 427], ["Human", "SPECIES", 195, 200], ["human", "SPECIES", 417, 422], ["human", "SPECIES", 417, 422], ["standard safety measures", "TREATMENT", 102, 126], ["dissection priority", "TREATMENT", 293, 312], ["the dissection area", "TREATMENT", 360, 379], ["DISSECTION", "OBSERVATION", 260, 270], ["dissection", "OBSERVATION", 293, 303], ["dissection", "OBSERVATION", 364, 374], ["human body", "ANATOMY", 417, 427]]], ["It needs to be ensured that only the specific area of the human body that is being dissected remains exposed, whereas the remaining body should be kept covered.", [["body", "ANATOMY", 64, 68], ["body", "ANATOMY", 132, 136], ["human", "ORGANISM", 58, 63], ["body", "ORGANISM_SUBDIVISION", 64, 68], ["body", "ORGANISM_SUBDIVISION", 132, 136], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["specific", "OBSERVATION_MODIFIER", 37, 45], ["area", "OBSERVATION_MODIFIER", 46, 50], ["human body", "ANATOMY", 58, 68]]], ["Care should be taken such that running count of the instruments used for dissection be maintained so as to ensure that at the end of dissection none of the items are left inside the dissected body (Daemen College, 2014\u20132015; Charles University, 2020; The Institute of Anatomical Sciences, 2020) (Table 3).", [["body", "ANATOMY", 192, 196], ["body", "ORGANISM_SUBDIVISION", 192, 196], ["the instruments", "TREATMENT", 48, 63], ["dissection", "TREATMENT", 73, 83], ["dissection", "TREATMENT", 133, 143], ["dissection", "OBSERVATION", 133, 143], ["left", "ANATOMY_MODIFIER", 166, 170]]], ["While applying incisions, standard protocol as documented in established anatomical texts or as devised at the institute level be followed.", [["incisions", "TREATMENT", 15, 24], ["standard protocol", "TREATMENT", 26, 43], ["incisions", "OBSERVATION", 15, 24]]], ["This is critical to the maintenance of well-defined skin flaps required to cover the dissected area after a session (Cahill et al., 2002).", [["skin", "ANATOMY", 52, 56], ["area", "ANATOMY", 95, 99], ["skin", "ORGAN", 52, 56], ["well-defined skin flaps", "TREATMENT", 39, 62], ["skin", "ANATOMY", 52, 56], ["flaps", "OBSERVATION", 57, 62]]], ["Students are to be encouraged towards respectful handling of any human tissue removed at the time of dissection.", [["tissue", "ANATOMY", 71, 77], ["human", "ORGANISM", 65, 70], ["tissue", "TISSUE", 71, 77], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["any human tissue", "TREATMENT", 61, 77], ["dissection", "PROBLEM", 101, 111], ["dissection", "OBSERVATION", 101, 111]]], ["Accordingly, these human tissues should not be allowed to accumulate in the vicinity of the dissection area.", [["tissues", "ANATOMY", 25, 32], ["human", "ORGANISM", 19, 24], ["tissues", "TISSUE", 25, 32], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["dissection", "OBSERVATION", 92, 102]]], ["Therefore during dissection and definitely at the end of a session it is imperative that the removed tissues should either be preserved (if applicable) or may be disposed into designated bins (preferably colour coded) kept in the premises (Daemen College, 2014\u20132015; Charles University, 2020; The Institute of Anatomical Sciences, 2020) (Table 3).", [["tissues", "ANATOMY", 101, 108], ["tissues", "TISSUE", 101, 108], ["dissection", "TREATMENT", 17, 27], ["dissection", "OBSERVATION", 17, 27]]], ["It has to be ensured at all cost that at the end of a session none of the removed tissue should be left behind on the dissection table.", [["tissue", "ANATOMY", 82, 88], ["tissue", "TISSUE", 82, 88], ["the removed tissue", "TREATMENT", 70, 88], ["left", "ANATOMY_MODIFIER", 99, 103], ["dissection", "OBSERVATION", 118, 128]]], ["This ethical practice supports academic discipline and is a mark of respect to the donor whose body is being dissected.", [["body", "ANATOMY", 95, 99], ["body", "ORGANISM_SUBDIVISION", 95, 99]]], ["Similarly, it is also necessary to ensure that none of the instruments used for dissection be left on the dissection table.", [["the instruments", "TREATMENT", 55, 70], ["dissection", "TREATMENT", 80, 90], ["dissection", "OBSERVATION", 80, 90], ["left", "ANATOMY_MODIFIER", 94, 98], ["dissection", "OBSERVATION", 106, 116]]], ["At the end of a session the instruments are to be washed, dried and kept in a organized manner at a designated space (University of New South Wales, 2015; The Institute of Anatomical Sciences, 2020) (Table 3).", [["a session the instruments", "TREATMENT", 14, 39]]], ["It is advisable that all the recommendations as detailed above (which are actually practiced in most medical schools across the globe) are displayed as signage at different locations of the dissection room and also at the entry point (Table 3).", [["globe", "ANATOMY", 128, 133], ["dissection", "OBSERVATION", 190, 200]]], ["Another useful suggestion would be to display popular messages (both pictorial and text) as available in the internet or in published literature which reminds us about the noble act of body donation and how one selfless act of a person kindles the blessing of knowledge in the mind of thousands (Ghosh, 2017a) (Table 3).", [["body", "ANATOMY", 185, 189], ["body", "ORGANISM_SUBDIVISION", 185, 189], ["person", "SPECIES", 229, 235]]], ["Conveying such relevant messages through innovative means possibly strikes a chord with the students and contributes to cultivating the basics of medical ethics in their young minds.Decision on Anonymity of the Human Body Should be the Call of the Institute / Department ::: IDEAL ETHICAL BEHAVIOUR EXPECTED IN DISSECTION ROOMA very pertinent ethical guideline as applied to dissection room activities is to maintain the anonymity of the donated body.", [["body", "ANATOMY", 446, 450], ["Human", "ORGANISM", 211, 216], ["body", "ORGANISM_SUBDIVISION", 446, 450], ["Human", "SPECIES", 211, 216], ["ethical guideline", "TREATMENT", 343, 360], ["dissection room activities", "TREATMENT", 375, 401], ["DISSECTION", "OBSERVATION", 311, 321]]], ["In fact few medical schools have incorporated this idea into their dissection program and these have been detailed by Ghosh and Kumar (2019) in a systematic review.", [["few", "OBSERVATION_MODIFIER", 8, 11]]], ["However majority of medical schools and anatomists are till date inclined towards maintaining the anonymity of the human body during dissection (Williams et al., 2014; Jones and King, 2017).", [["body", "ANATOMY", 121, 125], ["human", "ORGANISM", 115, 120], ["body", "ORGANISM_SUBDIVISION", 121, 125], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 115, 120], ["human body", "ANATOMY", 115, 125], ["dissection", "OBSERVATION", 133, 143]]], ["It is interesting to note that the trend of maintaining anonymity of a human body being dissected can be traced back and associated with the long history as well as cascading events analogous to human dissection.", [["body", "ANATOMY", 77, 81], ["human", "ORGANISM", 71, 76], ["body", "ORGANISM_SUBDIVISION", 77, 81], ["human", "ORGANISM", 195, 200], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 195, 200], ["a human body", "TREATMENT", 69, 81], ["human dissection", "TREATMENT", 195, 211], ["dissection", "OBSERVATION", 201, 211]]], ["These events and their influence on anonymity of human body have been detailed by Jones and King (2017) in their review article.", [["body", "ANATOMY", 55, 59], ["human", "ORGANISM", 49, 54], ["body", "ORGANISM_SUBDIVISION", 55, 59], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["These events", "PROBLEM", 0, 12]]], ["Based on their observation they have recommended four (04) options in this context whereby the first option refers to maintenance of complete anonymity and remaining options suggest disclosing the identity albeit in a graded manner.", [["options", "TREATMENT", 59, 66]]], ["Researchers have noted that the ethical implications as to whether anonymity of a human body is to be maintained or otherwise essentially hinges on communication between the donor and the beneficiary institution/department at the time of receiving the informed consent (Riederer and Bueno-L\u00f3pez, 2014; Jones and King, 2017).", [["body", "ANATOMY", 88, 92], ["human", "ORGANISM", 82, 87], ["body", "ORGANISM_SUBDIVISION", 88, 92], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87]]], ["As mentioned previously maintenance of anonymity is age long tradition which is more suited to the previously prevalent practice of using unclaimed human bodies as consent of the individual was not available for using his/her mortal remains for dissection.", [["human", "ORGANISM", 148, 153], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["unclaimed human bodies", "TREATMENT", 138, 160], ["dissection", "PROBLEM", 245, 255], ["dissection", "OBSERVATION", 245, 255]]], ["However in present times in the light of popular body donation programs the decision towards revealing the identity of the donor should be at best entrusted to the concerned department.", [["body", "ANATOMY", 49, 53], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["popular body donation programs", "TREATMENT", 41, 71]]], ["In addition to donor consent, another factor also needs to be considered while resolving this ethical dilemma.", [["this ethical dilemma", "PROBLEM", 89, 109]]], ["This is about the outcome of a dissection program where identity of the donor is revealed to the students (Jones and King, 2017).", [["a dissection program", "TREATMENT", 29, 49], ["dissection", "OBSERVATION", 31, 41]]], ["If it is observed that such an experiment actually enriches the dissection program or contributes to enhancement in terms of skills acquired by students then this should justify the decision.", [["the dissection program", "TREATMENT", 60, 82], ["dissection", "OBSERVATION", 64, 74]]], ["However, if the evidence points otherwise like students are having problems to cope with the identity/personal information of the donor then the decision calls for review/revision.Maintaining Dignity of the Donor is Paramount During Communication ::: IDEAL ETHICAL BEHAVIOUR EXPECTED IN DISSECTION ROOMAnother significant ethical consideration as applied to the dissection room activity is the nature of communication between the students as well as between student and staff.", [["revision", "TREATMENT", 171, 179], ["DISSECTION", "OBSERVATION", 287, 297], ["dissection", "OBSERVATION", 362, 372]]], ["This ethical aspect has implications on the communications within the dissection room premises as well as outside (Table 3).", [["dissection", "OBSERVATION", 70, 80]]], ["They are also required to maintain the same decorum with regards to the donor while they are interacting with their family members/relatives/friends /general public (Ghosh, 2017a).", [["decorum", "CANCER", 44, 51]]], ["This ethical aspect mandates strict compliance throughout the duration of the human dissection course.", [["human", "ORGANISM", 78, 83], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["the human dissection course", "TREATMENT", 74, 101], ["strict compliance", "OBSERVATION_MODIFIER", 29, 46], ["dissection", "OBSERVATION", 84, 94]]], ["Adherence to this ethical practice may possibly shape their outlook towards the patients and the society in general.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["this ethical practice", "TREATMENT", 13, 34]]], ["Mutual respect is an integral element of physician-patient relationship and is the cornerstone of ethical medical practice.", [["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58]]], ["In maintaining a respectful attitude towards the human remains of the donor, a student not only uplifts his own moral standard but also projects a better reflection of oneself within the society in general.Maintaining Dignity of the Donor is Paramount During Communication ::: IDEAL ETHICAL BEHAVIOUR EXPECTED IN DISSECTION ROOMHowever it is important to remember that this particular aspect pertaining to respectful communication should not encourage lack of communication at any stage of dissection course.", [["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["dissection course", "TREATMENT", 490, 507], ["DISSECTION", "OBSERVATION", 313, 323], ["dissection", "OBSERVATION", 490, 500]]], ["Particularly care has to be taken at the beginning of the course, when the students probably comes in close contact with the mortal remains of a person for the first time in their life.", [["person", "SPECIES", 145, 151]]], ["Subsequently they are confronted with issues related to death and dying and undergo a myriad of emotional thoughts (Pabst, 1993; Tschernig et al., 2000).", [["death", "DISEASE", 56, 61], ["death", "PROBLEM", 56, 61]]], ["Organizing group based academic activities dedicated for this purpose during the initial phase of dissection course is critical to the ethical build-up of a future physician as it provides a role model to deal with their patients later on during clinical practice (Tschernig et al., 2000).Maintaining Dignity of the Donor is Paramount During Communication ::: IDEAL ETHICAL BEHAVIOUR EXPECTED IN DISSECTION ROOMThe best way to learn is to practice and best practices are those which shape the future towards the better.", [["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 221, 229], ["dissection course", "TREATMENT", 98, 115], ["dissection", "OBSERVATION", 98, 108]]], ["It may be opined that there is no better place than the dissection room, in presence of the mortal remains of a human donor, for honing the skills as applied to ethical practice for a medical student.", [["human", "ORGANISM", 112, 117], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["a human donor", "TREATMENT", 110, 123], ["may be", "UNCERTAINTY", 3, 9], ["no", "UNCERTAINTY", 31, 33], ["dissection", "OBSERVATION", 56, 66], ["mortal", "OBSERVATION", 92, 98]]], ["Although all of these issues may not strictly align with measures intended to cultivate principles of medical ethics among medical students, however from a cumulative perspective, they possibly contribute to the overall ethical outlook of these future professionals.Human Remains Should be Graciously Cremated Post Dissection ::: ETHICAL GUIDELINES RECOMMEND RESPECTFUL DISPOSAL OF DISSECTED REMAINSThe disposal of the dissected human body should be undertaken in the form of cremation/burial as early as possible after it has been used for the purpose for which its retention was authorized by the donor (Ghosh, 2017a).", [["body", "ANATOMY", 435, 439], ["Human", "ORGANISM", 266, 271], ["human", "ORGANISM", 429, 434], ["body", "ORGANISM_SUBDIVISION", 435, 439], ["Human", "SPECIES", 266, 271], ["human", "SPECIES", 429, 434], ["Human", "SPECIES", 266, 271], ["human", "SPECIES", 429, 434], ["the dissected human body", "TREATMENT", 415, 439], ["cremation/burial", "TREATMENT", 476, 492], ["Dissection", "OBSERVATION", 315, 325]]], ["It would be pertinent to mention here that the time interval between acquisition of the human body and its disposal post dissection should comply with the time duration (or a range) committed to the donor while receiving his/her consent (FICEM, 2012; Riederer and Bueno-L\u00f3pez, 2014) (Table 4).", [["body", "ANATOMY", 94, 98], ["human", "ORGANISM", 88, 93], ["body", "ORGANISM_SUBDIVISION", 94, 98], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["the human body", "TREATMENT", 84, 98], ["dissection", "TREATMENT", 121, 131], ["human body", "ANATOMY", 88, 98], ["dissection", "OBSERVATION", 121, 131]]], ["It is essential that disposal of a dissected body implies disposal of all its parts.", [["body", "ANATOMY", 45, 49], ["body", "ORGANISM_SUBDIVISION", 45, 49], ["a dissected body", "TREATMENT", 33, 49]]], ["Exceptions to the above clause may be considered by the oversight committee in case of anatomical tissue wastes being generated on a daily basis during dissection (as it would not be practical to store them until such time as the body being disposed), if a body part needs to be disposed before the dissection on the remaining body gets completed (possibly due to risk of damage/deterioration to the concerned part which is against ethical preservation) or when a body part is to be preserved as a specimen for display and prior consent to this regard is in place (Queensland Health, 2017) (Table 4).Funeral Ceremonies Should be Organized in Honour of the Donor ::: ETHICAL GUIDELINES RECOMMEND RESPECTFUL DISPOSAL OF DISSECTED REMAINSDisposal of the dissected human body essentially refers to its cremation or burial.", [["tissue", "ANATOMY", 98, 104], ["body", "ANATOMY", 230, 234], ["body", "ANATOMY", 257, 261], ["body", "ANATOMY", 327, 331], ["body", "ANATOMY", 464, 468], ["specimen", "ANATOMY", 498, 506], ["body", "ANATOMY", 767, 771], ["tissue", "TISSUE", 98, 104], ["body", "ORGANISM_SUBDIVISION", 230, 234], ["body", "ORGANISM_SUBDIVISION", 257, 261], ["body", "ORGANISM_SUBDIVISION", 327, 331], ["body", "ORGANISM_SUBDIVISION", 464, 468], ["human", "ORGANISM", 761, 766], ["body", "ORGANISM_SUBDIVISION", 767, 771], ["human", "SPECIES", 761, 766], ["human", "SPECIES", 761, 766], ["anatomical tissue wastes", "TREATMENT", 87, 111], ["dissection", "TREATMENT", 152, 162], ["the dissection", "PROBLEM", 295, 309], ["damage/deterioration", "PROBLEM", 372, 392], ["ethical preservation", "TREATMENT", 432, 452], ["the dissected human body", "TREATMENT", 747, 771], ["dissection", "OBSERVATION", 152, 162], ["dissection", "OBSERVATION", 299, 309]]], ["In fact most medical schools perceives the occasion as an opportunity to bid adieu to a noble person who has enlightened the students with knowledge and through selfless act contributed towards the welfare of the society (Ghosh, 2017a).", [["person", "SPECIES", 94, 100]]], ["Research shows that most of the potential body donors wish for a respectful and ceremonial cremation of their remains after anatomical dissection (Richardson and Hurwitz, 1995; Rizzolo, 2002).", [["body", "ANATOMY", 42, 46], ["body", "ORGANISM_SUBDIVISION", 42, 46], ["donors", "ORGANISM", 47, 53], ["a respectful and ceremonial cremation", "TREATMENT", 63, 100], ["dissection", "OBSERVATION", 135, 145]]], ["Hence from an ethical perspective it is the responsibility of all stakeholders involved in the exercise of human dissection to fulfil the last wish of the donor.", [["human", "ORGANISM", 107, 112], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["human dissection", "TREATMENT", 107, 123], ["the donor", "TREATMENT", 151, 160], ["dissection", "OBSERVATION", 113, 123]]], ["In this context, as reported in the literature, there are two major trends which are emerging globally.", [["two", "OBSERVATION_MODIFIER", 58, 61], ["major", "OBSERVATION_MODIFIER", 62, 67]]], ["Medical schools such as The Basic Biomedical Sciences Division at University of South Dakota, United States; School of Medicine, University of Alabama, Birmingham, United States and School of Anatomy, Physiology and Human Biology, The University of Western Australia, arrange for funeral services whereby all dissected cadavers are properly cremated and the ashes are either handed over to the family members or they are buried at the cemetery with a memorabilia displaying a note of acknowledgement in the cemetery area (Ramsey-Stewart et al., 2010; Pawlina et al., 2011; Ghosh, 2017a).", [["cadavers", "ANATOMY", 319, 327], ["Human", "ORGANISM", 216, 221], ["cadavers", "ORGANISM", 319, 327], ["Human", "SPECIES", 216, 221]]], ["Participating in funeral ceremonies, which effectively constitutes the final journey of the wilful donor, is in accordance with ethical practice and a reflection of the humanistic side of dissection programs.", [["ethical practice", "TREATMENT", 128, 144], ["dissection programs", "TREATMENT", 188, 207], ["dissection", "OBSERVATION", 188, 198]]], ["Such events are effectively aimed to instil an appreciation for the humanity of the donors in the young minds of medical students and possibly enhance the societal impact of the practice of human dissection.Funeral Ceremonies Should be Organized in Honour of the Donor ::: ETHICAL GUIDELINES RECOMMEND RESPECTFUL DISPOSAL OF DISSECTED REMAINSFuneral ceremonies provide an ideal platform for the students to be confronted with the ethical dimensions of clinical practice.", [["donors", "ORGANISM", 84, 90], ["human", "ORGANISM", 190, 195], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 190, 195], ["human dissection", "TREATMENT", 190, 206], ["human dissection", "OBSERVATION", 190, 206]]], ["Since dissection course in most cases is the first contact for medical students with a dead person, hence they are mostly unaware about the model ethical practice with regards to the mortal remains of the donor.", [["person", "SPECIES", 92, 98], ["dissection", "OBSERVATION", 6, 16], ["course", "OBSERVATION_MODIFIER", 17, 23]]], ["Consequently malpractices at the student level are often reported like students taking photographs while posing next to the donor or even recording video clips.", [["clips", "OBSERVATION", 154, 159]]], ["Participation of students in funeral ceremonies contribute to strengthening their spiritual outlook and developing a respectful attitude towards the body of the donor.", [["body", "ANATOMY", 149, 153], ["body", "ORGANISM_SUBDIVISION", 149, 153]]], ["There is evidence in literature that participation in ceremonies remarkably improve the behaviour of students during dissection thus reducing chances of ethical transgressions (Pabst et al., 2017).", [["dissection", "TREATMENT", 117, 127], ["ethical transgressions", "PROBLEM", 153, 175], ["dissection", "OBSERVATION", 117, 127]]], ["Ideally a memorial plaque should also be erected at the place as a mark of respect to the donor (Queensland Health, 2017) (Table 4).Records of Cremation Process to be Maintained in Meticulous Manner ::: ETHICAL GUIDELINES RECOMMEND RESPECTFUL DISPOSAL OF DISSECTED REMAINSFrom ethical perspective, significance of maintaining record at the department/institute level for cremation of dissected body is paramount (Table 4).", [["plaque", "ANATOMY", 19, 25], ["body", "ANATOMY", 394, 398], ["body", "ORGANISM_SUBDIVISION", 394, 398], ["a memorial plaque", "PROBLEM", 8, 25], ["plaque", "OBSERVATION", 19, 25]]], ["Such measures effectively check any possible malpractice pertaining to dissected remains and also ensures handling of precious human tissues in a respectful manner (Tomasini, 2008).", [["tissues", "ANATOMY", 133, 140], ["human", "ORGANISM", 127, 132], ["tissues", "TISSUE", 133, 140], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132]]], ["While removing the body for cremation, it would be prudent to cross-check the details of the donor with those recorded at the time of receiving the human body.", [["body", "ANATOMY", 19, 23], ["body", "ANATOMY", 154, 158], ["body", "ORGANISM_SUBDIVISION", 19, 23], ["human", "ORGANISM", 148, 153], ["body", "ORGANISM_SUBDIVISION", 154, 158], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["cremation", "TREATMENT", 28, 37], ["the donor", "TREATMENT", 89, 98], ["the human body", "TREATMENT", 144, 158], ["human body", "ANATOMY", 148, 158]]], ["Further the person in-charge who has authorized the removal of the human remains for cremation should be recorded with his/her signature.", [["human", "ORGANISM", 67, 72], ["person", "SPECIES", 12, 18], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["the removal", "TREATMENT", 48, 59], ["cremation", "TREATMENT", 85, 94]]], ["Moreover the name of the family member(s) who have attended the funeral service and/or have received the ashes after cremation should also be recorded with signature(s).", [["the ashes", "TREATMENT", 101, 110], ["cremation", "TREATMENT", 117, 126]]], ["The date and time of cremation ceremony with all the details thereof (venue and participants with course of events) needs to be recorded.", [["participants", "SPECIES", 80, 92]]], ["It is also advisable to maintain a record of the financial expenditures borne by the institute on account of the cremation ceremony under separate heads as applicable (Table 4).", [["the cremation ceremony", "TREATMENT", 109, 131]]], ["Maintaining record of the cremation process of dissected remains of a donor in a transparent manner speak volumes about the overall performance of the body donation program.", [["body", "ANATOMY", 151, 155], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["the body donation program", "TREATMENT", 147, 172]]], ["It is a testimony to the fact that the cremation of the mortal remains of the donor has been carried out as per ethical standards followed by medical schools across the globe.CONCLUSIONThe dissection room experience provides an opportunity for nurturing the principles of ethical practice among medical students early in the curriculum.", [["ethical practice", "TREATMENT", 272, 288], ["globe", "ANATOMY", 169, 174], ["dissection", "OBSERVATION", 189, 199]]], ["Following ethical guidelines as applied to every possible activity within the dissection room is the desired path for setting standards before the students.", [["ethical guidelines", "TREATMENT", 10, 28], ["dissection", "OBSERVATION", 78, 88]]], ["It is like propping up live simulation, albeit on a smaller scale, of ideal behaviour in the clinical scenario.", [["a smaller scale", "TREATMENT", 50, 65]]], ["This review article is an attempt to collate the recommendations documented by researchers in the context of dissection room activities.", [["dissection", "OBSERVATION", 109, 119]]], ["As discussed previously, the present review includes recommendations pertinent to all activities related to human dissection (Table 1, Table 2, Table 3, Table 4).", [["human", "ORGANISM", 108, 113], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["human dissection", "TREATMENT", 108, 124], ["dissection", "OBSERVATION", 114, 124]]], ["Some of these activities like source of the human body to be dissected, details concerning its preservation and storage, safety instructions for staff members, documentation of records, are apparently beyond the purview of medical students during dissection course.", [["body", "ANATOMY", 50, 54], ["human", "ORGANISM", 44, 49], ["body", "ORGANISM_SUBDIVISION", 50, 54], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["dissection course", "TREATMENT", 247, 264], ["dissection", "OBSERVATION", 247, 257]]], ["Nevertheless, these are integral elements of dissection related activities and it would not be prudent to keep medical students unexposed to these details.", [["dissection", "PROBLEM", 45, 55], ["dissection", "OBSERVATION", 45, 55]]], ["It may be opined that it is always better to set as much ideal examples as possible before the students in the context of ethical practice in human dissection.", [["human", "ORGANISM", 142, 147], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147], ["ethical practice in human dissection", "TREATMENT", 122, 158], ["human dissection", "OBSERVATION", 142, 158]]], ["As a part of good practices in the context of human dissection, medical students may be exposed to these details (which are apparently not directly related to the dissection room activity pertaining to anatomy curriculum) through academic sessions (seminars/group discussion/workshops) either at the beginning of the course or at suitable intervals.", [["human", "ORGANISM", 46, 51], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["human dissection", "TREATMENT", 46, 62], ["dissection", "OBSERVATION", 52, 62], ["dissection", "OBSERVATION", 163, 173]]], ["Knowledge about the practice of high standards at multiple levels in the context of human dissection would undoubtedly enhance the ethical outlook of the students.CONCLUSIONIt may be mentioned here that the recommendations mentioned in this review are in accordance with the guidelines (and modifications thereof) issued by IFAA and other recognised anatomical bodies.", [["human", "ORGANISM", 84, 89], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["human dissection", "TREATMENT", 84, 100], ["dissection", "OBSERVATION", 90, 100], ["anatomical bodies", "OBSERVATION", 350, 367]]], ["Most of the recommendations have already been embraced as part of anatomical dissection linked to successful ongoing body donation programs in medical schools across the globe.", [["body", "ANATOMY", 117, 121], ["body", "ORGANISM_SUBDIVISION", 117, 121], ["anatomical dissection", "PROBLEM", 66, 87], ["successful ongoing body donation programs", "TREATMENT", 98, 139], ["dissection", "OBSERVATION", 77, 87], ["globe", "ANATOMY", 170, 175]]], ["This review article will serve its intended purpose if it is able to guide anatomists towards thinking about the ethical dimension of human dissection.", [["human", "ORGANISM", 134, 139], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["human dissection", "TREATMENT", 134, 150], ["human", "ANATOMY", 134, 139], ["dissection", "OBSERVATION", 140, 150]]]], "80163c27e3a9374a6ac0ab8a59c48be3cf7e4e53": [["COVID-19, the clinical syndrome caused by the novel coronavirus, SARS-CoV-2, continues to rapidly spread, leading to significant stressors on global healthcare infrastructure.", [["COVID-19", "CHEMICAL", 0, 8], ["SARS", "DISEASE", 65, 69], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV", "SPECIES", 65, 73], ["COVID", "TEST", 0, 5], ["the clinical syndrome", "PROBLEM", 10, 31], ["the novel coronavirus", "PROBLEM", 42, 63], ["SARS", "PROBLEM", 65, 69], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["stressors", "OBSERVATION", 129, 138]]], ["The manifestations of COVID-19 in solid organ transplant recipients are only beginning to be understood with cases reported to date in transplant recipients on chronic immunosuppression.", [["solid organ", "ANATOMY", 34, 45], ["COVID-19", "CHEMICAL", 22, 30], ["COVID-19", "CHEMICAL", 22, 30], ["COVID-19", "GENE_OR_GENE_PRODUCT", 22, 30], ["solid", "CANCER", 34, 39], ["organ", "ORGAN", 40, 45], ["recipients", "ORGANISM", 146, 156], ["COVID", "TEST", 22, 27], ["solid organ transplant recipients", "TREATMENT", 34, 67], ["transplant recipients", "TREATMENT", 135, 156], ["chronic immunosuppression", "TREATMENT", 160, 185], ["organ", "ANATOMY", 40, 45], ["transplant", "OBSERVATION", 46, 56], ["chronic", "OBSERVATION_MODIFIER", 160, 167], ["immunosuppression", "OBSERVATION", 168, 185]]], ["Herein, we report the first case of COVID-19 in a lung transplant recipient in the immediate posttransplant period, and we describe the epidemiologic challenges in identifying the source of infection in this unique situation.K E Y W O R D Scoronavirus, COVID-19, lung transplant Sixty hours after hospital admission, the donor was taken to the operating room for organ procurement following cardiac death.", [["lung", "ANATOMY", 50, 54], ["lung", "ANATOMY", 263, 267], ["organ", "ANATOMY", 363, 368], ["cardiac", "ANATOMY", 391, 398], ["COVID-19", "CHEMICAL", 36, 44], ["infection", "DISEASE", 190, 199], ["K", "CHEMICAL", 225, 226], ["cardiac death", "DISEASE", 391, 404], ["K", "CHEMICAL", 225, 226], ["COVID-19", "CELL", 36, 44], ["lung", "ORGAN", 50, 54], ["lung", "ORGAN", 263, 267], ["organ", "ORGAN", 363, 368], ["K", "SPECIES", 225, 226], ["COVID", "TEST", 36, 41], ["a lung transplant recipient", "TREATMENT", 48, 75], ["infection", "PROBLEM", 190, 199], ["Scoronavirus", "PROBLEM", 239, 251], ["COVID", "TEST", 253, 258], ["lung transplant", "TREATMENT", 263, 278], ["organ procurement", "TREATMENT", 363, 380], ["cardiac death", "PROBLEM", 391, 404], ["lung", "ANATOMY", 50, 54], ["transplant", "OBSERVATION", 55, 65], ["infection", "OBSERVATION", 190, 199], ["lung", "ANATOMY", 263, 267], ["transplant", "OBSERVATION", 268, 278], ["cardiac", "ANATOMY", 391, 398], ["death", "OBSERVATION", 399, 404]]], ["A repeat bronchoscopic examination revealed minimal airway secretions.", [["airway", "ANATOMY", 52, 58], ["airway secretions", "PATHOLOGICAL_FORMATION", 52, 69], ["A repeat bronchoscopic examination", "TEST", 0, 34], ["minimal airway secretions", "PROBLEM", 44, 69], ["minimal", "OBSERVATION_MODIFIER", 44, 51], ["airway", "ANATOMY", 52, 58], ["secretions", "OBSERVATION", 59, 69]]], ["Having met programmatic parameters for quality, the lungs were procured and prepared for transport ( Figure 1B ).K E Y W O R D SThe recipient underwent bilateral sequential LT via thoracosternotomy with 86 minutes of cardiopulmonary bypass.", [["lungs", "ANATOMY", 52, 57], ["cardiopulmonary", "ANATOMY", 217, 232], ["K", "CHEMICAL", 113, 114], ["K", "CHEMICAL", 113, 114], ["lungs", "ORGAN", 52, 57], ["K", "SPECIES", 113, 114], ["bilateral sequential LT via thoracosternotomy", "TREATMENT", 152, 197], ["cardiopulmonary bypass", "TREATMENT", 217, 239], ["lungs", "ANATOMY", 52, 57], ["bilateral", "ANATOMY_MODIFIER", 152, 161], ["cardiopulmonary", "ANATOMY", 217, 232], ["bypass", "OBSERVATION", 233, 239]]], ["Ischemic times for the right and left allografts were 246 and 335 minutes, respectively.", [["right", "ANATOMY", 23, 28], ["left allografts", "ANATOMY", 33, 48], ["allografts", "ORGAN", 38, 48], ["the right and left allografts", "TREATMENT", 19, 48], ["right", "ANATOMY_MODIFIER", 23, 28], ["left", "ANATOMY_MODIFIER", 33, 37], ["allografts", "OBSERVATION", 38, 48]]], ["Induction immunosuppression included intraoperative corticosteroids and basiliximab with a second basiliximab dose on postoperative day (POD) 4.", [["basiliximab", "CHEMICAL", 72, 83], ["basiliximab", "CHEMICAL", 98, 109], ["basiliximab", "CHEMICAL", 72, 83], ["basiliximab", "CHEMICAL", 98, 109], ["basiliximab", "SIMPLE_CHEMICAL", 72, 83], ["basiliximab", "SIMPLE_CHEMICAL", 98, 109], ["Induction immunosuppression", "TREATMENT", 0, 27], ["intraoperative corticosteroids", "TREATMENT", 37, 67], ["basiliximab", "TREATMENT", 72, 83], ["a second basiliximab dose", "TREATMENT", 89, 114]]], ["Maintenance immunosuppression with mycophenolate mofetil (MMF) and corticosteroids was started immediately postoperatively, and tacrolimus, started on POD3, was titrated to a goal trough of 10-12 ng/mL.", [["mycophenolate mofetil", "CHEMICAL", 35, 56], ["MMF", "CHEMICAL", 58, 61], ["corticosteroids", "CHEMICAL", 67, 82], ["tacrolimus", "CHEMICAL", 128, 138], ["mycophenolate mofetil", "CHEMICAL", 35, 56], ["MMF", "CHEMICAL", 58, 61], ["corticosteroids", "CHEMICAL", 67, 82], ["tacrolimus", "CHEMICAL", 128, 138], ["mycophenolate mofetil", "SIMPLE_CHEMICAL", 35, 56], ["MMF", "SIMPLE_CHEMICAL", 58, 61], ["corticosteroids", "SIMPLE_CHEMICAL", 67, 82], ["tacrolimus", "SIMPLE_CHEMICAL", 128, 138], ["POD3", "SIMPLE_CHEMICAL", 151, 155], ["Maintenance immunosuppression", "TREATMENT", 0, 29], ["mycophenolate mofetil", "TREATMENT", 35, 56], ["MMF)", "TREATMENT", 58, 62], ["corticosteroids", "TREATMENT", 67, 82], ["tacrolimus", "TREATMENT", 128, 138], ["a goal trough", "TEST", 173, 186], ["immunosuppression", "OBSERVATION", 12, 29], ["mycophenolate mofetil", "OBSERVATION", 35, 56]]], ["Four days of empiric antibiotics were administered per protocol and discontinued once intraoperative donor and recipient cultures finalized negative.K E Y W O R D SThe patient was liberated from mechanical ventilation on POD1.K E Y W O R D SShe developed worsening hypoxemia with extensive pulmonary edema on chest radiography, consistent with grade 3 primary graft dysfunction (Figure 2) , and was reintubated on POD2.", [["pulmonary", "ANATOMY", 290, 299], ["chest", "ANATOMY", 309, 314], ["graft", "ANATOMY", 360, 365], ["K", "CHEMICAL", 149, 150], ["K", "CHEMICAL", 226, 227], ["hypoxemia", "DISEASE", 265, 274], ["pulmonary edema", "DISEASE", 290, 305], ["primary graft dysfunction", "DISEASE", 352, 377], ["K", "CHEMICAL", 149, 150], ["patient", "ORGANISM", 168, 175], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 290, 305], ["graft", "TISSUE", 360, 365], ["POD2", "GENE_OR_GENE_PRODUCT", 414, 418], ["recipient cultures", "CELL_LINE", 111, 129], ["patient", "SPECIES", 168, 175], ["K", "SPECIES", 149, 150], ["empiric antibiotics", "TREATMENT", 13, 32], ["intraoperative donor and recipient cultures", "TEST", 86, 129], ["mechanical ventilation", "TREATMENT", 195, 217], ["worsening hypoxemia", "PROBLEM", 255, 274], ["extensive pulmonary edema", "PROBLEM", 280, 305], ["chest radiography", "TEST", 309, 326], ["grade 3 primary graft dysfunction", "PROBLEM", 344, 377], ["mechanical ventilation", "OBSERVATION", 195, 217], ["worsening", "OBSERVATION_MODIFIER", 255, 264], ["hypoxemia", "OBSERVATION", 265, 274], ["extensive", "OBSERVATION_MODIFIER", 280, 289], ["pulmonary", "ANATOMY", 290, 299], ["edema", "OBSERVATION", 300, 305], ["chest", "ANATOMY", 309, 314], ["consistent with", "UNCERTAINTY", 328, 343], ["primary", "OBSERVATION_MODIFIER", 352, 359], ["graft dysfunction", "OBSERVATION", 360, 377]]], ["On POD6, she became diaphoretic and febrile (39\u00b0C) with onset of atrial fibrillation/flutter.K E Y W O R D SVancomycin and cefepime were started, but all cultures remained negative.", [["diaphoretic", "ANATOMY", 20, 31], ["atrial", "ANATOMY", 65, 71], ["cultures", "ANATOMY", 154, 162], ["febrile", "DISEASE", 36, 43], ["atrial fibrillation", "DISEASE", 65, 84], ["/flutter", "DISEASE", 84, 92], ["K", "CHEMICAL", 93, 94], ["SVancomycin", "CHEMICAL", 107, 118], ["cefepime", "CHEMICAL", 123, 131], ["K", "CHEMICAL", 93, 94], ["SVancomycin", "CHEMICAL", 107, 118], ["cefepime", "CHEMICAL", 123, 131], ["atrial", "MULTI-TISSUE_STRUCTURE", 65, 71], ["E Y W O R D SVancomycin", "SIMPLE_CHEMICAL", 95, 118], ["cefepime", "SIMPLE_CHEMICAL", 123, 131], ["K", "SPECIES", 93, 94], ["diaphoretic", "PROBLEM", 20, 31], ["febrile", "PROBLEM", 36, 43], ["atrial fibrillation", "PROBLEM", 65, 84], ["flutter", "PROBLEM", 85, 92], ["R D SVancomycin", "TREATMENT", 103, 118], ["cefepime", "TREATMENT", 123, 131], ["all cultures", "TEST", 150, 162], ["atrial", "ANATOMY", 65, 71], ["fibrillation", "OBSERVATION", 72, 84], ["flutter", "OBSERVATION", 85, 92]]], ["Bronchoscopy on POD8 revealed airway inflammatory changes and purulent secretions.", [["airway", "ANATOMY", 30, 36], ["purulent secretions", "ANATOMY", 62, 81], ["airway", "MULTI-TISSUE_STRUCTURE", 30, 36], ["Bronchoscopy", "TEST", 0, 12], ["airway inflammatory changes", "PROBLEM", 30, 57], ["purulent secretions", "PROBLEM", 62, 81], ["airway", "ANATOMY", 30, 36], ["inflammatory", "OBSERVATION", 37, 49], ["purulent", "OBSERVATION_MODIFIER", 62, 70], ["secretions", "OBSERVATION", 71, 81]]], ["BAL bacterial and fungal cultures and multiplex respiratory viral panel were negative.", [["cultures", "ANATOMY", 25, 33], ["BAL", "ORGANISM_SUBSTANCE", 0, 3], ["fungal cultures", "CELL", 18, 33], ["BAL bacterial", "TEST", 0, 13], ["fungal cultures", "TEST", 18, 33], ["multiplex respiratory viral panel", "TEST", 38, 71], ["fungal cultures", "OBSERVATION", 18, 33]]], ["Inflammatory markers were markedly elevated (Table 1) .", [["Inflammatory markers", "TEST", 0, 20], ["markedly elevated", "PROBLEM", 26, 43], ["markedly", "OBSERVATION_MODIFIER", 26, 34], ["elevated", "OBSERVATION_MODIFIER", 35, 43]]], ["Given concern for infection, MMF was decreased to 500 mg every 12 hours, and SARS-CoV-2 RT-PCR testing via nasopharyngeal swab (NPS) was obtained on POD9, returning positive 35 hours later.", [["nasopharyngeal swab", "ANATOMY", 107, 126], ["infection", "DISEASE", 18, 27], ["MMF", "CHEMICAL", 29, 32], ["MMF", "CHEMICAL", 29, 32], ["MMF", "SIMPLE_CHEMICAL", 29, 32], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 107, 126], ["infection", "PROBLEM", 18, 27], ["MMF", "TREATMENT", 29, 32], ["SARS", "TEST", 77, 81], ["CoV", "TEST", 82, 85], ["PCR testing", "TEST", 91, 102], ["nasopharyngeal swab", "TEST", 107, 126], ["concern for", "UNCERTAINTY", 6, 17], ["infection", "OBSERVATION", 18, 27], ["nasopharyngeal", "ANATOMY", 107, 121]]], ["She was placed in droplet and contact precautions and transferred to a designated COVID-19 ward.K E Y W O R D SThe patient's condition deteriorated with worsening oxygenation and hemodynamic instability requiring escalating doses of vasopressors.", [["hemodynamic instability", "DISEASE", 179, 202], ["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["droplet", "TREATMENT", 18, 25], ["contact precautions", "TREATMENT", 30, 49], ["worsening oxygenation", "PROBLEM", 153, 174], ["hemodynamic instability", "PROBLEM", 179, 202], ["escalating doses of vasopressors", "TREATMENT", 213, 245], ["hemodynamic instability", "OBSERVATION", 179, 202]]], ["She developed acute kidney injury (AKI) requiring renal replacement therapy and atrial arrhythmias recurred, requiring amiodarone and cardioversion.", [["kidney", "ANATOMY", 20, 26], ["renal", "ANATOMY", 50, 55], ["atrial", "ANATOMY", 80, 86], ["acute kidney injury", "DISEASE", 14, 33], ["AKI", "DISEASE", 35, 38], ["atrial arrhythmias", "DISEASE", 80, 98], ["amiodarone", "CHEMICAL", 119, 129], ["amiodarone", "CHEMICAL", 119, 129], ["kidney", "ORGAN", 20, 26], ["renal", "ORGAN", 50, 55], ["atrial", "MULTI-TISSUE_STRUCTURE", 80, 86], ["amiodarone", "SIMPLE_CHEMICAL", 119, 129], ["acute kidney injury", "PROBLEM", 14, 33], ["AKI", "PROBLEM", 35, 38], ["renal replacement therapy", "TREATMENT", 50, 75], ["atrial arrhythmias", "PROBLEM", 80, 98], ["amiodarone", "TREATMENT", 119, 129], ["cardioversion", "TREATMENT", 134, 147], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["kidney", "ANATOMY", 20, 26], ["injury", "OBSERVATION", 27, 33], ["AKI", "OBSERVATION", 35, 38], ["renal", "ANATOMY", 50, 55], ["replacement", "OBSERVATION", 56, 67], ["atrial", "ANATOMY", 80, 86], ["arrhythmias", "OBSERVATION", 87, 98]]], ["Treatment with chloroquine and azithromycin was initiated on POD11.", [["chloroquine", "CHEMICAL", 15, 26], ["azithromycin", "CHEMICAL", 31, 43], ["chloroquine", "CHEMICAL", 15, 26], ["azithromycin", "CHEMICAL", 31, 43], ["chloroquine", "SIMPLE_CHEMICAL", 15, 26], ["azithromycin", "SIMPLE_CHEMICAL", 31, 43], ["chloroquine", "TREATMENT", 15, 26], ["azithromycin", "TREATMENT", 31, 43]]], ["Remdesivir was contraindicated due to severe AKI; tocilizumab was considered, but not administered due to an unclear risk to benefit ratio in this recently transplanted patient.", [["Remdesivir", "CHEMICAL", 0, 10], ["AKI", "DISEASE", 45, 48], ["tocilizumab", "CHEMICAL", 50, 61], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["tocilizumab", "SIMPLE_CHEMICAL", 50, 61], ["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176], ["Remdesivir", "TREATMENT", 0, 10], ["severe AKI", "PROBLEM", 38, 48], ["tocilizumab", "TREATMENT", 50, 61], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["AKI", "OBSERVATION", 45, 48]]], ["Prone positioning was considered although never implemented due to improving oxygenation with lung protective ventilation ( Figure 2 ).", [["lung", "ANATOMY", 94, 98], ["lung", "ORGAN", 94, 98], ["Prone positioning", "TREATMENT", 0, 17], ["lung protective ventilation", "TREATMENT", 94, 121], ["lung", "ANATOMY", 94, 98], ["protective ventilation", "OBSERVATION", 99, 121]]], ["Following an initial period of vasopressor escalation, hemodynamics stabilized.", [["vasopressor escalation", "TREATMENT", 31, 53], ["vasopressor escalation", "OBSERVATION", 31, 53]]], ["On POD14, chloroquine was discontinued due to QTc prolongation and new data indicating lack of benefit.", [["chloroquine", "CHEMICAL", 10, 21], ["chloroquine", "CHEMICAL", 10, 21], ["POD14", "SIMPLE_CHEMICAL", 3, 8], ["chloroquine", "SIMPLE_CHEMICAL", 10, 21], ["chloroquine", "TREATMENT", 10, 21], ["QTc prolongation", "PROBLEM", 46, 62], ["new data", "TEST", 67, 75]]], ["6 MMF was discontinued, and the tacrolimus trough goal was decreased to 8 ng/mL.K E Y W O R D SRepeat SARS-CoV-2 RT-PCR testing via NPS on POD12 and POD14 was negative.", [["MMF", "CHEMICAL", 2, 5], ["tacrolimus", "CHEMICAL", 32, 42], ["MMF", "CHEMICAL", 2, 5], ["tacrolimus", "CHEMICAL", 32, 42], ["MMF", "SIMPLE_CHEMICAL", 2, 5], ["tacrolimus", "SIMPLE_CHEMICAL", 32, 42], ["POD14", "GENE_OR_GENE_PRODUCT", 149, 154], ["POD12", "DNA", 139, 144], ["POD14", "DNA", 149, 154], ["MMF", "TREATMENT", 2, 5], ["the tacrolimus trough goal", "TREATMENT", 28, 54], ["SRepeat SARS", "TEST", 94, 106], ["CoV", "TEST", 107, 110], ["PCR testing", "TEST", 116, 127], ["NPS", "TEST", 132, 135], ["POD14", "TEST", 149, 154], ["negative", "OBSERVATION", 159, 167]]], ["The patient was transferred back to the cardiothoracic intensive care unit on POD28 and underwent tracheostomy on POD30.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["tracheostomy", "TREATMENT", 98, 110], ["tracheostomy", "OBSERVATION", 98, 110]]], ["MMF was reinstituted on POD34 at 500 mg every 12 hours.", [["MMF", "CHEMICAL", 0, 3], ["POD34", "CHEMICAL", 24, 29], ["MMF", "CHEMICAL", 0, 3], ["MMF", "SIMPLE_CHEMICAL", 0, 3], ["POD34", "SIMPLE_CHEMICAL", 24, 29], ["MMF", "TREATMENT", 0, 3], ["POD34", "TREATMENT", 24, 29]]], ["As of POD57, she has been liberated from mechanical gram-specific variables must be taken into account.| D ISCUSS I ONWe have described the epidemiological and treatment chal-", [["POD57", "GENE_OR_GENE_PRODUCT", 6, 11], ["mechanical gram", "TEST", 41, 56]]]], "PMC7120441": [["IntroductionMost work on parasite-induced behavioural change in hosts focuses on the mechanisms underlying these changes and their direct consequences for parasite and host fitness (see other chapters in this volume).", [["behavioural change", "PROBLEM", 42, 60], ["these changes", "PROBLEM", 107, 120], ["parasite", "PROBLEM", 155, 163], ["host fitness", "PROBLEM", 168, 180]]], ["However, infected hosts do not exist in isolation; they form part of a community of organisms that interact through an array of trophic links.", [["infected hosts", "PROBLEM", 9, 23], ["infected", "OBSERVATION", 9, 17], ["isolation", "OBSERVATION", 40, 49], ["trophic links", "OBSERVATION", 128, 141]]], ["Here, we broaden the focus of parasite-modified behaviour to examine the indirect consequences of such behavioural changes for species that interact with the host, and explore how this may impact community structure.", [["such behavioural changes", "PROBLEM", 98, 122]]], ["In particular, we review our work on crustacean host-parasite systems where we find that parasites affect a range of trophic interactions between invasive and native host species.", [["parasites", "PROBLEM", 89, 98], ["host species", "OBSERVATION", 166, 178]]], ["We examine the potential significance of these parasite-induced behavioural effects in the biological invasion process.IntroductionFrom a population perspective, we usually think of the direct effects of parasitism on the host \u2013 the morbidity and mortality induced by the parasite in hosts.", [["these parasite", "PROBLEM", 41, 55], ["the biological invasion process", "PROBLEM", 87, 118], ["parasitism", "PROBLEM", 204, 214], ["parasite", "OBSERVATION", 47, 55], ["invasion", "OBSERVATION", 102, 110], ["parasitism", "OBSERVATION", 204, 214]]], ["However, recent theoretical and empirical research suggests that the indirect effects of parasitism may be equally important in structuring communities (Hudson et al. 2006; Hatcher and Dunn 2011).", [["parasitism", "PROBLEM", 89, 99], ["parasitism", "OBSERVATION", 89, 99]]], ["Indirect interactions occur when the impact of one species on another affects populations of a third species, with these interactions being density- or trait-mediated.", [["Indirect interactions", "PROBLEM", 0, 21], ["one species", "PROBLEM", 47, 58], ["a third species", "PROBLEM", 93, 108]]], ["Change in population density has been regarded as the main mechanism driving such indirect interactions.", [["Change in population density", "PROBLEM", 0, 28], ["population", "OBSERVATION_MODIFIER", 10, 20], ["density", "OBSERVATION", 21, 28]]], ["For example, the decline in the Iberian Lynx was an indirect result of parasite (myxamatosis & rabbit haemorrhagic disease) induced decline in its rabbit prey (Ferrer and Negro 2004).", [["myxamatosis", "DISEASE", 81, 92], ["rabbit haemorrhagic disease", "DISEASE", 95, 122], ["rabbit", "ORGANISM", 95, 101], ["rabbit", "ORGANISM", 147, 153], ["rabbit", "SPECIES", 95, 101], ["rabbit", "SPECIES", 147, 153], ["rabbit", "SPECIES", 95, 101], ["rabbit", "SPECIES", 147, 153], ["the decline in the Iberian Lynx", "PROBLEM", 13, 44], ["parasite (myxamatosis & rabbit haemorrhagic disease)", "PROBLEM", 71, 123], ["decline", "OBSERVATION_MODIFIER", 17, 24], ["Iberian Lynx", "OBSERVATION", 32, 44], ["parasite", "OBSERVATION", 71, 79]]], ["However, indirect interactions can also be caused by changes in behaviour, development or physiology; for example parasite (nematode) induced vulnerability to predation mediates population cycles in snowshoe hares (Murray et al. 1997).", [["snowshoe hares", "SPECIES", 199, 213], ["changes in behaviour", "PROBLEM", 53, 73], ["example parasite (nematode)", "PROBLEM", 106, 133]]], ["Such effects, known as trait-mediated indirect effects (Werner and Peacor 2003) can theoretically be as important as density-mediated effects for community structure and function (Abrams and Matsuda 1996) and are now considered an important driving factor in community ecology (Ohgushi et al. 2012).IntroductionTrait-mediated interactions may be especially relevant in parasite-host systems because parasites do not necessarily kill their hosts, at least not immediately, but frequently modify host behaviour or development (reviewed in Lefevre et al. 2009; Thomas et al. 2010 and chapters in this issue).", [["parasites", "PROBLEM", 399, 408]]], ["Such trait changes may have no apparent deleterious effect on hosts measured in isolation.", [["Such trait changes", "PROBLEM", 0, 18], ["apparent deleterious effect", "PROBLEM", 31, 58], ["no apparent", "UNCERTAINTY", 28, 39]]], ["However, if these trait modifications reduce host fitness when interacting with other species, we can nevertheless regard them as aspects of virulence; we have referred to such characteristics as \u201ccryptic virulence\u201d (MacNiel et al. 2003c; Hatcher and Dunn 2011).IntroductionIn our laboratories at The University of Leeds and Queen\u2019s University Belfast, we are particularly interested in the roles played by parasites in biological invasions (Prenter et al. 2004; Dunn 2009; Hatcher and Dunn 2011; Dunn et al. 2012).", [["virulence", "PROBLEM", 141, 150]]], ["Parasites (here we use the term to include macro- and microparasites and parasitoids) are an important consideration in biological invasions for a number of reasons (Fig. 3.1).", [["Parasites", "PROBLEM", 0, 9], ["macro", "TEST", 43, 48], ["microparasites and parasitoids", "TREATMENT", 54, 84]]], ["Firstly, some invasions may succeed partly because the introduced species leaves behind its parasites (and their deleterious effects) in the native range (a mechanism known as enemy release; Mitchell and Power 2003; Torchin et al. 2003).", [["some invasions", "PROBLEM", 9, 23], ["the introduced species", "PROBLEM", 51, 73], ["its parasites", "PROBLEM", 88, 101], ["invasions", "OBSERVATION", 14, 23]]], ["In other cases, introduced species arrive with their parasites, but the parasites go on to infect populations of related host species in the recipient range (the phenomenon of spillover; Daszak et al. 2000), often with highly deleterious effects on the new host.", [["their parasites", "PROBLEM", 47, 62], ["the parasites", "PROBLEM", 68, 81], ["host species", "OBSERVATION", 121, 133], ["deleterious", "OBSERVATION", 226, 237]]], ["Parasite spillback or dilution may also occur (from an invasions perspective, where native parasites in the invaders new invaded range cross into introduced hosts; Kelly et al. 2009).", [["Parasite spillback or dilution", "PROBLEM", 0, 30], ["native parasites", "PROBLEM", 84, 100], ["invasions", "OBSERVATION", 55, 64]]], ["In addition, many parasites are themselves invasive, and the process of disease emergence shares many similarities with that of biological invasion (Hatcher et al. 2012a, b; Dunn and Hatcher 2015).", [["many parasites", "PROBLEM", 13, 27], ["disease emergence", "PROBLEM", 72, 89], ["many", "OBSERVATION_MODIFIER", 13, 17], ["parasites", "OBSERVATION", 18, 27], ["disease", "OBSERVATION", 72, 79]]]], "9b2d1c90b6e6dc56b7d95942902cb1e5057d49dc": [["IntroductionInfluenza A virus (IAV), a member of Orthomyxoviridae family, is still a threat to human health and a burden on the health services (Salomon and Webster, 2009) .", [["Influenza A virus", "DISEASE", 12, 29], ["Influenza A virus", "ORGANISM", 12, 29], ["IAV", "ORGANISM", 31, 34], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 49, 65], ["human", "ORGANISM", 95, 100], ["Influenza A virus", "SPECIES", 12, 29], ["human", "SPECIES", 95, 100], ["Influenza A virus", "SPECIES", 12, 29], ["IAV", "SPECIES", 31, 34], ["human", "SPECIES", 95, 100]]], ["Despite many advances, IAVs are still a challenge for the scientists.", [["IAVs", "CANCER", 23, 27], ["IAVs", "TREATMENT", 23, 27]]], ["IAVs are highly contagious and causative agents of seasonal flu epidemics resulting in morbidity, mortality and huge economic losses.", [["IAVs", "DISEASE", 0, 4], ["flu epidemics", "DISEASE", 60, 73], ["IAVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["IAVs", "PROBLEM", 0, 4], ["seasonal flu epidemics", "PROBLEM", 51, 73], ["morbidity", "PROBLEM", 87, 96], ["huge economic losses", "PROBLEM", 112, 132], ["huge", "OBSERVATION_MODIFIER", 112, 116], ["economic losses", "OBSERVATION", 117, 132]]], ["Based on the circulating strains, seasonal influenza vaccines are developed annually or biannually, if needed, by WHO but the immunity provided is short-lived due to continuous change in the virus strains.", [["influenza", "DISEASE", 43, 52], ["the circulating strains", "PROBLEM", 9, 32], ["seasonal influenza vaccines", "TREATMENT", 34, 61], ["continuous change in the virus strains", "PROBLEM", 166, 204], ["virus strains", "OBSERVATION", 191, 204]]], ["Therefore, vaccination is usually required every year to be protected from seasonal flu that leads to increase in vaccine cost along with shortage of vaccines in developing countries.", [["flu", "DISEASE", 84, 87], ["vaccination", "TREATMENT", 11, 22], ["seasonal flu", "PROBLEM", 75, 87], ["vaccine cost", "TREATMENT", 114, 126], ["shortage of vaccines", "TREATMENT", 138, 158]]], ["But the two main problems with vaccination are the time required to select, manufacture and deliver vaccine and the variable annual immunization rates (Couch, 2008) .", [["vaccination", "TREATMENT", 31, 42], ["manufacture and deliver vaccine", "TREATMENT", 76, 107], ["the variable annual immunization rates", "TREATMENT", 112, 150], ["main", "OBSERVATION_MODIFIER", 12, 16]]], ["Besides vaccination, the antiviral agents are the therapeutic options to treat the infection.", [["infection", "DISEASE", 83, 92], ["vaccination", "TREATMENT", 8, 19], ["the antiviral agents", "TREATMENT", 21, 41], ["the therapeutic options", "TREATMENT", 46, 69], ["the infection", "PROBLEM", 79, 92], ["infection", "OBSERVATION", 83, 92]]], ["Antivirals against M2 protein and neuraminidase are available but their irrational use has led to the emergence of resistant strains (Agrawal et al., 2010; Hayden and Hay, 1992; Poland et al., 2009) .", [["M2 protein", "GENE_OR_GENE_PRODUCT", 19, 29], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 34, 47], ["M2 protein", "PROTEIN", 19, 29], ["neuraminidase", "PROTEIN", 34, 47], ["Antivirals", "TREATMENT", 0, 10], ["M2 protein", "TREATMENT", 19, 29], ["neuraminidase", "TREATMENT", 34, 47], ["resistant strains", "PROBLEM", 115, 132]]], ["Thus, there is a continued requirement of new antiviral agents against IAV.IntroductionThe non-structural protein NS1 of IAV is a multifunctional protein associated with various viral functions including mRNA processing regulation via interactions with the cleavage and http://dx.doi.org/10.1016/j.antiviral.2015.01.015 0166-3542/\u00d3 2015 Elsevier B.V. All rights reserved.IntroductionAbbreviations: IAV, influenza A virus; NS1, non-structural 1; RBD, RNA binding domain; CPSF30, cleavage and polyadenylation and specificity factor 30; PI3K, phosphoinositide 3-kinase; IFN, interferon; PKR, protein kinase R; OAS, 2 0 5 0oligoadenylate synthetase; dsRNA, double-stranded RNA; mAbs, monoclonal antibodies. polyadenylation and specificity factor 30 (CPSF30), inhibition of cellular apoptosis by interaction with the p85b regulatory subunit of phosphoinositide 3-kinase (PI3K), limitation of interferon (IFN) production and the IFN-induced proteins, such as protein kinase R (PKR) and 2 0 5 0 -oligoadenylate synthetase (OAS)/RNase L by binding to double-stranded RNA (dsRNA) (Hale et al., 2008; Min and Krug, 2006) , and inhibition of mRNA splicing by binding to U6 snRNA (Qiu et al., 1995; Wang and Krug, 1998) .", [["cellular", "ANATOMY", 769, 777], ["influenza A virus", "DISEASE", 403, 420], ["IAV", "ORGANISM", 71, 74], ["NS1", "GENE_OR_GENE_PRODUCT", 114, 117], ["IAV", "ORGANISM", 121, 124], ["IAV,", "ORGANISM", 398, 402], ["influenza A virus", "ORGANISM", 403, 420], ["NS1, non-structural 1", "GENE_OR_GENE_PRODUCT", 422, 443], ["RBD", "GENE_OR_GENE_PRODUCT", 445, 448], ["CPSF30", "GENE_OR_GENE_PRODUCT", 470, 476], ["specificity factor 30", "GENE_OR_GENE_PRODUCT", 511, 532], ["PI3K", "GENE_OR_GENE_PRODUCT", 534, 538], ["phosphoinositide 3-kinase", "GENE_OR_GENE_PRODUCT", 540, 565], ["IFN", "GENE_OR_GENE_PRODUCT", 567, 570], ["interferon", "GENE_OR_GENE_PRODUCT", 572, 582], ["PKR", "GENE_OR_GENE_PRODUCT", 584, 587], ["protein kinase R", "GENE_OR_GENE_PRODUCT", 589, 605], ["2 0 5 0oligoadenylate synthetase", "SIMPLE_CHEMICAL", 612, 644], ["specificity factor 30", "GENE_OR_GENE_PRODUCT", 723, 744], ["CPSF30", "GENE_OR_GENE_PRODUCT", 746, 752], ["cellular", "CELL", 769, 777], ["p85b", "GENE_OR_GENE_PRODUCT", 812, 816], ["phosphoinositide 3-kinase", "GENE_OR_GENE_PRODUCT", 839, 864], ["PI3K", "GENE_OR_GENE_PRODUCT", 866, 870], ["interferon", "GENE_OR_GENE_PRODUCT", 887, 897], ["IFN", "GENE_OR_GENE_PRODUCT", 899, 902], ["IFN", "GENE_OR_GENE_PRODUCT", 923, 926], ["protein kinase R", "GENE_OR_GENE_PRODUCT", 953, 969], ["PKR", "GENE_OR_GENE_PRODUCT", 971, 974], ["2 0 5 0 -oligoadenylate synthetase", "GENE_OR_GENE_PRODUCT", 980, 1014], ["RNase L", "GENE_OR_GENE_PRODUCT", 1021, 1028], ["U6", "GENE_OR_GENE_PRODUCT", 1159, 1161], ["non-structural protein", "PROTEIN", 91, 113], ["NS1", "PROTEIN", 114, 117], ["multifunctional protein", "PROTEIN", 130, 153], ["NS1", "PROTEIN", 422, 425], ["non-structural 1", "PROTEIN", 427, 443], ["RBD", "PROTEIN", 445, 448], ["RNA binding domain", "PROTEIN", 450, 468], ["CPSF30", "PROTEIN", 470, 476], ["polyadenylation and specificity factor 30", "PROTEIN", 491, 532], ["PI3K", "PROTEIN", 534, 538], ["phosphoinositide 3-kinase", "PROTEIN", 540, 565], ["IFN", "PROTEIN", 567, 570], ["interferon", "PROTEIN", 572, 582], ["PKR", "PROTEIN", 584, 587], ["protein kinase R; OAS, 2 0 5 0oligoadenylate synthetase", "PROTEIN", 589, 644], ["dsRNA, double-stranded RNA", "PROTEIN", 646, 672], ["mAbs", "PROTEIN", 674, 678], ["monoclonal antibodies", "PROTEIN", 680, 701], ["specificity factor 30", "PROTEIN", 723, 744], ["CPSF30", "PROTEIN", 746, 752], ["p85b regulatory subunit", "PROTEIN", 812, 835], ["phosphoinositide 3-kinase", "PROTEIN", 839, 864], ["PI3K", "PROTEIN", 866, 870], ["interferon", "PROTEIN", 887, 897], ["IFN", "PROTEIN", 899, 902], ["IFN", "PROTEIN", 923, 926], ["protein kinase R (PKR) and 2 0 5 0 -oligoadenylate synthetase", "PROTEIN", 953, 1014], ["OAS", "PROTEIN", 1016, 1019], ["RNase L", "PROTEIN", 1021, 1028], ["U6 snRNA", "RNA", 1159, 1167], ["influenza A virus", "SPECIES", 403, 420], ["IAV", "SPECIES", 71, 74], ["influenza A virus", "SPECIES", 403, 420], ["new antiviral agents", "TREATMENT", 42, 62], ["IAV", "PROBLEM", 71, 74], ["IAV", "PROBLEM", 121, 124], ["a multifunctional protein", "PROBLEM", 128, 153], ["various viral functions", "PROBLEM", 170, 193], ["mRNA processing regulation", "TREATMENT", 204, 230], ["the cleavage", "TREATMENT", 253, 265], ["IAV", "PROBLEM", 398, 401], ["influenza A virus", "PROBLEM", 403, 420], ["NS1", "PROBLEM", 422, 425], ["RBD", "PROBLEM", 445, 448], ["RNA binding domain", "PROBLEM", 450, 468], ["CPSF30", "TEST", 470, 476], ["polyadenylation", "TEST", 491, 506], ["specificity factor", "TEST", 511, 529], ["PI3K", "TEST", 534, 538], ["phosphoinositide", "TEST", 540, 556], ["kinase", "TEST", 559, 565], ["IFN", "TEST", 567, 570], ["interferon", "TEST", 572, 582], ["PKR", "TEST", 584, 587], ["protein kinase", "TEST", 589, 603], ["OAS", "TEST", 607, 610], ["0oligoadenylate synthetase", "TEST", 618, 644], ["dsRNA", "PROBLEM", 646, 651], ["double-stranded RNA", "TREATMENT", 653, 672], ["monoclonal antibodies", "TEST", 680, 701], ["polyadenylation", "PROBLEM", 703, 718], ["specificity factor", "TEST", 723, 741], ["cellular apoptosis", "PROBLEM", 769, 787], ["phosphoinositide", "TEST", 839, 855], ["interferon (IFN) production", "TREATMENT", 887, 914], ["the IFN-induced proteins", "TEST", 919, 943], ["protein kinase", "TEST", 953, 967], ["PKR", "TEST", 971, 974], ["-oligoadenylate synthetase (OAS)/RNase L", "PROBLEM", 988, 1028], ["double-stranded RNA (dsRNA", "TREATMENT", 1043, 1069], ["mRNA splicing", "PROBLEM", 1131, 1144], ["non-structural protein NS1", "OBSERVATION", 91, 117], ["cellular apoptosis", "OBSERVATION", 769, 787], ["stranded RNA", "OBSERVATION_MODIFIER", 1050, 1062]]], ["NS1 has two functionally distinct domains: the N-terminal RNA binding domain (RBD), consisting of three a-helices, and the C-terminal effector domain, consisting of seven b-strands and three a-helices.", [["C", "CHEMICAL", 123, 124], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["a-helices", "GENE_OR_GENE_PRODUCT", 104, 113], ["NS1", "PROTEIN", 0, 3], ["N-terminal RNA binding domain", "PROTEIN", 47, 76], ["RBD", "PROTEIN", 78, 81], ["a-helices", "PROTEIN", 104, 113], ["C-terminal effector domain", "PROTEIN", 123, 149], ["b-strands", "PROTEIN", 171, 180], ["a-helices", "PROTEIN", 191, 200], ["the N-terminal RNA binding domain (RBD)", "PROBLEM", 43, 82], ["the C-terminal effector domain", "PROBLEM", 119, 149], ["distinct", "OBSERVATION_MODIFIER", 25, 33], ["domains", "OBSERVATION_MODIFIER", 34, 41], ["N-terminal RNA", "OBSERVATION", 47, 61], ["terminal", "ANATOMY_MODIFIER", 125, 133], ["effector domain", "OBSERVATION", 134, 149], ["b-strands", "OBSERVATION", 171, 180]]], ["The RBD domain binds with low affinity to several RNA species in a sequence independent manner (Chien et al., 2004; Hatada and Fukuda, 1992; Qian et al., 1995) , and effector domain predominantly interacts with host-cell proteins and also functionally stabilizes RBD domain (Wang et al., 2002) .", [["cell", "ANATOMY", 216, 220], ["cell", "CELL", 216, 220], ["RBD domain", "PROTEIN", 4, 14], ["effector domain", "PROTEIN", 166, 181], ["host-cell proteins", "PROTEIN", 211, 229], ["RBD domain", "PROTEIN", 263, 273], ["The RBD domain binds", "PROBLEM", 0, 20], ["low affinity", "PROBLEM", 26, 38], ["several RNA species", "PROBLEM", 42, 61], ["low affinity", "OBSERVATION_MODIFIER", 26, 38]]], ["NS1, a well conserved protein, is expressed at very high levels in infected cells (Krug and Etkind, 1973; Palese and Shaw, 2007) .", [["cells", "ANATOMY", 76, 81], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["cells", "CELL", 76, 81], ["NS1", "PROTEIN", 0, 3], ["infected cells", "CELL_TYPE", 67, 81], ["NS1", "PROBLEM", 0, 3], ["infected cells", "OBSERVATION", 67, 81]]], ["Therefore, NS1 protein is a good target for therapeutics development and several small molecules have been found to inhibit NS1 function resulting in reduced viral replication (Engel, 2013; Nayak et al., 2014; Woo et al., 2013) .", [["NS1", "GENE_OR_GENE_PRODUCT", 11, 14], ["NS1", "GENE_OR_GENE_PRODUCT", 124, 127], ["NS1 protein", "PROTEIN", 11, 22], ["NS1", "PROTEIN", 124, 127], ["NS1 protein", "TEST", 11, 22], ["several small molecules", "PROBLEM", 73, 96], ["NS1 function", "TEST", 124, 136], ["reduced viral replication", "PROBLEM", 150, 175], ["small", "OBSERVATION_MODIFIER", 81, 86], ["molecules", "OBSERVATION", 87, 96], ["reduced", "OBSERVATION_MODIFIER", 150, 157], ["viral replication", "OBSERVATION", 158, 175]]], ["In our previous study, we generated a panel of new monoclonal antibodies (mAbs) against the RNA binding domain of NS1 (NS1(RBD)) .", [["NS1", "GENE_OR_GENE_PRODUCT", 114, 117], ["NS1(RBD)", "GENE_OR_GENE_PRODUCT", 119, 127], ["monoclonal antibodies", "PROTEIN", 51, 72], ["mAbs", "PROTEIN", 74, 78], ["RNA binding domain", "PROTEIN", 92, 110], ["NS1", "PROTEIN", 114, 117], ["NS1", "PROTEIN", 119, 122], ["RBD", "PROTEIN", 123, 126], ["a panel", "TEST", 36, 43], ["new monoclonal antibodies", "TEST", 47, 72], ["NS1", "PROBLEM", 114, 117]]], ["Here we report the biophysical characterization of one of these mAbs, named as 2H6, and NS1(RBD) protein interaction, and inhibition of viral replication by targeting NS1 protein in infected cells.", [["cells", "ANATOMY", 191, 196], ["2H6", "GENE_OR_GENE_PRODUCT", 79, 82], ["NS1(RBD)", "GENE_OR_GENE_PRODUCT", 88, 96], ["NS1", "GENE_OR_GENE_PRODUCT", 167, 170], ["cells", "CELL", 191, 196], ["mAbs", "PROTEIN", 64, 68], ["2H6", "PROTEIN", 79, 82], ["NS1", "PROTEIN", 88, 91], ["RBD", "PROTEIN", 92, 95], ["NS1 protein", "PROTEIN", 167, 178], ["infected cells", "CELL_TYPE", 182, 196], ["the biophysical characterization", "TEST", 15, 47], ["these mAbs", "TEST", 58, 68], ["NS1(RBD) protein interaction", "PROBLEM", 88, 116], ["viral replication", "TREATMENT", 136, 153], ["NS1 protein in infected cells", "PROBLEM", 167, 196], ["viral replication", "OBSERVATION", 136, 153], ["infected cells", "OBSERVATION", 182, 196]]], ["2H6 has been shown to bind to NS1 of different IAV subtypes, namely H5N1, H3N2 and H1N1 .Cell lines and virusA549, 293T and MDCK cells were purchased from American Type Culture Collection (Manassas, VA, USA).", [["Cell lines", "ANATOMY", 89, 99], ["A549", "ANATOMY", 109, 113], ["293T", "ANATOMY", 115, 119], ["MDCK cells", "ANATOMY", 124, 134], ["2H6", "CHEMICAL", 0, 3], ["H5N1, H3N2 and H1N1", "DISEASE", 68, 87], ["2H6", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS1", "GENE_OR_GENE_PRODUCT", 30, 33], ["IAV subtypes", "ORGANISM", 47, 59], ["H5N1, H3N2", "ORGANISM", 68, 78], ["Cell lines", "CELL", 89, 99], ["virusA549", "CELL", 104, 113], ["293T", "CELL", 115, 119], ["MDCK cells", "CELL", 124, 134], ["2H6", "PROTEIN", 0, 3], ["NS1", "PROTEIN", 30, 33], ["Cell lines", "CELL_LINE", 89, 99], ["virusA549", "CELL_LINE", 104, 113], ["293T", "CELL_LINE", 115, 119], ["MDCK cells", "CELL_LINE", 124, 134], ["H3N2", "SPECIES", 74, 78], ["different IAV subtypes", "PROBLEM", 37, 59], ["H5N1", "PROBLEM", 68, 72], ["H3N2", "PROBLEM", 74, 78], ["H1N1", "PROBLEM", 83, 87], ["Cell lines", "TEST", 89, 99], ["virusA549", "TEST", 104, 113], ["MDCK cells", "TEST", 124, 134], ["virusA549", "OBSERVATION", 104, 113]]], ["All cell lines were cultured at 37\u00b0C in 5% CO 2 in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum.", [["cell lines", "ANATOMY", 4, 14], ["fetal bovine serum", "ANATOMY", 115, 133], ["CO 2", "CHEMICAL", 43, 47], ["cell lines", "CELL", 4, 14], ["bovine", "ORGANISM", 121, 127], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["cell lines", "CELL_LINE", 4, 14], ["bovine", "SPECIES", 121, 127], ["bovine", "SPECIES", 121, 127], ["All cell lines", "TREATMENT", 0, 14], ["Dulbecco's Modified Eagle's Medium (DMEM)", "TREATMENT", 51, 92], ["10% fetal bovine serum", "TREATMENT", 111, 133], ["cell lines", "OBSERVATION", 4, 14]]], ["A/Puerto Rico/8/1934(H1N1) (PR8) virus was obtained from the American Type Culture Collection and grown in embryonated chicken eggs as previously described (Narasaraju et al., 2011) .Generation of anti-M1 monoclonal antibodyThe cDNA encoding for the M1 gene from a H5N1 isolate (A/chicken/Hatay/2004(H5N1)), GenBank accession number AM040045) was cloned into the pGEX-6P1 vector (GE Healthcare, Uppsala, Sweden).", [["eggs", "ANATOMY", 127, 131], ["Puerto Rico/8/1934(H1N1) (PR8) virus", "ORGANISM", 2, 38], ["chicken", "ORGANISM", 119, 126], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 127, 131], ["anti-M1", "GENE_OR_GENE_PRODUCT", 197, 204], ["M1", "GENE_OR_GENE_PRODUCT", 250, 252], ["chicken/Hatay/2004(H5N1)", "ORGANISM", 281, 305], ["anti-M1 monoclonal antibody", "PROTEIN", 197, 224], ["cDNA", "DNA", 228, 232], ["M1 gene", "DNA", 250, 257], ["pGEX-6P1 vector", "DNA", 363, 378], ["chicken", "SPECIES", 119, 126], ["chicken", "SPECIES", 281, 288], ["Puerto Rico/8/1934(H1N1) (PR8) virus", "SPECIES", 2, 38], ["chicken", "SPECIES", 119, 126], ["A/chicken/Hatay/2004(H5N1)", "SPECIES", 279, 305], ["virus", "PROBLEM", 33, 38], ["embryonated chicken eggs", "PROBLEM", 107, 131], ["anti-M1 monoclonal antibody", "TEST", 197, 224], ["The cDNA", "TREATMENT", 224, 232], ["a H5N1 isolate", "TREATMENT", 263, 277], ["A/chicken/Hatay", "TREATMENT", 279, 294], ["embryonated chicken eggs", "OBSERVATION", 107, 131], ["monoclonal antibody", "OBSERVATION", 205, 224]]], ["Glutathione S-transferase (GST)-fused M1 protein was then expressed in Escherichia coli BL21(DE3) (Novagen, EMD Chemicals, Inc., Madison, WI, USA) and purified as previously described .", [["Glutathione", "CHEMICAL", 0, 11], ["Glutathione", "CHEMICAL", 0, 11], ["Glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 0, 25], ["GST", "GENE_OR_GENE_PRODUCT", 27, 30], ["Escherichia coli", "ORGANISM", 71, 87], ["BL21", "ORGANISM", 88, 92], ["DE3", "CELL", 93, 96], ["Novagen", "GENE_OR_GENE_PRODUCT", 99, 106], ["Glutathione S-transferase", "PROTEIN", 0, 25], ["GST", "PROTEIN", 27, 30], ["M1 protein", "PROTEIN", 38, 48], ["Escherichia coli BL21", "SPECIES", 71, 92], ["Escherichia coli BL21", "SPECIES", 71, 92], ["DE3", "SPECIES", 93, 96], ["Glutathione S-transferase (GST)", "TEST", 0, 31], ["fused M1 protein", "PROBLEM", 32, 48], ["Escherichia coli BL21", "TREATMENT", 71, 92], ["Escherichia coli", "OBSERVATION", 71, 87]]], ["The GST-fusion protein was then used to immunize mice and generate hybridomas as previously described (Oh et al., 2010) .", [["hybridomas", "ANATOMY", 67, 77], ["GST", "GENE_OR_GENE_PRODUCT", 4, 7], ["mice", "ORGANISM", 49, 53], ["hybridomas", "CELL", 67, 77], ["GST", "PROTEIN", 4, 7], ["fusion protein", "PROTEIN", 8, 22], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["The GST-fusion protein", "TREATMENT", 0, 22]]], ["The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the Biological Resource Centre, ASTAR, Singapore (Protocol Number: 110694).", [["The protocol", "TREATMENT", 0, 12]]], ["All the procedures were carried out in strict accordance with the recommendations of the NACLAR guidelines in Singapore.", [["the NACLAR guidelines", "TREATMENT", 85, 106]]], ["All efforts were made to minimize suffering and euthanasia was performed using carbon dioxide.Expression and purification of NS1 in bacteriaThe gene encoding N-terminus of NS1 (1-73 aa) of A/chicken/ Hatay/2004(H5N1) was cloned into modified pET-28a expression vector (Novagen) with N-terminal His-SUMO tag.", [["carbon dioxide", "CHEMICAL", 79, 93], ["carbon dioxide", "CHEMICAL", 79, 93], ["N", "CHEMICAL", 158, 159], ["N-", "CHEMICAL", 283, 285], ["carbon dioxide", "SIMPLE_CHEMICAL", 79, 93], ["NS1", "GENE_OR_GENE_PRODUCT", 125, 128], ["NS1", "GENE_OR_GENE_PRODUCT", 172, 175], ["chicken/ Hatay/2004(H5N1", "ORGANISM", 191, 215], ["pET-28a", "GENE_OR_GENE_PRODUCT", 242, 249], ["Novagen", "GENE_OR_GENE_PRODUCT", 269, 276], ["NS1", "PROTEIN", 125, 128], ["N-terminus", "PROTEIN", 158, 168], ["NS1", "PROTEIN", 172, 175], ["pET-28a expression vector", "DNA", 242, 267], ["Novagen", "PROTEIN", 269, 276], ["N-terminal His-SUMO tag", "PROTEIN", 283, 306], ["chicken", "SPECIES", 191, 198], ["A/chicken/ Hatay/2004(H5N1)", "SPECIES", 189, 216], ["euthanasia", "PROBLEM", 48, 58], ["carbon dioxide", "TREATMENT", 79, 93], ["NS1 in bacteria", "PROBLEM", 125, 140], ["The gene encoding N-terminus of NS1", "TREATMENT", 140, 175], ["A/chicken/ Hatay", "TREATMENT", 189, 205], ["SUMO tag", "OBSERVATION", 298, 306]]], ["The wild-type NS1(RBD) and its mutants (R38AK41A, S42A and T49A) were expressed in E. coli BL21(DE3)-RILP overnight at 20\u00b0C, and protein expression was induced using 0.4 mM isopropyl b-D-thiogalactoside (IPTG).", [["isopropyl b-D-thiogalactoside", "CHEMICAL", 173, 202], ["IPTG", "CHEMICAL", 204, 208], ["isopropyl b-D-thiogalactoside", "CHEMICAL", 173, 202], ["IPTG", "CHEMICAL", 204, 208], ["NS1", "GENE_OR_GENE_PRODUCT", 14, 17], ["RBD", "GENE_OR_GENE_PRODUCT", 18, 21], ["E. coli BL21", "ORGANISM", 83, 95], ["DE3)-RILP", "GENE_OR_GENE_PRODUCT", 96, 105], ["isopropyl b-D-thiogalactoside", "SIMPLE_CHEMICAL", 173, 202], ["IPTG", "SIMPLE_CHEMICAL", 204, 208], ["wild-type NS1", "PROTEIN", 4, 17], ["RBD", "PROTEIN", 18, 21], ["R38AK41A", "PROTEIN", 40, 48], ["S42A", "PROTEIN", 50, 54], ["T49A", "PROTEIN", 59, 63], ["RILP", "PROTEIN", 101, 105], ["E. coli BL21", "SPECIES", 83, 95], ["E. coli BL21", "SPECIES", 83, 95], ["The wild-type NS1(RBD", "PROBLEM", 0, 21], ["RILP", "TEST", 101, 105], ["isopropyl b-D-thiogalactoside (IPTG", "TREATMENT", 173, 208], ["coli BL21", "OBSERVATION", 86, 95]]], ["Cells were harvested by centrifugation and the cell pellet was resuspended in lysis buffer which was followed by passing it through a cell disruptor (www.avestin.com) for five times.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 47, 51], ["cell", "ANATOMY", 134, 138], ["Cells", "CELL", 0, 5], ["cell", "CELL", 47, 51], ["cell", "CELL", 134, 138], ["the cell pellet", "TREATMENT", 43, 58], ["lysis buffer", "TREATMENT", 78, 90], ["a cell disruptor", "TREATMENT", 132, 148]]], ["After ultracentrifugation at 40,000 rpm for 1 h, the supernatants were loaded onto Ni-NTA affinity column for purification.", [["supernatants", "ANATOMY", 53, 65], ["Ni-NTA", "CHEMICAL", 83, 89], ["Ni-NTA", "CHEMICAL", 83, 89], ["Ni-NTA", "SIMPLE_CHEMICAL", 83, 89], ["ultracentrifugation", "TREATMENT", 6, 25], ["the supernatants", "TREATMENT", 49, 65]]], ["Pooled eluted fractions were dialysed overnight against dialysis buffer (20 mM Tris (pH 7.4), 100 mM NaCl) supplemented with Ulp1 protease for His-SUMO cleavage.", [["NaCl", "CHEMICAL", 101, 105], ["Tris", "CHEMICAL", 79, 83], ["NaCl", "CHEMICAL", 101, 105], ["Ulp1 protease", "GENE_OR_GENE_PRODUCT", 125, 138], ["His-SUMO", "GENE_OR_GENE_PRODUCT", 143, 151], ["Ulp1 protease", "PROTEIN", 125, 138], ["SUMO", "PROTEIN", 147, 151], ["Pooled eluted fractions", "PROBLEM", 0, 23], ["dialysis buffer", "TREATMENT", 56, 71], ["pH", "TEST", 85, 87], ["Ulp1 protease", "TREATMENT", 125, 138], ["His-SUMO cleavage", "TREATMENT", 143, 160], ["eluted fractions", "OBSERVATION", 7, 23], ["SUMO cleavage", "OBSERVATION", 147, 160]]], ["The fractions were reloaded onto Ni-NTA affinity column to remove His-SUMO tag.", [["fractions", "ANATOMY", 4, 13], ["Ni-NTA", "CHEMICAL", 33, 39], ["Ni-NTA", "CHEMICAL", 33, 39], ["Ni-NTA", "SIMPLE_CHEMICAL", 33, 39], ["His-SUMO tag", "PROTEIN", 66, 78], ["Ni-NTA affinity column", "TREATMENT", 33, 55], ["SUMO tag", "OBSERVATION", 70, 78]]], ["The flow through was then loaded onto HiLoad 26/60 Superdex 75 column (GE Healthcare), equilibrated in 25 mM Tris (pH 7.4), 500 mM NaCl and 10 mM DTT for further purification.", [["NaCl", "CHEMICAL", 131, 135], ["Tris", "CHEMICAL", 109, 113], ["NaCl", "CHEMICAL", 131, 135], ["DTT", "CHEMICAL", 146, 149], ["DTT", "SIMPLE_CHEMICAL", 146, 149], ["HiLoad", "TEST", 38, 44], ["pH", "TEST", 115, 117], ["500 mM NaCl", "TREATMENT", 124, 135], ["10 mM DTT", "TEST", 140, 149], ["further purification", "TEST", 154, 174], ["flow", "OBSERVATION", 4, 8]]], ["The purified proteins were dialysed against dialysis buffer again and concentrated to 3 mg/mL in a Centriprep-10 (Amicon).", [["purified proteins", "PROTEIN", 4, 21], ["The purified proteins", "TREATMENT", 0, 21], ["dialysis buffer", "TREATMENT", 44, 59], ["a Centriprep", "TREATMENT", 97, 109]]], ["Purified NS1 fragments were then subjected to Tricine-SDS-PAGE on a 15% gel which was stained using coomassie blue to visualize the purity of proteins.Purification of 2H6 whole antibody and preparation of 2H6antigen-binding fragment (Fab)Antibody was purified from ascites by HiTrap Protein A column (GE Healthcare) according to manufacturer's instructions.", [["fragments", "ANATOMY", 13, 22], ["ascites", "ANATOMY", 265, 272], ["ascites", "DISEASE", 265, 272], ["coomassie blue", "CHEMICAL", 100, 114], ["NS1", "GENE_OR_GENE_PRODUCT", 9, 12], ["Tricine", "SIMPLE_CHEMICAL", 46, 53], ["coomassie", "SIMPLE_CHEMICAL", 100, 109], ["2H6antigen-binding fragment", "GENE_OR_GENE_PRODUCT", 205, 232], ["Fab", "GENE_OR_GENE_PRODUCT", 234, 237], ["NS1 fragments", "DNA", 9, 22], ["2H6 whole antibody", "PROTEIN", 167, 185], ["2H6antigen-binding fragment (Fab)Antibody", "PROTEIN", 205, 246], ["coomassie blue", "SPECIES", 100, 114], ["Purified NS1 fragments", "PROBLEM", 0, 22], ["a 15% gel", "TREATMENT", 66, 75], ["coomassie blue", "TREATMENT", 100, 114], ["Purification", "TEST", 151, 163], ["2H6 whole antibody", "TREATMENT", 167, 185], ["preparation of 2H6antigen-binding fragment", "TREATMENT", 190, 232], ["Antibody", "TEST", 238, 246], ["ascites", "PROBLEM", 265, 272], ["HiTrap Protein A column (GE Healthcare", "TREATMENT", 276, 314], ["NS1 fragments", "OBSERVATION", 9, 22], ["binding fragment", "OBSERVATION", 216, 232], ["ascites", "OBSERVATION", 265, 272]]], ["Briefly, ascites was diluted in 1\u00c2 phosphate buffer saline (PBS) and injected in pre-equilibrated Protein A column.", [["ascites", "ANATOMY", 9, 16], ["ascites", "DISEASE", 9, 16], ["phosphate buffer", "CHEMICAL", 35, 51], ["phosphate", "CHEMICAL", 35, 44], ["phosphate buffer saline", "SIMPLE_CHEMICAL", 35, 58], ["ascites", "PROBLEM", 9, 16], ["1\u00c2 phosphate buffer saline (PBS", "TREATMENT", 32, 63], ["ascites", "OBSERVATION", 9, 16], ["column", "ANATOMY", 108, 114]]], ["The whole antibody was eluted from the column using 25 mM glycine (pH 2.2) elution buffer and then subjected to papain cleavage according to manufacturer's instructions.", [["glycine", "CHEMICAL", 58, 65], ["glycine", "CHEMICAL", 58, 65], ["glycine", "SIMPLE_CHEMICAL", 58, 65], ["papain", "GENE_OR_GENE_PRODUCT", 112, 118], ["The whole antibody", "TEST", 0, 18], ["25 mM glycine (pH", "TREATMENT", 52, 69], ["elution buffer", "TREATMENT", 75, 89], ["papain cleavage", "TREATMENT", 112, 127]]], ["In brief, whole antibody was incubated with immobilized papain (Thermo Scientific) in digestion buffer (20 mM sodium phosphate (pH 7), 10 mM EDTA, 20 mM cysteine) overnight at 37\u00b0C which was followed by Fab purification by HiTrap Protein L column (GE Healthcare) according to manufacturer's instructions.Circular dichroism (CD) spectroscopyFar-UV CD spectra (260-190 nm) were recorded using a Jasco J-810 spectropolarimeter (Jasco Corporation, Tokyo, Japan).", [["sodium phosphate", "CHEMICAL", 110, 126], ["cysteine", "CHEMICAL", 153, 161], ["sodium phosphate", "CHEMICAL", 110, 126], ["EDTA", "CHEMICAL", 141, 145], ["cysteine", "CHEMICAL", 153, 161], ["papain", "SIMPLE_CHEMICAL", 56, 62], ["sodium phosphate", "SIMPLE_CHEMICAL", 110, 126], ["EDTA", "SIMPLE_CHEMICAL", 141, 145], ["whole antibody", "PROTEIN", 10, 24], ["whole antibody", "TEST", 10, 24], ["immobilized papain", "TREATMENT", 44, 62], ["digestion buffer", "TREATMENT", 86, 102], ["mM sodium phosphate (pH", "TEST", 107, 130], ["EDTA", "TEST", 141, 145], ["20 mM cysteine", "TREATMENT", 147, 161], ["Fab purification", "TREATMENT", 203, 219], ["HiTrap Protein L column (GE Healthcare", "TREATMENT", 223, 261], ["Circular dichroism", "TEST", 304, 322], ["spectroscopyFar", "TEST", 328, 343], ["UV CD spectra", "TEST", 344, 357], ["a Jasco J", "TREATMENT", 391, 400]]], ["The cuvette chamber and instrument optics were continuously purged with 30 L of nitrogen/min before and during the measurements.", [["nitrogen", "CHEMICAL", 80, 88], ["The cuvette chamber", "TREATMENT", 0, 19], ["instrument optics", "TREATMENT", 24, 41], ["nitrogen/min", "TREATMENT", 80, 92], ["the measurements", "TEST", 111, 127], ["cuvette chamber", "OBSERVATION", 4, 19]]], ["The spectra were recorded using a scanning speed of 50 nm/min, a resolution of 0.1 nm and a bandwidth of 1 nm.", [["a scanning speed", "TEST", 32, 48]]], ["NS1(RBD) (10 lM) and 2H6-Fab (5 lM) were dissolved in 1 mM phosphate buffer (pH 7.4) and placed in a cuvette with 0.1 cm path length.", [["phosphate", "CHEMICAL", 59, 68], ["phosphate", "CHEMICAL", 59, 68], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["2H6-Fab", "SIMPLE_CHEMICAL", 21, 28], ["NS1", "PROTEIN", 0, 3], ["RBD", "PROTEIN", 4, 7], ["2H6", "PROTEIN", 21, 24], ["Fab", "PROTEIN", 25, 28], ["NS1(RBD)", "TEST", 0, 8], ["1 mM phosphate buffer", "TREATMENT", 54, 75], ["pH", "TEST", 77, 79], ["a cuvette", "TREATMENT", 99, 108]]], ["An average of three scans was taken to increase the signal to noise ratio and the baseline was subtracted.Gel filtration chromatographyThe NS1(RBD) and 2H6-Fab were mixed in 1:1 M ratio and incubated overnight at 4\u00b0C. The NS1(RBD) and 2H6-Fab complex formation was examined by gel filtration chromatography on a HiLoad 16/60 Superdex 200 column (GE Healthcare).", [["2H6-Fab", "SIMPLE_CHEMICAL", 152, 159], ["NS1", "GENE_OR_GENE_PRODUCT", 222, 225], ["2H6-Fab", "GENE_OR_GENE_PRODUCT", 235, 242], ["NS1", "PROTEIN", 139, 142], ["RBD", "PROTEIN", 143, 146], ["2H6", "PROTEIN", 152, 155], ["Fab", "PROTEIN", 156, 159], ["NS1", "PROTEIN", 222, 225], ["RBD", "PROTEIN", 226, 229], ["2H6", "PROTEIN", 235, 238], ["Fab complex", "PROTEIN", 239, 250], ["three scans", "TEST", 14, 25], ["noise ratio", "TEST", 62, 73], ["Gel filtration chromatography", "TEST", 106, 135], ["The NS1(RBD", "TEST", 135, 146], ["2H6-Fab", "TREATMENT", 152, 159], ["The NS1(RBD", "TEST", 218, 229], ["gel filtration chromatography", "TEST", 277, 306], ["a HiLoad", "TREATMENT", 310, 318], ["NS1", "OBSERVATION", 222, 225]]], ["The sample was injected in the column equilibrated with 50 mM Tris (pH 7.4) buffer containing 150 mM NaCl and eluted with the same buffer using AKTA purifier system (GE Healthcare Life Sciences, Piscataway, NJ, USA) at a flow rate of 1 mL/min.", [["sample", "ANATOMY", 4, 10], ["NaCl", "CHEMICAL", 101, 105], ["Tris", "CHEMICAL", 62, 66], ["NaCl", "CHEMICAL", 101, 105], ["The sample", "TEST", 0, 10], ["50 mM Tris (pH", "TREATMENT", 56, 70], ["150 mM NaCl", "TREATMENT", 94, 105], ["AKTA purifier system", "TREATMENT", 144, 164], ["a flow rate", "TEST", 219, 230]]], ["The gel filtration fractions were analyzed by SDS/PAGE on 4-20% ready gel (Bio-Rad).Surface plasmon resonance (SPR)The affinities for NS1(RBD) and NS1(RBD)-T49A binding to 2H6 antibody were determined using Biacore\u2122 3000 (GE Healthcare Life Sciences, Piscataway, NJ, USA) at 25\u00b0C. Briefly, 2H6 antibody (20 lg/ mL) diluted in 10 mM sodium acetate buffer (pH 5) was immobilized at a flow rate of 10 lL/min for 7 min on the surface of a CM5 chip (GE Healthcare) following the standard 1-ethyl-3-(3-dimethylpropyl)-carbodiimide (EDC) plus N-hydroxysuccinimide (NHS) (GE Healthcare) coupling chemistry.", [["surface", "ANATOMY", 422, 429], ["sodium acetate", "CHEMICAL", 332, 346], ["1-ethyl-3-(3-dimethylpropyl)-carbodiimide", "CHEMICAL", 483, 524], ["EDC", "CHEMICAL", 526, 529], ["N-hydroxysuccinimide", "CHEMICAL", 536, 556], ["sodium acetate", "CHEMICAL", 332, 346], ["1-ethyl-3-(3-dimethylpropyl)-carbodiimide", "CHEMICAL", 483, 524], ["EDC", "CHEMICAL", 526, 529], ["N-hydroxysuccinimide", "CHEMICAL", 536, 556], ["NHS", "CHEMICAL", 558, 561], ["NS1", "GENE_OR_GENE_PRODUCT", 134, 137], ["NS1(RBD)-T49A", "GENE_OR_GENE_PRODUCT", 147, 160], ["2H6 antibody", "GENE_OR_GENE_PRODUCT", 172, 184], ["2H6 antibody", "GENE_OR_GENE_PRODUCT", 290, 302], ["sodium acetate", "SIMPLE_CHEMICAL", 332, 346], ["1-ethyl-3-(3-dimethylpropyl)-carbodiimide", "SIMPLE_CHEMICAL", 483, 524], ["EDC", "SIMPLE_CHEMICAL", 526, 529], ["N-hydroxysuccinimide", "SIMPLE_CHEMICAL", 536, 556], ["NHS", "SIMPLE_CHEMICAL", 558, 561], ["NS1", "PROTEIN", 134, 137], ["RBD", "PROTEIN", 138, 141], ["NS1", "PROTEIN", 147, 150], ["RBD", "PROTEIN", 151, 154], ["T49A", "PROTEIN", 156, 160], ["2H6 antibody", "PROTEIN", 172, 184], ["2H6 antibody", "PROTEIN", 290, 302], ["The gel filtration fractions", "TREATMENT", 0, 28], ["Surface plasmon resonance", "TEST", 84, 109], ["SPR", "TEST", 111, 114], ["The affinities", "TEST", 115, 129], ["NS1(RBD)", "TEST", 134, 142], ["NS1(RBD)", "TEST", 147, 155], ["T49A binding", "PROBLEM", 156, 168], ["2H6 antibody", "TEST", 172, 184], ["antibody", "TEST", 294, 302], ["10 mM sodium acetate buffer", "TREATMENT", 326, 353], ["pH", "TEST", 355, 357], ["a flow rate", "TEST", 380, 391], ["a CM5 chip (GE Healthcare", "TREATMENT", 433, 458], ["carbodiimide (EDC)", "TREATMENT", 512, 530], ["hydroxysuccinimide (NHS)", "TREATMENT", 538, 562]]], ["Kinetic measurements were carried out by 3 min injection at a flow rate of 20 lL/min of serial dilutions of NS1(RBD) and NS1(RBD)-T49A in HBS-EP buffer (GE Healthcare) from 400-25 nM and 12.5-0.78 lM, respectively and dissociation for 3 min.", [["NS1", "GENE_OR_GENE_PRODUCT", 108, 111], ["HBS-EP", "SIMPLE_CHEMICAL", 138, 144], ["NS1", "PROTEIN", 108, 111], ["RBD", "PROTEIN", 112, 115], ["NS1", "PROTEIN", 121, 124], ["RBD", "PROTEIN", 125, 128], ["T49A", "PROTEIN", 130, 134], ["Kinetic measurements", "TEST", 0, 20], ["a flow rate", "TEST", 60, 71], ["serial dilutions", "TREATMENT", 88, 104], ["NS1(RBD", "TREATMENT", 108, 115], ["NS1", "TEST", 121, 124], ["RBD", "TEST", 125, 128], ["HBS", "TEST", 138, 141]]], ["The 2H6 immobilized chip surface was regenerated by injection of 10 mM glycine (pH 2) for 45 s at a flow rate of 30 lL/min after each cycle.", [["surface", "ANATOMY", 25, 32], ["glycine", "CHEMICAL", 71, 78], ["glycine", "CHEMICAL", 71, 78], ["glycine", "SIMPLE_CHEMICAL", 71, 78], ["2H6", "PROTEIN", 4, 7], ["The 2H6 immobilized chip surface", "TREATMENT", 0, 32], ["10 mM glycine (pH", "TREATMENT", 65, 82], ["a flow rate", "TEST", 98, 109]]], ["Binding of 2H6 to all concentration series of NS1(RBD) and NS1(RBD)-T49A were analyzed using a 1:1 binding model.", [["2H6", "SIMPLE_CHEMICAL", 11, 14], ["NS1", "GENE_OR_GENE_PRODUCT", 46, 49], ["NS1(RBD)-T49A", "GENE_OR_GENE_PRODUCT", 59, 72], ["2H6", "PROTEIN", 11, 14], ["NS1", "PROTEIN", 46, 49], ["RBD", "PROTEIN", 50, 53], ["NS1", "PROTEIN", 59, 62], ["RBD", "PROTEIN", 63, 66], ["T49A", "PROTEIN", 68, 72], ["NS1(RBD", "TEST", 46, 53], ["NS1(RBD)", "TEST", 59, 67], ["a 1:1 binding model", "TREATMENT", 93, 112]]], ["The data were corrected by subtraction of a ''buffer only'' control as well as zero 2H6 antibody flow cell.Enzyme-linked immunosorbent assay (ELISA)Purified wild-type and mutant NS1(RBD) proteins were diluted at different concentrations into 0.05 M carbonate-bicarbonate buffer (pH 9.6).", [["cell", "ANATOMY", 102, 106], ["carbonate-bicarbonate", "CHEMICAL", 249, 270], ["carbonate", "CHEMICAL", 249, 258], ["bicarbonate", "CHEMICAL", 259, 270], ["cell", "CELL", 102, 106], ["mutant NS1", "ORGANISM", 171, 181], ["carbonate-bicarbonate", "SIMPLE_CHEMICAL", 249, 270], ["2H6 antibody flow cell", "CELL_LINE", 84, 106], ["mutant NS1(RBD) proteins", "PROTEIN", 171, 195], ["The data", "TEST", 0, 8], ["a ''buffer only'' control", "TREATMENT", 42, 67], ["Enzyme", "TEST", 107, 113], ["immunosorbent assay", "TEST", 121, 140], ["ELISA", "TEST", 142, 147], ["mutant NS1(RBD) proteins", "TREATMENT", 171, 195], ["0.05 M carbonate", "TREATMENT", 242, 258], ["bicarbonate buffer", "TREATMENT", 259, 277], ["pH", "TEST", 279, 281], ["antibody flow cell", "OBSERVATION", 88, 106]]], ["Proteins (50 lL) were then coated onto 96-well ELISA plates (Nunc) overnight at 4\u00b0C. The wells were blocked in 5% milk in PBS with 0.1% Tween 20 (PBST) for 1 h at 37\u00b0C followed by addition of 100 lL of 2H6 whole antibody (5 lg/mL) as primary antibody to each well and incubated at 37\u00b0C for 2-3 h.", [["milk", "ANATOMY", 114, 118], ["Tween 20", "CHEMICAL", 136, 144], ["milk", "ORGANISM_SUBSTANCE", 114, 118], ["2H6 whole antibody", "PROTEIN", 202, 220], ["primary antibody", "PROTEIN", 234, 250], ["Proteins", "TEST", 0, 8], ["5% milk in PBS", "TREATMENT", 111, 125], ["2H6 whole antibody", "TREATMENT", 202, 220]]], ["The wells were then washed in PBST followed by the addition of goat antimouse horse-radish peroxidase (HRP)-conjugated antibody (Pierce) as secondary antibody and incubated at 37\u00b0C for 1 h.", [["goat", "ORGANISM", 63, 67], ["radish peroxidase", "SIMPLE_CHEMICAL", 84, 101], ["HRP", "SIMPLE_CHEMICAL", 103, 106], ["Pierce", "SIMPLE_CHEMICAL", 129, 135], ["goat antimouse horse-radish peroxidase (HRP)-conjugated antibody", "PROTEIN", 63, 127], ["Pierce", "PROTEIN", 129, 135], ["secondary antibody", "PROTEIN", 140, 158], ["goat", "SPECIES", 63, 67], ["horse", "SPECIES", 78, 83], ["radish", "SPECIES", 84, 90], ["goat", "SPECIES", 63, 67], ["radish", "SPECIES", 84, 90], ["PBST", "TREATMENT", 30, 34], ["goat antimouse horse", "TREATMENT", 63, 83], ["conjugated antibody (Pierce)", "TREATMENT", 108, 136], ["secondary antibody", "PROBLEM", 140, 158]]], ["Tetramethylbenzidine substrate (Pierce) was added and reaction was stopped using 0.2 M sulfuric acid.", [["Tetramethylbenzidine", "CHEMICAL", 0, 20], ["sulfuric acid", "CHEMICAL", 87, 100], ["Tetramethylbenzidine", "CHEMICAL", 0, 20], ["sulfuric acid", "CHEMICAL", 87, 100], ["Tetramethylbenzidine", "SIMPLE_CHEMICAL", 0, 20], ["Pierce", "SIMPLE_CHEMICAL", 32, 38], ["sulfuric acid", "SIMPLE_CHEMICAL", 87, 100], ["Tetramethylbenzidine substrate (Pierce)", "TREATMENT", 0, 39], ["0.2 M sulfuric acid", "TREATMENT", 81, 100]]], ["Absorbance at 450 nm was recorded using an absorbance reader (Tecan Infinite M200).Transient transfection of 2H6-single-chain variable fragment (scFv) and western blot analysisVariable heavy (V H ) and variable light (V L ) genes were obtained from RNA extracted from the 2H6 or 7G12 hybridoma as described previously (Dang et al., 2013) .", [["7G12 hybridoma", "ANATOMY", 279, 293], ["variable light (V L", "GENE_OR_GENE_PRODUCT", 202, 221], ["7G12 hybridoma", "CELL", 279, 293], ["2H6", "PROTEIN", 109, 112], ["scFv", "PROTEIN", 145, 149], ["heavy (V H ) and variable light (V L ) genes", "DNA", 185, 229], ["2H6 or 7G12 hybridoma", "CELL_LINE", 272, 293], ["Transient transfection", "PROBLEM", 83, 105], ["2H6-single-chain variable fragment (scFv", "TREATMENT", 109, 149], ["western blot analysis", "TEST", 155, 176], ["variable light (V L ) genes", "PROBLEM", 202, 229], ["transfection", "OBSERVATION", 93, 105], ["fragment", "OBSERVATION", 135, 143]]], ["7G12 is a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome (SARS) coronavirus (Lip et al., 2006) .", [["7G12", "CHEMICAL", 0, 4], ["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 68, 113], ["7G12", "SIMPLE_CHEMICAL", 0, 4], ["7G12", "PROTEIN", 0, 4], ["monoclonal antibody", "PROTEIN", 10, 29], ["spike protein", "PROTEIN", 44, 57], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 61, 113], ["a monoclonal antibody", "TEST", 8, 29], ["severe acute respiratory syndrome", "PROBLEM", 61, 94], ["SARS) coronavirus", "PROBLEM", 96, 113], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory syndrome", "OBSERVATION", 74, 94]]], ["Subsequently, the 2H6-scFv and 7G12-scFv were constructed by using overlap PCR to link them via a GGGSGGGSGGGS linker.", [["2H6-scFv", "GENE_OR_GENE_PRODUCT", 18, 26], ["7G12-scFv", "GENE_OR_GENE_PRODUCT", 31, 40], ["2H6", "PROTEIN", 18, 21], ["scFv", "PROTEIN", 22, 26], ["7G12", "PROTEIN", 31, 35], ["scFv", "PROTEIN", 36, 40], ["GGGSGGGSGGGS linker", "PROTEIN", 98, 117], ["the 2H6-scFv", "TREATMENT", 14, 26], ["7G12-scFv", "TREATMENT", 31, 40], ["overlap PCR", "TEST", 67, 78], ["a GGGSGGGSGGGS linker", "TREATMENT", 96, 117]]], ["Finally, the 2H6-scFv and 7G12-scFv were cloned into the pXJ40-FLAG or pXJ40-Myc CMV expression vector so that a FLAG or Myc epitope is fused to its N terminus.", [["N", "CHEMICAL", 149, 150], ["2H6-scFv", "GENE_OR_GENE_PRODUCT", 13, 21], ["7G12-scFv", "GENE_OR_GENE_PRODUCT", 26, 35], ["pXJ40-FLAG", "GENE_OR_GENE_PRODUCT", 57, 67], ["pXJ40-Myc", "GENE_OR_GENE_PRODUCT", 71, 80], ["FLAG", "GENE_OR_GENE_PRODUCT", 113, 117], ["Myc", "GENE_OR_GENE_PRODUCT", 121, 124], ["2H6", "PROTEIN", 13, 16], ["scFv", "PROTEIN", 17, 21], ["7G12", "PROTEIN", 26, 30], ["scFv", "PROTEIN", 31, 35], ["pXJ40-FLAG or pXJ40-Myc CMV expression vector", "DNA", 57, 102], ["FLAG", "PROTEIN", 113, 117], ["Myc epitope", "PROTEIN", 121, 132], ["N terminus", "PROTEIN", 149, 159], ["the 2H6-scFv", "TREATMENT", 9, 21], ["7G12-scFv", "TREATMENT", 26, 35], ["Myc CMV expression vector", "TREATMENT", 77, 102], ["a FLAG or Myc epitope", "TREATMENT", 111, 132], ["Myc CMV", "OBSERVATION", 77, 84], ["Myc epitope", "OBSERVATION", 121, 132], ["terminus", "OBSERVATION_MODIFIER", 151, 159]]], ["The plasmids were then transfected into 80% confluent 293T or A549 cells by using X-treme GENE HP (Roche) according to the manufacturer's instructions.", [["plasmids", "ANATOMY", 4, 12], ["293T", "ANATOMY", 54, 58], ["A549 cells", "ANATOMY", 62, 72], ["293T", "CELL", 54, 58], ["A549 cells", "CELL", 62, 72], ["plasmids", "DNA", 4, 12], ["80% confluent 293T", "CELL_LINE", 40, 58], ["A549 cells", "CELL_LINE", 62, 72], ["The plasmids", "TREATMENT", 0, 12], ["A549 cells", "TEST", 62, 72], ["plasmids", "OBSERVATION", 4, 12]]], ["After 24 h (293T) or 48 h (A549) post-transfection, the cells were rinsed using PBS and inoculated with PR8 for 1 h.", [["293T", "ANATOMY", 12, 16], ["A549", "ANATOMY", 27, 31], ["cells", "ANATOMY", 56, 61], ["A549", "CELL", 27, 31], ["cells", "CELL", 56, 61], ["PR8", "ORGANISM", 104, 107], ["the cells", "TREATMENT", 52, 61], ["PBS", "TREATMENT", 80, 83], ["PR8", "TREATMENT", 104, 107]]], ["The viral media were collected for titration by plaque assay.", [["plaque", "ANATOMY", 48, 54], ["The viral media", "TREATMENT", 0, 15], ["plaque assay", "TEST", 48, 60], ["viral media", "OBSERVATION", 4, 15]]], ["The transfected cells were lysed in lysis buffer (50 mM Tris (pH 8.0), 0.1% NP-40 and 150 mM NaCl) at 4\u00b0C for 2 h, and the cell lysates were subsequently collected.", [["cells", "ANATOMY", 16, 21], ["cell lysates", "ANATOMY", 123, 135], ["NaCl", "CHEMICAL", 93, 97], ["NaCl", "CHEMICAL", 93, 97], ["cells", "CELL", 16, 21], ["cell lysates", "CELL", 123, 135], ["transfected cells", "CELL_LINE", 4, 21], ["The transfected cells", "TREATMENT", 0, 21], ["lysis buffer", "TREATMENT", 36, 48], ["Tris", "TEST", 56, 60], ["pH", "TEST", 62, 64], ["NP", "TEST", 76, 78], ["NaCl", "TEST", 93, 97], ["the cell lysates", "TEST", 119, 135], ["transfected cells", "OBSERVATION", 4, 21]]], ["The cell lysates (50 lg) were resolved using electrophoresis on an SDSpolyacrylamide gel and transferred to a nitrocellulose membrane (Bio-Rad).", [["cell lysates", "ANATOMY", 4, 16], ["membrane", "ANATOMY", 125, 133], ["nitrocellulose", "CHEMICAL", 110, 124], ["cell lysates", "CELL", 4, 16], ["SDSpolyacrylamide", "SIMPLE_CHEMICAL", 67, 84], ["membrane", "CELLULAR_COMPONENT", 125, 133], ["The cell lysates", "TEST", 0, 16], ["electrophoresis", "TEST", 45, 60], ["an SDSpolyacrylamide gel", "TREATMENT", 64, 88], ["a nitrocellulose membrane", "TREATMENT", 108, 133], ["cell lysates", "OBSERVATION", 4, 16]]], ["Antibodies against FLAG (Sigma), Myc (Santa Cruz), M1 (as described above), b-actin (Sigma) were used.", [["FLAG", "GENE_OR_GENE_PRODUCT", 19, 23], ["Sigma", "GENE_OR_GENE_PRODUCT", 25, 30], ["Myc", "GENE_OR_GENE_PRODUCT", 33, 36], ["b-actin", "GENE_OR_GENE_PRODUCT", 76, 83], ["FLAG", "PROTEIN", 19, 23], ["Sigma", "PROTEIN", 25, 30], ["Myc", "PROTEIN", 33, 36], ["Santa Cruz", "PROTEIN", 38, 48], ["M1", "PROTEIN", 51, 53], ["b-actin", "PROTEIN", 76, 83], ["Sigma", "PROTEIN", 85, 90], ["Antibodies", "TEST", 0, 10], ["M1", "ANATOMY", 51, 53]]], ["After washing, the membrane was incubated with a HRP-conjugated secondary antibody (Pierce).", [["membrane", "ANATOMY", 19, 27], ["membrane", "CELLULAR_COMPONENT", 19, 27], ["HRP", "SIMPLE_CHEMICAL", 49, 52], ["HRP", "PROTEIN", 49, 52], ["secondary antibody", "PROTEIN", 64, 82], ["Pierce", "PROTEIN", 84, 90], ["a HRP", "TEST", 47, 52]]], ["The membranes were then washed and enhanced chemiluminescence substrate (Pierce) was added for detection using ChemiDoc\u2122 MP Imaging System (Bio-Rad).Plaque assay in MDCK cellsMDCK cells were seeded in 6-well plates.", [["membranes", "ANATOMY", 4, 13], ["Plaque", "ANATOMY", 149, 155], ["MDCK cellsMDCK cells", "ANATOMY", 165, 185], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["MDCK cellsMDCK cells", "CELL", 165, 185], ["MDCK cellsMDCK cells", "CELL_LINE", 165, 185], ["enhanced chemiluminescence substrate (Pierce)", "TREATMENT", 35, 80], ["ChemiDoc\u2122 MP Imaging System", "TEST", 111, 138], ["Plaque assay", "TEST", 149, 161], ["MDCK cellsMDCK cells", "TEST", 165, 185]]], ["After 24 h incubation, plates were rinsed using PBS, and subsequently adsorbed with serially diluted supernatants containing viruses for 1 h at 37\u00b0C. The medium was discarded and the cells were rinsed using PBS.", [["supernatants", "ANATOMY", 101, 113], ["cells", "ANATOMY", 183, 188], ["cells", "CELL", 183, 188], ["plates", "TREATMENT", 23, 29], ["PBS", "TREATMENT", 48, 51], ["serially diluted supernatants containing viruses", "TREATMENT", 84, 132], ["the cells", "TREATMENT", 179, 188], ["PBS", "TREATMENT", 207, 210], ["medium", "OBSERVATION_MODIFIER", 154, 160]]], ["The cells were overlaid with 2 mL of DMEM supplemented by 0.3% agar and 2 lg/mL TPCK-trypsin (Thermo Scientific).", [["cells", "ANATOMY", 4, 9], ["TPCK-trypsin", "CHEMICAL", 80, 92], ["TPCK", "CHEMICAL", 80, 84], ["cells", "CELL", 4, 9], ["TPCK-trypsin", "SIMPLE_CHEMICAL", 80, 92], ["trypsin", "PROTEIN", 85, 92], ["DMEM", "TREATMENT", 37, 41]]], ["After incubation at 37\u00b0C for 2 days, the cells were fixed using 10% formalin for 1 h and stained using a 0.1% crystal violet solution.Statistical analysisThe two-tailed Student's t test was applied to evaluate the statistical significance of differences measured from the data sets obtained in 3 independent experiments. p < 0.05 was considered statistically significant.The 2H6-Fab and NS1(RBD) protein forms a multimeric complexIn order to characterize the interaction between mAb 2H6 and NS1 protein, the NS1(RBD) protein was expressed in E. coli and purified while the 2H6-Fab was obtained from ascites fluid after papain cleavage (see Supplementary Fig. S1 ).", [["cells", "ANATOMY", 41, 46], ["ascites fluid", "ANATOMY", 599, 612], ["formalin", "CHEMICAL", 68, 76], ["ascites", "DISEASE", 599, 606], ["formalin", "CHEMICAL", 68, 76], ["cells", "CELL", 41, 46], ["formalin", "SIMPLE_CHEMICAL", 68, 76], ["2H6-Fab", "GENE_OR_GENE_PRODUCT", 375, 382], ["NS1(RBD)", "GENE_OR_GENE_PRODUCT", 387, 395], ["mAb 2H6", "GENE_OR_GENE_PRODUCT", 479, 486], ["NS1", "GENE_OR_GENE_PRODUCT", 491, 494], ["NS1", "GENE_OR_GENE_PRODUCT", 508, 511], ["RBD", "GENE_OR_GENE_PRODUCT", 512, 515], ["E. coli", "ORGANISM", 542, 549], ["2H6-Fab", "GENE_OR_GENE_PRODUCT", 573, 580], ["ascites fluid", "ORGANISM_SUBSTANCE", 599, 612], ["S1", "GENE_OR_GENE_PRODUCT", 659, 661], ["2H6", "PROTEIN", 375, 378], ["Fab", "PROTEIN", 379, 382], ["NS1(RBD) protein", "PROTEIN", 387, 403], ["mAb 2H6", "PROTEIN", 479, 486], ["NS1 protein", "PROTEIN", 491, 502], ["NS1(RBD) protein", "PROTEIN", 508, 524], ["2H6", "PROTEIN", 573, 576], ["Fab", "PROTEIN", 577, 580], ["S1", "PROTEIN", 659, 661], ["E. coli", "SPECIES", 542, 549], ["E. coli", "SPECIES", 542, 549], ["the cells", "TREATMENT", 37, 46], ["10% formalin", "TREATMENT", 64, 76], ["a 0.1% crystal violet solution", "TREATMENT", 103, 133], ["Statistical analysis", "TEST", 134, 154], ["Student's t test", "TEST", 169, 185], ["the data sets", "TEST", 268, 281], ["The 2H6-Fab and NS1(RBD) protein", "TEST", 371, 403], ["mAb", "TEST", 479, 482], ["NS1 protein", "TEST", 491, 502], ["the NS1(RBD) protein", "TEST", 504, 524], ["E. coli", "PROBLEM", 542, 549], ["ascites fluid", "PROBLEM", 599, 612], ["papain cleavage", "TREATMENT", 619, 634], ["E. coli", "OBSERVATION", 542, 549], ["ascites", "OBSERVATION", 599, 606]]], ["Far-UV CD spectroscopy was then used to analyze the secondary structures of NS1(RBD) and 2H6-Fab.", [["NS1", "GENE_OR_GENE_PRODUCT", 76, 79], ["2H6-Fab", "GENE_OR_GENE_PRODUCT", 89, 96], ["NS1", "PROTEIN", 76, 79], ["RBD", "PROTEIN", 80, 83], ["2H6", "PROTEIN", 89, 92], ["Fab", "PROTEIN", 93, 96], ["UV CD spectroscopy", "TEST", 4, 22]]], ["The spectrum showed minima at 208 and 220 nm for NS1(RBD) protein (Fig. 1A) , which indicates that it is rich in a-helices and is consistent with the three-dimensional structures of NS1(RBD) protein (Hale, 2014) .", [["NS1(RBD) protein", "GENE_OR_GENE_PRODUCT", 49, 65], ["a-helices", "GENE_OR_GENE_PRODUCT", 113, 122], ["NS1(RBD)", "GENE_OR_GENE_PRODUCT", 182, 190], ["NS1(RBD) protein", "PROTEIN", 49, 65], ["Fig. 1A", "PROTEIN", 67, 74], ["a-helices", "PROTEIN", 113, 122], ["NS1(RBD) protein", "PROTEIN", 182, 198], ["The spectrum", "TEST", 0, 12], ["NS1(RBD) protein", "TEST", 49, 65], ["consistent with", "UNCERTAINTY", 130, 145], ["NS1", "OBSERVATION", 182, 185]]], ["The spectrum for 2H6-Fab showed minimum at 216 nm and maximum at 202 nm ( Fig. 1B) , which indicates that it is composed of b-sheeted structure (Satow et al., 1986; Tetin et al., 2003) .The 2H6-Fab and NS1(RBD) protein forms a multimeric complexNext, NS1(RBD) and 2H6-Fab were mixed in 1:1 M ratio, incubated overnight at 4\u00b0C and then subjected to size exclusion chromatography.", [["2H6", "CHEMICAL", 17, 20], ["2H6-Fab", "SIMPLE_CHEMICAL", 17, 24], ["2H6-Fab", "GENE_OR_GENE_PRODUCT", 190, 197], ["NS1(RBD)", "GENE_OR_GENE_PRODUCT", 202, 210], ["NS1", "GENE_OR_GENE_PRODUCT", 251, 254], ["2H6-Fab", "GENE_OR_GENE_PRODUCT", 264, 271], ["C", "GENE_OR_GENE_PRODUCT", 324, 325], ["2H6", "PROTEIN", 17, 20], ["Fab", "PROTEIN", 21, 24], ["2H6", "PROTEIN", 190, 193], ["Fab", "PROTEIN", 194, 197], ["NS1(RBD) protein forms", "PROTEIN", 202, 224], ["multimeric complexNext", "PROTEIN", 227, 249], ["NS1", "PROTEIN", 251, 254], ["RBD", "PROTEIN", 255, 258], ["2H6", "PROTEIN", 264, 267], ["Fab", "PROTEIN", 268, 271], ["The spectrum", "TEST", 0, 12], ["maximum", "TEST", 54, 61], ["The 2H6-Fab and NS1(RBD) protein", "TEST", 186, 218], ["a multimeric complexNext", "TEST", 225, 249], ["size exclusion chromatography", "TEST", 348, 377]]], ["Three peaks were obtained after separation on a Superdex 200 column ( Fig. 2A) .", [["a Superdex 200 column", "TREATMENT", 46, 67]]], ["The 2H6-Fab and NS1(RBD) protein co-eluted in the first peak and the free 2H6-Fab eluted out as the major peak (Fig. 2B) .", [["2H6-Fab", "GENE_OR_GENE_PRODUCT", 4, 11], ["NS1(RBD)", "GENE_OR_GENE_PRODUCT", 16, 24], ["2H6", "PROTEIN", 4, 7], ["Fab", "PROTEIN", 8, 11], ["NS1(RBD) protein", "PROTEIN", 16, 32], ["2H6", "PROTEIN", 74, 77], ["Fab", "PROTEIN", 78, 81], ["The 2H6-Fab and NS1(RBD) protein", "TEST", 0, 32]]], ["The 7G12 antibody, which binds to the spike protein of SARS coronavirus (Lip et al., 2006) , was used as a negative control for this experiment.", [["SARS coronavirus", "DISEASE", 55, 71], ["7G12 antibody", "GENE_OR_GENE_PRODUCT", 4, 17], ["SARS coronavirus", "ORGANISM", 55, 71], ["7G12 antibody", "PROTEIN", 4, 17], ["spike protein", "PROTEIN", 38, 51], ["SARS coronavirus", "SPECIES", 55, 71], ["The 7G12 antibody", "TEST", 0, 17], ["SARS coronavirus", "PROBLEM", 55, 71]]], ["In contrast to the results for 2H6-Fab, 7G12-Fab and NS1(RBD) eluted out of the column separately when the mixture was run on a Superdex 200 column (see Supplementary Fig. S2 ).The 2H6-Fab and NS1(RBD) protein forms a multimeric complexThis result clearly indicates that NS1(RBD) interacts with 2H6-Fab and the elution time suggests that the antibody-antigen complex has a molecular weight greater than 158 kDa ( Fig. 2A) .", [["2H6-Fab", "GENE_OR_GENE_PRODUCT", 31, 38], ["7G12-Fab", "GENE_OR_GENE_PRODUCT", 40, 48], ["NS1", "GENE_OR_GENE_PRODUCT", 53, 56], ["2H6-Fab", "GENE_OR_GENE_PRODUCT", 181, 188], ["NS1(RBD)", "GENE_OR_GENE_PRODUCT", 193, 201], ["NS1", "GENE_OR_GENE_PRODUCT", 271, 274], ["RBD", "GENE_OR_GENE_PRODUCT", 275, 278], ["2H6-Fab", "GENE_OR_GENE_PRODUCT", 295, 302], ["antibody-antigen", "GENE_OR_GENE_PRODUCT", 342, 358], ["2H6", "PROTEIN", 31, 34], ["Fab", "PROTEIN", 35, 38], ["7G12", "PROTEIN", 40, 44], ["Fab", "PROTEIN", 45, 48], ["NS1", "PROTEIN", 53, 56], ["RBD", "PROTEIN", 57, 60], ["S2", "PROTEIN", 172, 174], ["2H6", "PROTEIN", 181, 184], ["Fab", "PROTEIN", 185, 188], ["NS1(RBD) protein", "PROTEIN", 193, 209], ["multimeric complex", "PROTEIN", 218, 236], ["NS1", "PROTEIN", 271, 274], ["RBD", "PROTEIN", 275, 278], ["2H6", "PROTEIN", 295, 298], ["Fab", "PROTEIN", 299, 302], ["antibody-antigen complex", "PROTEIN", 342, 366], ["Fab", "TEST", 35, 38], ["7G12", "TEST", 40, 44], ["Fab", "TEST", 45, 48], ["NS1(RBD)", "TEST", 53, 61], ["a Superdex 200 column", "TREATMENT", 126, 147], ["The 2H6-Fab and NS1(RBD) protein", "TEST", 177, 209], ["NS1(RBD)", "PROBLEM", 271, 279], ["the antibody", "TEST", 338, 350], ["column", "ANATOMY", 80, 86], ["multimeric complex", "OBSERVATION", 218, 236]]], ["Dynamic light scattering (DLS) was performed on the fraction containing this complex and the results reveal that it is homogenous and has an estimated molecular weight of 400 kDa (see Supplementary Fig. S3 ).", [["Dynamic light scattering (DLS)", "TEST", 0, 30], ["homogenous", "OBSERVATION_MODIFIER", 119, 129]]], ["Given that NS1(RBD) exists as a dimer of $18 kDa, binding to 2H6-Fab of $50 kDa will yield an expected size of $120 kDa assuming the complex has a globular structure.", [["NS1", "GENE_OR_GENE_PRODUCT", 11, 14], ["2H6-Fab", "GENE_OR_GENE_PRODUCT", 61, 68], ["NS1", "PROTEIN", 11, 14], ["RBD", "PROTEIN", 15, 18], ["dimer", "PROTEIN", 32, 37], ["2H6", "PROTEIN", 61, 64], ["Fab", "PROTEIN", 65, 68], ["globular structure", "PROTEIN", 147, 165], ["a globular structure", "PROBLEM", 145, 165], ["size", "OBSERVATION_MODIFIER", 103, 107], ["globular structure", "OBSERVATION", 147, 165]]], ["This may imply that the antigen-antibody complex is actually multimeric in nature.", [["antigen-antibody complex", "PROTEIN", 24, 48], ["the antigen-antibody complex", "TEST", 20, 48]]], ["The occurrence of multimeric antigen-antibody complex has been reported in several studies (Sanny and Price, 1997; Santora et al., 2001) .", [["multimeric antigen-antibody complex", "GENE_OR_GENE_PRODUCT", 18, 53], ["multimeric antigen-antibody complex", "PROTEIN", 18, 53], ["multimeric antigen-antibody complex", "PROBLEM", 18, 53], ["multimeric antigen", "OBSERVATION", 18, 36]]], ["However, it cannot be ruled out that the complex does not have a globular structure and hence, show non-ideal chromatographic behavior.", [["non-ideal chromatographic behavior", "PROBLEM", 100, 134], ["globular", "OBSERVATION", 65, 73], ["non-ideal", "OBSERVATION", 100, 109], ["chromatographic behavior", "OBSERVATION", 110, 134]]], ["In-depth studies using more sophisticated biophysical techniques like nuclear magnetic resonance will be needed to get a better insight.NS1(RBD)-T49A substitution mutant exhibited less affinity towards 2H6 antibodyResidues 42-53 in NS1 were previously shown to be required for interaction with 2H6 .", [["NS1", "GENE_OR_GENE_PRODUCT", 136, 139], ["RBD", "GENE_OR_GENE_PRODUCT", 140, 143], ["2H6 antibody", "GENE_OR_GENE_PRODUCT", 202, 214], ["NS1", "GENE_OR_GENE_PRODUCT", 232, 235], ["2H6", "SIMPLE_CHEMICAL", 294, 297], ["NS1", "PROTEIN", 136, 139], ["RBD", "PROTEIN", 140, 143], ["T49A", "PROTEIN", 145, 149], ["2H6 antibody", "PROTEIN", 202, 214], ["NS1", "PROTEIN", 232, 235], ["2H6", "PROTEIN", 294, 297], ["NS1(RBD)", "TEST", 136, 144], ["substitution mutant", "PROBLEM", 150, 169], ["Residues", "TEST", 214, 222]]], ["Since the side-chains of residues S42 and T49 make direct hydrogen bond with the double stranded RNA (dsRNA) backbone and dsRNA binding affinity is reduced by up to 10-fold when either of them is mutated (Cheng et al., 2009) , two substitution mutants, NS1(RBD)-S42A and NS1(RBD)-T49A, were generated.", [["S42", "CHEMICAL", 34, 37], ["hydrogen", "CHEMICAL", 58, 66], ["S42", "AMINO_ACID", 34, 37], ["T49", "AMINO_ACID", 42, 45], ["NS1(RBD)-S42A", "GENE_OR_GENE_PRODUCT", 253, 266], ["NS1(RBD)-T49A", "GENE_OR_GENE_PRODUCT", 271, 284], ["double stranded RNA", "RNA", 81, 100], ["NS1", "PROTEIN", 253, 256], ["RBD", "PROTEIN", 257, 260], ["S42A", "PROTEIN", 262, 266], ["NS1", "PROTEIN", 271, 274], ["RBD", "PROTEIN", 275, 278], ["T49A", "PROTEIN", 280, 284], ["residues S42", "PROBLEM", 25, 37], ["direct hydrogen bond", "TREATMENT", 51, 71], ["the double stranded RNA (dsRNA) backbone", "TREATMENT", 77, 117], ["dsRNA binding affinity", "PROBLEM", 122, 144], ["two substitution mutants", "TEST", 227, 251], ["NS1(RBD)", "TEST", 253, 261], ["NS1(RBD)", "TEST", 271, 279], ["reduced", "OBSERVATION_MODIFIER", 148, 155]]], ["To determine if these residues in NS1 are critical for interaction with 2H6, we performed a comparative ELISA (Fig. 3A) .", [["NS1", "GENE_OR_GENE_PRODUCT", 34, 37], ["NS1", "PROTEIN", 34, 37], ["2H6", "PROTEIN", 72, 75], ["these residues in NS1", "PROBLEM", 16, 37], ["a comparative ELISA", "TEST", 90, 109]]], ["The results show that NS1(RBD) and NS1(RBD)-S42A bound comparably to 2H6 at all the antigen con-centrations tested, while the binding of NS1(RBD)-T49A was significantly decreased when 0.125 or 0.031 lg/mL of protein was used for coating.", [["NS1", "GENE_OR_GENE_PRODUCT", 22, 25], ["NS1(RBD)-S42A", "GENE_OR_GENE_PRODUCT", 35, 48], ["NS1(RBD)-T49A", "GENE_OR_GENE_PRODUCT", 137, 150], ["NS1", "PROTEIN", 22, 25], ["RBD", "PROTEIN", 26, 29], ["NS1", "PROTEIN", 35, 38], ["RBD", "PROTEIN", 39, 42], ["S42A", "PROTEIN", 44, 48], ["2H6", "PROTEIN", 69, 72], ["NS1", "PROTEIN", 137, 140], ["RBD", "PROTEIN", 141, 144], ["T49A", "PROTEIN", 146, 150], ["NS1", "TEST", 22, 25], ["RBD", "TEST", 26, 29], ["NS1(RBD)", "TEST", 35, 43], ["S42A bound", "PROBLEM", 44, 54], ["NS1(RBD)", "TEST", 137, 145], ["protein", "TEST", 208, 215], ["NS1", "OBSERVATION", 22, 25]]], ["No binding to Bovine serum albumin (BSA), which was used as a negative control, was observed.", [["serum", "ANATOMY", 21, 26], ["Bovine", "ORGANISM", 14, 20], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["albumin", "SIMPLE_CHEMICAL", 27, 34], ["BSA", "SIMPLE_CHEMICAL", 36, 39], ["Bovine", "SPECIES", 14, 20], ["Bovine", "SPECIES", 14, 20], ["Bovine serum albumin (BSA", "TEST", 14, 39]]], ["A double substitution mutant NS1(RBD)-R38AK41A was also tested because these two residues, which lie upstream of the 2H6 binding domain, have previously been shown to be important for RNA binding (Wang et al., 1999) .", [["NS1", "PROTEIN", 29, 32], ["RBD", "PROTEIN", 33, 36], ["R38AK41A", "PROTEIN", 38, 46], ["2H6 binding domain", "PROTEIN", 117, 135], ["A double substitution mutant NS1(RBD", "PROBLEM", 0, 36], ["these two residues", "PROBLEM", 71, 89], ["RNA binding", "PROBLEM", 184, 195]]], ["The NS1(RBD)-R38AK41A mutant has similar binding to 2H6 as NS1(RBD) confirming that residues upstream of S42 are not likely to be involved in the interaction.NS1(RBD)-T49A substitution mutant exhibited less affinity towards 2H6 antibodySince T49 appears to play a key role in the NS1(RBD)-2H6 interaction, SPR was next used to compare the 2H6 antibody-binding affinity between NS1(RBD) and NS1(RBD)-T49A.", [["T49", "CHEMICAL", 242, 245], ["NS1", "GENE_OR_GENE_PRODUCT", 4, 7], ["RBD", "GENE_OR_GENE_PRODUCT", 8, 11], ["NS1", "GENE_OR_GENE_PRODUCT", 59, 62], ["S42", "GENE_OR_GENE_PRODUCT", 105, 108], ["NS1", "GENE_OR_GENE_PRODUCT", 158, 161], ["RBD", "GENE_OR_GENE_PRODUCT", 162, 165], ["2H6 antibody", "GENE_OR_GENE_PRODUCT", 224, 236], ["T49", "GENE_OR_GENE_PRODUCT", 242, 245], ["NS1", "GENE_OR_GENE_PRODUCT", 280, 283], ["NS1", "GENE_OR_GENE_PRODUCT", 377, 380], ["NS1(RBD)-T49A", "GENE_OR_GENE_PRODUCT", 390, 403], ["NS1", "PROTEIN", 4, 7], ["RBD", "PROTEIN", 8, 11], ["R38AK41A mutant", "PROTEIN", 13, 28], ["2H6", "PROTEIN", 52, 55], ["NS1", "PROTEIN", 59, 62], ["RBD", "PROTEIN", 63, 66], ["S42", "PROTEIN", 105, 108], ["NS1", "PROTEIN", 158, 161], ["RBD", "PROTEIN", 162, 165], ["T49A", "PROTEIN", 167, 171], ["2H6 antibody", "PROTEIN", 224, 236], ["T49", "PROTEIN", 242, 245], ["NS1", "PROTEIN", 280, 283], ["RBD", "PROTEIN", 284, 287], ["2H6", "PROTEIN", 289, 292], ["2H6 antibody", "PROTEIN", 339, 351], ["NS1", "PROTEIN", 377, 380], ["RBD", "PROTEIN", 381, 384], ["NS1", "PROTEIN", 390, 393], ["RBD", "PROTEIN", 394, 397], ["T49A", "PROTEIN", 399, 403], ["The NS1(RBD", "TEST", 0, 11], ["NS1(RBD)", "TEST", 158, 166], ["substitution mutant", "PROBLEM", 172, 191], ["the 2H6 antibody", "TEST", 335, 351], ["NS1(RBD", "TREATMENT", 377, 384], ["NS1(RBD)", "TEST", 390, 398], ["not likely", "UNCERTAINTY", 113, 123]]], ["2H6 antibody was immobilized on a biosensor chip and various concentrations of NS1(RBD) or NS1(RBD)-T49A were passed through the chip.", [["NS1", "GENE_OR_GENE_PRODUCT", 79, 82], ["2H6 antibody", "PROTEIN", 0, 12], ["NS1", "PROTEIN", 79, 82], ["RBD", "PROTEIN", 83, 86], ["NS1", "PROTEIN", 91, 94], ["RBD", "PROTEIN", 95, 98], ["T49A", "PROTEIN", 100, 104], ["2H6 antibody", "TEST", 0, 12], ["a biosensor chip", "TREATMENT", 32, 48], ["NS1(RBD", "TREATMENT", 79, 86], ["NS1(RBD)", "TEST", 91, 99]]], ["The kinetics of association and dissociation were recorded in SPR sensorgram.", [["dissociation", "PROBLEM", 32, 44], ["SPR sensorgram", "TEST", 62, 76]]], ["The kinetic rate constants kon and koff were determined from the ascending rate of resonance units during association and the descending rate during dissociation.", [["the descending rate during dissociation", "PROBLEM", 122, 161], ["constants kon", "OBSERVATION", 17, 30], ["ascending", "ANATOMY_MODIFIER", 65, 74], ["descending", "OBSERVATION_MODIFIER", 126, 136]]], ["The results show that NS1(RBD) has high affinity to 2H6 with K D of 43.5 \u00b1 4.24 nM (Fig. 3B) whereas NS1(RBD)-T49A has a significantly lower affinity (K D = 12.1 \u00b1 1.28 lM) (Fig. 3C) , indicating that the T49 residue is important for strong binding between NS1 and 2H6.", [["K", "CHEMICAL", 61, 62], ["NS1", "GENE_OR_GENE_PRODUCT", 22, 25], ["K D", "SIMPLE_CHEMICAL", 61, 64], ["NS1", "GENE_OR_GENE_PRODUCT", 101, 104], ["NS1", "GENE_OR_GENE_PRODUCT", 257, 260], ["NS1", "PROTEIN", 22, 25], ["RBD", "PROTEIN", 26, 29], ["2H6", "PROTEIN", 52, 55], ["NS1", "PROTEIN", 101, 104], ["RBD", "PROTEIN", 105, 108], ["T49A", "PROTEIN", 110, 114], ["NS1", "PROTEIN", 257, 260], ["2H6", "PROTEIN", 265, 268], ["NS1(RBD", "TEST", 22, 29], ["high affinity", "PROBLEM", 35, 48], ["K D", "TEST", 61, 64], ["nM", "TEST", 80, 82], ["NS1", "TEST", 101, 104], ["RBD", "TEST", 105, 108], ["a significantly lower affinity", "PROBLEM", 119, 149], ["K D", "TEST", 151, 154], ["the T49 residue", "PROBLEM", 201, 216], ["NS1", "OBSERVATION", 22, 25]]], ["The CD spectrum of NS1(RBD)-T49A reveals that its secondary structure is similar to that of NS1(RBD) (Fig. 1A) , indicating the substitution does not cause gross structural change.Intracellular expression of 2H6 caused a reduction in viral replicationSince 2H6 binds to the RBD of NS1, it may have the ability to inhibit the function of NS1 in the infected cells.", [["Intracellular", "ANATOMY", 180, 193], ["cells", "ANATOMY", 357, 362], ["2H6", "CHEMICAL", 208, 211], ["NS1(RBD)-T49A", "GENE_OR_GENE_PRODUCT", 19, 32], ["NS1(RBD) (Fig. 1A", "GENE_OR_GENE_PRODUCT", 92, 109], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 180, 193], ["2H6", "GENE_OR_GENE_PRODUCT", 208, 211], ["NS1", "GENE_OR_GENE_PRODUCT", 281, 284], ["NS1", "GENE_OR_GENE_PRODUCT", 337, 340], ["cells", "CELL", 357, 362], ["NS1", "PROTEIN", 19, 22], ["RBD", "PROTEIN", 23, 26], ["T49A", "PROTEIN", 28, 32], ["NS1", "PROTEIN", 92, 95], ["RBD", "PROTEIN", 96, 99], ["Fig. 1A", "PROTEIN", 102, 109], ["2H6", "PROTEIN", 208, 211], ["2H6", "PROTEIN", 257, 260], ["RBD", "PROTEIN", 274, 277], ["NS1", "PROTEIN", 281, 284], ["NS1", "PROTEIN", 337, 340], ["infected cells", "CELL_TYPE", 348, 362], ["The CD spectrum", "TEST", 0, 15], ["NS1(RBD)", "TEST", 19, 27], ["NS1", "PROBLEM", 92, 95], ["the substitution", "PROBLEM", 124, 140], ["gross structural change", "PROBLEM", 156, 179], ["a reduction", "TREATMENT", 219, 230], ["viral replication", "TREATMENT", 234, 251], ["NS1", "PROBLEM", 281, 284], ["NS1", "PROBLEM", 337, 340], ["NS1", "OBSERVATION", 19, 22], ["secondary structure", "OBSERVATION", 50, 69], ["structural change", "OBSERVATION", 162, 179], ["reduction", "OBSERVATION_MODIFIER", 221, 230], ["viral replication", "OBSERVATION", 234, 251], ["NS1", "OBSERVATION", 337, 340], ["infected cells", "OBSERVATION", 348, 362]]], ["To express 2H6 intracellularly, the 2H6-scFv gene was cloned in a mammalian expression plasmid and transiently transfected into A549 cells.", [["plasmid", "ANATOMY", 87, 94], ["A549 cells", "ANATOMY", 128, 138], ["2H6", "GENE_OR_GENE_PRODUCT", 11, 14], ["2H6-scFv", "GENE_OR_GENE_PRODUCT", 36, 44], ["A549 cells", "CELL", 128, 138], ["2H6", "PROTEIN", 11, 14], ["2H6-scFv gene", "DNA", 36, 49], ["mammalian expression plasmid", "DNA", 66, 94], ["A549 cells", "CELL_LINE", 128, 138], ["the 2H6-scFv gene", "TREATMENT", 32, 49], ["a mammalian expression plasmid", "TREATMENT", 64, 94], ["A549 cells", "OBSERVATION", 128, 138]]], ["After 48 h, the cells were inoculated with 0.01 MOI of PR8 virus and the amount of virus secreted was determined by plaque quantitation at 12, 24, and 48 h post infection (hpi).", [["cells", "ANATOMY", 16, 21], ["plaque", "ANATOMY", 116, 122], ["infection", "DISEASE", 161, 170], ["cells", "CELL", 16, 21], ["PR8 virus", "ORGANISM", 55, 64], ["PR8 virus", "SPECIES", 55, 64], ["the cells", "PROBLEM", 12, 21], ["PR8 virus", "TREATMENT", 55, 64], ["virus secreted", "PROBLEM", 83, 97], ["plaque quantitation", "TEST", 116, 135], ["infection", "PROBLEM", 161, 170], ["amount", "OBSERVATION_MODIFIER", 73, 79], ["virus", "OBSERVATION", 83, 88], ["plaque", "OBSERVATION", 116, 122], ["infection", "OBSERVATION", 161, 170]]], ["As shown in Fig. 4A , the viral growth in the 2H6-scFv transfected A549 cells was reduced by approximately 0.5 log PFU/mL at 24 and 48 hpi when compared to cells transfected with vector only.", [["A549 cells", "ANATOMY", 67, 77], ["cells", "ANATOMY", 156, 161], ["2H6", "GENE_OR_GENE_PRODUCT", 46, 49], ["A549 cells", "CELL", 67, 77], ["cells", "CELL", 156, 161], ["2H6-scFv transfected A549 cells", "CELL_LINE", 46, 77], ["the viral growth", "TEST", 22, 38], ["A549 cells", "TEST", 67, 77], ["viral", "OBSERVATION_MODIFIER", 26, 31], ["growth", "OBSERVATION_MODIFIER", 32, 38]]], ["To determine if viral inhibition by 2H6-scFv is specific, the scFv of an irrelevant antibody 7G12, which binds to the spike protein of SARS coronavirus (Lip et al., 2006) , was also used in this experiment.", [["SARS coronavirus", "DISEASE", 135, 151], ["2H6-scFv", "GENE_OR_GENE_PRODUCT", 36, 44], ["7G12", "GENE_OR_GENE_PRODUCT", 93, 97], ["SARS coronavirus", "ORGANISM", 135, 151], ["2H6", "PROTEIN", 36, 39], ["scFv", "PROTEIN", 40, 44], ["scFv", "PROTEIN", 62, 66], ["7G12", "PROTEIN", 93, 97], ["spike protein", "PROTEIN", 118, 131], ["SARS coronavirus", "SPECIES", 135, 151], ["viral inhibition", "PROBLEM", 16, 32], ["the scFv", "TEST", 58, 66], ["an irrelevant antibody", "TEST", 70, 92], ["the spike protein", "TEST", 114, 131], ["SARS coronavirus", "PROBLEM", 135, 151]]], ["The viral growth in the 7G12-scFv transfected A549 cells did not show reduction when compared to cells transfected with vector only.Intracellular expression of 2H6 caused a reduction in viral replicationAs only $50% of the A549 cells were transfected (data not shown), the experiment was repeated using the highly transfectable 293T cells.", [["A549 cells", "ANATOMY", 46, 56], ["cells", "ANATOMY", 97, 102], ["Intracellular", "ANATOMY", 132, 145], ["A549 cells", "ANATOMY", 223, 233], ["293T cells", "ANATOMY", 328, 338], ["2H6", "CHEMICAL", 160, 163], ["A549 cells", "CELL", 46, 56], ["cells", "CELL", 97, 102], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 132, 145], ["2H6", "GENE_OR_GENE_PRODUCT", 160, 163], ["A549 cells", "CELL", 223, 233], ["293T cells", "CELL", 328, 338], ["7G12-scFv transfected A549 cells", "CELL_LINE", 24, 56], ["2H6", "PROTEIN", 160, 163], ["A549 cells", "CELL_LINE", 223, 233], ["highly transfectable 293T cells", "CELL_LINE", 307, 338], ["The viral growth", "TEST", 0, 16], ["a reduction", "TREATMENT", 171, 182], ["viral replicationAs", "TREATMENT", 186, 205], ["the A549 cells", "PROBLEM", 219, 233], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["growth", "OBSERVATION_MODIFIER", 10, 16], ["reduction", "OBSERVATION_MODIFIER", 173, 182], ["viral", "OBSERVATION_MODIFIER", 186, 191], ["A549 cells", "OBSERVATION", 223, 233], ["293T cells", "OBSERVATION", 328, 338]]], ["Following that, the cells were infected with 2 MOI of PR8 and harvested at 4, 8, and 12 hpi for western blot analysis.", [["cells", "ANATOMY", 20, 25], ["cells", "CELL", 20, 25], ["PR8", "ORGANISM", 54, 57], ["PR8", "SPECIES", 54, 57], ["PR8", "TREATMENT", 54, 57], ["western blot analysis", "TEST", 96, 117]]], ["Consistent with the results obtained in A549 cells, the level of the M1 viral protein in the infected cells was significantly reduced in 2H6-scFv transfected cells when compared to the vector or 7G12-scFv transfected cells at 12 hpi ( Fig. 4B and C) .", [["A549 cells", "ANATOMY", 40, 50], ["cells", "ANATOMY", 102, 107], ["cells", "ANATOMY", 158, 163], ["cells", "ANATOMY", 217, 222], ["A549 cells", "CELL", 40, 50], ["M1", "GENE_OR_GENE_PRODUCT", 69, 71], ["cells", "CELL", 102, 107], ["cells", "CELL", 158, 163], ["cells", "CELL", 217, 222], ["A549 cells", "CELL_LINE", 40, 50], ["M1 viral protein", "PROTEIN", 69, 85], ["infected cells", "CELL_TYPE", 93, 107], ["2H6-scFv transfected cells", "CELL_LINE", 137, 163], ["7G12", "PROTEIN", 195, 199], ["scFv transfected cells", "CELL_LINE", 200, 222], ["the M1 viral protein", "TEST", 65, 85], ["the infected cells", "PROBLEM", 89, 107], ["the vector", "TEST", 181, 191], ["M1", "ANATOMY", 69, 71], ["infected cells", "OBSERVATION", 93, 107], ["reduced", "OBSERVATION_MODIFIER", 126, 133]]], ["The average reduction in normalized M1 expression in 2H6-scFv transfected cells when compared to vector and 7G12-scFv transfected cells at 12 hpi is 27% and 49% respectively.", [["cells", "ANATOMY", 74, 79], ["cells", "ANATOMY", 130, 135], ["2H6-scFv", "GENE_OR_GENE_PRODUCT", 53, 61], ["cells", "CELL", 74, 79], ["7G12-scFv", "GENE_OR_GENE_PRODUCT", 108, 117], ["cells", "CELL", 130, 135], ["M1", "PROTEIN", 36, 38], ["2H6-scFv transfected cells", "CELL_LINE", 53, 79], ["7G12-scFv transfected cells", "CELL_LINE", 108, 135], ["The average reduction", "TREATMENT", 0, 21], ["vector", "TEST", 97, 103], ["average", "OBSERVATION_MODIFIER", 4, 11], ["reduction", "OBSERVATION_MODIFIER", 12, 21], ["normalized", "OBSERVATION_MODIFIER", 25, 35], ["M1 expression", "OBSERVATION", 36, 49]]], ["These results suggest that the binding of 2H6 to NS1 could hinder the role of NS1 in infection and cause a reduction in viral replication and release.ConclusionOur results show that the murine mAb 2H6 binds tightly to the NS1 protein and the affinity of this interaction is significantly reduced when T49 is substituted by A. When the 2H6-scFv is expressed intracellularly, it binds to NS1 expressed in the infected cells and caused a significant reduction in viral protein expression and release of progeny virus.", [["cells", "ANATOMY", 416, 421], ["infection", "DISEASE", 85, 94], ["2H6", "GENE_OR_GENE_PRODUCT", 42, 45], ["NS1", "GENE_OR_GENE_PRODUCT", 49, 52], ["NS1", "GENE_OR_GENE_PRODUCT", 78, 81], ["murine", "ORGANISM", 186, 192], ["mAb 2H6", "GENE_OR_GENE_PRODUCT", 193, 200], ["NS1", "GENE_OR_GENE_PRODUCT", 222, 225], ["2H6", "GENE_OR_GENE_PRODUCT", 335, 338], ["scFv", "GENE_OR_GENE_PRODUCT", 339, 343], ["NS1", "GENE_OR_GENE_PRODUCT", 386, 389], ["cells", "CELL", 416, 421], ["progeny virus", "ORGANISM", 500, 513], ["2H6", "PROTEIN", 42, 45], ["NS1", "PROTEIN", 49, 52], ["NS1", "PROTEIN", 78, 81], ["murine mAb 2H6", "PROTEIN", 186, 200], ["NS1 protein", "PROTEIN", 222, 233], ["T49", "PROTEIN", 301, 304], ["2H6", "PROTEIN", 335, 338], ["scFv", "PROTEIN", 339, 343], ["NS1", "PROTEIN", 386, 389], ["infected cells", "CELL_TYPE", 407, 421], ["murine", "SPECIES", 186, 192], ["NS1", "TREATMENT", 49, 52], ["NS1 in infection", "PROBLEM", 78, 94], ["a reduction", "TREATMENT", 105, 116], ["viral replication", "TREATMENT", 120, 137], ["the murine mAb", "TREATMENT", 182, 196], ["the NS1 protein", "TEST", 218, 233], ["the 2H6-scFv", "TREATMENT", 331, 343], ["NS1", "PROBLEM", 386, 389], ["the infected cells", "PROBLEM", 403, 421], ["a significant reduction in viral protein expression", "PROBLEM", 433, 484], ["progeny virus", "PROBLEM", 500, 513], ["infection", "OBSERVATION", 85, 94], ["reduction", "OBSERVATION_MODIFIER", 107, 116], ["viral replication", "OBSERVATION", 120, 137], ["infected cells", "OBSERVATION", 407, 421], ["significant", "OBSERVATION_MODIFIER", 435, 446], ["reduction", "OBSERVATION_MODIFIER", 447, 456], ["viral protein expression", "OBSERVATION", 460, 484], ["progeny virus", "OBSERVATION", 500, 513]]], ["Since the side-chains of T49 are involved in RNA binding (Cheng et al., 2009) , it is likely that the binding of 2H6 has a negative impact on the ability of NS1 to bind to RNA and hence, resulting in a reduction of viral replication.", [["2H6", "CHEMICAL", 113, 116], ["T49", "GENE_OR_GENE_PRODUCT", 25, 28], ["2H6", "GENE_OR_GENE_PRODUCT", 113, 116], ["NS1", "GENE_OR_GENE_PRODUCT", 157, 160], ["T49", "PROTEIN", 25, 28], ["2H6", "PROTEIN", 113, 116], ["NS1", "PROTEIN", 157, 160], ["NS1", "TREATMENT", 157, 160], ["viral replication", "TREATMENT", 215, 232], ["viral replication", "OBSERVATION", 215, 232]]], ["NS1 is a viable drug target as it is involved in various processes that are crucial for viral replication and propagation (Hale et al., 2008) .", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS1", "PROTEIN", 0, 3], ["NS1", "PROBLEM", 0, 3], ["viral replication", "PROBLEM", 88, 105]]], ["In the past, few small chemical compounds have been shown to inhibit both NS1 function and virus replication (Basu et al., 2009; Walkiewicz et al., 2011) .", [["NS1", "GENE_OR_GENE_PRODUCT", 74, 77], ["NS1", "PROTEIN", 74, 77], ["few small chemical compounds", "PROBLEM", 13, 41], ["few", "OBSERVATION_MODIFIER", 13, 16], ["small", "OBSERVATION_MODIFIER", 17, 22], ["chemical compounds", "OBSERVATION", 23, 41]]], ["But the precise mechanisms of action of these chemical compounds are still unknown and remain to be elucidated.", [["these chemical compounds", "PROBLEM", 40, 64], ["chemical compounds", "OBSERVATION", 46, 64]]], ["Earlier, the function of CPSF30 binding site of the NS1 has been shown to be inhibited by the second and third zinc fingers (F2F3), a 61 residues fragment of CPSF30, resulting in the inhibition of IAV replication without detectable effects on cellular functions (Twu et al., 2006) .", [["cellular", "ANATOMY", 243, 251], ["zinc", "CHEMICAL", 111, 115], ["CPSF30", "GENE_OR_GENE_PRODUCT", 25, 31], ["NS1", "GENE_OR_GENE_PRODUCT", 52, 55], ["CPSF30", "GENE_OR_GENE_PRODUCT", 158, 164], ["IAV", "ORGANISM", 197, 200], ["cellular", "CELL", 243, 251], ["CPSF30 binding site", "DNA", 25, 44], ["NS1", "PROTEIN", 52, 55], ["zinc fingers", "PROTEIN", 111, 123], ["F2F3", "PROTEIN", 125, 129], ["61 residues fragment", "PROTEIN", 134, 154], ["CPSF30", "PROTEIN", 158, 164], ["IAV", "SPECIES", 197, 200], ["CPSF30 binding site", "PROBLEM", 25, 44], ["the NS1", "PROBLEM", 48, 55], ["a 61 residues fragment of CPSF30", "PROBLEM", 132, 164], ["IAV replication", "TREATMENT", 197, 212], ["NS1", "OBSERVATION", 52, 55], ["third", "ANATOMY_MODIFIER", 105, 110], ["zinc fingers", "ANATOMY", 111, 123], ["IAV replication", "OBSERVATION", 197, 212]]], ["Our approach of expressing 2H6-scFv in the cells to block IAV replication during infection is similar to their method of expressing F2F3 intracellularly to bind NS1 and inhibit its interaction with CPSF30.", [["cells", "ANATOMY", 43, 48], ["infection", "DISEASE", 81, 90], ["2H6-scFv", "GENE_OR_GENE_PRODUCT", 27, 35], ["cells", "CELL", 43, 48], ["IAV", "ORGANISM", 58, 61], ["F2F3", "GENE_OR_GENE_PRODUCT", 132, 136], ["NS1", "GENE_OR_GENE_PRODUCT", 161, 164], ["CPSF30", "GENE_OR_GENE_PRODUCT", 198, 204], ["2H6", "PROTEIN", 27, 30], ["scFv", "PROTEIN", 31, 35], ["F2F3", "PROTEIN", 132, 136], ["NS1", "PROTEIN", 161, 164], ["CPSF30", "PROTEIN", 198, 204], ["IAV", "SPECIES", 58, 61], ["expressing 2H6-scFv in the cells", "TREATMENT", 16, 48], ["block IAV replication", "TREATMENT", 52, 73], ["infection", "PROBLEM", 81, 90], ["CPSF30", "TREATMENT", 198, 204], ["infection", "OBSERVATION", 81, 90]]], ["Interestingly, a recent publication has also reported the abilities of 3 NS1 specific-human scFvs to inhibit replication of influenza A virus (Yodsheewan et al., 2013) .", [["influenza A", "DISEASE", 124, 135], ["NS1", "GENE_OR_GENE_PRODUCT", 73, 76], ["human", "ORGANISM", 86, 91], ["scFvs", "GENE_OR_GENE_PRODUCT", 92, 97], ["influenza A virus", "ORGANISM", 124, 141], ["NS1", "PROTEIN", 73, 76], ["human scFvs", "PROTEIN", 86, 97], ["human", "SPECIES", 86, 91], ["influenza A virus", "SPECIES", 124, 141], ["human", "SPECIES", 86, 91], ["influenza A virus", "SPECIES", 124, 141], ["human scFvs", "TREATMENT", 86, 97], ["influenza A virus", "PROBLEM", 124, 141]]], ["However, the mechanisms of binding are different as they bound to residues 7-18, 75-90 and 179-190 of NS1, respectively.ConclusionThese studies open up a new opportunity to restrict viral replication by targeting different NS1 domains via different modes of inhibition.", [["NS1", "GENE_OR_GENE_PRODUCT", 102, 105], ["NS1", "GENE_OR_GENE_PRODUCT", 223, 226], ["NS1", "PROTEIN", 102, 105], ["NS1 domains", "PROTEIN", 223, 234], ["These studies", "TEST", 130, 143], ["viral replication", "TREATMENT", 182, 199], ["different NS1 domains", "TREATMENT", 213, 234], ["different modes of inhibition", "TREATMENT", 239, 268]]], ["In future studies, it will be important to use a combination of different NS1 inhibiting molecules to determine if this can increase the potency of viral inhibition and/or minimize the chance of viral escape both in vitro and in vivo.", [["NS1", "GENE_OR_GENE_PRODUCT", 74, 77], ["NS1", "PROTEIN", 74, 77], ["future studies", "TEST", 3, 17], ["different NS1 inhibiting molecules", "TREATMENT", 64, 98], ["viral inhibition", "TREATMENT", 148, 164], ["viral escape", "PROBLEM", 195, 207], ["viral escape", "OBSERVATION", 195, 207]]], ["Delivery of antibody or scFv into the cells is an important aspect of antiviral therapy.", [["cells", "ANATOMY", 38, 43], ["scFv", "GENE_OR_GENE_PRODUCT", 24, 28], ["cells", "CELL", 38, 43], ["antibody", "PROTEIN", 12, 20], ["scFv", "PROTEIN", 24, 28], ["Delivery", "TREATMENT", 0, 8], ["antibody or scFv into the cells", "PROBLEM", 12, 43], ["antiviral therapy", "TREATMENT", 70, 87], ["antiviral therapy", "OBSERVATION", 70, 87]]], ["Thus, viral expression vectors such as adenovirus or lentivirus can be used for 2H6-scFv delivery.", [["adenovirus", "ORGANISM", 39, 49], ["lentivirus", "ORGANISM", 53, 63], ["2H6-scFv", "GENE_OR_GENE_PRODUCT", 80, 88], ["2H6", "PROTEIN", 80, 83], ["scFv", "PROTEIN", 84, 88], ["adenovirus", "SPECIES", 39, 49], ["lentivirus", "SPECIES", 53, 63], ["viral expression vectors", "TREATMENT", 6, 30], ["adenovirus or lentivirus", "TREATMENT", 39, 63], ["2H6-scFv delivery", "TREATMENT", 80, 97]]], ["Moreover, cytoplasmic transduction peptide (CTP), a stretch of basic residues, has been extensively documented for its efficient delivery of biomolecules (Gump and Dowdy, 2007; Kim et al., 2006) .", [["cytoplasmic", "ANATOMY", 10, 21], ["CTP", "CHEMICAL", 44, 47], ["cytoplasmic", "ORGANISM_SUBSTANCE", 10, 21], ["CTP", "SIMPLE_CHEMICAL", 44, 47], ["cytoplasmic transduction peptide", "TEST", 10, 42], ["CTP", "TEST", 44, 47], ["a stretch of basic residues", "PROBLEM", 50, 77], ["stretch", "OBSERVATION_MODIFIER", 52, 59], ["basic residues", "OBSERVATION", 63, 77]]], ["Recently, hepatitis B virus replication has been reported to be inhibited by intracellular delivery of scFv against core protein via CTP (Xun et al., 2013) .", [["intracellular", "ANATOMY", 77, 90], ["hepatitis B", "DISEASE", 10, 21], ["CTP", "CHEMICAL", 133, 136], ["hepatitis B virus", "ORGANISM", 10, 27], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 90], ["scFv", "GENE_OR_GENE_PRODUCT", 103, 107], ["CTP", "SIMPLE_CHEMICAL", 133, 136], ["scFv", "PROTEIN", 103, 107], ["core protein", "PROTEIN", 116, 128], ["hepatitis B virus", "SPECIES", 10, 27], ["hepatitis B virus", "SPECIES", 10, 27], ["hepatitis B virus replication", "TREATMENT", 10, 39], ["intracellular delivery of scFv", "TREATMENT", 77, 107], ["CTP", "TEST", 133, 136]]], ["As an alternative to viral expression vectors, 2H6-scFv can be fused with CTP for the efficient cytoplasmic translocation of the scFv into the cells.", [["cytoplasmic", "ANATOMY", 96, 107], ["cells", "ANATOMY", 143, 148], ["CTP", "CHEMICAL", 74, 77], ["CTP", "CHEMICAL", 74, 77], ["2H6-scFv", "GENE_OR_GENE_PRODUCT", 47, 55], ["CTP", "SIMPLE_CHEMICAL", 74, 77], ["cytoplasmic", "ORGANISM_SUBSTANCE", 96, 107], ["scFv", "GENE_OR_GENE_PRODUCT", 129, 133], ["cells", "CELL", 143, 148], ["viral expression vectors", "DNA", 21, 45], ["2H6", "PROTEIN", 47, 50], ["scFv", "PROTEIN", 51, 55], ["scFv", "PROTEIN", 129, 133], ["viral expression vectors", "TREATMENT", 21, 45], ["2H6-scFv", "TREATMENT", 47, 55], ["CTP", "TEST", 74, 77], ["cytoplasmic translocation", "OBSERVATION", 96, 121], ["scFv", "ANATOMY", 129, 133], ["cells", "ANATOMY", 143, 148]]], ["The expression levels of M1 were showed in graphs after normalization with actin.", [["M1", "GENE_OR_GENE_PRODUCT", 25, 27], ["actin", "GENE_OR_GENE_PRODUCT", 75, 80], ["M1", "PROTEIN", 25, 27], ["actin", "PROTEIN", 75, 80], ["The expression levels", "TEST", 0, 21], ["actin", "TREATMENT", 75, 80]]], ["All experiments were performed in triplicate, and the average values with standard deviations are plotted.", [["All experiments", "TEST", 0, 15]]], ["Differences in M1 expression between 2H6-scFv and vector transfected cells or between 2H6-scFv and 7G12-scFv transfected cells were evaluated by unpaired t-test ( \u2044 , p < 0.05; \u2044\u2044\u2044 , p < 0.001).", [["cells", "ANATOMY", 69, 74], ["cells", "ANATOMY", 121, 126], ["M1", "GENE_OR_GENE_PRODUCT", 15, 17], ["2H6-scFv", "GENE_OR_GENE_PRODUCT", 37, 45], ["cells", "CELL", 69, 74], ["2H6-scFv", "GENE_OR_GENE_PRODUCT", 86, 94], ["7G12-scFv", "GENE_OR_GENE_PRODUCT", 99, 108], ["cells", "CELL", 121, 126], ["M1", "PROTEIN", 15, 17], ["2H6", "PROTEIN", 37, 40], ["scFv", "PROTEIN", 41, 45], ["vector transfected cells", "CELL_LINE", 50, 74], ["2H6", "PROTEIN", 86, 89], ["scFv", "PROTEIN", 90, 94], ["7G12", "PROTEIN", 99, 103], ["scFv transfected cells", "CELL_LINE", 104, 126], ["p", "TEST", 167, 168], ["\u2044\u2044\u2044", "TEST", 177, 180]]]], "8412ff05f4f1282ea7dafd7125bc3f4c80d977ee": [["7, 8 Most importantly, from a veterinary standpoint, camelids and ruminants differ in susceptibility to infectious and parasitic diseases.", [["infectious and parasitic diseases", "DISEASE", 104, 137], ["parasitic diseases", "PROBLEM", 119, 137], ["infectious", "OBSERVATION_MODIFIER", 104, 114], ["parasitic diseases", "OBSERVATION", 119, 137]]], ["The differences between camelids and ruminants should exclude camelids from being classified as ruminants.", [["camelids", "PROBLEM", 62, 70]]], ["Camelids have consistently been subjected to sudden, adverse regulations (some inappropriate) when an emerging disease of livestock appears on the scene.CLASSIFICATION AND EVOLUTIONThe closing of the Canadian border to camelids when bovine spongiform encephalitis was diagnosed in a cow in Alberta, Canada, is a case in point.", [["bovine spongiform encephalitis", "DISEASE", 233, 263], ["bovine spongiform encephalitis", "ORGANISM", 233, 263], ["bovine", "SPECIES", 233, 239], ["cow", "SPECIES", 283, 286], ["bovine spongiform encephalitis", "PROBLEM", 233, 263], ["disease", "OBSERVATION", 111, 118], ["spongiform", "OBSERVATION_MODIFIER", 240, 250], ["encephalitis", "OBSERVATION", 251, 263]]], ["The fact that camelids have never been diagnosed with any of the transmissible spongiform encephalopathies anywhere in the world (and are not ruminants) was not given proper consideration.CLASSIFICATION AND EVOLUTIONWhen questioned about that action, the response was that ruminants are defined by an \"encyclopedia\" as animals that chew a cud, are cloven hoofed, and have three-or four-chambered stomachs.", [["stomachs", "ANATOMY", 396, 404], ["spongiform encephalopathies", "DISEASE", 79, 106], ["camelids", "CANCER", 14, 22], ["stomachs", "ORGAN", 396, 404], ["the transmissible spongiform encephalopathies", "PROBLEM", 61, 106], ["transmissible", "OBSERVATION_MODIFIER", 65, 78], ["spongiform", "OBSERVATION_MODIFIER", 79, 89], ["encephalopathies", "OBSERVATION", 90, 106], ["stomachs", "ANATOMY", 396, 404]]], ["Regulators completely disregarded the scientific literature that clearly shows that foregut fermentation, complex multicompartmentalized stomachs, food regurgitation, and rechewing are not limited to \"ruminants\" but are found in species as diverse as kangaroos and nonhuman primates.", [["foregut", "ANATOMY", 84, 91], ["stomachs", "ANATOMY", 137, 145], ["food regurgitation", "DISEASE", 147, 165], ["foregut", "ORGANISM_SUBDIVISION", 84, 91], ["stomachs", "MULTI-TISSUE_STRUCTURE", 137, 145], ["kangaroos", "ORGANISM", 251, 260], ["nonhuman primates", "ORGANISM", 265, 282], ["foregut fermentation", "PROBLEM", 84, 104], ["complex multicompartmentalized stomachs", "PROBLEM", 106, 145], ["food regurgitation", "PROBLEM", 147, 165], ["stomachs", "ANATOMY", 137, 145], ["food regurgitation", "OBSERVATION", 147, 165]]], ["13 In kangaroos, regurgitation and rechewing is referred to as merycism (Greek, \"chewing the cud\").", [["kangaroos", "ORGANISM", 6, 15], ["regurgitation", "PROBLEM", 17, 30], ["regurgitation", "OBSERVATION", 17, 30]]], ["Foregut fermentation and multicompartmented stomachs are also seen in many species,WHY BE CONCERNED?The risk of emerging, reemerging, foreign, and intentionally introduced animal disease is real, and many perceive this as a growing problem.", [["stomachs", "ANATOMY", 44, 52], ["animal disease", "DISEASE", 172, 186], ["stomachs", "ORGAN", 44, 52], ["Foregut fermentation", "TREATMENT", 0, 20], ["multicompartmented stomachs", "PROBLEM", 25, 52], ["animal disease", "PROBLEM", 172, 186], ["stomachs", "ANATOMY", 44, 52], ["foreign", "OBSERVATION", 134, 141]]], ["The understanding of animal-human pathogen relationships relies on scientific information about various species and populations of animals.", [["human", "ORGANISM", 28, 33], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33]]], ["National regulatory statutes that provide disease protection between animals and humans must be current and must utilize up-to-date scientific data to protect human health and our food supply while not jeopardizing or overregulating any one animal.WHY BE CONCERNED?In the United States, the U.S. Department of Agriculture (USDA), the Department of the Interior (DOI), and the Department of Homeland Security (DHS) are the federal agencies tasked with protecting the nation's wildlife, livestock industries, companion animals, human population, and the food supply from disease.", [["DOI", "CHEMICAL", 362, 365], ["humans", "ORGANISM", 81, 87], ["human", "ORGANISM", 159, 164], ["human", "ORGANISM", 526, 531], ["humans", "SPECIES", 81, 87], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 526, 531], ["humans", "SPECIES", 81, 87], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 526, 531], ["disease protection", "TREATMENT", 42, 60], ["disease", "PROBLEM", 569, 576]]], ["The need for regulations has become more acute with the advent of modern transportation systems that allow movement of animals from any part of the world in a matter of hours.", [["modern transportation systems", "TREATMENT", 66, 95], ["acute", "OBSERVATION_MODIFIER", 41, 46]]], ["Also, our animal and human populations, along with the U.S. food supply, will now and always need to be protected against the threat of intentionally introduced animal and human disease because bioterrorism will remain a threat.WHY BE CONCERNED?In a late December 2003 news conference, then-Secretary of Agriculture Ann Veneman made the following statement while talking about a case of bovine spongiform encephalopathy that had been diagnosed Dec. 23, 2003 , in a cow in the state of Washington: \"The USDA has a primary goal of using science as the basis for decisions involving livestock health matters.\"WHY BE CONCERNED?It is not clear that all federal regulatory officials always use known science to draft regulations and apply them to risk situations.", [["bovine spongiform encephalopathy", "DISEASE", 387, 419], ["human", "ORGANISM", 21, 26], ["human", "ORGANISM", 172, 177], ["bovine", "ORGANISM", 387, 393], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 172, 177], ["bovine", "SPECIES", 387, 393], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 172, 177], ["human disease", "PROBLEM", 172, 185], ["bovine spongiform encephalopathy", "PROBLEM", 387, 419], ["not", "UNCERTAINTY", 629, 632], ["clear", "OBSERVATION_MODIFIER", 633, 638]]], ["Current scientific including the hippopotamus, kangaroo, colobus monkey, and peccary.", [["hippopotamus", "ANATOMY", 33, 45], ["colobus monkey", "ANATOMY", 57, 71], ["kangaroo", "ORGANISM", 47, 55], ["colobus monkey", "ORGANISM", 57, 71], ["colobus monkey", "SPECIES", 57, 71], ["colobus monkey", "SPECIES", 57, 71], ["hippopotamus", "ANATOMY", 33, 45], ["colobus monkey", "OBSERVATION", 57, 71]]], ["4 Modern paleontologic and taxonomic scientists clearly state that camelids belong in a separate suborder Tylopoda (Latin, \"padded foot\") in the order Artiodactyla, which is distinct from the suborder Ruminantia* (Box 46-1).WHY BE CONCERNED?Camelid evolution began in North America 40 to 50 million years ago in the early Eocene epoch.", [["foot", "ORGANISM_SUBDIVISION", 131, 135], ["foot", "ANATOMY", 131, 135], ["distinct", "OBSERVATION_MODIFIER", 174, 182], ["early", "OBSERVATION_MODIFIER", 316, 321], ["Eocene epoch", "OBSERVATION", 322, 334]]], ["6, 7 Separation of the Tylopoda and Ruminantia occurred early in the evolutionary process, when the progenitors of both groups were small goat-sized animals with simple stomachs.", [["progenitors", "ANATOMY", 100, 111], ["stomachs", "ANATOMY", 169, 177], ["progenitors", "CELL", 100, 111], ["stomachs", "ORGAN", 169, 177], ["goat", "SPECIES", 138, 142], ["the Tylopoda and Ruminantia", "PROBLEM", 19, 46], ["simple stomachs", "PROBLEM", 162, 177], ["Ruminantia", "OBSERVATION_MODIFIER", 36, 46], ["small", "OBSERVATION_MODIFIER", 132, 137], ["sized", "OBSERVATION_MODIFIER", 143, 148], ["simple", "OBSERVATION_MODIFIER", 162, 168], ["stomachs", "ANATOMY", 169, 177]]], ["33 Tylopods and ruminants continued to evolve by what is known as parallel evolution, which is the development of similarities in separate but related evolutionary lineages through the operation of similar selective factors acting on both lines 6, 7, 33 (Figure 46-1) .WHY BE CONCERNED?The Pleistocene epoch was characterized by a series of periods of extreme cold and glaciations in northern North America and Europe.", [["selective factors", "PROTEIN", 206, 223], ["the operation", "TREATMENT", 181, 194], ["extreme cold and glaciations", "PROBLEM", 352, 380], ["selective", "OBSERVATION_MODIFIER", 206, 215], ["Pleistocene epoch", "OBSERVATION", 290, 307]]], ["The last glacial retreat occurred about 10,000 years ago, marking the beginning of the Recent epoch.WHY BE CONCERNED?Asia and Alaska are now separated by the 90-km (56-mile)-wide Bering Strait.", [["glacial", "OBSERVATION_MODIFIER", 9, 16], ["retreat", "OBSERVATION_MODIFIER", 17, 24], ["epoch", "OBSERVATION", 94, 99]]], ["However, during the height of one of the early Pleistocene glacial periods, the sea level was lowered sufficiently to expose a wide land bridge.", [["the early Pleistocene glacial periods", "TREATMENT", 37, 74], ["the sea level", "TEST", 76, 89], ["a wide land bridge", "TREATMENT", 125, 143], ["Pleistocene", "OBSERVATION_MODIFIER", 47, 58], ["glacial periods", "OBSERVATION", 59, 74]]], ["Plant and animal species moved back and forth across this bridge; the camel line of Camelidae migrated from North America into Asia, where the evolutionary process continued and domestication took place.WHY BE CONCERNED?Progenitors of the South American camelids (SACs) (guanaco, vicu\u00f1a, llama, and alpaca) migrated to South America at the beginning of the Pleistocene epoch (~3 million years ago), when an open land connection between North and South America developed.", [["SACs", "ANATOMY", 264, 268], ["Camelidae", "GENE_OR_GENE_PRODUCT", 84, 93], ["SACs", "CANCER", 264, 268], ["guanaco, vicu\u00f1a", "ORGANISM", 271, 286], ["llama", "ORGANISM", 288, 293], ["alpaca", "ORGANISM", 299, 305], ["llama", "SPECIES", 288, 293], ["animal species", "PROBLEM", 10, 24], ["llama", "ANATOMY", 288, 293], ["Pleistocene epoch", "OBSERVATION", 357, 374]]], ["6 Evolution continued in South America, where llama and alpaca were domesticated.", [["llama", "ORGANISM", 46, 51], ["alpaca", "ORGANISM", 56, 62], ["llama", "SPECIES", 46, 51], ["llama", "ANATOMY", 46, 51]]], ["9,10,35DIFFERENCES BETWEEN CAMELIDS AND RUMINANTSAnatomic and physiologic differences between camelids and ruminants abound (Table 46-1) .DIFFERENCES BETWEEN CAMELIDS AND RUMINANTSSusceptibility to infectious and parasitic agents is of greater concern.", [["infectious and parasitic agents", "DISEASE", 198, 229], ["physiologic differences between camelids", "PROBLEM", 62, 102], ["infectious", "PROBLEM", 198, 208], ["parasitic agents", "TREATMENT", 213, 229], ["physiologic", "OBSERVATION_MODIFIER", 62, 73], ["differences", "OBSERVATION_MODIFIER", 74, 85], ["infectious", "OBSERVATION", 198, 208]]], ["The USDA Animal and Plant Health Inspection Service (APHIS) has stated that camelids should be classified as ruminants because, \"regardless of their taxonomic classification, camelids meet the definition of ruminants and are regulated as ruminants based on their susceptibility to ruminant diseases such as foot and mouth disease, tuberculosis (Mycobacterium bovis, M. tuberculosis, and M. avium), brucellosis, Johne's disease, etc.\" 11 It is true that there are diseases that camelids, cattle, sheep, and goats all acquire, but a careful appraisal of Tables 46-2 through 46-9 should dispel the myth that Text continued on page 383Differences Between Camelids and Ruminants South American Camelids RuminantsEvolutionary pathways Diverged 40 million years ago.", [["foot", "ANATOMY", 307, 311], ["mouth", "ANATOMY", 316, 321], ["ruminant diseases", "DISEASE", 281, 298], ["foot and mouth disease", "DISEASE", 307, 329], ["tuberculosis", "DISEASE", 331, 343], ["Mycobacterium bovis, M. tuberculosis", "DISEASE", 345, 381], ["M. avium)", "DISEASE", 387, 396], ["brucellosis", "DISEASE", 398, 409], ["Johne's disease", "DISEASE", 411, 426], ["camelids", "DISEASE", 477, 485], ["foot", "ORGANISM_SUBDIVISION", 307, 311], ["mouth", "ORGANISM_SUBDIVISION", 316, 321], ["Mycobacterium bovis", "ORGANISM", 345, 364], ["M. tuberculosis", "ORGANISM", 366, 381], ["M. avium", "ORGANISM", 387, 395], ["sheep", "ORGANISM", 495, 500], ["goats", "ORGANISM", 506, 511], ["Mycobacterium bovis", "SPECIES", 345, 364], ["M. tuberculosis", "SPECIES", 366, 381], ["M. avium", "SPECIES", 387, 395], ["cattle", "SPECIES", 487, 493], ["sheep", "SPECIES", 495, 500], ["goats", "SPECIES", 506, 511], ["Mycobacterium bovis", "SPECIES", 345, 364], ["M. tuberculosis", "SPECIES", 366, 381], ["M. avium", "SPECIES", 387, 395], ["Johne", "SPECIES", 411, 416], ["cattle", "SPECIES", 487, 493], ["sheep", "SPECIES", 495, 500], ["goats", "SPECIES", 506, 511], ["ruminant diseases", "PROBLEM", 281, 298], ["foot and mouth disease", "PROBLEM", 307, 329], ["tuberculosis (Mycobacterium bovis", "PROBLEM", 331, 364], ["M. tuberculosis", "PROBLEM", 366, 381], ["M. avium", "PROBLEM", 387, 395], ["brucellosis", "PROBLEM", 398, 409], ["Johne's disease", "PROBLEM", 411, 426], ["diseases", "PROBLEM", 463, 471], ["foot", "ANATOMY", 307, 311], ["mouth", "ANATOMY", 316, 321], ["Mycobacterium bovis", "OBSERVATION", 345, 364], ["diseases", "OBSERVATION", 463, 471]]], ["Diverged 40 million years ago.BloodRed blood cells Elliptic and small (6.5 mm).BloodRound and large (10 mm).BloodPredominant white blood cell Neutrophil.BloodLymphocyte.LeukocytesUp to 22,000.", [["BloodRed blood cells", "ANATOMY", 30, 50], ["white blood cell", "ANATOMY", 125, 141], ["BloodLymphocyte", "ANATOMY", 153, 168], ["BloodRed blood cells", "CELL", 30, 50], ["white blood cell Neutrophil", "CELL", 125, 152], ["BloodLymphocyte", "CELL", 153, 168], ["BloodRed blood cells", "CELL_TYPE", 30, 50], ["BloodPredominant white blood cell Neutrophil", "CELL_TYPE", 108, 152], ["BloodLymphocyte", "CELL_TYPE", 153, 168], ["BloodRed blood cells", "TEST", 30, 50], ["Elliptic", "TEST", 51, 59], ["BloodPredominant white blood cell Neutrophil", "TEST", 108, 152], ["BloodLymphocyte", "TEST", 153, 168], ["LeukocytesUp", "TEST", 169, 181], ["blood cells", "OBSERVATION", 39, 50], ["Elliptic", "OBSERVATION_MODIFIER", 51, 59], ["small", "OBSERVATION_MODIFIER", 64, 69], ["6.5 mm", "OBSERVATION_MODIFIER", 71, 77], ["large", "OBSERVATION_MODIFIER", 94, 99], ["10 mm", "OBSERVATION_MODIFIER", 101, 106], ["white blood cell Neutrophil", "OBSERVATION", 125, 152]]], ["Up to 12,000.LeukocytesBlood glucose levels Higher than ruminants (73-121 mg/dL).", [["Leukocytes", "ANATOMY", 13, 23], ["Blood", "ANATOMY", 23, 28], ["glucose", "CHEMICAL", 29, 36], ["glucose", "CHEMICAL", 29, 36], ["Leukocytes", "ORGANISM_SUBSTANCE", 13, 23], ["Blood", "ORGANISM_SUBSTANCE", 23, 28], ["glucose", "SIMPLE_CHEMICAL", 29, 36], ["Leukocytes", "CELL_TYPE", 13, 23], ["Leukocytes", "TEST", 13, 23], ["Blood glucose levels", "TEST", 23, 43], ["ruminants", "TEST", 56, 65]]], ["18-65 mg/dL.IntegumentHorns or antlers None.IntegumentUsually present in male.IntegumentFoot Triangular-shaped toenails and fat pad Has hooves and sole. covered by soft, flexible slipper.Upper lipSplit and prehensile.", [["toenails", "ANATOMY", 111, 119], ["toenails", "TISSUE", 111, 119], ["fat", "TISSUE", 124, 127], ["fat pad", "TREATMENT", 124, 131], ["Foot", "ANATOMY", 88, 92], ["Triangular", "ANATOMY_MODIFIER", 93, 103], ["shaped", "OBSERVATION_MODIFIER", 104, 110], ["toenails", "OBSERVATION", 111, 119], ["fat pad", "OBSERVATION", 124, 131], ["soft", "ANATOMY", 164, 168], ["flexible slipper", "OBSERVATION", 170, 186], ["prehensile", "OBSERVATION_MODIFIER", 206, 216]]], ["Not split.Upper lipFlank fold None.", [["split", "OBSERVATION", 4, 9], ["lipFlank fold", "ANATOMY", 16, 29]]], ["Unguligrade ending in a hoof.Musculoskeletal systemSecond and third phalanges Horizontal.", [["hoof", "ANATOMY", 24, 28], ["Unguligrade", "CHEMICAL", 0, 11], ["hoof", "ORGANISM_SUBDIVISION", 24, 28], ["hoof", "ANATOMY", 24, 28], ["systemSecond", "ANATOMY", 45, 57], ["third phalanges", "ANATOMY", 62, 77]]], ["Almost vertical.FootNot cloven.", [["vertical", "OBSERVATION_MODIFIER", 7, 15], ["Not", "UNCERTAINTY", 20, 23], ["cloven", "OBSERVATION", 24, 30]]], ["Cloven.DewclawsNone.DewclawsMany have dewclaws.Digestive systemForegut fermenter, with regurgitation, Same (parallel evolution). rechewing, and reswallowing.StomachThree compartments not homologous Four compartments; susceptible to with rumen, reticulum, omasum, and bloat. abomasum; all compartments have glandular epithelium; stomach motility from caudad to craniad; resistant to bloat.StomachDental formula* I 1/3, C 1/1, PM 1-2/1-2, I 0/3, C 0/1, PM 3/3, M 3/3 \u00b5 2 = 32 M 3/3 \u00b5 2 = 28-32 Vicu\u00f1a has incisors that continue to erupt.OvulationInduced.", [["StomachThree compartments", "ANATOMY", 157, 182], ["rumen", "ANATOMY", 237, 242], ["reticulum", "ANATOMY", 244, 253], ["omasum", "ANATOMY", 255, 261], ["compartments", "ANATOMY", 288, 300], ["glandular epithelium", "ANATOMY", 306, 326], ["stomach", "ANATOMY", 328, 335], ["caudad", "ANATOMY", 350, 356], ["craniad", "ANATOMY", 360, 367], ["incisors", "ANATOMY", 503, 511], ["reticulum", "CELLULAR_COMPONENT", 244, 253], ["abomasum", "ORGAN", 274, 282], ["glandular epithelium", "TISSUE", 306, 326], ["stomach", "ORGAN", 328, 335], ["incisors", "ORGAN", 503, 511], ["Cloven", "TREATMENT", 0, 6], ["Digestive systemForegut fermenter", "TREATMENT", 47, 80], ["regurgitation", "PROBLEM", 87, 100], ["bloat", "PROBLEM", 267, 272], ["abomasum", "PROBLEM", 274, 282], ["glandular epithelium", "PROBLEM", 306, 326], ["stomach motility", "PROBLEM", 328, 344], ["caudad to craniad", "PROBLEM", 350, 367], ["bloat", "PROBLEM", 382, 387], ["incisors", "PROBLEM", 503, 511], ["regurgitation", "OBSERVATION", 87, 100], ["reticulum", "ANATOMY", 244, 253], ["omasum", "ANATOMY", 255, 261], ["bloat", "OBSERVATION", 267, 272], ["glandular epithelium", "ANATOMY", 306, 326], ["stomach", "ANATOMY", 328, 335], ["bloat", "OBSERVATION", 382, 387], ["incisors", "ANATOMY", 503, 511]]], ["34 In fact, they are quite resistant to many regulated ruminant diseases.Estrous cycleFoot-and-mouth disease (FMD) virus is highly contagious in cattle and sheep.", [["ruminant diseases", "DISEASE", 55, 72], ["FMD", "DISEASE", 110, 113], ["cattle", "ORGANISM", 145, 151], ["sheep", "ORGANISM", 156, 161], ["cattle", "SPECIES", 145, 151], ["sheep", "SPECIES", 156, 161], ["Estrous cycleFoot-and-mouth disease (FMD) virus", "SPECIES", 73, 120], ["cattle", "SPECIES", 145, 151], ["sheep", "SPECIES", 156, 161], ["many regulated ruminant diseases", "PROBLEM", 40, 72], ["Estrous cycleFoot", "PROBLEM", 73, 90], ["mouth disease (FMD) virus", "PROBLEM", 95, 120], ["ruminant diseases", "OBSERVATION", 55, 72], ["mouth", "ANATOMY", 95, 100], ["disease", "OBSERVATION", 101, 108], ["contagious", "OBSERVATION_MODIFIER", 131, 141]]], ["When llamas and alpacas were first imported from South America to the United States for the blossoming private llama industry, government officials expressed concern that llamas and alpacas might pose a risk for the introduction of FMD to the United States.", [["llamas", "ORGANISM", 5, 11], ["alpacas", "ORGANISM", 16, 23], ["llamas", "ORGANISM", 171, 177], ["alpacas", "ORGANISM", 182, 189], ["FMD", "SPECIES", 232, 235]]], ["It was concluded that llamas and alpacas could be infected by inoculation but did not acquire FMD when cohabiting with infected swine, in contrast with almost 100% of cattle that acquired the infection.", [["infection", "DISEASE", 192, 201], ["llamas", "ORGANISM", 22, 28], ["alpacas", "ORGANISM", 33, 40], ["swine", "ORGANISM", 128, 133], ["cattle", "ORGANISM", 167, 173], ["swine", "SPECIES", 128, 133], ["cattle", "SPECIES", 167, 173], ["llamas", "SPECIES", 22, 28], ["FMD", "SPECIES", 94, 97], ["swine", "SPECIES", 128, 133], ["cattle", "SPECIES", 167, 173], ["llamas and alpacas", "PROBLEM", 22, 40], ["the infection", "PROBLEM", 188, 201], ["llamas", "OBSERVATION", 22, 28], ["infection", "OBSERVATION", 192, 201]]], ["6, 25, 30 The virus could not be detected after 14 days postinoculation.Estrous cycleThe same could be said for vesicular stomatitis.", [["vesicular", "ANATOMY", 112, 121], ["vesicular stomatitis", "DISEASE", 112, 132], ["6, 25, 30", "CHEMICAL", 0, 9], ["vesicular stomatitis", "ORGANISM", 112, 132], ["The virus", "PROBLEM", 10, 19], ["Estrous cycle", "TREATMENT", 72, 85], ["vesicular stomatitis", "PROBLEM", 112, 132], ["virus", "OBSERVATION", 14, 19], ["could not be", "UNCERTAINTY", 20, 32], ["vesicular stomatitis", "OBSERVATION", 112, 132]]], ["Only one animal has been diagnosed with the natural disease.", [["the natural disease", "PROBLEM", 40, 59], ["natural disease", "OBSERVATION", 44, 59]]], ["2 Bovine tuberculosis (TB) caused by Mycobacterium bovis is another concern of government officials.", [["Bovine tuberculosis", "DISEASE", 2, 21], ["TB", "DISEASE", 23, 25], ["Mycobacterium bovis", "DISEASE", 37, 56], ["Bovine", "ORGANISM", 2, 8], ["Mycobacterium bovis", "ORGANISM", 37, 56], ["Bovine", "SPECIES", 2, 8], ["Mycobacterium bovis", "SPECIES", 37, 56], ["Mycobacterium bovis", "SPECIES", 37, 56], ["2 Bovine tuberculosis (TB", "PROBLEM", 0, 25], ["Mycobacterium bovis", "PROBLEM", 37, 56], ["Bovine", "OBSERVATION_MODIFIER", 2, 8], ["tuberculosis", "OBSERVATION", 9, 21], ["Mycobacterium bovis", "OBSERVATION", 37, 56]]], ["Llamas and alpacas have developed the disease under natural conditions, when cohabiting with infected elk, but have shown resistance to acquiring TB, in contrast to ruminants.", [["TB", "DISEASE", 146, 148], ["alpacas", "ORGANISM", 11, 18], ["elk", "ORGANISM", 102, 105], ["elk", "SPECIES", 102, 105], ["the disease under natural conditions", "PROBLEM", 34, 70], ["infected elk", "PROBLEM", 93, 105], ["disease", "OBSERVATION", 38, 45], ["natural conditions", "OBSERVATION", 52, 70]]], ["31 Llamas and alpacas have been experimentally infected with Brucella abortus, but the natural disease does not occur in these species.", [["Brucella abortus", "DISEASE", 61, 77], ["alpacas", "ORGANISM", 14, 21], ["Brucella abortus", "ORGANISM", 61, 77], ["Brucella abortus", "SPECIES", 61, 77], ["Brucella abortus", "SPECIES", 61, 77], ["Brucella abortus", "PROBLEM", 61, 77], ["the natural disease", "PROBLEM", 83, 102], ["Llamas", "OBSERVATION", 3, 9], ["infected", "OBSERVATION_MODIFIER", 47, 55], ["Brucella abortus", "OBSERVATION", 61, 77], ["natural", "OBSERVATION_MODIFIER", 87, 94], ["disease", "OBSERVATION", 95, 102]]], ["12, 13 There are no reports of the transmission of any regulated ruminant disease from camelids to ruminants.CONCLUSIONCamelids are not ruminants taxonomically, anatomically, physiologically, or behaviorally.", [["ruminant disease", "DISEASE", 65, 81], ["any regulated ruminant disease", "PROBLEM", 51, 81], ["no reports of", "UNCERTAINTY", 17, 30], ["ruminant disease", "OBSERVATION", 65, 81]]], ["Camelids also are not a threat to the livestock industry because they either have total resistance to infection or have minimal susceptibility to the infectious and parasitic diseases of ruminants.", [["infection", "DISEASE", 102, 111], ["infectious and parasitic diseases of ruminants", "DISEASE", 150, 196], ["total resistance to infection", "PROBLEM", 82, 111], ["minimal susceptibility", "PROBLEM", 120, 142], ["the infectious and parasitic diseases of ruminants", "PROBLEM", 146, 196], ["infection", "OBSERVATION", 102, 111], ["minimal", "OBSERVATION_MODIFIER", 120, 127], ["infectious", "OBSERVATION_MODIFIER", 150, 160], ["parasitic", "OBSERVATION_MODIFIER", 165, 174]]]], "263ae556fb92ab6dd5ca0156830252ad04cae4e8": [["VTE, type and clinical presentation of VTE (symptomatic or incidentally detected pulmonary embolism [PE] or deep vein thrombosis [DVT] ).", [["pulmonary", "ANATOMY", 81, 90], ["deep vein", "ANATOMY", 108, 117], ["VTE", "DISEASE", 0, 3], ["VTE", "DISEASE", 39, 42], ["pulmonary embolism", "DISEASE", 81, 99], ["PE", "DISEASE", 101, 103], ["deep vein thrombosis", "DISEASE", 108, 128], ["DVT", "DISEASE", 130, 133], ["pulmonary", "ORGAN", 81, 90], ["deep vein", "MULTI-TISSUE_STRUCTURE", 108, 117], ["VTE", "PROBLEM", 0, 3], ["VTE", "PROBLEM", 39, 42], ["symptomatic", "PROBLEM", 44, 55], ["incidentally detected pulmonary embolism", "PROBLEM", 59, 99], ["PE", "PROBLEM", 101, 103], ["deep vein thrombosis", "PROBLEM", 108, 128], ["DVT", "PROBLEM", 130, 133], ["pulmonary", "ANATOMY", 81, 90], ["embolism", "OBSERVATION", 91, 99], ["PE", "OBSERVATION", 101, 103], ["deep", "ANATOMY_MODIFIER", 108, 112], ["vein", "ANATOMY", 113, 117], ["thrombosis", "OBSERVATION", 118, 128], ["DVT", "OBSERVATION", 130, 133]]], ["Any disagreement was resolved by consensus between the two review authors or by involving a third review author.", [["Any disagreement", "PROBLEM", 0, 16]]]]}